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Abstract 
In 1992, the expansion of a CTG repeat within the 3’ UTR of the DMPK gene was 
identified as the cause of myotonic dystrophy type 1 (DM1), the most common form of 
adult onset muscular dystrophy affecting one in 8,000 Caucasians. The array-length 
determines the severity and age of onset of the disease. This expansion, once transcribed, 
sequesters a developmental splicing regulator MBNL1 in the form of nuclear foci. The 
MBNL1 antagonist, CUG-BP1, also a developmental splicing regulator, is raised by some 
unknown mechanism in DM1 patients. This alteration between the dynamic balance of 
these two proteins results in the missplicing of genes, which are thought to contribute 
profoundly to the multisystemic pathology of DM1. The disease is primarily RNA 
mediated, but how the mutant transcript brings about such pleiotropic effects is not yet 
clear. Recent research indicates a more direct involvement of CUG-BP1, and other 
potential factors may be important. To identify the full range of targets and the pathogenic 
consequences, we sought to mimic the pathogenesis of myotonic dystrophy type 1 with 
temporal and spatial control: Temporal to reproduce the developmental pathogenesis of the 
congenital form, and spatial to isolate tissue specific pathology. To do this, we attempted 
to use the Cre-lox system for the conditional expression of an EGFP reporter-linked 
expanded CUG repeat RNA in the mouse. Expression of the transgene was controlled by 
Cre excision of a transcriptional stop, placed upstream of the EGFP-expanded repeat open 
reading frame. The transgenes were constructed and tested successfully, and a normal 
length repeat transgenic line was established. Unfortunately generation of the expanded 
repeat line was not successful. The constructs were used to generate cell-culture models of 
DM1, in both human and murine cells, which mimicked the nuclear foci formation and 
MBNL1 co-localisation seen in patient cells. Expression of exogenous MBNL1/GFP 
fusion protein in this model resulted in an increase in the size of foci, indicating that 
MBNL1 protein is limiting within the cell, and may possibly play a protective role. The 
murine DM1 cell-culture model was used to investigate the effects of expanded CUG 
repeat expression on splicing within the transcriptome. The differential effect between 5 
and 250 repeat RNA expression using Affymetrix whole transcript and exon arrays was 
compared. Using whole genome arrays, 6 genes were down-regulated and 128 up-
regulated. With exon arrays, 58 genes showed alternative exon usage. Six genes were 
selected for further bioinformatics analysis: MtmR4, which has possible neuromuscular 
involvement; Kcnk4, Narg1, Ttyh1 and Bptf, potentially related to brain development; and 
Cacna1c, a promising candidate for heart conductance defects and sudden death. 3 
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To Mum and Dad:  
“Although my nature like a butterfly is to sip the nectar from many flowers, here is the 
proof I can also gorge on a single bloom.” 8 
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1  Introduction 
The birth of a first grandchild is usually an uplifting and joyous event. Often, in families 
with the myotonic dystrophy type 1 mutation, it is devastating. Grandparents and parents 
are frequently asymptomatic, unaware that they have the mutation until a congenitally 
affected grandchild is born. 
1.1 The nature of myotonic dystrophy 
Myotonic Dystrophy Type 1 (DM1) is the most common form of adult muscular dystrophy 
with an occurrence of 1 in 8,000 individuals worldwide. The symptoms are pleiotropic, not 
purely affecting muscle, manifesting clinically as myotonia; progressive muscle weakness 
and wasting; cardiac conduction defects; cataracts; insulin resistance; premature frontal 
balding and testicular atrophy in males; reduced fertility in females; and in the more severe 
form, mental handicap and respiratory distress (Harper, 2001). The severity of symptoms is 
extremely variable ranging from asymptomatic or only mildly affected adults in old age, to 
severely affected neonates. Genetically the disease shows autosomal dominance, and 
anticipation, whereby the severity of a disease is greater, and the age of onset becomes 
earlier through successive generations of the affected family. 
1.1.1 Pathology  
DM1 is often diagnosed late in the progression of the disease probably because of the 
tolerant, uncomplaining nature of the patients, a symptom in itself. Facial weakness 
including ptosis and wasting of the jaw muscles is a constant and characteristic feature, 
which can be severe in children with the congenital form of the disease, affecting speech 
and swallowing. Neck and distal limb weakness is also apparent. The definitive clinical 
diagnosis, which excludes other forms of muscular dystrophy including fascio-scapulo 
humeral dystrophy (FSHD), autosomal recessive limb-girdle dystrophy (ARLD) and 
Becker dystrophy, is of myotonia (36% of patients) in conjunction with progressive muscle 
wasting. Histologically, muscle defects have been well characterised. Patient muscle tissue 
shows centralised nuclei; poor fibre packing; ringed fibres, predominance of type 1 fibres 
and type 1I fibre atrophy (Borg et al., 1987; Tohgi et al., 1997; Vihola et al., 2003). In the 
brain, cell loss, neuronal inclusion bodies and tau-associated pre-senile neurofibriliary 
tangles are evident (Kiuchi et al., 1991; Sergeant et al., 2001). Christine Haworth    Chapter 1, 16 
 
DM1 is not purely a muscular disorder and the patient may present with other seemingly 
unrelated systemic indications such as cardiac conduction defects –particularly heart block 
and atrial arrhythmias; cardiomyopathy; aspiration pneumonia; alveolar hypoventilation 
(breathing difficulties leading to lethargy and daytime sleepiness); minor sensory loss of 
the peripheral nerves; mild mental retardation –severe in the congenital form; 
hypersomnia; testicular atrophy; diabetes; cataract; retinal degeneration; ocular hypotonia; 
skeletal deformities of the jaw and palate; cranial hyperostosis; air sinus enlargement; 
premature balding and calcifying epithelioma (stony tumour of the face or arms). Mental 
retardation and skeletal deformities are more pronounced in childhood cases and include 
talipes (deformities of the foot) and scoliosis (lateral spinal curvature). The causes of death 
are primarily cardiac and respiratory related, sudden death from cardiac arrhythmia 
accounting for 29% of deaths (Harper, 2001).  
1.1.2 Unstable tandem repeat diseases  
Myotonic dystrophy belongs to a growing group of inherited human disorders associated 
with the expansion of microsatellite repeats, which were until the 1990’s thought to be 
commonplace benign stretches of DNA. The repeats are usually stable at around 30 
repeats, but arrays over 40 repeats tend to be unstable (Harper, 2001). Since then, the cause 
of several diseases has been attributed to the aberrant expansion of these regions, most of 
which are neurological such as the spinocerebellar ataxias; Huntington disease; 
spinobulbar muscular atrophy; fragile X syndrome and Fredrich ataxia (Wells et al., 2006). 
Most of the repeat regions within these genes are highly polymorphic throughout the 
general population where normal and affected individuals fall into ranges, rather than 
having a definitive cut-off point. There are defining features shared amongst microsatellite 
repeat disorders. Repeat expansions show both somatic and germline instability, expanding 
throughout the lifetime of the individual, which contributes to the pathology, since longer 
repeat lengths result in more severe symptoms. Genetic anticipation is also observed, 
whereby the longer the inherited tract length, the earlier the age of onset of the disease and 
the more severe the clinical presentation (Wells et al., 2006).  
Not all CTG repeat tracts cause disease. The SEF2-1 gene on chromosome 18q21.1 
(Breschel et al., 1997) for instance contains a heritable intronic expanding CTG repeat, and 
the ERDA1 locus 17q213, a polymorphic CTG repeat array (Schalling et al., 1993; 
Nakamoto et al., 1997) which lack pathogenic effect. Of those expansions that are 
symptomatic there are two subclasses of disease, defined by the location of the repeat 
region relative to the gene. The first contains the repeats within the reading frame of the Christine Haworth    Chapter 1, 17 
 
gene leading to long stretches of the same amino acid, usually glutamine (in-frame CAG 
repeats), incorporated into the translated protein. The second subclass comprises those 
tracts situated within non-coding regions of the gene such as the promoter region; 5’UTR; 
intron or 3' UTR (Figure 1). In this class, except for those within the promoter region, 
which are not transcribed, expanded repeats are transcribed but not translated. Myotonic 
dystrophy falls into the second category in that the expanded RNA is transcribed but not 
translated (Brook et al., 1992). Additionally, the mutation is situated within the promoter 
region of a flanking gene where it is not transcribed (Boucher et al., 1995). 
 
 
Figure 1 The relative positions of disease associated expanded repeats within a fictitious 
gene. Schematic diagram. Diseases are classed depending whether they are within coding or 
untranslated regions. * HDL2 isoforms generated by alternative splicing. † The DM1 mutation is 
positioned within the 3’UTR of DMPK and the promoter region of SIX5. Abbreviations: FRAXA, 
Fragile X Syndrome (Fu et al., 1991); FRAXE, Fragile XE Mental retardation (Chakrabarti et al., 
1996; Gu et al., 1996; Gecz et al., 1997); FRDA, Friedreich ataxia (Campuzano et al., 1996); SCA , 
Spinocerebellar ataxia (Gatchel et al., 2005); HD, Huntington disease (Group, 1993); DM1, 
Myotonic dystrophy type 1 (Aslanidis et al., 1992; Brook et al., 1992; Buxton et al., 1992; Harley et 
al., 1992); SBMA, Spinobulbar muscular atrophy (La Spada et al., 1991); DRPLA, 
Dentatorubralpallidoluysian atrophy (Ikeuchi et al., 1995) HDL2, Huntington disease-like 2 
(Margolis et al., 2001; Holmes et al., 2001). 
 
1.1.3 The myotonic dystrophy mutation 
In molecular terms, DM1 is associated with the expansion of a CTG repeat in the 3’ UTR 
of the DM protein kinase (DMPK) gene, and within the promoter region of the flanking 
gene SIX5, which maps to chromosome 19q13.3 (Buxton et al., 1992; Boucher et al., 
1995), a gene-dense region of the genome (Figure 2). A correlation exists between the 
length of the repeat tract, and the age of onset and severity of the disease. Each DMPK 
allele in unaffected individuals has between 5 and 37 CTG repeats, with tracts upwards of Christine Haworth    Chapter 1, 18 
 
50 repeats becoming disease-associated. Expansions can be divided into three groups 
(mild; moderate and congenital) depending on the severity of the disease, which also 
relates to the age of onset. Mild or asymptomatic (late onset) cases have 50 to 100 repeats. 
Myotonia and weakness are rare in these patients, the most common finding being 
cataracts. Moderate (adult onset) cases have 100 to 500 repeats. These patients are likely to 
suffer one or several features of DM1 including myotonia; progressive muscle weakness –
becoming debilitating in the fifth and sixth decades; cardiac conduction defects; respiratory 
failure; cataracts and gonadal and endocrine abnormalities. The symptoms tend to be more 
acute with increased repeat length. In severe (congenital) cases repeat lengths from 500 up 
to ~3000 are detected (Harley et al., 1993). Hypotonia is present from birth, adult onset 
symptoms are also present from early childhood, and there is much more involvement of 
the central nervous system –congenital patients being mentally retarded, with an average 
IQ of 66 (Harper, 2001). 
The DMPK protein itself belongs to the family of serine-threonine kinases and is expressed 
highly in skeletal muscle and heart and in lower levels in smooth muscle (Lam et al., 
2000). Using antibodies, forms of DMPK protein between 42 to 84 kDa have been 
identified, expressed primarily in muscle, heart and brain, and at low level ubiquitously 
(van der Ven et al., 1993; Maeda et al., 1995; Salvatori et al., 1997; Shimokawa et al., 
1997; Pham et al., 1998; Beffy et al., 2005). There is some controversy over the full extent 
of DMPK expression since different sized proteins have been found in different tissues 
using different antibodies. Using a phage display generated monoclonal antibody panel to 
DMPK epitopes, Lam et al. (2000) reported exclusive expression of the 80KDa form, and 
only in skeletal muscle, smooth muscle and heart. They suggested that the previously 
observed size and tissue distribution using first generation antibodies, was probably caused 
by cross reaction between DMPK related proteins such as the 72KDa myotonic dystrophy 
related cdc-42 binding kinase (MRCK) (Leung et al., 1998). However, the second-
generation antibody specificity could be limited by antigen conformational artefacts of the 
phage display technique, resulting in some epitopes avoiding recognition, and so the 
controversy continues.  
The DMPK gene has 15 exons. Initially, many alternatively spliced DMPK transcripts were 
identified in mouse and humans (Jansen et al., 1992). However further analysis using 
existing cDNA and EST expression data for both species (Jansen et al., 1992; Fu et al., 
1993; Mahadevan et al., 1993; Shaw et al., 1993), and sequencing of these libraries 
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in mouse may be more complex than in humans, (Groenen et al., 2000). Using transgenic 
mice over-expressing hDMPK, Groenen et al. made a detailed comparison of the splicing 
behaviour of human and mouse DMPK genes. They showed that most isoforms were 
expressed in many tissues including heart, skeletal muscle, liver and brain, but the 
proportions differed, with predominant isoforms specific to heart; skeletal muscle, brain 
and smooth muscle tissue. Several additional splicing events were specific to mouse. Using 
RT-PCR, six major alternatively spliced DMPK isoforms have been identified in the 
human and the mouse (Brook et al., 1992; Jansen et al., 1992; Groenen et al., 2000), and a 
seventh minor isoform in DM1, which includes a novel terminal exon resulting in the 
excision of the expanded repeat tract (Tiscornia et al., 2000). This form of the transcript 
has been shown to freely exit the nucleus in DM1 patients, whereas forms with expanded 
repeats are retained. All isoforms include an N-terminal leucine rich domain –which 
possibly regulates DMPK activity (in Wells et al., 2006, chapter 5), a serine-threonine 
kinase domain and a coiled-coil region putatively involved in multimerisation and 
substrate binding (van Herpen et al., 2005). Variation occurs via alternative splicing 
between exons 12 and 15 producing 3 different C-termini involved in isoform specific 
subcellular localisation to either the endoplasmic reticulum, mitochondrial membrane (van 
Herpen et al., 2005) or cytosol (Wansink et al., 2003). For each of these 3’ variations there 
is a “VSGGG” motif “with” and “without” version, formed from an extension of exon 8 
during splicing. The seventh minor isoform, translated from the repeat-free transcript also 
includes a “VSGGG” motif, and a unique C-terminus which may direct localisation 
elsewhere within the cell. The function of the “VSGGG” motif is not yet known, but is 
thought to be a target for conformational regulation (Groenen et al., 2000).  
The biological function of DMPK has been widely studied since the discovery of its 
involvement in DM1, and considerable progress has been made with the identification of 
activators, substrates and functional domains within the protein. This information allows 
speculation and hypothesis about the biological significance of the DMPK gene product 
within the cell, but the full explanation has not yet been elucidated. Kinases are known to 
regulate the majority of cellular pathways, especially those involved in signal transduction. 
The DMPK protein like other kinases regulates substrate activity and is regulated itself, by 
phosphorylation. There is evidence that DMPK is involved in ion homeostasis and aspects 
of actin cytoskeleton remodelling (Jin et al., 2000), specifically myotube differentiation 
(Beffy et al., 2005), via Rac-1 and Raf-1 signalling (Shimizu et al., 2000). In vitro, 
substrates of DMPK include CUG-BP1, a developmental splicing regulator strongly 
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nucleus in DM1 patients (Timchenko et al., 2001). Phosphorylation of CUG-BP1 results in 
a decreased nuclear concentration of this form in DM1 patients (Roberts et al., 1997), so 
DMPK may contribute to the regulation of cellular CUG-BP1 distribution. However, 
CUG-BP1 has not been confirmed as a DMPK substrate in vivo. 
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Figure 2 Schematic diagram depicting the gene-dense region around the myotonic 
dystrophy protein kinase gene (DMPK). Abbreviations: RSHL1, Radial Spoke Head Like protein; 
DMWD, Myotonic Dystrophy WD gene; UTR, Untranslated region; SIX, sine oculis-like. 
 
 
1.1.4 Somatic variation and anticipation 
The somatic variation of expanded repeats was originally uncovered by the diffuse signals 
observed on Southern blot analysis of repeat region restriction fragments (Buxton et al., 
1992; Wong et al., 1995). The use of small pool PCR techniques later revealed these 
fragments to comprise a heterogeneous mosaic of variable repeat lengths which tend to be 
expansion biased, age dependent and tissue specific (Monckton et al., 1995; Wong et al., 
1995). Instability of DM1 CTG repeats has been reported in a wide range of human tissues, 
including peripheral blood lymphocytes, liver, pancreas, kidney, brain and heart (Lavedan 
et al., 1993; Kinoshita et al., 1996; Martorell et al., 1998 ). Furthermore, instability in 
muscle is high compared to other tissues such as blood (Thornton et al., 1994), which 
could account for the major muscle involvement of the myotonic dystrophy phenotype. 
Germline instability is clearly responsible for much of the phenotypic variation and 
intergenerational effects (Harper, 2001). In sperm, the repeat array is also unstable and 
expansion biased, concordant with anticipation, but the overall expansion rate is not as 
high as in the soma. This may be due to contractions which have been observed in, and are 
restricted to the male germline (Shelbourne et al., 1992; Monckton et al., 1995; Martorell 
et al., 2000), or selection against the transmission of large expansions (Jansen et al., 1994). 
Consequently in congenital cases, the mutant allele is usually inherited from an affected 
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The fact that mutant DMPK alleles are unstable and expand throughout the lifetime of the 
individual both somatically and within the germline supports the observed genetic 
anticipation, whereby subsequent generations of an affected family suffer earlier disease 
onset and increasingly severe symptoms. Alleles with repeat arrays at the longer end of the 
'normal' range have been termed 'pre-mutation' and people possessing these lengths are at 
high risk of having affected family members within a limited number of generations 
(Martorell et al., 2001).  
In vivo data suggests the actual mechanism of expansion is independent of cell division. In 
mice, as in humans, there is no obvious correlation between cell division rates and the 
tissue specificity of somatic mosaicism in vitro (Gomes-Pereira et al., 2001 and 
unpublished data) and in vivo. Indeed, expansions continue to accumulate in post-mitotic 
tissues such as brain, arguing against a major role for cell division in repeat expansion (Lia 
et al., 1998; Fortune et al., 2000; Kennedy et al., 2000). Mouse models indicate repeat 
instability is dependent on the mismatch repair process rather than replication. In a DM1 
context, Pms2 (a MutL homologue) null mice, demonstrated increased somatic instability 
(Gomes-Pereira et al., 2004). Also in DM1 mice, expansion was found to be dependent on 
Msh3 (a mutS homologue) (Foiry et al., 2006). In Huntington transgenic mice, instability 
was found to be dependent on Msh2 (a MutS homologue), both somatically and within the 
germline (Manley et al., 1999; Kovtun et al., 2001). MSH2 was also required for germline 
contractions in sperm in DM1 transgenic mice expressing >300 repeats (Savouret et al., 
2004). Research suggests then that major components of mismatch repair including MSH2; 
MSH3 and PMS2 are required to bring about repeat expansion. 
The two principal aspects of DM1 –instability of the repeat expansion and pathogenesis of 
the disease, are currently under intense academic scrutiny. Since the severity and the age of 
onset in myotonic dystrophy relate to the length of the expansion, the rate of somatic 
instability has strong implications for the pathogenesis and progression of the disease. 
Longer repeats elicit more severe symptoms, which appear earlier probably by advancing 
the pathogenic response (Gomes-Pereira et al., 2006 for review). This may produce 
different phenotypic effects depending on the developmental stage of the affected 
individual, accounting for the congenital form. Research into mechanisms in these areas 
could lead to treatment of the condition by either impeding expansion from an early age; 
actual reduction in repeat length, or modification of the downstream effects caused by 
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1.1.5 Pathogenesis 
The genetic mutation was identified in the mid 1990s (Aslanidis et al., 1992; Brook et al., 
1992; Buxton et al., 1992; Harley et al., 1992), and yet our knowledge of how the CTG 
expansion leads to the DM1 phenotype is still incomplete. Current research is focussed in 
three main areas: Haploinsufficiency of DMPK; Chromatin disruption and RNA gain of 
function.  
1.1.5.1  DMPK haploinsufficiency 
Once the myotonic dystrophy mutation was uncovered, it was expected that expansions of 
CUG repeats would affect transcription or translation of DMPK leading to 
haploinsufficiency. Messenger RNA levels were assessed by researchers and in some cases 
found to be reduced in adult (Fu et al., 1993; Hofmann-Radvanyi et al., 1993; Eriksson et 
al., 1999) as well as unaffected in adult (Inukai et al., 2000), and raised (Sabouri et al., 
1993) and reduced (Hofmann-Radvanyi et al., 1993) in congenital tissues. Conflicting 
reports as to whether mRNA transcripts were increased or decreased may have stemmed 
from the different methods and position of PCR primers used in each study, and the 
different tissue types analysed (Hofmann-Radvanyi et al., 1993). Krahe et al. showed that 
the levels of unprocessed pre-mRNA was equivalent between wild type (wt) and disease 
alleles, and that the overall amount of processed polyA+ DMPK transcript (wt and mutant) 
was equivalent between unaffected and affected individuals, but that processed (polyA+ 
and spliced) levels of the disease allele were reduced compared to wild type (Krahe et al., 
1995). Around the same time, analysis of the intracellular localisation of transcripts had 
shown mutant DMPK RNA to become aggregated and retained within the nucleus in 
discrete foci in patient tissues (Taneja et al., 1995). Later, this was also shown in myoblast 
culture expressing CUG repeat tracts (Davis et al., 1997), and that differentiation of the 
myoblasts was inhibited by expression of the CUG expansions (Amack et al., 1999). This 
lead researchers to postulate that aberrant RNA processing of the DMPK gene leading to 
haploinsufficiency of myotonic dystrophy protein kinase (DMPK), could be the cause of 
disease development. This hinted that the method of RNA extraction used by researchers –
whether nuclear RNA in addition to cytoplasmic RNA had been recovered, was vital in the 
interpretation of previously published results. It has already been mentioned that six major 
cell-type specific alternatively-spliced isoforms of DMPK have been detected to date 
(Groenen et al., 2000). In addition, Tiscornia et al. reported a novel isoform of DMPK 
lacking repeats not retained in the nucleus in DM1 cells. This would result in imbalances in 
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corroborating the theory that the position of the PCR primers –whether they were within 
alternatively spliced exons, and the type of tissue analysed could have been important. 
Using antiserum directed against DMPK, levels of the protein were reduced in patient 
tissue and cells, adding credence to the haploinsufficiency hypothesis (Fu et al., 1993; 
Koga et al., 1994). However a more recent publication (Narang et al., 2000) reports that 
the antisera used in these experiments was not specific for DMPK –cross-reacting with 
other proteins, and that using a DMPK-specific antibody, levels are moderately raised in 
adult DM1 tissues but in congenital cases a slight decline is apparent. In contrast, Salvatori 
et al. showed a decrease of DMPK to 50% normal levels in 16 adult DM1 skeletal muscle 
samples. The lowest concentration of DMPK protein correlated to those samples 
containing the least number of type 1 skeletal muscle fibres, but did not correlate with 
repeat length (Salvatori et al., 2005). 
Aside from the conflicting reports of DMPK mRNA and DMPK protein levels to date, 
there are other anomalies to the haploinsufficiency hypothesis. Mouse models homozygous 
for the loss of Dmpk have been extensively analysed phenotypically and pathologically and 
so far develop only a mild myopathy (Jansen et al., 1996) and cardiac conduction defects 
(Berul et al., 1999). In isolated cardiac myocytes, abnormal contractile activity and 
calcium cycling (Pall et al., 2003), and abnormal sodium channel gating (Lee et al., 2003) 
was apparent. Homozygous loss of DMPK in mice has therefore failed to reproduce many 
of the multisystemic effects observed in DM1, such as myotonia; progressive muscle 
wasting; diabetes and cataracts. In addition, individuals homozygous for the DM1 mutation 
have been documented, and diploid production of mutant DMPK mRNA did not adversely 
affect the clinical presentation in these patients (Martorell et al., 1996). It has to be noted 
however that in this particular study, the length of repeats, are not the same with 1000/60; 
61/38 and 51/120 respectively which makes assessing “homozygotes” difficult. If the 
effect of the repeats were additive, then the gain would not be expected to increase disease 
severity into the next category. Nevertheless, these observations, and the fact that no other 
DM1 cases have been identified arising from a point mutation or a deletion within the 
coding region, support the view that the complete clinical pathology of DM1 does not 
result from simple loss of function alone. 
1.1.5.2  Disruption of chromatin structure 
 The DMPK gene is located within a gene dense region of 19.3q (Figure 2). Expression of 
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(Otten et al., 1995), and therefore could affect transcription of surrounding genes. Using 
electron microscopy and competitive nucleosome reconstitution, blocks of repeats n=75 
and n=100 have been shown to form unusually stable nucleosomes in vitro which could 
reasonably be expected to profoundly alter local chromatin structure (Wang et al., 1995). 
More recently Flippova et al. showed that CTG repeats at the DM1 locus are a component 
of a CTCF-dependent insulator element, and that repeat expansion results in conversion of 
the region to heterochromatin (Filippova et al., 2001). Cho et al. confirmed this and also 
showed that an antisense transcript emanating from the adjacent SIX5 regulatory region 
extending into the insulator element is produced, and converted into 21 nucleotide (nt) 
fragments. CTCF restricted the extent of the antisense RNA at the wt DM1 locus and 
constrained the methylation to the nucleosome associated with the CTG repeat, whereas 
the expanded allele in congenital DM1 was associated with loss of CTCF binding, spread 
of heterochromatin, and regional CpG methylation (Cho et al., 2005). The presence of 21 
nucleotide repeats and associated histone methylation would suggest a role in gene 
silencing, which would be expected to have a profound effect on DMPK expression in 
congenital DM when CTCF insulation failed.  
Of the genes surrounding the site of the DM1 mutation, SIX5 (formerly known as DM 
locus-associated homeodomain protein, DMAHP) has been the most extensively studied. 
SIX5 contains a Six domain and a homeodomain (Boucher et al., 1995) as first 
characterised in sine oculis, a homeobox gene essential for the development of the eye in 
Drosophila melanogaster (Cheyette et al., 1994). The 5' UTR and promoter region of SIX5 
is associated with a CpG island at the 3' end of DMPK, extends over 3.5 Kb and is 
interrupted by the DM1 CTG repeat (Figure 2). RT-PCR analysis shows that SIX5 is 
expressed in a number of human tissues, including skeletal muscle, heart and brain 
(Boucher et al., 1995), and in DM1, levels have been shown to be reduced (Thornton et al., 
1997). As a result, SIX5 was selected as a candidate gene for DM1 pathogenesis due to 
haploinsufficiency. However, mice homozygous for loss of SIX5 expression had no 
apparent abnormalities of skeletal muscle function, but did develop lenticular opacities at a 
higher rate than controls (Klesert et al., 2000). Sarkar et al. demonstrated that 
heterozygous loss of SIX5 in mice was sufficient to produce cataracts (Sarkar et al., 2000). 
SIX5 deficiency could contribute to the cataract phenotype in myotonic dystrophy 
providing evidence of multigenic involvement. The cataracts lacked the characteristic 
posterior positioning and red-green iridescence seen in patients (Ranum et al., 2004) 
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Of the other genes surrounding the DM1 locus (Figure 2), DMWD is normally expressed 
highly in brain and testes (Jansen et al., 1992)–tissues affected in myotonic dystrophy. 
Reduced expression is evident in the cytoplasm of DM1 skeletal muscle (Eriksson et al., 
1999; Westerlaken et al., 2003). Radial Spokehead-Like gene, (RSHL1) has been 
implicated in sperm motility (Eriksson et al., 2001). Both fertility and brain function are 
affected in DM1, but little is known about the function of these genes, so how their 
disruption would affect the phenotype is not yet clear. 
1.1.5.3  Gain of function  
The evidence in support of a gain of function of the mutant allele arises from its dominance 
and from a broad correlation between the length of the repeat and the severity of the 
disease. The first experimental evidence for a dominant effect of mutant DMPK transcripts 
on RNA metabolism was postulated in 1995. In DM1 patients, Wang et al. found relatively 
small decreases of DM kinase RNA in the total RNA pool from muscle, but dramatic 
disease-specific decreases of both the mutant and wt DM kinase RNAs in the poly(A)+ 
fraction (Wang et al., 1995). They postulated a trans-dominant effect of the expanded 
repeat RNA upon both WT and expanded transcripts. This data didn’t hold up however 
since the levels of allele-specific RNA were not measured directly, but extrapolated by 
combining two sets of data –the relative levels of each allele based on a restriction site 
difference, and the relative levels of DMPK polyA RNA (WT and mutant) compared to 
creatine kinase. As mentioned earlier, using direct allele-specific measurement, Krahe et 
al. showed that the levels of polyA+ RNA from normal and mutant alleles were equivalent, 
and that the DM allele pre-mRNA was incorrectly processed at the splicing level. The 
unstable repeat impaired post-transcriptional pre-mRNA processing (Krahe et al., 1995). 
The misleading results from Wang et al. could be explained then, if the quantitative 
measurements were based on PCR primer position spanning an intron. Around the same 
time, Taneja et al. discovered foci of CUG transcripts within the nucleus of patient cells 
(Taneja et al., 1995). Subsequently, attention has focussed on binding interactions, both 
RNA secondary structure and RNA-protein interactions, and their possible effects in vivo.  
Timchenko et al. isolated two novel forms of a hetero-nuclear binding protein (hnRNP) 
(CUG)n triplet-repeat binding protein CUGBP1 and CUGBP2 and proposed that repeat 
expansion leads to sequestration of these hnRNPs on mutant transcripts (Timchenko et al., 
1996). Napierala and Krzyosiak demonstrated that expanded CUG transcripts formed 
stable duplex hairpin structures in vitro (Napierala et al., 1997). The RNA dominant 
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acts at the RNA level, by forming long dsRNAs that sequester certain RNA-binding 
proteins. CUGBP1 was shown to regulate alternative splicing of the human cardiac 
troponin T (cTnT) muscle fibre protein. In the embryo, exon5 of cTnT is included in the 
transcript whereas in the adult it is not. Splicing of cTnT was disrupted in DM1 striated 
muscle and in normal cells expressing transcripts that contained CUG repeats (Philips et 
al., 1998). CUG-BP1 levels and activity are increased in DM1 cells (Timchenko et al., 
2001). Exon-skipping or alternative splicing of the insulin receptor has also been shown to 
occur when CUGBP1 is over-expressed in normal cells, or when an expanded CUG repeat 
is expressed in normal cells (Savkur et al., 2001). As mentioned earlier, the symptoms of 
myotonic dystrophy include cardiac myopathy and insulin resistance. So, altered splicing 
of genes regulated post-transcriptionally by CUG-BP1 may play a pivotal role in DM1 
pathogenesis.  
Michalowski et al. tested the hairpin model. They demonstrated similar RNA secondary 
structure and found in vitro, that purified CUGBP1 bound to the hairpin base but not to the 
stem. In DM1 cells they found no change in the intracellular localisation of CUGBP1, and 
no association with nuclear foci concluding that sequestration of CUGBP1 was unlikely 
(Michalowski et al., 1999). This is not necessarily what happens in vivo however. In the 
cell, processes are dynamic, occurring within a complex assortment of proteins, substrates, 
and catalysts. As RNA in transcribed for instance, proteins may bind as the RNA is 
generated, before it has formed a secondary double-stranded structure. In this form CUG-
BP1 could bind. Preliminary research indicates this to be the case in that cytoplasmic RNA 
foci are associated with CUG-BP1 (Timchenko, unpublished). 
Miller et al. proposed that DM1 is caused by aberrant recruitment of triplet repeat 
expansion (EXP) proteins to the mutant DMPK repeat array, since in DM1 cells they 
accumulated in nuclear foci (Miller et al., 2000). EXP, activated during mammalian 
myoblast differentiation (Miller et al., 2000), is homologous to the Drosophila muscleblind 
proteins required for terminal differentiation of muscle and photoreceptor cells (Begemann 
et al., 1997). EXP proteins have since been renamed muscleblind-like (MBNL) of which 
there are three proteins in the human and mouse, MBNL1; 2 and 3 all of which co-localise 
with nuclear foci in DM1 and DM2 myoblasts (Fardaei et al., 2002). In humans, the 
expression pattern varies between tissues, with MBNL3 expression mostly confined to the 
placenta. MBNL2 expression is equally and abundantly expressed in tissues examined 
(pancreas; kidney; skeletal muscle; liver; lung; placenta; brain and heart) and MBNL1 is 
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is similar for MBNL2, low levels of MBNL3, and MBNL1 were expressed most highly in 
heart (Kanadia et al., 2003).  
With the discovery of aberrant splicing of the CLC-1 voltage-dependent chloride channel 
in DM1 patient skeletal muscle (Cooper et al., 2001), evidence was growing in favour of a 
splicing disorder. This channel is responsible for maintaining resting membrane potential 
(Bretag, 1987) and there is a direct relation of CLC-1 dysfunction to myotonia (Steinmeyer 
et al., 1991; Gronemeier et al., 1994), and myotonic disorders  such as autosomal dominant 
myotonia congenita (George et al., 1993) and the “myotonic mouse” (Gurnett et al., 1995). 
It has been reported that CUGBP1 belongs to a family of RNA binding proteins involved 
in the developmental regulation of alternative splicing (Ladd et al., 2001), but CUG-BP1 
did not co-localise with nuclear foci and as such was not a likely candidate for 
sequestration on the CUG repeat array. Attention therefore focused on the MBNL double-
stranded CUG binding proteins. The muscle and eye pathology and the RNA splicing 
defects of Clcn1 were recreated in a mouse model by disruption of the Mbnl1 gene. 
Myotonia and cataracts were amongst the symptoms, and Tnnt2 (cTnT) and TnnT3 splicing 
was also shown to be defective, as found in DM1 skeletal muscle (Kanadia et al., 2003). 
Further research has shown MBNL1 to developmentally regulate alternative splicing in 
genes some of which related to DM symptoms; such as the insulin receptor and cardiac 
troponin T (Ho et al., 2004; Dansithong et al., 2005), in a dynamic balance between itself 
and CUG-BP1 (Ladd et al., 2005). MBNL1 also regulates protein Tau, although the 
connection between disruption and DM1 pathology has not yet been resolved (Leroy et al., 
2006). 
Yet, sequestration of MBNL1 to foci may not be the cause. Ho et al. showed that the 
formation of foci and co-localisation of MBNL1 are separable events. They expressed 
expanded CAG or CUG repeats in DM1 myoblasts and found that both expansions 
aggregated into nuclear foci, and both expansions co-localised with MBNL1, but mis-
regulated splicing was seen only by expressing CUG repeats (Ho et al., 2005). Foci 
formation may not be the basis, but merely a marker of pathogenesis: It may even be 
protective. More recently a reversible mouse model of DM1 has been developed, 
employing controllable expression of the DMPK 3' UTR with and without expanded CTG 
repeats. Here the researchers were surprised to find that mice over-expressing a normal 
length repeat of 5 CUGs reproduced cardinal features of myotonic dystrophy, including 
myotonia; cardiac conduction abnormalities; histopathology and RNA splicing defects, but 
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detected in skeletal muscle, as seen in individuals with DM1 (Mahadevan et al., 2006). An 
expanded CUG repeat is known to produce a long single hairpin in vitro (Michalowski et 
al., 1999) and long CUG hairpins have been shown to induce dicer cleavage and RNAi 
knockdown of DMPK (Krol et al., 2007). Krol et al demonstrated that CNG hairpins are 
also formed in the triplet expansion disorders Huntington disease, and spinocerebellar 
ataxia type 1 and constitute another class of dicer targets, uncovering a previously 
unknown mechanism involving dicer-controlled down-regulation of mutant transcripts in 
the triplet repeat disease process. It is possible that dicer cleavage of CUG hairpins could 
release increased amounts of short CUG repeats into the cytoplasm increasing CUG-BP1 
levels as a result of titration by binding to the short repeat RNAs. In this case foci could be 
protective up to a point, preventing toxic short repeats from entering the cytoplasm via 
dicer cleavage, leading to elevated CUGBP1. MBNL1-associated foci were also found to 
lack pathogenic effect in Drosophila (Houseley et al., 2005). These accounts are consistent 
with the report of foci formation being separable from missplicing (Ho et al., 2005), since 
cleaved CAG repeats may not alter CUG-BP1 levels. MBNL1 disruption however, leads to 
muscle; eye and RNA splicing abnormalities characteristic of DM disease (Kanadia et al., 
2003), which is inconsistent with a protective role of MBNL1 sequestration. In this model 
however, symptoms only occur in the homozygote –a total functional knockdown is 
apparent, which does not truly replicate the disease state since in vivo there is a certain 
amount of association and disassociation of MBNL1 within foci (Ho et al., 2005). 
Could dicer CUG hairpin cleavage play a role in congenital DM? It has recently been 
reported that dicer is required for embryonic skeletal muscle development (O'Rourke J et 
al., 2007). In the congenital form the repeat tracts are lengthy and could reasonably be 
expected to deplete dicer reserves within the cell, affecting other miRNA-controlled 
functions such as myogenesis. 
1.1.6 Myotonic dystrophy type 2 
As mentioned earlier, not all cases of DM arise from DMPK associated CTG repeat 
expansions. The DM type 1 mutation accounts for 98% of myotonic dystrophy cases 
(Harper, 1989). Recently, a second mutation – myotonic dystrophy type 2 (DM2), was 
discovered, accounting for the majority of the remaining 2% of cases, caused by an 
uninterrupted CCTG expansion within the first intron of the cellular nucleic acid binding 
protein (CNBP) gene (Liquori et al., 2001), also known as ZNF9. Type 2 symptoms are 
almost identical to those of type 1. The notable distinctions are the lack of the congenital 
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developmental abnormalities and retardation (Day et al., 2003). In general, symptoms are 
less pronounced and occur later in life. It is not clear whether anticipation is present, but 
the length of repeat is much greater, ranging between 75 and 11,000 CCTG repeats 
(Liquori et al., 2001). 
Although expansions in CNBP cause DM-like symptoms, the affected gene product –a 
sterol regulated single stranded nucleic acid binding protein (Rajavashisth et al., 1989) is 
apparently unrelated to DMPK. The function is currently under intensive scrutinisation. 
Six of the seven fingers can be substituted into HIV1 nucleocapsid and support viral 
genomic RNA replication (McGrath et al., 2003). CNBP can bind to IRES (internal 
ribosome entry site) sequences and may stimulate cap independent translation as part of a 
ribonucleoprotein complex (Gerbasi et al., 2007). It is active throughout development, 
mediating neural crest expansion (Weiner et al., 2007) and regulating forebrain formation 
in the mouse (Shimizu et al., 2003). Mouse models homozygous for CNBP gene disruption 
are embryonic lethal, confirming an essential role in development. Interestingly, when 
heterozygous for CNBP gene disruption, mice demonstrate cardinal features of DM such 
as abnormal muscle histology; myotonic discharges and heart conduction defects, and a 
reduction in the levels of Clcn1 expression (Chen et al., 2007), suggesting that CBNP 
haploinsufficiency plays an important role in DM2 pathogenesis. However in DM2 
patients, CNBP levels are unaffected (Botta et al., 2006; Margolis et al., 2006). As a result, 
these seemingly conflicting reports suggest that even if haploinsufficiency of CNBP does 
cause a DM-like phenotype, it still may not actually make any contribution in DM2 
patients.  
The genes surrounding the DM2 mutation (KIAA1160, Rab 11B, glycoproteinIX, 
FLJ11631, and FLJ12057) do not bear any obvious similarities to those surrounding 
DMPK (Figure 2). It is therefore unlikely that any disruption of chromatin structure by the 
repeats, leading to altered regulation of neighbouring genes, would result in diseases with 
such remarkably similar features. Molecularly, parallels arise on inspection of the 
expanded RNAs. Both DM1 and DM2 transcripts are retained within the nucleus and co-
localise with MBNL1 (Mankodi et al., 2001; Fardaei et al., 2002). Similar splicing defects 
for the insulin receptor and the chloride channel are also observed between DM1 and DM2 
in muscle biopsies (Savkur et al., 2004; Botta et al., 2007), and also for microtubule 
associated protein Tau (Maurage et al., 2005). It would not be unreasonable then to 
hypothesise that sequestration of MBNL1, leading to alterations of the dynamics of CUG-
BP1 and MBNL1 regulation, is also pivotal to the mis-regulated splicing in DM2.  Christine Haworth    Chapter 1, 30 
 
1.1.7 Alternative splicing: Dynamic control by CUG-BP1 and 
MBNL1 
The cardiac troponin T gene is misspliced in myotonic dystrophy, the embryonic exon 5 
inappropriately included in the adult. In 1998, Philips et al. reported that in the chicken 
homologue (ccTNT), CUG-BP1 promoted inclusion by binding to muscle specific 
enhancers (MSE). Four enhancers were found to be essential for enhanced exon inclusion –
one upstream and three downstream of the exon. CUG-BP1 was found to specifically bind 
to a sequence containing CUGCUG, common to the human gene, within enhancers two 
and four. Using a human cTNT minigene system they determined that the CUG sequences 
were essential for exon inclusion (Philips et al., 1998). Ho et al. investigated the 
involvement of MBNL1 proteins and determined that they also regulated exon 5 alternative 
splicing in cTNT, and additionally, promoted exon 11 exclusion in the insulin receptor 
gene –another transcript misspliced in DM. In the cTNT gene, MBNL1 was found to bind 
to introns surrounding exon 5 in both chicken and in human. Two MBNL1 binding sites 
which affected splicing regulation were defined upstream of the human exon 5, a site 
distinct from the CUG-BP1 binding site. They also noted that in ccTNT, MBNL1 bound 
weakly to MSE1 (upstream) and strongly to MSE4 (downstream) where the CUG-BP1 
binding site is located, indicating antagonistic regulation with CUG-BP1 (Ho et al., 2004). 
CUG-BP1 is down-regulated in adult heart compared to the embryo, concomitant with 
exon 5 exclusion, and is also down-regulated in other tissues during development (Ladd et 
al., 2005). This suggests that competition between CUG-BP1 and MBNL1 for binding 
sites could be a plausible mechanism for developmentally regulated splicing. Recent work 
demonstrates that as little as 6 bases are sufficient for MBNL1 binding (Warf et al., 2007), 
via a structured GC-rich stem-loop containing pyrimidine mis-matches, in both normal 
splicing substrates and pathogenic RNA. Under the electron microscope MBNL1 forms a 
ring-like structure, which binds the double-stranded RNA stem. It is possible then that 
CUG and CCUG expansions may trap MBNL1 protein within stacked ring structures along 
the double-stranded hairpin (Warf et al., 2007; Yuan et al., 2007). 
It seems clear that alteration of the dynamic balance between CUG-BP1 and MBNL1 
splicing regulators causes inappropriate generation of foetal isoforms during adulthood. 
Some misspliced genes can be attributed to a symptom in both myotonic dystrophy type 1 
and type 2, although the association is not clear for some genes such as cardiac troponin T, 
or protein Tau. If the pathogenesis arises from an RNA gain of function, the differences 
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temporal or spatial expression patterns of the DMPK and CNBP genes themselves, to 
expression of the surrounding genes due to structural effects of the repeat, or to the specific 
function of DMPK and CNBP, separately or in combination. While each of the hypotheses 
addresses part of the pathogenesis, it is most likely that a number of complex mechanisms 
operate in concert, leading to the substantial clinical variability between patients. 
 
1.2 RNA processing disorders 
When the DM1 mutation was first discovered, it was expected that expansion of the CTG 
repeat tract would result in a simple loss of function of the DMPK gene product, perhaps 
by interference with transcription or translation. As research has evolved, evidence for a 
gain of function of the toxic RNA has become pivotal in understanding the pathogenesis in 
DM, to join a growing group of RNA processing disorders. Insights into the disease 
mechanism of other members of this group could shed light on the mechanism of DM 
pathology.  
1.2.1 Ocularpharyngeal muscular dystrophy 
Ocularpharyngeal muscular dystrophy (OPMD) is a progressive myopathy, which shares 
some characteristics of myotonic dystrophy, namely ptosis and dysphagia due to muscle 
weakness in the face and neck. Difficulty in swallowing can become so severe as to result 
in death by choking, aspiration pneumonia or malnutrition. Limb-girdle muscles are also 
affected to a lesser extent (Hill et al., 2001). Usually inherited as an autosomal dominant 
disease, OPMD is caused by the expansion of a GCG trinucleotide repeat within the coding 
region of the polyA binding protein 2 (PABP2) gene, leading to extension of an alanine 
stretch within the protein. Functionally, PABP2 binds with high affinity to the polyA tail 
of messenger RNA via a specific RNA binding domain and is involved in its 
polyadenylation, controlling adenylate addition to approximately 250 nucleotides (Wahle, 
1991; Wahle, 1995). PABP2 also has an oligomerisation domain, and expansion of the 
alanine stretch promotes atypical oligomerisation of the protein to form intranuclear 
inclusions in muscle cells: The inclusions, considered to be the pathological hallmark of 
the disease, comprise oligomerised PABP2 protein; mRNA and other RNA binding 
proteins (Fan et al., 2003), some of which have been identified. It is not clear as to whether 
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RNA traps, and their presence leads to apoptosis (Fan et al., 2001). In mouse models there 
is a close correlation with the presence of inclusions to pathology and that symptoms tend 
to be more severe with longer repeat lengths (Hino et al., 2004). Interference with 
aggregate formation reduces toxicity (Bao et al., 2002; Bao et al., 2004), but interference 
of oligomerisation domains of expanded PABP2 leads to their solublisation and a 
subsequent increase in toxicity implying inclusions may be protective (Messaed et al., 
2007). Inclusions are located in speckles –domains within the nucleus that are enriched in 
polyA+ RNA, splicing factors and other mRNA processing machinery that are thought to 
represent mRNA processing centres, and the nucleolus –sites of ribosome assembly. The 
mutant protein inhibits myogenesis in cell-culture where the expression of several muscle-
specific proteins, alpha actinin; muscle creatine kinase; myogenin and myoD is reduced 
(Wang et al., 2006). It is not clear why pathology is limited to muscle cells –since 
presumably PABP2 is ubiquitously expressed. Where this disease becomes particularly 
interesting in the context of DM1, is that CUG-BP1, a splicing regulator implicated in 
DM1 pathology, plays a role in deadenylation (Paillard et al., 2003; Moraes et al., 2006). 
Since in DM1 the concentration and activity of CUG-BP1 increases, it follows that 
deadenylation may increase. If in OPMD adenylation is disrupted, then both mutant 
mechanisms could result in short polyA tails, which would affect mRNA stability (Lewis 
et al., 1997; Cougot et al., 2004; Kuhn et al., 2004). Indeed, some characteristic symptoms 
–progressive myopathy, ptosis and dysphagia, are shared by both disorders. 
1.2.2 Spinal muscular atrophy 
Spinal muscular atrophy is a spliceopathy rather than a microsatellite repeat disorder. It is 
the second largest autosomal recessive cause of infant mortality after cystic fibrosis 
affecting 1:6,000-10,000 live births (Wirth, 2000). It comprises a group of neuromuscular 
disorders characterised by the selective destruction of α-motor neurons within the spinal 
cord leading to progressive muscle atrophy in the limbs and trunk. Life expectancy is 
reduced, and between individuals the disease severity is highly variable ranging from 
difficulty in standing, to becoming wheel chair bound. Severely affected infants often die 
from respiratory insufficiency by the age of two. 
On chromosome 5q, in normal DNA, there is an inverted duplication of a 500 kb element 
spanning at least four genes. The disease is caused by deletions of, or mutations in, the 
telomeric copy of one of these genes –the survival of motor neurone 1 gene (SMN1) 
(Lefebvre et al., 1995). The severity of the disorder is modified by expression of one or 
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for the primary mutation (Gavrilov et al., 1998; Vitali et al., 1999; Harada et al., 2002). 
Since SMN1 is ubiquitously expressed, it is thought that SMN2 expression can 
satisfactorily rescue the mutation in all tissues except motor neurones, although the reason 
for this is not clear. The centromeric copies are almost identical to the SMN1 gene except 
for a translationally silent C-T transition, which results in predominant exon 7 skipping 
(Lorson et al., 1999; Monani et al., 1999) creating defective oligomerisation within the 
resultant protein (Lorson et al., 1998).  
In eukaryotes, nuclear pre-mRNA splicing is essential for mRNA biogenesis, carried out 
by the spliceosome. In terms of function, the SMN1 protein forms part of a large 
macromolecular complex involved in the assembly of small nuclear ribonucleoproteins 
(snRNPs) –major components of the spliceosome. Although snRNPs have been shown to 
self associate from their component parts in an ATP independent manner (Sumpter et al., 
1992; Raker et al., 1996; Raker et al., 1999), recent research suggests that SMN1 complex 
is absolutely required for the efficiency and accuracy of snRNP assembly (Pellizzoni et al., 
2002), akin to the role of chaperones in protein folding. The molecular consequences of 
reduced levels of full-length SMN1 in motor neurones are not known, but may lead to the 
formation of aberrant snRNPs, which could contribute to the specificity and function of the 
spliceosome affecting downstream mRNA processing. There has been no association 
between the location of foci and the spliceosome in DM1 (Houseley et al., 2005), and no 
other evidence of spliceosomal involvement , therefore it is unlikely to contribute to DM 
pathogenesis. 
1.2.3 Fascioscapulohumeral muscular dystrophy 
Fascioscapulohumeral muscular dystrophy is the third most prevalent muscular dystrophy 
after the dystrophinopathies (including Duchenne and Becker muscular dystrophy) and 
myotonic dystrophy, affecting 1 in 20,000 of the population. There is a progressive loss of 
all skeletal muscle, with noticeable weakness usually starting with facial, scapular/back 
and upper arm muscles (Tyler et al., 1950). High frequency hearing loss and retinal 
abnormalities are also common associations (Gurwin et al., 1985). With patients ranging 
from asymptomatic to wheelchair bound, the clinical spectrum is highly variable, as is the 
age of onset, but most carriers of the mutation are symptomatic by their second decade. 
Genetically the mutation is autosomal dominant, and is associated with the deletion of a 
number of 3.2 Kb repeat units termed D4Z4 on chromosome 4q35 (van Deutekom et al., 
1993). The normal population carries 11-100 D4Z4 repeat units, but in affected individuals 
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severity of the disease: One to three repeats causes more severe symptoms (Lunt et al., 
1995; Tawil et al., 1996). Although the mutation was mapped to the region in 1993, the 
pathogenesis is not clear. The D4Z4 repeat units contain an open reading frame, DUX4, but 
expression of this gene has not been established. The mutation however is within a gene-
dense region and so the expression of flanking genes has been extensively studied. A 
repressor complex controlling upstream FRG1 transcription levels, binds to D4Z4 repeats 
(Gabellini et al., 2002), and so a deletion of these repeats could result in de-repression of 
the target gene, leading to increased expression levels. Recently Gabellini et al. generated 
transgenic mice over-expressing the human DUX4 flanking genes FRG2; FRG1 and ANT1 
in skeletal muscle. Those mice expressing FRG2 and ANT1 seemed normal, but those 
expressing FRG1 developed a muscular dystrophy with features characteristic of human 
FSHD (Gabellini et al., 2006). Fascinatingly, over-expression of FRG1 resulted in the 
missplicing of some genes also targeted in myotonic dystrophy, namely MTMR1 and 
TNNT3, but not CLC1. These results were corroborated in FSHD patient cell-cultures, and 
in mouse C2C12 muscle cells over expressing FRG1. The FRG1 protein is located in the 
nucleolus, cajal bodies and speckles (van Koningsbruggen et al., 2004), and so is predicted 
to be involved in RNA processing, perhaps as a component of the spliceosome. Recent 
research carried out to discover which proteins associated with FRG1, identified RNA 
biogenesis proteins SMN1 and PABP2 as binding partners, mutations in which are also 
associated with neuromuscular disorders (spinal muscular atrophy, see 1.2.2 and 
ocularpharyngeal muscular dystrophy, see 1.2.1) (van Koningsbruggen et al., 2007). 
Interestingly there is a link between adenylation factor PABP2 and FRG1, which initiated a 
literature search for any association of CUG-BP1 with FRG-1, but none was found. 
1.2.4 Fragile X syndrome and fragile X-associated tremor/ataxia 
Fragile X syndrome is the most prevalent heritable single gene form of mental retardation. 
Symptoms are broad, ranging from severe mental retardation and autism to those with a 
normal IQ, although these patients usually have some form of learning disability. Females 
tend to suffer less severe symptoms since the disorder is X-linked recessive. The mutation 
is caused by the expansion of a CGG triplet repeat within the 5’UTR of the fragile X 
mental retardation 1 gene (FMR1) and in the unaffected population the repeat tract varies 
between 5 and 44. Arrays greater than 200 are considered full mutation and give rise to 
fragile X syndrome, but the presence of 50-200 repeats –the premutation range gives rise 
to the neurodegenerative disorder fragile X-associated tremor/ataxia syndrome (FXTAS) 
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fragile X syndrome in that patients tend to be affected later in life rather than from 
childhood, with gait ataxia and intention tremor, and more variably parkinsonism and 
numbness in the lower extremities. Although the same mutation is causative in both fragile 
X syndrome and FXTAS, it is thought that pathogenesis follows two different mechanisms. 
Fragile X syndrome is clearly borne of protein deficiency due to silencing of the gene by 
methylation (Lim et al., 2005; Ladd et al., 2007), whereas in FXTAS, the gene is 
transcriptionally active with elevated levels and altered sites of initiation, suggesting a gain 
of function mechanism. Post mortem, ubiquitinated FMR1 mRNA-positive nuclear 
inclusions in cells of the central nervous system are the cardinal feature of FXTAS 
(Tassone et al., 2004). Other proteins identified from purified inclusions include the RNA 
binding proteins MBNL1 (instrumental in DM missplicing) and hnRNP A2 as well as heat 
shock proteins HSP27 and αB-crystallin, and neurofilament proteins –one of which is 
mutated in Charcot-Marie-Tooth disease of the axonal type (peripheral neuropathy) (De 
Sandre-Giovannoli et al., 2002).  
Recent research indicates that FMR protein effects microRNA-guided translational 
repression as part of the miRNP assembly by exchange of the complex-associated micro 
RNA for the target mRNA (Plante et al., 2006; Plante et al., 2006). Micro RNAs 
(miRNAs) are thought to translationally regulate ~30% of the genes in the human genome. 
They are borne from extensive processing of non-coding RNA, transcribed from 
endogenous miRNA genes; first to stem-loop double-stranded primer RNA by the 
microprocessor complex containing drosher, then to single-stranded miRNA by a complex 
containing dicer and transactivating response RNA-binding protein (TRBP). This complex 
associates with AGO2 to form the microribonucleoprotein (miRNP) or RNA induced 
silencing complex (RISC), which recognises the mRNA target, leading to cleavage if the 
miRNA is a perfect match, or transcriptional repression if not (Ouellet et al., 2006). It is 
thought that FMR1 is involved in post-transcriptional gene control. Micro CUG RNAs 
(21nt) have been detected in the total RNA of DM1 cells, so it is possible that DMPK is 
regulated by dicer (Krol et al., 2007). There is then a possibility that the expanded repeat 
also disrupts the post-transcriptional control of other genes in DM1 by disruption of the 
same process.  
1.2.5 Huntington disease-like 2 
Huntington disease-like 2 (HDL2) is an autosomal dominant progressive disorder almost 
indistinguishable from Huntington disease (HD). The diseases are characterized by 
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marked striatal atrophy and moderate cortical atrophy, and intranuclear inclusions. The 
inclusions in HDL2 are not huntingtin or junctophilin-3 (the affected gene in HDL2) 
positive however. Death occurs approximately 20 years after onset, which is usually the 
fourth decade, but longer repeat tracts elicit an earlier onset. Whereas HD is caused by the 
expansion of a CAG repeat leading to an extended polyglutamine repeat within the 
Huntingtin protein, the HDL2 CTG repeat is situated within the alternatively-spliced 
junctophilin-3 gene (JPH3), and manifests variably –in frame to code for polyalanine or 
polyleucine, or non-coding within the 3’UTR, the repeat region is removed from the full-
length transcript (Margolis et al., 2001). How the expansion in HDL2 leads to an almost 
identical phenotype to HD is unclear, but an RNA gain-of function mechanism seems 
likely. The HDL2 repeat is transcribed in the CTG orientation producing RNA foci that co-
localise with MBNL1. Missplicing is apparent in amyloid precursor protein (APP) and 
microtubule associated protein tau (MAPT) (Rudnicki et al., 2007). If MBNL1 depletion is 
involved in missplicing as in DM, the differences in target genes may relate to the 
expression pattern of JPH3 compared to DMPK. Myotonic dystrophy protein kinase is 
present at low levels in brain and high in heart, skeletal muscle and testis (Sarkar et al., 
2004). Junctophilin-3 is expressed at high levels in brain, is modest in testis and minimal 
elsewhere (Takeshima et al., 2000). 
1.2.6 Friedreich ataxia 
Friedreich ataxia (FRDA) is a progressive neurodegenerative disorder caused by an 
unstable GAA repeat expansion within intron 1 of the frataxin (FXN) gene (Campuzano et 
al., 1996). Symptoms include gait instability and general clumsiness, sensory loss and 
muscle weakness, and less often cardiomyopathy, scoliosis and diabetes (Geoffroy et al., 
1976). Onset varies between 5 and 25 years of age. Frataxin is a mitochondrial protein and 
current research suggests that loss of frataxin impairs mitochondrial iron handling and 
respiratory chain function contributing to increased oxidative stress and cell damage 
leading to spinal atrophy (Campuzano et al., 1997; Lodi et al., 1999; Bradley et al., 2000; 
Cavadini et al., 2002). The disease is recessive and point mutations are rare (2-4%), but 
can cause the disease (Puccio et al., 2000). It is thought that an expansion over 60 repeats 
allows the formation of “sticky” triplex DNA formation, which inhibits transcription of the 
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1.2.7 Spinocerebellar ataxias 8, 10 and 12 
The spinocerebellar ataxias (SCAs) encompass a large group of dominantly inherited 
progressive disorders in which the cerebellum slowly degenerates. Coordination of 
movement is generally affected involving gait, speech and hand and eye motor control, 
which deteriorates over time. Mental function is not affected. Spinocerebellar ataxias are 
grouped into three types; CAG repeat expansions encoding a polyglutamine stretch; non-
coding repeat expansions and non-repeat associated (deletion; missense; nonsense and 
splicing) mutations. SCA 8, 10 and 12 belong to the non-coding expansion group, although 
SCA 8 is now also associated with group 1 since recent research shows it is bi-
directionally transcribed resulting in a polyglutamine expansion in the ataxin 8 (ATXN8) 
gene, and a complementary mRNA ataxin 8 opposite strand (ATXN8OS) containing an 
untranslated CUG expansion (Moseley et al., 2006). Moseley et al. generated a successful 
transgenic SCA8 mouse model by expressing the human ATXN8OS gene with 116 CTG 
repeats, demonstrating the pathogenicity of the CUG repeats. Little is known about the 
function of the ATXN8OS gene, but in light of these results, an RNA mediated gain of 
function mechanism is still likely.  
The SCA 10 mutation consists of an expanded ATTCT repeat within exon 9 of the 
ATXN10 gene, expressed in brain. Little is known about the function ATXN10, but in 
SCA10 patient-derived cell-lines, transcription levels are normal and the RNA is correctly 
processed. Mouse models null for the gene do not survive embryogenesis in the 
homozygotes, and heterozygotes show no phenotype (Wakamiya et al., 2006) indicating 
that a simple loss or gain of function of the protein is doubtful. 
The SCA12 CAG repeat is located within exon 7 of the PPP2R2B gene (Holmes et al., 
1999), which encodes a brain-specific regulatory subunit Bβ of the ubiquitous PP2A 
phosphatase (Mayer et al., 1991). This gene is alternatively spliced, the different isoforms 
determining substrate specificity and subcellular localisation. The disease pathogenesis has 
not yet been established, but no evidence that SCA12 is a polyglutamine disease has been 
found. Expansions were not detected in western blots of patient derived cell-lines or in 
SCA12 brains (Holmes, 2003). Research by Holmes et al. suggests that the mutation 
increases expression levels of the predominant Bβ isoforms (Bβ1), which use the exon 7 
alternative promoter, perhaps shifting PP2A target specificity (Holmes, 2000). 
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1.3 Transgenic mouse models of myotonic dystrophy 
Many mouse models have been generated to further understand the progression of disease 
in myotonic dystrophy. Not all models have been created with pathogenesis in mind -a 
large amount of research has focussed on the repeat expansion and instability. Published 
DM1-related mouse model data is compared here from a pathogenesis perspective. The 
transgenes are summarised in Figure 3. 
1.3.1 Gene deficiency and over-expression models 
These models have already been discussed in relation to the pathogenesis of DM1 in 
Pathogenesis 1.1.5, but to recap: Of the gene disruption models, transgenic mice deficient 
in DMPK (Dm15 or Dmpk gene in mice) did not show significant myopathy, but have 
shown cardiac conduction abnormalities (Reddy et al., 1996; Berul et al., 2000). Mice 
lacking the adjacent Six5 gene developed cataracts with either heterozygous or 
homozygous loss, but of a different type, not posterior subcapsular iridescent cataracts, 
(Klesert et al., 2000; Sarkar et al., 2000). MBNL1 disruption in contrast, lead to muscle, 
eye and RNA splicing abnormalities characteristic of DM disease (Kanadia et al., 2003). 
Transgenic mice over-expressing CUG-BP1 in muscle and heart also replicated DM1-like 
features in these tissues, including abnormal muscle histology and disrupted splicing (Ho 
et al., 2005). None of these single gene disruption models mimic the complete 
multisystemic phenotype of the disease including the congenital form in DM1. However, 
both the MBNL1 deficiency and CUG-BP1 over-expression models are consistent with a 
mechanism for DM pathogenesis in which expanded repeats result in alteration in the 
dynamic balance between MBNL1 and CUG-BP1, and have trans-dominant effects on 
specific pre-mRNA targets. 
1.3.2 Expressed transgenes 
If the phenotype of myotonic dystrophy results from a gain of function of the mutant 
DMPK transcript, one would expect that the mouse models generated to date would reflect 
this. Not all models were specifically created to answer pathogenesis hypotheses, so 
analysis of the models in this way is slightly hampered by the fact that the researchers who 
created them tended to concentrate on either the mechanism of repeat expansion or the 
mechanism of pathogenesis, and publish accordingly. Of the mouse models, some 
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Gourdon et al. 1997: The DM1 region including upstream DMWD and downstream SIX5 
was used for this transgenic model. Fifty-five CTG repeats are present within the DMPK 
3’UTR and all three genes are expressed at wild type levels. Although the repeat tract was 
found to be unstable, no phenotype was observed. The same research group then produced 
mice using the same region with 20 repeats in the normal line or 300 repeats for the 
expanded line (Seznec et al., 2000). The levels of CTG expression were again found to be 
consistent with wild type levels. There was no phenotype observed with 20 repeats, but 
with 300 repeats, mice displayed clinical, histological, molecular and electrophysiological 
abnormalities in skeletal muscle consistent with those observed in DM1 patients. 
Abnormal tau expression was also observed in the brain. In addition, mice had crossed 
teeth, perhaps indicating a weakness in the jaw musculature. A proportion of offspring 
expressing sufficient mRNA exhibited myotonia (Seznec et al., 2001) An abnormal 
glucose and insulin response was evident in the expanded repeat mice and molecularly, 
tissue and age-dependent abnormal regulation of IR mRNA splicing was found in skeletal 
muscles, adipose tissue, liver and pancreas (Guiraud-Dogan et al., 2007). 
Jansen et al. 1996, restricted the DM1 region used for their mice to the last exon of 
DMWD and the DMPK gene, which included 20 CTG repeats within the 3’UTR. DMPK 
levels were altered between 0 to 10 fold depending on the line, due to multicopy 
integration. Offspring suffered high pre and neonatal mortality, as high as 50% in Tg 
positive mice through female transmission, where the females themselves often became 
sick and occasionally died, and 20% mortality when transmitted through the male 
germline. Mice developed cardiac hypertrophy, but no DM-like pathology or phenotype 
was detected. O’Cochlain et al. analysed mice expressing 26 copies of the human DMPK 
gene with 11 CTG repeats. The mice exhibited hypertrophic cardiomyopathy with 
dysrhythmia, myotonic myopathy and hypotension, all distinctive muscle traits of DM1 
(O'Cochlain et al., 2004). 
In their mouse model, Monckton et al. 1998, reduced the region still further, to the 
DMPK 3’UTR that contained 162 repeats. Transcription was directed from the EF1α 
promoter. They reported myotonia in three of four lines at 2 years of age. The mice also 
suffered ataxia, testicular atrophy and infertility so severe as to lose the lines (Monckton, 
1998). 
Mankodi et al. 2000, included 5 and 250 CTG repeats within the 3’UTR of a gene 
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promoter to skeletal muscle. In the 250 CTG repeat, but not the 5 CTG repeat mice 
myotonia was present from four weeks before muscle pathology was histologically 
defined, and transcripts were retained in the nucleus within discrete foci. 
Mankodi et al., 2000, Seznec et al. 2000 (Figure 3) and Monckton et al. (unpublished, 
personal communication) have communicated findings of myotonia and other aspects of 
DM pathology in their mice. Clearly in these examples, mice expressing CTG repeats with 
expansions of 162 repeats and above exhibit DM-related symptoms, including the hallmark 
myotonia. None of the other mouse lines presented myotonia, perhaps either because the 
repeat expansion was insufficient to cause disease within the lifetime of the mouse 
(Gourdon et al., 1997, 55 repeats), or expression levels were insufficient due to transgene 
positional effects. The most interesting model here is that of Mankodi et al. 2000, since 
myotonia was reproduced in mice simply by expressing a modified human skeletal actin 
gene containing 250 CTG repeats within the 3’ UTR. The repeat sequence comprised a 
dimerised (CTG)130 fragment devoid of flanking sequences from the DM1 region 
(Mankodi et al., 2000). Over-expression of MBNL1 in the same transgenic line rescued the 
pathogenic effect: Skeletal muscle from the HSA
LR transgenic mouse line was subjected to 
in vivo mediated transduction with a recombinant adeno-associated viral vector over-
expressing MBNL1, which rescued the myotonia. This reversal occurred concurrently with 
restoration of the normal adult-splicing patterns of four pre-mRNAs misspliced in DM 
muscle (Clcn1, Cypher, Serca1 and Tnnt3) (Kanadia et al., 2006): Strong evidence for the 
MBNL1 depletion hypothesis. 
Removal of toxic RNA was also shown to alleviate DM-like symptoms in an inducible 
mouse model of DM1, an important finding indicating that in the future, treatment of DM 
may become a possibility. Mahadevan et al. produced a tet responsive GFP reporter 
flanked by the DMPK 5’ UTR, and the DMPK 3’UTR containing 5 or 200 CTG repeats. 
Induction of expression resulted in a major phenotype in the 5 repeat mice a few days after 
induction, and after nine months without induction due to a leaky promoter. Although foci 
were seen in the 200 repeat mice, no phenotype was observed probably because expression 
was too low. Cessation of transcription restored function and splicing anomalies. As with 
the HSA-(CTG)5/200 model (Mankodi et al., 2000), no DMPK protein was expressed 
giving clear delineation of the contribution of DMPK 5’ and 3’UTR mRNA to DM 
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Figure 3 Transgenic mouse models of myotonic dystrophy. Schematic diagram summarising 
the transgenes used, and a brief description of the phenotype produced. Notably DM like 
symptoms only arise on the expression of large repeats, the deficiency of MBNL or the over-
expression of CUG-BP1. Abbreviations: EF1α , elongation factor 1α promoter; HSA, human 
skeletal actin, and see figure 1 legend. N.B. The listed phenotypic effects are not exhaustive, in 
cases where research groups primarily focus on instability, the phenotype has often not been 
stated. 
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1.4 Project outline  
Myotonic dystrophy type 1 is a multisystemic disease caused essentially by the 
dysregulated splicing of MBNL1 and CUG-BP1 pre-mRNA targets, some whose function 
can be directly related to a clinical feature, such as the chloride channel to myotonia, or the 
insulin receptor to diabetes. Many symptoms nevertheless have yet resisted explanation: 
Cataracts, testicular atrophy, heart block, anaesthetic sensitivity and mental retardation for 
example. The purpose of this thesis is to increase understanding of the gain of function 
hypothesis –the pathogenesis of an expressed expanded CUG repeat tract, within multiple 
organ systems using both in vivo and in vitro approaches. To delineate cause and effect, we 
attempted to use the Cre-lox system for the conditional expression of an expanded CTG 
repeat in the mouse, to mimic the pathogenesis of myotonic dystrophy type 1 with 
temporal and spatial control. We successfully generated a 5 repeat transgenic line, but not 
an expanded repeat line. The constructs generated were validated in vitro, and formed the 
basis of a cell-culture model, which reproduced the pathogenic marker of DM1, 
MBNL1-associated foci. This culture system was then used to identify further genes 
possibly misspliced in DM1, by comparing the effects of repeat expression on downstream 
RNA processing, using differential expression and alternative exon microarray analysis. 
The pore-forming unit of the cardiac L-type calcium channel (Cacna1c) was identified as a 
candidate gene, mutations in which are known to cause conduction defects identical to 
those observed in myotonic dystrophy type 1.Christine Haworth    Chapter 2, 44 
 
2  Materials and methods 
 
2.1 Materials 
All chemicals, molecular biology reagents, disposable tissue culture plastics, enzymes and 
kits used during the duration of this project were obtained from standard suppliers, such as 
Biorad, Fisher Scientific, Invitrogen, New England Biolabs, Pierce, Promega, Merck Ltd., 
Qiagen, and Sigma unless otherwise stated. 
2.1.1 Tissue culture disposable materials 
Tissue culture disposable plastic materials are listed in Table 2.1 below. 
Table 2.1. Tissue culture materials and suppliers. 
Disposable Materials  Supplier 
100 and 35 mm polystyrene tissue culture dishes  Corning 
25 tissue culture flasks  Costar and Iwaki 
5, 10 and 25 ml pipettes  Corning 
6 and 96-well tissue culture microplates  Iwaki 
60 x 15 mm polystyrene tissue culture dishes  Corning 
75 and 150 cm
2 tissue culture flasks  Iwaki 
Cell scrapers  Sigma 
Cryo 1°C freezing container  Nalgene 
8-well chamber glass slides  Nalge Nunc 
15 and 50 ml Falcon Tubes  Corning 
 
2.1.2 Size markers 
For DNA, 1Kb+ ladder from Invitrogen was used throughout unless otherwise stated. For 
protein, Seeblue prestained molecular weight markers (also Invitrogen) were used. 
2.1.3 Constructs 
The GFP/MBNL fusion construct was kindly donated by Marion Hamshere of the Institute 
of Genetics, University of Nottingham (Fardaei et al., 2001). Christine Haworth    Chapter 2, 45 
 
 pCre (aka pCAGGS-nls-CRE) was kindly donated by Andras Nagy of the Samuel 
Lunenfeld Research Institute, Toronto. 
2.1.4 Kits 
Reagents used throughout this project in kit form are listed in Table 2. 
Table 2 
Kit  Manufacturer 
Qiaprep spin miniprep kit  Qiagen 
Endofree maxiprep kit  Qiagen 
RNeasy mini kit  Qiagen 
DNeasy BLOOD AND TISSUE  KIT  Qiagen 
Supersignal west pico chemiluminescent substrate kit  Pierce 
ECL+ chemiluminescence detection system  Amersham Biosciences 
PGEM T-easy vector system  Promega 
Ready-to-go DNA labelling beads (-dCTP)  Amersham Biosciences 
Nucleon  BACC kit  Nucleon 
CelLytic NuCLEAR extraction kit  Sigma 
 
2.1.5 Microscopy and photography 
A Nikon TNS phase contrast microscope and a Zeiss Axiovert S100 fluorescence 
microscope were used routinely during the course of this project. Other items of equipment 
used throughout this project are listed in Table 3. 
Table 3 
Equipment  Manufacturer 
Axiovert 100S Fluorescent microscope  Zeiss 
Filter sets: 
   EGFP: FITC filter set number 9 
 
Zeiss 
   Cy3: Rhodamine filter set number 15  Zeiss 
   DAPI, AMCA and Alexafluor 350: DAPI filter set number 2  Zeiss 
Axiophot II with Axiocam digital imaging system  Zeiss 
UVP gel documentation system 7500  UVP 
EOS 300 SLR  Canon 
400ASA colour negative film  Kodak 
EOS 350D Digital SLR  Canon Christine Haworth    Chapter 2, 46 
 
LSM 510 Meta confocal imaging system  Zeiss 
X-ray film  Konica and Kodak 
 
2.1.6 Membranes and miscellaneous 
Hybond N+ was obtained from Amersham Pharmacia Biotech, Immobilon P PVDF 
membrane from Millipore, and Na-45 paper from Schleicher and Schulell. Schleicher & 
Schuell also supplied gel blotting paper. Saran wrap was obtained from Dow. 
Snakeskin™ dialysis tubing was obtained from Pierce. 
Precast Nupage 4-12% bis-Tris polyacrylamide gels were supplied by Invitrogen.  
Calibrite beads used to test FACS recovery modes, were manufactured by BD Biosciences. 
2.1.7 Cell-lines and bacterial hosts 
Cell-lines and bacterial hosts are listed in Table 4. 
Table 4 
Cell-line/Strain  Description 
   
Mammalian: 
Cos-7 
 
African green monkey, kidney 
HeLa  Human, epithelial, fibroblast 
DmtD  Kidney cell-line derived from DM transgenic mouse model Dmt162 
(Monckton et al., 1997, see figure 3 for transgene)  
3T3  Murine embryonic fibroblast, J2 
CGR8.8  ES cell-line derived from strain 129/Ola 
DM1 fibroblast  DM1 fibroblast cells lines donated by J.D. Brook, University of Nottingham 
   
Bacterial: 
Top10f’ 
 
F´[lacIq Tn10 (TetR)] mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(ara-leu)7697 galU galK rpsL endA1 nupG 
 
JM109  F′ [traD36 proABlacIqZΔM15] e14-(McrA-) recA1 endA1 gyrA96 thi-1 
hsdR17(rK- mK+) supE44 relA1Δ(lac-proAB)  
 
DH5α  F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rk-, Christine Haworth    Chapter 2, 47 
 
mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1  
 
Stbl2 (for 
information –not 
used) 
F-, mcrA Δ(mcrBC-hsdRMS-mrr) recA1 endA1 lon gyrA96 thi supE44 relA1 
Δ(lac-proAB) 
   
 
2.1.8 Antibodies 
Antibodies used throughout this project are listed in Table 5. 
Table 5 
Antibody    Supplier 
     
Mouse anti vimentin  530513  Pharmingen 
Rabbit anti EXP42 (MBNL1)  Polyclonal  Maurice Swanson* 
Mouse anti MBNL1  MCA-MBNL  Universal Biologicals 
Mouse anti CUG-BP1  Clone 3B1  Abcam 
FITC conjugated rabbit anti GFP  Ab6662-100  Abcam 
AMCA conjugated anti-rabbit  111-156-003  Stratech 
Alexafluor350 conjugated anti-rabbit  A-21062  Molecular probes 
FITC conjugated anti-mouse  Ab50084  Abcam 
HRP-conjugated anti mouse  115-035-003  Stratech 
     
*Miller et al., 2000. 
2.1.9 Equipment 
Equipment used throughout this project is listed in Table 6. 
Table 6 
Model  Manudacturer 
   
FacsCalibur  BD Biosciences 
Genepulser II  Biorad 
37ºC Humidified tissue culture incubator  Sanyo 
X-cell II gel system  Invitrogen 
Novex blot module  Invitrogen 
DU 530 UV/Vis spectrophotometer  Beckman Christine Haworth    Chapter 2, 48 
 
Nanodrop ND-1000 UV/Vis spectrophotometer  Thermo Fisher Scientific 
Biometra Uno II thermal cycler  Biometra 
Agilent 2100 Bioanalyser  Agilent Technologies 
   
 
2.1.10  Solutions 
2.1.10.1  General 
Solutions were made up as described in (Sambrook et al., 1989). 
0.5 M EDTA pH 8.0 
0.5 M EDTA with NaOH to pH 8.0. 
 
1 kb+ ladder 
60 ng/µl 1 kb ladder, 1X DNA loading dye in 1X TBE. 
 
1 M Tris•HCl pH 8.0 
1 M Trizma base and HCl to pH 8.0. 
 
10 mg/ml BSA 
10 mg/ml (w/v) in 18Ω milliQ water. 
 
10% (w/v) SDS 
10% (w/v) SDS in H2O. 
 
100 X Denhardt’s solution 
2% (w/v) Ficoll
®400, 2% (w/v) polyvinylpyrolidone, 2% (w/v) BSA. 
 
10X DNA loading dye 
50% (w/v) Glycerol, 0.25% (w/v) xylene cyanol, 0.25% (w/v) bromophenol blue. 
 
1X TBE 
90 mM Trizma base, 90 mM orthoboric acid, 2 mM EDTA. 
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1X TBST 
20 mM Tris•Cl pH7.6, 137 mM NaCl, 0.06% Tween-20. 
 
1X TBSTM2.5 
1 X TBST, 2.5% w/v Marvel skimmed milk powder. 
 
1X TBSTM5 
1 X TBST, 5% w/v Marvel skimmed milk powder. 
 
2 X RNA loading Dye 
5 X DNA loading dye and 0.4% SDS in DEPC-treated water. 
 
2.5 kb molecular ruler 
333 ng/µl of 2.5 kb molecular ruler, 1X TE, 1X Orange G loading dye. 
 
20X SSC 
3.0 M NaCl, 0.3 M sodium citrate. 
 
20X SSPE 
3.0 M NaCl, 0.2 M NaH2PO4, 20 mM EDTA, pH 8.0. 
 
3 M Sodium acetate pH 5.2 
3 M sodium acetate, pH 5.2 
 
3% H2O2 
3% (v/v) H2O2. 
 
4% Paraformaldehyde 
4% Paraformaldehyde (w/v) in PBS-MgCl2. 
 
5X Orange G loading dye 
0.06 % (w/v) Orange G, 50 % (v/v) glycerol in H2O. 
 
70% (v/v) Ethanol 
70% (v/v) absolute ethanol in H2O. Christine Haworth    Chapter 2, 50 
 
75% (v/v) Ethanol 
75% (v/v) absolute ethanol in H2O. 
 
80% (v/v) Ethanol 
80 % (v/v) absolute ethanol in H2O. 
 
DAPI  
10ng/µl in Vectashield mounting medium (Vector Laboratories).  
 
Denaturing solution 
0.5 M NaOH, 1.5 M NaCl in H2O. 
 
Depurinating solution 
0.25 M HCl in H2O. 
 
dNTP 
Equal molar amounts of dATP; dGTP; dCTP and dTTP. 
 
Ethidium bromide 
Stock solution: 25 mM in H2O. 
 
Guanidinium thiocyanate, 1M 
0.118g/ml (w/v) in DEPC treated water. 
 
Injection buffer 
10mM Tris; 0.1mM EDTA prepared by diluting 1M Tris.Cl Ph7.4 and 500mM EDTA 
(Sigma) with 18Ω MilliQ water. This was sterilised with a 2 micron syringe and filter. 
 
Lysis buffer 
50 mM Tris•HCl pH 8.0, 100 mM EDTA pH 8.0, 0.5% (w/v) SDS in H2O. 
 
Neutralising solution 
1.5 M NaCl, 0.5 M Trizma base and HCl to pH 7.5. 
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PBS 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 2 mM KH2PO4, pH 7.4. 
 
PBS-MgCl2 
PBS, 5mM MgCl2, pH 7.4. 
 
PBST 
PBS; 0.1% Triton X-100 
 
Phenol 
Phenol saturated with 10 mM Tris pH 8.0, 1 mM EDTA.  
 
Phenol:chloroform:isomayl alcohol, 25:24:1 
Phenol:chloroform:isomayl alcohol, 25:24:1, saturated with 10 mM Tris pH 8.0, 1 mM 
EDTA. 
 
Proteinase K 
Stock solution: 20 mg/ml proteinase K in filter sterilised 50 mM Tris•HCl pH 8.0. 
 
RNA in situ buffer 
40% v/v formamide, 1mM DTT, 1mg/ml E.coli tRNA, 1mg/ml sonicated salmon sperm 
DNA, 10% dextran sulphate, 0.2% BSA, 2X SSC. 
 
Southern blot hybridisation solution 
7% (w/v) SDS, 1M NaPO4, 2 mM EDTA. 
 
TAE 
40 mM Tris•acetate, 1 mM EDTA in H2O. 
 
TE 
10 mM Tris•HCl pH 8.0, 1 mM EDTA pH 8.0 in H2O. 
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2.1.10.2  Bacterial culture 
Bacterial cultures were grown in LB supplemented with the appropriate antibiotic 
overnight with shaking. Colonies were grown on LB agar plates with the appropriate 
antibiotic, X-gal and/or IPTG as stated, inverted, overnight at 37ºC.  
Ampicillin 
Stock solution: 50 mg/ml (w/v) in H2O. 
Working solution 50µg/ml. 
 
IPTG 
Stock solution: 100 mg/ml (w/v) in H2O.  
Working solution 10µg/ml. 
 
Luria-Bertani (LB) medium 
3% (w/v) Bacto
® tryptone, 0.5% (w/v) Bacto
® yeast extract, 1% (w/v) NaCl. 
LB agar contained 1.5% (w/v) agar. 
 
SOB medium 
2% (w/v) Bacto
® tryptone, 0.5% (w/v) Bacto
® yeast extract, 0.85 mM NaCl, 0.25 mM KCl 
pH 7.0 with NaOH. Sterilized 10 mM MgSO4 added prior to use. 
 
SOC medium 
0.04% (w/v) glucose in SOB medium. 
 
X-gal 
Stock solution: 50mg/ml (w/v) in dimethylformamide. 
Working concentration: 50 µg/ml. 
 
2.1.10.3  Cell culture  
Tissue culture media such as DMEM, GMEM and Opti-MEM, serum, antibiotics, ESGRO 
and solutions were obtained from Invitrogen or Sigma. 
2.1.10.3.1  General 
Culture medium 
1 X DMEM; 1 X penicillin and streptomycin solution; 1 X non-essential amino acids; 10% 
foetal bovine serum. 
 
Trypsin/EDTA solution 
Stock solution: 5.0 g/l trypsin, 2.0 g/l EDTA, 8.5 g/l NaCl (stored at -20°C). 
Working concentration: 0.5 g trypsin, 0.2 g EDTA•4Na/l in PBS. 
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Stock solution: 10,000 U/ml penicillin, 10,000 µg/ml streptomycin. Penicillin G (sodium 
salt) and streptomycin sulphate in PBS. 
 
10X Dulbecco’s phosphate buffered saline (PBS) 
136 mM NaCl, 26mM KCl, 15mM KH2PO4, 8mM Na2HPO4•7H2O. 
 
Foetal bovine serum (FBS) 
Origin E.C. Virus and mycoplasma tested. 
 
Gancyclovir 
2 mg/ml (w/v) in distilled water. 
 
G418 
50 mg/ml (w/v) disulphide salt solution (Sigma). 
 
 
2.1.10.3.2  ES cells 
Culture medium 
1X GMEM, 0.25% sodium bicarbonate, 1 X non-essential amino acids, 1X sodium 
pyruvate, 1X glutamax, 1X penicillin and streptomycin solution, 1% β mercaptoethanol, 5 
X 10
6 U leukaemia inhibitory factor (ESGRO).  
 
G418, 50 mg/ml 
Powder 1g (w/v). Filter sterilised (0.2 µM). 
 
TVP 
0.025% trypsin, 1% chicken serum, 1 mM EDTA, in PBS 
 
Foetal bovine serum (FBS), heat inactivated 
Origin E.C. Virus and mycoplasma tested, Heat inactivated. Batch tested for ES cell 
plating efficiency and colony morphology. 
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2.2 DNA methods 
2.2.1 Preparation of plasmid DNA 
For ES cell electroporation and some microinjections, plasmid DNA was isolated from 
their bacterial hosts by standard alkaline lysis followed by CsCl purification (Sambrook et 
al., 1989). All other plasmid DNA was isolated using commercially available kits as 
directed by the manufacturer: Qiaquick Spin Miniprep kits (50µl distilled water used for 
elution) were used to obtain DNA for cloning and restriction analysis and Qiagen Endo-
free Maxi prep kits were used to for the other microinjections and cell transfection.  
2.2.2 Purification of DNA  
After restriction digest, DNA was purified by electrophoresis through an appropriate 
concentration of Seakem agarose containing 15µg/ml Ethidium Bromide in 0.5 X TBE. 
The DNA fragment was retrieved in the following ways depending on the final use. 
2.2.2.1  Transfection into cultured cells 
The fragment was electrophoresed onto Na45 paper (Scleicher & Schuell), and eluted as 
directed by the manufacturer. 
2.2.2.2  Pronuclear injection 
The fragment was electrophoresed onto Na45 paper (Scleicher & Schuell), and eluted as 
directed by the manufacturer. 
Or the fragment was excised from the gel and eluted by electrophoresis into 0.5 X TBE in 
dialysis tubing. The buffer containing the DNA was applied to an Elutip-d DEAE sephacell 
column (Scleicher & Schuell) and the DNA collected as described by the manufacturer.  
Regardless of the purification method, DNA was diluted to the required concentration 
using injection buffer. Debris was removed by centrifugation at 14,000 rpm in a microfuge. 
The top 75% of the solution was transferred to a new tube and the remainder discarded.  
2.2.3 DNA extraction from cultured cells 
DNA was prepared using a Nucleon or Qiagen blood and tissue kit as directed by the 
manufacturer. Christine Haworth    Chapter 2, 55 
 
2.2.4 Preparation of mouse tail lysates 
Half to one centimetre of tail tip was placed in a 1.5 ml screw top eppendorf tube with 550 
µl of lysis buffer and 15 µl of 20 mg/ml of proteinase K. The tissue was incubated 
overnight at 60°C. The lysate was vortexed briefly and centrifuged at 21,000 g for 5 
minutes to pellet the debris. The supernatant was transferred to a fresh tube and stored at 
4°C. One to two µl were used in a 10µl PCR. 
If PCRs during genotyping failed, the DNA was further purified. The supernatant (250 µl) 
was transferred into a fresh tube and an equal volume of phenol added and mixed 
vigorously by vortexing for 5 seconds. The mixture was centrifuged for 5 minutes at 
21,000 g to separate the two phases. The upper phase was placed into a clean tube, and 250 
µl of phenol:chloroform:isoamyl alcohol (25:24:1) was added and mixed vigorously by 
vortexing for 5 seconds. The mixture was centrifuged for 5 minutes at 21,000 g. The upper 
phase was removed and transferred into a clean tube. In order to remove any remaining 
traces of phenol, 250 µl of chloroform were added and vortexed for 5 seconds, followed by 
centrifugation for 5 minutes at 21,000 g. The upper aqueous phase was removed and 
transferred into a clean tube, and 25 µl of 3 M sodium acetate pH 5.2 was added and mixed 
briefly by inverting the tube 5 to 10 times. The DNA was finally precipitated by the 
addition of 500 µl of ice-cold absolute ethanol, followed by incubation at –20°C for at least 
1 hour, and 30 minutes centrifugation at 21,000 g in a bench top centrifuge. The 
supernatant was decanted off, the pellet rinsed with 1 ml of ice-cold 80% (v/v) ethanol, and 
the precipitate collected by centrifugation at 21,000 g in a bench top centrifuge. The DNA 
pellet was either air dried at room temperature for 30 to 60 minutes, or at 4°C overnight. 
Once dried, the DNA pellet was dissolved in 100 to 200 µl of TE at 60°C for 30 minutes, 
or at 37°C overnight. 
2.2.5 Determination of DNA concentration 
DNA samples were diluted 1:100 in H2O and the spectrophotometer baseline corrected 
with H2O. The OD was measured and the concentration calculated as 100 x 50 x OD260 
mg/ml. The purity was checked using the 260/280 ratio, which for DNA should 
approximate 1.8. 
Alternatively, DNA concentrations were determined by electrophoresis on agarose gels, 
followed by densitometry estimation against low molecular weight DNA mass ladder 
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2.2.6 Oligonucleotides and PCR 
The oligonucleotides used in this project were synthesised by Genosys and supplied 
desalted, except for the LoxP-EGFP and LoxP-Neo forward primers, which were HPLC 
purified. Fluorescent primers were purified by PAGE.  
2.2.6.1  Primer pairs used for construct sequences 
Forward and reverse primer sets used to generate DNA fragments for cloning into the 
founder and targeting constructs are detailed in Table 7. 
Table 7 
Sequence  Forward and Reverse Primer Sequences  Template DNA 
     
LoxP-EGFP  5’-CACGTAGTGATAACTTCGTATAGCATACATTATA
CGAAGTTATGTCGCCACCATGGTGAG-3’ 
5’-GGATCCTCTAGAAGCTCTAGGCTCGAGTTACTT
GTACAGC-3’ 
pIRES-EGFP 
LoxP-Neo  5’-GCTAGCATAACTTCGTATAGCATACATTATACG
AAGTTATAGAGCCACCATGATTGAACA-3’ 
5’ GCGGCCGCTCAGAAGAACTCGTC-3’ 
pCIneo 
ERDA  5’-GGATCCTGCATGCATCATATGTTGCTTTTC-3’ 
5’-TCTAGACCTTCCTTCCACCTTATTTTTC-3’ 
Human genomic 
DNA 
DM repeat 
region 
Round1 (DM-A) 
5’-AGTGCAGTTCACAACCGCTCCGAGC-3’ 
Round 1 (DM-BR) 
5’-GTGGAGGATGGAACACGGAC-3’ 
Round 2 (XhoI DM-H) 
5’-CTCGAGTCTCCGCCCAGCTCCAGTCC-3’ 
Round 2 (EcoRI DM-BR) 
5’
-GAATTCGTGGAGGATGGAACACGGAC-3’ 
Patient sample 
numbers: 
175 1001; 101 
5053; 137 3666 
BGH PolyA  5’-GAATTCAGCTCGCTGATCAGCCTC-3’ 
5’-GGATCCCCAGCTGGTTCTTTCC-3’ 
pIRES-EGFP 
Thymidine 
Kinase 
5’-GCCTTGTCGACGCCACCATGGCTTCGTACC-3’ 
5’- GAATTCTCAGTTAGCCTCCCCCATCTC-3’ 
HSV UL97 gene 
PGK 
Promoter 
Isolated on a 500bp TaqI restriction fragment, with 
filled in recessed termini. 
pPNT 
Neo cassette  The XhoI site was removed from pPNT (this was 
situated within the neo cassette fragment). The 
cassette was then isolated on an XbaI (filled-in 
terminus) –NotI fragment. This was then cloned into 
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the NotI and SfoI (filled-in terminus) sites of the TK 
construct. 
     
Note –Areas underlined comprise 5’ extensions which contain restriction sites and/or a LoxP site. 
They have no homology to the template DNA. 
 
2.2.6.2  PCR  Primers and conditions 
Polymerase chain reactions were carried out on DNA and first strand cDNA templates in a 
biometra Uno II thermocycler in 1 X PCR buffer as detailed below, with 0.5U taq 
polymerase and 10 picomoles of forward and reverse primers per 10 µl reaction, unless 
otherwise stated. Genomic samples were denatured once at 94ºC for 2 m before cycling. 
Conditions are listed in Table 8. 
Buffer A: 45mM Tris•Cl pH 8.8; 11mM (NH4)2SO4; 4.5mM MgCl2; 0.113mg/ml BSA; 
4.4µM EDTA; 1mM each dNTP. 
Buffer B: 16mM (NH4)2SO4; 67mM Tris-HCl (pH 8.8 at 25°C); 0.01% Tween-20; 1 mM 
MgCl2; 200nM dNTP. 
Buffer C: 16mM (NH4)2SO4; 67mM Tris-HCl (pH 8.8 at 25°C); 0.01% Tween-20; 
6pMoles primer, 2.5 mM MgCl2; 500mM dNTP. 
Table 8 
PCR: Primers and products  Cycles 
 
SP-PCR
A (DMA-BR) 
Forward: 5’- AGTGCAGTTCACAACCGCTCCGAGC -3’ 
Reverse: 5’- CGTGGAGGATGGAACACGGAC -3’ 
 
94
oC 45s 
64
oC 45s        X 28, 72
oC10m. 
72
oC 3m 
Cre excision
A  
Forward: 5’-CAAGGTTACAAGACAGGTTTAAGGAG-3’ 
Reverse: 5’-GGACACGCTGAACTTGTGG-3’ 
94
oC 45s 
60
oC 45s        X 28, 72
oC10m. 
72
oC 1m 
EGFP
A 
Forward: 5’-CGACCACATGAAGCAGCACGA-3’ 
Reverse: 5’-GTTGTCGGGCAGCAGCAC-3’ 
94
oC 45s 
66
oC 45s        X 25, 72
oC 10m. 
72
oC 1m 
DMH-BR
A  
Forward: 5’-TCTCCGCCCAGCTCCAGTCC-3’ 
Reverse: 5’-CGTGGAGGATGGAACACGGAC-3’ 
96
oC 45s 
65
oC 45s        X 25, 72
oC 10m. 
72
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Concatomer
B  
Forward: 5’-GG AGTGGGATTTTGGTAGGCATC-3’ 
Reverse: 5’-GGGCTATGAACTAATGACCCCG-3’ 
94
oC 45s 
62ºC 45s        X 25, 72
oC 10m. 
72
oC 45s 
Clcn1
B  (6pMoles primer) 
Forward: 5’-GGAATACCTCACACTCAAGGCC-3’ 
Reverse: 5’-CACGGAACACAAAGGCACTGAATGT-3’ 
94
oC 45s 
63
oC 45s        X 32, 72
oC 10m. 
72
oC 45s 
cTnnt2
C  
Forward: 5’-GCCGAGGAGGTGGTGGAGGAGTA-3’ 
Reverse: 5’-GTCTCAGCCTCACCCTCAGGCTCA-3’ 
94
oC 45s 
72
oC 45s        X 32, 72
oC 10m. 
72
oC 45s 
Int-Neo
B 
Forward: 5’-CAAGGTTACAAGACAGGTTTAAGGAG-3’ 
Reverse: 5’-GCAGCCTCTGTTCCACATAC-3’ 
94
oC 45s 
57
oC 45s        X 30, 72
oC 10m. 
72
oC 1m 
MuSF
A  
Forward: 5’-GCCCCTGCCTCACCGTATAG-3’ 
Reverse: 5’-CTGGGGTCCACCACTTCAAG-3’ 
94
oC 45s 
62
oC 45s        X 29, 72
oC 10m. 
72
oC 3m 
DM-QR
A 
Forward: 5’-CACTGTGGAGTCCAGAGCTTTG-3’ 
Reverse: 5’-CACTGTGGAGTCCAGAGCTTTG-3’ 
94
oC 45s 
62
oC 45s         X 28, 72
oC 10m. 
72
oC 45s 
GAPDH
A   
Forward: 5’-AACGACCCCTTCATTGAC-3’ 
Reverse: 5’-TCCACGACATACTCAGCAC-3’ 
94
oC 45s 
60
oC 45s          X 27, 72
oC 10m. 
72
oC 45s 
CMV
A   94
oC 45s 
Forward:  5’-CATGTCCAATATGACCGCCATG-3’ 
Reverse: 5’-GCAGCCTCTGTTCCACATAC-3’ 
58
oC 45s        X 25, 72
oC 10m. 
72
oC 1m 
Superscript letters denote which PCR buffer was used 
 
2.2.6.3  Small pool PCR 
Small-pool (SP-PCR) analyses (Jeffreys et al., 1994; Monckton et al., 1994) were 
performed to assess the levels of trinucleotide repeat instability in different batches of 
EcoRI restricted pLoxEGFP250 constructs used throughout this project. Single molecule 
SP-PCR, where the DNA template is diluted to a low concentration, was used to amplify a 
rare 750 bp repeat from HindIII restricted patient DNA. 
DNA was serially diluted in 1X TE, containing 0.1 µM of carrier primer DM-A, the 
forward primer for subsequent PCR, to give between 10 and 10,000 DNA molecules per 
µl. The amplification of 1µl of each DNA solution was carried out in a final volume of 7 
µl, with 0.175 U of Taq DNA polymerase, 0.2 µM of each primer DM-A and DM-BR, in 
1X PCR buffer A. Cycling conditions are detailed in (Table 8). Christine Haworth    Chapter 2, 59 
 
2.2.7 Gel electrophoresis 
DNA molecules were separated using 0.6-1.5% agarose gel electrophoresis depending on 
the fragment size. NuSieve agarose gel electrophoresis was used to separate the products of 
the Clcn1and Tnnt2 PCR products (2% (w/v) NuSieve: 1% (w/v) agarose). Gels were 
prepared in 0.5 X TBE and when cool ethidium bromide was added to a final concentration 
of 500 nM. Samples and DNA size markers were mixed with 1/10 volume of DNA loading 
dye and electrophoresed at 80 volts (V) at room temperature in 0.5X TBE until the 
fragments had separated. The gels were visualised using a UV transilluminator 
(wavelength 254 nm) and photographed. 
2.2.8 Southern transfer 
DNA was transferred to Hybond N+ membrane using the squashblot method. After 
electrophoresis, gels were rinsed in deionised water, incubated in depurinating solution for 
10 minutes, denaturing solution for 30 minutes and neutralising solution for 30 minutes. 
Incubations were performed with gentle shaking.  
A piece of Hybond N+ nylon membrane the same size as the gel was wet in deionised 
water then dipped in neutralising solution. A piece of Saran Wrap, larger in size than the 
gel, was placed on the bench, with a piece of gel blotting paper, the same size as the gel 
and wet in neutralising solution, layered on top. The gel was inverted and placed on the 
Saran Wrap, and the membrane layered on top of the gel. Any air bubbles trapped under 
the membrane were carefully removed. Two sheets of gel blotting paper were rinsed in 
neutralising solution and layered onto the membrane. The blot was topped with a thick 
layer of paper towels, a glass plate and a weight. The DNA was transferred from the gel 
onto the membrane by capillary action for 3 to 16 hours. The blot was dismantled and the 
membrane placed on a piece of dry gel blotting paper DNA side up, and baked for at least 
20 minutes in an 80°C oven. The DNA was cross-linked to the membrane by exposure to 
1,200 J/m2 UV light. 
2.2.9 Preparation of radiolabelled DNA 
Fragments (30ng linearised template DNA and 5ng 1Kb+ ladder) were radiolabelled using 
Ready-to-go DNA labelling beads (Amersham Biosciences) and α[32P]dCTP, as directed 
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2.2.10  Southern hybridisation 
Filters to be hybridised were placed in a hybridisation bottle and rotated at 65°C for 30 
minutes with 10 ml of Southern blot hybridisation solution. The radiolabelled probe was 
denatured at 100°C for 5 minutes and quenched on ice for two minutes before being added 
to the bottle, which contained 10 ml of fresh Southern blot hybridisation solution. 
Hybridisation was performed at 65°C overnight in a rotating hybridisation oven. 
Following hybridisation, the filters were briefly washed inside the bottle in 0.2% (w/v) 
SDS, 0.2X SSPE at room temperature. The filters were then washed twice in the same 
washing solution for 30 minutes at 65°C. Finally the filters were transferred onto a flat tray 
and washed by gently shaking them at room temperature in the same solution. The filters 
were baked at 80°C until dry, and exposed to X-ray film at room temperature. 
Autoradiographs were developed after approximately 4 hours exposure. 
2.2.11  Cloning techniques 
2.2.11.1  Endonuclease restriction of DNA 
Restriction digests were carried out to obtain DNA fragments for cloning, transfection and 
microinjection, and to verify inserts and whole constructs based on the fragment size or 
banding pattern obtained. 
DNA (200ng-1µg) was restricted in a 10µl volume with 5-10 units of enzyme in the 
recommended restriction buffer at 37
oC for 1.5 to 2 hours. EcoRI and XhoI double digests 
were carried out by first incubating in XhoI buffer for 1 hr, then diluting the sample to 20µl 
in the recommended EcoRI buffer and incubating for a further hour. This avoided star 
activity by EcoRI due to low salt buffer. Where more DNA was required the reactions 
were scaled up proportionately. 
2.2.11.2  Filling in of recessed 3’ ends 
Residual restriction enzymes were first heat inactivated by heating to 70ºC for 10 m One 
unit of Klenow (DNA polymerase 1 large fragment) (Promega) and 1µl 10mM dNTP mix, 
was added to 10µl of restriction endonuclease digestion mix and incubated for 30 m at 
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2.2.11.3  Ligation 
Linear vector DNA (50 ng) was incubated with insert DNA at 8
oC overnight in the buffer 
provided, with 1 unit T4 ligase (Promega). 
Ligations were carried out with a 3:1 insert:vector molar ratio. Where the concentration of 
insert was not known because the sample was too small, 3 ligations were set up with 1, 3 
and 5 µl insert.  
2.2.11.4  Transformation of bacterial hosts 
On ice, 0.5 µl of the ligation reaction mix was added to 20 µl commercially prepared 
chemically competent cells and mixed by pipetting. After 30 minutes on ice, the tubes were 
place at 42
oC for 45 s then on ice for 2 m, 180 µl SOC medium was added and the samples 
incubated at 37
oC for 30 m to express the β-lactamase gene. One and nine tenths of the 
transfection mix were plated onto 50 µg/ml ampicillin LB plates, allowed to dry and 
incubated inverted overnight at 37
oC. 
2.2.11.5  Culture of bacteria 
A single colony was picked using a sterile toothpick and added to either 5ml or 100ml of 
selective LB medium, and incubated at 37ºC overnight at 300 rpm in an orbital shaker. 
Cultures were generally processed for DNA or storage immediately, or stored at room 
temperature until required. Glycerol stocks were first streaked out to single colonies on 
selective L-agar plates and incubated inverted overnight, at 37ºC. 
2.2.11.6  Glycerol stocks 
Overnight bacterial cultures were mixed 1:1 with 40% Glycerol:peptone and stored at 
-80
oC. 
2.2.12  Transfection of DNA into cells 
2.2.12.1  Transient 
Most transfer of DNA into cultured cells was transient, in that the cells were used for 
analysis usually 24 hours later (unless otherwise stated), without selection for stable 
integrants. As such only a proportion of the cells resulting from transfection were positive 
for the construct –typically ~60% based on the EGFP positive cell count in fluorescent 
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2.2.12.2  Stable 
Cells with stably integrated transgenes were selected for using G418 at a concentration 
determined by trial and error. Cells were plated with a series of G418 concentrations in 
normal growth media. The lowest concentration leading to cell death after ten days 
treatment was chosen for selection. 
Hela: 425 µg/ml 
Cos7: 425 µg/ml 
DmtD2976 Kidney: 300 µg/ml 
CGR8.8 ES cells: 200 µg/ml 
Transfected cells were grown in selective medium until colonies appeared –usually 10 
days. The plates were washed twice in PBS. Colonies were dissociated using 50µl 
trypsin/EDTA or TVP as described previously (2.5.2), within cloning rings (Sigma) placed 
over the colony. The suspended cells were then transferred to 96-well plates containing 
normal growth medium, and incubated at 37ºC. The clones were expanded by allowing the 
cells to become 95% confluent, then dissociating the cells using trypsin. The suspension 
was then transferred to one well of a 6-well plate also containing growth medium. After the 
cells became 95% confluent, they were again dissociated and transferred to a 25cm
2 tissue 
culture flask containing growth medium. Once the cells reached 80% confluency, a 
proportion was frozen (2.5.4) for storage. 
2.2.12.3  Liposome based 
Liposome-based transfection was used for all applications except ES cell transfection. 
FACS samples were prepared using only Lipofectamine2000 (Invitrogen). 
Either Transit LT1 (Miras) or Lipofectamine2000 (Invitrogen) transfection reagents were 
used as directed by the manufacturer. Briefly, for each well, the DNA and the 
Lipofectamine2000 reagent were diluted into separate tubes containing 250µl Opti-MEM 
(Invitrogen), the diluted DNA was added to the diluted reagent and gently rocked to mix. 
The tube was allowed to rest at room temperature for between 20 and 60 minutes whilst the 
transfection complexes formed. Meanwhile, the medium was removed from the cells, 
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added dropwise. The plates were rocked to mix and incubated for 4 hours. After this time, 
the medium was supplemented with foetal bovine serum to 10%. The medium was 
changed after 24 hours. Before preparing samples for FACS, the transfections were 
optimised by varying the ratio of pLoxEGFP DNA to reagent, to give the highest number 
of fluorescent cells. Thereafter, 4 µg of DNA and 7.5 µl Lipofectamine was used for each 
35mm
2 transfection.  
2.2.12.4  Electroporation 
DNA was introduced into ES cells using the Genepulser II (Biorad) electoporation 
apparatus. First two 75 cm
2 flasks of cells at ~80% confluency were trypsinised as 
described in 2.5.2. The cells were washed 3 times in PBS in 15 ml falcon tubes, each time 
collecting the cells by centrifugation at 1000 rpm in a bench top centrifuge. The final pellet 
was resuspended in 0.5 ml PBS. The DNA was diluted with 150 µl PBS, then added to the 
cells and mixed gently. The cell-DNA mixture was then transferred to a genepulser cuvette 
and the current applied. The settings were 0.8KV, capacitance 3 for 0.1 second. The cells 
were left to recover for 5 minutes at room temperature. The transfected cells were diluted 
to 6mls with ES cell culture medium then divided between 6, 100mm diameter dishes 
containing 10mls ES cell growth medium and incubated for 24 hours at 37ºC. After this 
time, the medium was supplemented with G418 antiobiotic, to select for stable 
transfectants. 
 
2.3 RNA methods 
Care was taken to avoid contamination with RNAses. Gloves were worn at all times. All 
solutions were made up with water treated with 0.1% DEPC at 37ºC for two hours 
followed by autoclaving. Disposable plastic falcon tubes were used to store and make-up 
solutions, and disposable prepacked RNase-free pipette-tips were used. Benches were 
swabbed down with RNaseZap and rinsed with DEPC-water. 
2.3.1 Isolation of RNA 
Total RNA was prepared for all applications using the RNeasy RNA miniprep kit as 
directed by Qiagen. Purified RNA was later DNAse 1 treated if required using the RNeasy 
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µl RQ1 RNase-free DNAse1 (Promega) was added. The reaction was incubated at 37ºC for 
30 minutes. Ten microlitres of stop solution (Promega) was then added and the reaction 
incubated at 65ºC for 10 minutes. The resulting mix was added to 350 µl RNeasy RLT 
buffer (provided) and mixed. Absolute ehanol (250 µl) was added and mixed, and the 
solution added to the RNeasy spin column. The rest of the protocol was then followed as 
for the isolation of RNA from animal cells. 
2.3.2 Determination of RNA quality and concentration 
The RNA concentration was analysed using the Nanodrop ND-1000 spectrophotometer. 
The degradation level was either assessed using the Agilent 2100 Bioanalyser, or by 
electrophoresis on a guanidinium thiocyanate agarose gel.  
To make the guanidinium thiocyanate agarose gel the gel tray and equipment were soaked 
in 3% H2O2 for 10 m, then rinsed in DEPC treated water. One gram of agarose was added 
to 100 mls TAE and microwaved until dissolved. Once cooled to hand hot, 2 µl 10 mg/ml 
ethidium bromide and 0.5 µl 1M guanidinium thiocyanate were added and the gel poured. 
RNA samples were prepared by adding 9 µl 2 X RNA loading dye to 1 µl RNA and 
incubation at 85ºC for 10 minutes. Samples were loaded and run at 80v for 45 m in TAE, 
then photographed under UV. 
2.3.3 Complementary DNA synthesis 
First strand cDNA was synthesised using Superscript II (Invitrogen) from 5 µg total RNA 
template using 500 nM random hexamers in a final volume of 20 µl as directed by the 
manufacturer. The resulting cDNA was stored at -20ºC until required.  
2.3.4 Fluorescent in situ hybridisation  
Cells attached to coverslips were washed twice in PBS; 5 mM MgCl2 at 37ºC and 
transferred to a clean 6-well plate before fixing for 10 m at room temperature in 4% 
paraformaldehyde. Excess fixative was removed by washing 3 times for 10 m each in PBS-
MgCl2 at room temperature. Cells on each coverslip were pre-treated with 40% 
Formamide; 2 X SSC for 10 m, the solution removed and replaced with 200 µl in situ 
hybridisation buffer containing 10 pMol Cy3-(CAG)10 ,
 Cy3-(CTG)10 
 or Cy3-GFP. A 
square of parafilm was carefully placed over the cell layer and the whole plate sealed with 
tape. This was placed in a sealed moist chamber, at 37
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removed by a series of washes increasing in stringency: 2 X SSC twice for 30 m and 1 X 
SSC twice for 30 m. The slides were mounted with Vectastain containing DAPI at 
100ng/ml. The edges of the coverslips were sealed using ClariOn mounting medium 
(Sigma). 
2.3.5 Double labelling with ICC and FISH 
 Cells were fixed and washed as described previously (2.3.4). The cells were then fixed 
briefly in 70% ethanol for 10 m and rehydrated in PBS-MgCl2 for 10 m. Non-specific sites 
were blocked by incubating in PBST for 30 m. The primary antibody was diluted in PBST 
(anti-MBNL 1:100 or anti-vimentin 1:200) and incubated with the cells for 1hr at room 
temperature, or overnight at 4ºC. The antibody was removed by washing three times for 5 
minutes with PBST. Hybridisation of the secondary antibody (alexa 350 anti-rabbit 1:200 
or FITC anti mouse 1:200) was carried out in the same way as the primary antibody. The 
antibody was removed by washing three times for 5 minutes with PBST. The protocol 
described for fluorescent in situ hybridisation (2.3.4) was the followed from the 40% 
formamide; 2 X SSC pre-treatment step. 
2.3.6 Microarray analysis 
RNA samples were prepared using the Qiagen RNeasy mini kit without DNase treatment 
as requested by the Molecular Biology Support Unit at the University of Glasgow, who 
carried out the target preparation, hybridisation and normalisation calculations. Whole 
transcript levels were assessed using the Affymetrix mouse genome 430 2.0 array, and for 
exon level differences, the Affymetrix mouse exon 1.0 ST array was used. Whole 
transcript gene lists were generated by Pawel Herzyk of the MBSU, using rank product and 
iterative group analysis (Breitling et al., 2004; Breitling et al., 2004). Partek Genomics 
Suite® software was used to identify mis-spliced genes within the exon array data.  
2.4 Protein methods 
2.4.1 Isolation of protein 
Total protein was extracted from cells using the proprietary reagent CelLytic M lysis 
reagent from Sigma as directed, which isolates cytoplasmic and nuclear proteins. 
Nuclear and cytoplasmic fractions were obtained using the Sigma CelLytic NuCLEAR 
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2.4.2 Determination of protein concentration 
Protein concentration was estimated using the Bradford assay (Bradford, 1976). Twenty 
five µl of sample or BSA standard was mixed with 750 µl Coomassie Plus reagent (Pierce) 
at room temperatiure and left on the bench for 10 m. Using varying dilutions of 10 mg/ml 
BSA to give standards of: 10 mg/ml; 2 mg/ml; 1.5 mg/ml; 1 mg/ml; 0.75; 0.5; 0.25; 0.025 
and 0 mg/ml, the Nanodrop UV/Vis spectrophotometer software was used to set a standard 
curve. Test samples were then read using the calibrated machine. 
2.4.3 Immunodetection of protein 
Proteins were separated by 4-12% PAGE and transferred to Immobilon P PVDF membrane 
using a Novex blot module and the X-cell II apparatus as recommended by the 
manufacturer. Briefly, to each 12 µl of protein sample, 3 µl of 4X NuPAGE LDS sample 
buffer and 12 µl 10X NuPAGE reducing agent was added, and the samples heated to 70ºC 
for 10 m. They were then loaded onto the polyacrylamide gel and run in 1 X NuPAGE 
MOPS running buffer. After separation the proteins were transferred to the membrane in 1 
X transfer buffer consisting of 1X NuPAGE transfer buffer; 0.1%ml NuPAGE antioxidant 
and 10% Methanol, at 30 V for 1 hour. 
Membranes were pre-wet in methanol, then equilibrated in 1X TBST for 20 m, changing 
the solution after 10 m. Non-specific binding sites were blocked by incubation overnight in 
1X TBSTM5, shaking slowly at 4ºC. The primary antibody was diluted 1:2000 for both 
anti-CUG-BP1 and anti-MBNL1 in 1X TBSTM2.5, added to the membrane and incubated 
overnight, again at 4ºC. The membrane was washed four times for 15 minutes each at room 
temperature, in 1X TBSTM2.5. The HRP-congugated secondary antibody was diluted 
1:10,000 in 1X TBSTM2.5 and added to the membrane. Incubation was for 2 hrs at room 
temperature. The membrane was washed as described after the primary antibody 
incubation. A final wash of 15 m duration at room temperature was performed in 1X 
TBST. The chemiluminescent substrate mix was prepared as directed by the manufacturer 
(Supersignal, Pierce or ECL+, Amersham Biosciences) then pipetted onto the membrane 
and left for 5 minutes at room temperature. The membrane was blotted on Whatman paper 
to remove the surface liquid and covered with Saran wrap.  The membrane was exposed to 
x-ray film for varying amounts of time, typically 30 seconds, and the films developed. 
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2.5 Cell culture methods 
All reagent were pre-heated to 37ºC before use. ES cells were grown on gelatinised plates. 
Ten mls of 0.1% gelatin was placed in a 25 cm
2 flask and incubated at 4ºC overnight, or 
until required. Before use the gelatin was removed. 
2.5.1 Feeding cultured cells 
The medium was changed daily during ES cell culture and every 3 days for all other 
cultures unless otherwise stated. 
2.5.2 Subculturing cells 
Cells growing in 25 cm
2 flasks were washed twice in PBS before the addition of 0.5 ml 
trypsin/EDTA solution, or TVP solution for ES cells. The liquid was rocked gently over 
the cell-layer, then incubated at 37ºC for 5 m. The flask was tapped gently to dislodge the 
cells and a cell-scraper used to loosen the remaining cells if necessary. Ten mls of culture 
medium was added to stop the trypsin reaction. One tenth to one third (ES cells one third) 
of the cell suspension was transferred to a new flask, and 10 mls of culture medium added. 
The cells were rocked to mix and placed back into the incubator. Reagents were scaled 
proportionately for other dish and flask sizes. 
2.5.3 Thawing frozen cells 
Frozen cell samples stored in liquid nitrogen were quickly thawed by immersion of the 
cryovials in a water bath at 37°C. Five ml of fresh warm medium were added to the cells, 
and mixed gently by repeated pipetting. The cells were then collected by centrifugation at 
200 g for 5 minutes, resuspended in fresh culture medium, and finally plated on a tissue 
culture flask or plate. 
2.5.4 Freezing live cells for storage 
A single cell suspension was obtained following trypsin digestion of cells between 80 and 
95% confluency, as described previously (2.5.2). Cells were precipitated by centrifugation 
at 200 g for 5 minutes, resuspended in fresh culture medium at a concentration of ~1 x 10
6 
cells/ml (MEF and ES cell culture medium was supplemented with 50% foetal calf serum 
for freezing) and transferred into 2 ml cryovials. Dimethylsulphoxide (DMSO) was added 
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inverting the tubes. The vials were transferred into a freezing container with isopropanol at 
room temperature, and then slowly cooled to -70°C over at least 4 hours. Finally the frozen 
samples were moved to liquid nitrogen, where they were kept until needed.  
2.5.5 Determination of cell concentration 
Following trypsin digestion and neutralisation with standard growth medium, cells were 
counted on a haemocytometer, using a phase contrast microscope. The haemocytometer 
was covered with the coverslip and a drop of cell suspension was dropped at the edge of 
the coverslip on both sides of the chamber. At least 100 cells were counted, and the 
number of cells/ml calculated. 
 
2.5.6 Establishment of primary cell-lines 
2.5.6.1  Transgenic tail cell-lines 
Tg5 transgenic mice tails were tipped and kept on ice for up to 30 minutes until processed. 
Primary cultures were established by the explant technique. Tails were wiped using a tissue 
dipped in 70% ethanol, and the skin removed using sterile scissors and forceps. The skin 
was opened out and pressed hard onto a tissue culture dish inside down. Cuts were made 
1mm apart along the length of the tail, still attached at the top and fanned out to separate. 
4mls of medium was added dropwise so as not to dislodge the tissue and the dish incubated 
at 37ºC in a humidified 5% CO2 atmosphere. The standard growth medium consisted of 
Dulbecco’s modified Eagle medium with high glucose (DMEM) supplemented with 10% 
foetal bovine serum (FBS), 1 X non-essential amino acids, 100 U/ml of penicillin and 100 
µg/ml of streptomycin. The dish was not moved for the first 3 days. The medium was 
changed weekly until cells became 60-80% confluent they were subsequently subcultured 
at a 1:3 or 1:4 ratio during the first 5 passages and at a higher ratio (varying from 1:5 to 
1:10) thereafter, as described in section (2.5.2). 
2.5.6.2  MEF feeder cells 
2.5.6.2.1 Preparation 
All solutions were maintained at 37ºC. Three pregnant FVB/N mice 14 days post coitum 
were sacrificed by cervical dislocation. The embryos were collected by dissection and 
sacrificed by cervical snipping. The embryos were decapitated and the livers removed. The Christine Haworth    Chapter 2, 69 
 
embryos were stored in PBS for up to 30 minutes until all were processed. The embryos 
were washed three times in PBS then cut into very fine pieces within the 50 ml falcon tube 
and again washed three times in PBS. All the supernatant was removed and 15 ml trypsin-
versene added. The contents were incubated at 37ºC for 20 minutes with gentle agitation. 
Five ml of serum was then added to a fresh tube. Ten mls of DMEM was added to the 
embryo tube and the supernatant transferred to the serum tube. The volume was made up to 
50 ml with DMEM, then centrifuged at 1000 rpm in a table-top centrifuge for 5 minutes. 
The pellet was resuspended in general culture medium and the tissue allowed to settle for 2 
minutes. The supernatant was transferred to a fresh tube. The cells were counted using a 
haemocytometer and all but 9 X 10
7 cells frozen for storage (2.5.4). The reserved cells 
were inoculated into two 150 cm
2 tissue culture flasks and incubated until almost 
confluent. The cells were then trypsinised (2.5.2) and the total amount used to inoculate 
four 150 cm
2 tissue culture flasks which were incubated until confluent. These cells were 
also trypsinised and used to inoculate ten 150 cm
2 tissue culture flasks. Once these flasks 
were almost confluent the contents were arrested for growth by irradiation. 
2.5.6.2.2 Growth arrest 
 
Once the cells were confluent the flask lid was tightened the lid of the flasks and exposed 
to the gamma source for 3000 rads. The flask was then swabbed with 70% ethanol and 
returned to the incubator before trypsinisation as described previously (2.5.2) and freezing 
also as described previously (2.5.4). 
Use of a gamma source was kindly permitted by The Beatson Institute for Cancer Research 
in Glasgow. 
2.6 Pronuclear injection 
Pronuclear injection was carried out by the Molecular Biology Support Unit, at the 
University of Glasgow, with DNA diluted in injection buffer. Mouse strains are detailed in 
Table 9. 
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2.6.1 Mouse strains 
Table 9 
Strain  Use 
B6D2 -F1 Hybrid of C57B6/DBA2  Donor  
ICR  Foster mother 
T145  Vasectomised male 
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3  Design and generation of a murine model of 
DM1 pathogenesis 
3.1 Synopsis 
Myotonic dystrophy is a multisystemic disorder, not purely affecting muscle. The type 1 
mutation comprises an expansion of a CTG trinucleotide repeat within the 3’ UTR of the 
DMPK gene, and in type 2 the expansion of a CCTG repeat within the first intron of 
CNBP. The array-length determines the severity and age of onset of the disease. In both 
mutations, the repeats are transcribed but not translated. The RNA becomes trapped within 
the nucleus in the form of ribonuclear foci, which co-localise with the double stranded 
CUG binding protein MBNL1. Single stranded CUG binding protein CUG-BP1 works 
dynamically with MBNL1 to regulate alternative splicing during development to control 
mRNA isoform switching. Recruitment of MBNL to RNA aggregates results in depleted 
reserves within the nucleoplasm, affecting the MBNL1/CUG-BP1 balance, which leads to 
gene missplicing. As such, DM is an RNA mediated disease, but how this RNA brings 
about such pleiotropic effects is still unclear. Recent research also indicates a more direct 
involvement of CUG-BP, and other potential factors may be important. In order to 
delineate cause and effect we have attempted to use the Cre-lox system for the conditional 
expression of a toxic RNA in the mouse, to mimic the pathogenesis of myotonic dystrophy 
type 1 with temporal and spatial control. The nature of the transgene was essentially an 
EGFP reporter linked to an expanded CTG repeat within the 3’UTR, controlled by Cre-lox 
dependent excision of an SV40 transcriptional stop signal. Repeat tracts of 5 and 250 
repeats were cloned to recreate the normal and mutant alleles. The transgene was 
assembled, and each component and the Cre-lox mechanism tested and shown to be 
functional. Tracts of 800 repeats were originally intended to be cloned to reflect the 
congenital form, but proved unsuccessful due to probable rearrangements within the 
bacterial host. Pronuclear injection was used to generate the mouse model: One mouse line 
was established with the normal transgene, but attempts to produce the mutant mouse were 
unsuccessful. 
3.2 Introduction 
Myotonic dystrophy type 1 (DM1) is one of a large group of inherited human disorders 
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disease showing genetic anticipation and is characterised clinically by myotonia, muscle 
weakness, cardiac conduction defects, cataracts, mental retardation, premature frontal 
balding and testicular atrophy in males, and reduced fertility in females (Harper, 1998). So 
far two types of myotonic dystrophy have been characterised, type 1 and type 2. Both 
mutations are dominant, non-coding expansion disorders, consisting of expanded arrays of 
repeats located within the untranslated region of genes apparently unrelated to each other. 
The first consists of a CTG repeat expansion within the 3’ UTR of DMPK (Fu et al., 1992; 
Mahadevan et al., 1992) -a protein kinase putatively involved in cell elongation and fusion 
during skeletal muscle morphogenesis (Beffy et al., 2005). Type 2 consists of a CCTG 
repeat expansion within the first intron of exon 1 of the CNBP transcription factor gene 
(Liquori et al., 2001) thought to be involved in cell proliferation and tissue patterning 
during anterior-posterior axis, craniofacial and limb development (Shimizu et al., 2003), and 
gametogenesis (Liu et al., 2005). Comparisons of symptoms of the two types of myotonic 
dystrophy show remarkable similarity, with the most notable difference being the lack of 
any congenital form of the disease in DM2 (Day et al., 2003). How these expansions lead 
to the DM phenotype is still unclear. Many mouse models have been produced to address 
this (see chapter 1 for more detail), but none of the models to date have reproduced the 
complex multisystemic effects of DM pathogenesis. Knockout models that mimicked the 
haploinsufficiency of DMPK or surrounding genes perhaps affected by chromatin 
remodelling by the repeat, such as SIX5, only exhibited partial DM symptoms of mild 
myopathy and cardiac conduction defects (Berul et al., 2000; Jansen et al., 1996) and 
cataracts respectively (Klesert et al., 2000; Sarkar et al., 2000), but not myotonia, the 
benchmark symptom of the disease. As more mouse models were produced focussing on 
the DMPK 3’ UTR, it became apparent that only those expressing the repeat showed 
further symptoms characteristic of the disease: Results using an expanded CUG repeat-
expressing mouse showed late onset myotonia, testicular atrophy and infertility (Monckton 
et. al., unpublished results; also in chapter 1 of Wells et al., 1998). The discovery of the 
DM2 mutation, where patients suffer from a similar single locus mutation and multi-
systemic phenotype in the apparently unrelated gene CNBP, concentrated hypotheses 
towards RNA mediated pathogenesis. Evidence to support this came from a correlation 
between the length of the repeat and the severity of the disease; the DMPK or CNBP 
message from the mutant chromosome becoming trapped in the nucleus (Davis et al., 
1997); sequestration of RNA CUG binding protein MBNL1 to these foci (Fardaei et al., 
2002) and that levels of RNA CUG binding protein CUG-BP1 are altered in DM1 patients 
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mechanism. Mankodi et al. recreated the myotonia and muscle wasting characteristics of 
adult-onset DM1 by the expression of an expanded CUG repeat alone, lacking any 
associated DMPK sequences, from the human skeletal actin promoter {Mankodi, 2000 
#13}). They attributed the myotonia to missplicing of chloride channel 1 gene Clcn1 
(Charlet et al., 2002; Mankodi et al., 2002). Subsequently, splicing defects were found to 
explain many of the symptoms in DM (Kuyumcu-Martinez et al., 2006; for review, 
Mankodi et al., 2002). MBNL knockout mice and mice over-expressing CUG-BP1 
demonstrated the same tissue-specific missplicing seen in myotonic dystrophy patients 
(Kanadia et al., 2003; Ho et al., 2005). Although mouse models have now addressed many 
of the aspects of DM symptoms and pathogenesis, there are still unanswered questions. 
Infertility, sudden cardiac death, mental retardation, lethargy, cataracts and congenital 
onset are amongst some of the features still not fully explained.  
It seemed plausible that if the pathogenic mechanism between DM1 and DM2 was the 
same, then the differences must lie in the levels, and the patterns of expression during 
development and between different tissue types. In ideal terms, to generate a mouse model 
of any human genetic disease, one would modify the orthologous murine gene to contain 
the human mutation. This however would only allow replication of the disease in its 
multisystemic entirety. In order to delineate cause and effect we wanted to generate the 
ability to express long and short expansions temporally and/or spatially by limiting the 
expression of repeats in the mouse: temporal to gain insight into the pathogenesis of the 
congenital form; and spatial to link tissue specificity with the symptoms directly. 
3.2.1 Conditional expression 
Modelling the congenital form of DM1 by expressing large numbers of repeats in mice has 
not yet been successful. The severity of the phenotype would be unpredictable and could 
result in the morbidity or reduced viability of the line. By using a conditional system, 
tissue specific expression patterns can be limited maintaining function in other organs, and 
in the inactive state, promote fecundity of the line. In order to separate the phenotypic 
aspects of myotonic dystrophy and to overcome fertility problems caused by the ubiquitous 
expression of the expanded repeat tract (seen in Te162 mice, Monckton et al., 1998 and 
unpublished data), we aimed to produce a conditional CUG repeat expressing mouse 
model using Cre-lox site-specific excision. Many site-specific recombinase systems have 
been described from bacteria and yeast and their reactions vary in complexity. The yeast 
Flp-FRT and bacteriophage P1 Cre-lox mechanisms have been the most widely used in 
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and have high efficiency. They have been widely exploited as a tool for in vivo 
manipulation of DNA, usually for the removal of selection cassettes when targeting 
endogenous genes in ES cells or living animals. As a result of this there is now a growing 
bank of Cre-expressing transgenic mice with well-characterised limited expression patterns 
specific for tissues affected in myotonic dystrophy such as skeletal muscle: myosin light 
chain 1f (Bothe et al., 2000), actin promoter(Miwa et al., 2000), human alpha skeletal 
actin (Miniou et al., 1999); testes (Bunting et al., 1999) and eye (Utomo et al., 1999). An 
interferon responsive Cre-expressing mouse is also available, which allows the ubiquitous 
expression of the activated transgene upon administration of the drug by injection (Kuhn et 
al., 1995). 
 
Figure 4 Cre mediated transgene activation. A simplified diagram illustrating the activation of 
transcription. Expression of genes 3’ to the transcriptional stop signal is arrested. Cre binding 
results in excision of the regulatory element, allowing read-through of downstream sequences.  
In nature, bacteriophage P1 exists within its host as a low copy number plasmid, and uses 
Cre-lox to maximise genomic segregation. Cre recombinase catalyses the conversion of 
multimeric prophage molecules into single unit copies via site-specific recombination 
between two loxP sequences (Abremski et al., 1983; Hoess et al., 1984). The DNA 
between two of these sites is circularised, resulting in single molecules. Here, we utilise 
this mechanism as a means of transcriptional control. By the placement of a loxP-flanked 
polyadenylation signal between the promoter and the open reading frame, transcription is 
inhibited (Figure 4). Expression of the transgene will occur only after Cre mediated Christine Haworth    Chapter 3, 75 
 
excision and as such is defined by its pattern of expression. This system will enable us to 
activate the production of CUG repeat messenger RNA in a developmental or tissue 
specific manner by crossing with existing TgCre mice.  
 
 
Figure 5 Primary, targeting and activated transgenes Schematic representation of the targeting 
strategy. Stage 1: The primary transgene pStopEGFP•TK is randomly integrated into the mouse 
genome using ES cells. Stage 2: Targeting constructs pStopEGFP5; pStopEGFP250 and 
pStopEGFP800 derived from the primary construct have repeat cassettes in place of the TK 
cassette. Using homologous recombination, these constructs direct 5, 250 or 800 repeats to the 
3’UTR of the EGFP gene, at identical positions within the genome. EGFP and repeat expression is 
defined by the Cre recombinase expression pattern. Constructs and transgenes post Cre mediated 
excision contain one loxP site and are referred to as pLoxEGFP (0 repeats); pLoxEGFP5 (5 
repeats) and pLoxEGFP250 (250 repeats).  
In order to obtain transgenic mice that are free from positional effects differing only in the 
number of expanded repeats, we decided to use a two-stage process in ES cells. In the first 
stage, the primary TK construct would be randomly integrated into the genome and several 
clones selected based on Cre activated EGFP expression. These cell-lines would then be Christine Haworth    Chapter 3, 76 
 
used as a target for the integration of 5, 250 and 800 CTG repeats by homologous 
recombination (Figure 5). Once selected, cells from the clones would then be injected into 
blastocysts and transferred to the uterus of the foster mother. Chimeric offspring would 
then be set up for breeding and the F1 generation typed for germline transmission of the 
transgene. 
 
 
3.2.2 Transgene structure  
Selection of the promoter to drive EGFP and repeat expression was given much 
consideration. Although ideally we would have used the DMPK promoter, in this instance 
it was not possible since the full extent of the region was not known. Temporally, the 
chosen promoter needed to be active at least as early in development as the DMPK 
promoter, and in the tissues involved in this study. DMPK transcripts have been shown to 
be present in mice as early as day 10.5 p.c. (Jansen et al., 1996), and can first be detected 
in whole embryos at mid-gestation (Unigene expression analysis for Mm6529, based on 
EST data). This is equivalent to 9-11 days p.c. since total gestation time is 19 days in the 
mouse. Baskar and co-workers analysed the developmental expression pattern of the CMV 
immediate early promoter using a lacZ transgene reporter, and first detected expression as 
a dorsal stripe in the neural folds of mouse embryos at day 8.5 p.c. A broader pattern was 
exhibited at day 9.5 p.c. and included the somites, from which muscle is derived (Baskar et 
al., 1996). The CMV promoter is generally considered to be active over a broad range of 
cell-types, capable of producing high levels of transcript in vitro and in vivo, and has been 
used successfully in other transgenic mouse models (Hallauer et al., 2000, skeletal muscle; 
van den Pol et al., 1998, neurons). The expression profile and well-characterised aspect of 
the promoter made it a solid choice, although the level of expression is higher than that of 
the DMPK promoter, which could potentially pose problems since high levels of 
expression can stress the cell. This higher level may however result in earlier onset of 
disease, which could be beneficial when considering the lifespan of the mouse. When 
constructing living models, expression levels are difficult to control because of the strong 
influence of genomic context. The integration site can effect the levels of gene expression 
and even silence them in some cases (Mankodi et al., 2000). If the transgene integrates into 
an essential gene, morbidity or lethality can also occur. In this strategy, these positional 
effects can be selected for after integration since clones can be selected for expression 
levels in tissue culture by pCre activation before blastocyst injection, and for viability by 
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The pCIneo expression vector (Promega) was used as the backbone since it contained the 
chosen promoter and other elements required for expression in mammals, namely an intron 
based on that of chicken β-globin and the BGH polyadenylation signal.  
The loxP sequence is 34 bp long and arranged as an inverted repeat of 13 bp separated by 
an 8bp spacer region. This region contains two ATG codons, which could be utilised as 
initiation codons (Figure 6) resulting in missense translation of the EGFP reporter. To 
avoid this, both loxP sites were incorporated in reverse orientation. If two loxP sequences 
are present in trans, inverted with respect to each other, the intervening sequence is flipped 
to the opposite direction by Cre, so in order to give directionality during cloning, the 
sequences themselves were incorporated into the neomycin and EGFP forward PCR 
primers. 
To free the model of variations due to position rather than repeat length, the secondary 
repeat constructs needed to be targeted to the randomly integrated primary TK construct 
(Figure 5). Homologous recombination is a rare event, the frequency lying around 1 in 10
-5
 
to 1 in 10
-9
 integrants. Higher efficiencies are generally associated with longer flanking 
homologous sequences (Pinkert, 1994), with approximately 5000 bp of flanking 
homologous sequence optimal (Thomas et al., 1987). In our transgene there is 4465 bp 5’ 
homologous flanking region from the CMV promoter to the end of the EGFP ORF, but 
only 411 bp 3’ provided by the BGH PolyA, so in order to make the transgene sufficiently 
large for second stage targeting we included a 2600 bp stretch of the human ERDA1 region 
3’ to the non-homologous repeat section. The human ERDA1 region (17q21.3) is 
associated with CTG repeats polymorphic within the population which account for most of 
long CTG repeats detected by the repeat expansion detection (RED) method in the genome 
(Sidransky et al., 1998). Even though extensively researched (Schraen-Maschke et al., 
1999; Bowen et al., 2000; Meira-Lima et al., 2001; Mendlewicz et al., 2004), ERDA1 has 
not been linked to any disorder and is considered genetically inert. It has no homology to 
the mouse genome. In these constructs, part of the non-repeat ERDA1 DNA is used as 
random sequence to extend the TK/repeat flanking region of the construct, to facilitate 
second round targeting. 
 
Figure 6 The sequence of loxP. The inverted repeats are highlighted with arrows and possible 
initiation codons are in bold. 
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Both the neomycin and thymidine kinase genes need to be expressed in ES cells. Neomycin 
to enable positive selection for stable first-round integrants using the primary construct, 
and thymidine kinase (TK) to enable negative selection for second-round homologous 
recombinants, and so are placed under the control of the PGK promoter, which is widely 
used for ES cell targeting (Tybulewicz et al., 1991: Yu, 2000 #612; Rijli et al., 1994; Seidl 
et al., 1998). 
 
3.3 Transgene assembly 
 
Figure 7 Cloning strategy. Diagram depicting the assembly of the component parts. Numbers 
refer to the order of ligation into pCIneo. Fragments 2 and 4 were first assembled in pBluescript 
SKII+. Partial replacement of fragment 4 with fragment 5 converts the founder to the targeting 
construct. Primers, restriction fragments and templates are detailed in materials and methods. Not 
to scale. Christine Haworth    Chapter 3, 79 
 
 
The constructs were pieced together from components obtained by restriction digest, or 
PCR amplification, with each primer designed to incorporate a unique restriction site. A 
loxP site was incorporated into the forward amplimers 5’ to the Kozak sequence and the 
initiation codon of both the EGFP and neo ORF. PCR products were cloned into pTEasy 
and verified by sequencing. A cloning vector was used to assemble fragments before 
cloning into a modified pCIneo vector. These modifications comprised replacement of the 
vector (pCIneo) neomycin resistance with loxP-EGFP ORF, removal of the BamHI 
restriction site and the addition of a unique KpnI site upstream of the CMV promoter. At 
first, neomycin resistance (required to select for recombinant ES clones) was designed to 
be transcribed from the CMV promoter and terminate by the SV40 PolyA, but concerns 
arose about the function of the CMV immediate early promoter in undifferentiated cells 
after reports that the CMV promoter was inactive in ES cells (Chung et al., 2002). To 
counteract this, the PGK-neo-PolyA cassette from the targeting vector pPNT was cloned 
into the neo ORF in the reverse direction. Primer pairs and restriction fragments used for 
generation are detailed in chapter 2 “Materials and Methods”. Finished constructs were 
verified by restriction digest. 
3.4 Component function 
3.4.1 CMV promoter, EGFP and loxP interference 
Once gene expression has been activated by Cre excision, a single loxP site remains within 
the transcribed region. This sequence is 34 base pairs long: A 13bp inverted repeat 
separated by an 8bp spacer region. It was possible that this sequence could form a hairpin 
structure within the transcribed RNA, inhibiting translation, resulting in low levels of 
protein production (Figure 8A). The Kozak consensus sequence for ribosome binding lies 
2bp 3’ of the possible hairpin and so may not interfere with binding, allowing translation. 
To test the sufficiency of protein expression from the CMV promoter with the loxP site 
present, the loxP-EGFP ORF fragment was cloned into the MCS of the pCIneo vector (to 
generate pLoxEGFP), and transfected into mouse 3T3 cells. A high proportion of these 
cells glowed green when visualised by fluorescence microscopy (Figure 8B). No 
fluorescence was seen in cells transfected with reagent alone. It is clear then that the EGFP 
fragment used for the founder and targeting constructs is functional and that expression 
from the CMV promoter is strong enough to be visualised even when the loxP sequence is 
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EGFP is transcribed from a single copy gene as would be the situation created in the 
mouse, or if multiple copies are present within the cell and are in fact required in order to 
accumulate sufficient levels of the fluorescent protein. Therefore, we transfected pCDC2-
EGFP, also a strong promoter, which was available in our laboratory and pLoxEGFP in 
parallel to compare EGFP levels. Because the fluorescence was at least equivalent when 
judged by eye (figure 5C), and the loxP site is unavoidable in this strategy, we did not see 
it necessary to generate a further control construct with the CMV promoter and EGFP, 
without the loxP site. Since the CMV promoter is strong and frequently chosen for 
expression vectors carrying EGFP as a reporter (e.g. pIRES-EGFP, Clontech; pcDNA 6.2 
DEST series, Invitrogen) high levels of transcript should be produced.  
 
Figure 8 EGFP expression in the presence of the loxP site. A Schematic diagram of pCI lox 
EGFP Expression showing possible hairpin formation.  The ribosome is shown in blue at the Kozak 
sequence. B Fluorescent micrograph showing EGFP expression in mouse 3T3 cells. Photographed 
under UV excitation and brightfield. Magnification X10. C Fluorescent micrograph showing a 
comparison of EGFP expression from pLoxEGFP and pCDC2-EGFP plasmids in Cos7 cells 
(African green monkey). 
 
3.4.2 Neomycin 
The neomycin gene from Tn5 encodes an aminoglycoside 3'-phosphotransferase, which 
confers resistance to G418, an aminoglycoside antibiotic. G418 blocks polypeptide 
synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells, and so 
cells expressing the neomycin gene survive whilst those without it die. This would allow us 
to select ES cell clones transfected with the construct by adding G418 to the medium.  Christine Haworth    Chapter 3, 81 
 
Stable cell-lines were generated to test neomycin function. The lowest concentration of 
G418 resulting in cell death after ten days treatment was determined for the cell-types 
DmtD2976 Kidney pg 21; Cos7 and HeLa cells. The targeting transgenes pStopEGFP 
containing 5 and 250 repeats were then linearised and isolated on a KpnI-XbaI restriction 
fragment for DmtD2976 Kidney and Cos7 cells and an AclI fragment for the second set of 
Cos7 and HeLa cells (Figure 20), transfected into the cells, and selected for until colonies 
appeared. Colonies from each were picked and propagated. Untransfected cells from the 
same lines died in the same time period; therefore the neomycin gene is functional 
conferring G418 resistance. When analysed by PCR all clones with amplifiable DNA 
present were positive for the construct (Figure 9). 
 
Figure 9 A representative DNA analysis of stable cell lines Representative HeLa clones for 5 
repeats (1, 5, 6, 7, 12) and 250 repeats ( 2, 7, 10, 11, 12); co-transfected HeLa control 
(pStopEGFP250 and pCre); no DNA control; untransfected HeLa control and pStopEGFP250 
control. A PCR using DMR and QR amplimers specific for the human DMPK 3’ UTR and not 
present in the transgene. This confirms the presence of DNA in the sample. B PCR using primers 
within the EGFP ORF confirming the presence of the construct.  
3.4.3 Thymidine kinase 
Viral thymidine kinase (TK), the product of the CMV UL97 gene, specifically 
phosphorylates gancyclovir, a nucleoside analogue, precipitating chain termination and 
causing cell death once incorporated into the DNA during replication. It would be used as 
negative selection for cells that have lost the gene through homologous recombination, 
required for targeting the repeat constructs to the primary gene construct. 
The mouse cell lines described in 3.4.2 harbouring the founder construct, and control cells 
without were treated with 560ng/ml Gancyclovir for 5 days. The test cell lines died whilst 
control cells grew to confluence indicating that the TK gene is functional. Christine Haworth    Chapter 3, 82 
 
3.4.4 Transcriptional stop, loxP and Cre excision 
It is important to prevent transcription of the expanded repeats in the uninduced state. To 
facilitate this the SV40 PolyA signal, a widely used strong transcriptional terminator, has 
been positioned between the loxP sites. To further hinder any possible read-through 
transcription prior to Cre activation, the neomycin selection cassette has been positioned 
3’-5’ relative to the direction of transcription from the CMV promoter. To test the 
mechanism of activation and repression, murine 3T3 cells were transfected with the 
pStopEGFP5 targeting construct with and without Cre-expressing plasmid or pCre alone 
(Figure 10 top three rows).  
  
Figure 10 Cre activation of EGFP fluorescence. Brightfield and fluorescent micrographs showing 
EGFP fluorescence activated by Cre excision in 3T3 cells. EGFP fluorescence was only detected 
when cells were transfected with both pStopEGFP5 and pCre, or with the constitutively-expressing 
pLoxEGFP5. There were fewer EGFP fluorescent cells with pStopEGFP5+pCre compared to 
pLoxEGFP since the amount of transcriptional target (pStopEGFP5) was reduced by half in the co-
transfection, the other half made up by pCre. 
Fluorescence could only be detected in those cells transfected with both pStopEGFP5 and 
pCre plasmids indicating that Cre recombinase was required for activation of fluorescence, Christine Haworth    Chapter 3, 83 
 
and that fluorescence was repressed by the transcriptional control elements. The 
mechanism was also tested by using recombinant Cre in vitro. PStopEGFP5 and 
pStopEGFP250 plasmids were treated with recombinant Cre, and the resulting mixture 
transformed into JM109 cells. Cre-excised plasmids were isolated (Figure 11) and the 
pLoxEGFP5 derivative used to transfect 3T3 cells (Figure 10 bottom). The proportion of 
fluorescent cells was much higher in the pLoxEGFP5 sample compared to the co-
transfected samples because the total amount of DNA in each transfection was constant, 
and two plasmids were required for fluorescence in the co-transfection. Secondly, the 
starting amount of pStopEGFP5 plasmid was reduced by half, the other half made up by 
pCre, so fluorescence was further reduced. The same result has been obtained using DmtD 
Kidney; Cos7 and HeLa cells (data not shown). 
 
 
Figure 11 Analysis of lox constructs after in vitro treatment with recombinant Cre.  A BglII 
restriction analysis of transformants. pStopEGFP5 and pStopEGFP250 are untreated parental 
controls. The positions of fragments specific to excised or untreated constructs are indicated, 
unlabeled fragments are common to all. The asterix denotes plasmids identified with putative 
spontaneous deletions in the number of repeats. B DMH-BR PCR over the repeat region. Sample 
numbers 5, 9, and 14 are spontaneous deletions containing approximately 150, 100 and 150 
repeats respectively. Numbers correspond to 250 repeat clones in A. 
 
3.4.5 The repeats 
The CTG repeat has been shown to form a single hairpin in vitro (Michalowski et al., 
1999) which was thought may interfere with EGFP transcription if placed directly 3’ to the 
termination codon. To avert this, a portion of the DMPK 3’ UTR (113bp 5’ and 112bp 3’of  Christine Haworth    Chapter 3, 84 
 
 
Figure 12 Human DMPK 3’ UTR showing the position of nested primers used to amplify 
repeat sequences. A schematic diagram depicting the relative primer positions for semi-nested 
PCR. First round primers are blue. Second round primers are orange and include restriction site 5’ 
extensions for cloning. 
 
 
 
 
 
Figure 13 Cloning the repeats.  A Products of nested PCR used for cloning. Bands were excised 
as indicated by white boxes. Templates consisted of HindIII digested patient genomic DNA. PCR 
was carried out for 28 cycles or 7 cycles (*) and with varying dilutions of DNA. Products obtained 
using the highest dilution and lowest number of cycles was used for cloning, in order to minimise 
aberrant nucleotide incorporation during PCR. B Repeats after cloning. Note that there is slight 
variation in the length of cloned “60” repeats in sample A. The smaller 5 repeat band may be due to 
contaminating 5 repeat PCR product within the agarose. Unexpected band sizes were obtained for 
the 800 and 250 repeat samples C and D. 800 repeats would be 2620bp and 250 repeats 970bp. 
The vector backbone is 3Kb which indicates that many of the clones in sample C and D are 
probably undigested DNA. The largest insert contains no more than 40 repeats. 
 
the repeats: Accession # L19268), was included to act as a spacer between the end of the 
EGFP reading frame and the polyadenylation sequence. This region used includes the 
subsequently discovered splicing factor binding sites for hnRNP C; PTB; U2AF and PSF 
(Tiscornia et al., 2000). DMPK 3’ UTR regions containing CTG repeats were isolated from 
patient DNA samples previously characterised for the length of repeat (Hogg et. al. Christine Haworth    Chapter 3, 85 
 
unpublished results) by semi-nested PCR (Figure 12). The mutant alleles in these patients 
contained distributions around 60; 250 and 812 repeats, with normal alleles of 5; 11 and 5 
respectively. These samples would act as a template to amplify 5; 250 and 800 repeat 
arrays to model unaffected, and the adult onset and congenital forms of myotonic 
dystrophy type 1. The 60 repeat was also cloned for possible use at a later date. Once 
amplified the fragments were gel purified based on size as bands, or regions in the case of 
the 800 repeat since smears were obtained due to the mosaicism of repeat length in somatic 
tissues (Figure 13A). The DNA was isolated from the agarose and ligated into pTeasy, a 
PCR-product cloning vector. Using blue-white screening in JM109, transformants for the 5 
repeat and 60 repeat ligations were obtained, but not for 250 or 800 repeat ligations. Insert 
sizes were confirmed by restriction digestion and found to be correct for the 5 repeat, and 
varied between 55 and 60 repeats for the 60 (Figure 13B samples A and B). UTRs were 
verified by sequencing (MBSU, Glasgow). The transformations for 250 and 800 repeat 
lengths were repeated increasing the amount of ligation reaction. Colonies were analysed 
but did not digest completely with EcoRI, some insert bands were present, but not of the 
expected size ranging from mostly 5 repeats from the 800, to no more than 40 repeats for 
the 250 repeat insert (Figure 13B samples C and D). 
PCR amplification and cloning was repeated with more product obtained using 10ng 
HindIII DNA, XhoI-DM-H/EcoRI-DM-BR PCR, and a larger PCR volume. Bands were 
excised, ligated and cloned and as before. Unexpected results were obtained once again. 
From the results it looked as if some of the samples were not fully restricted since there 
were very large bands present. EcoRI digestion should release inserts of 1kb for 250 
repeats and 2.6Kb for the 800 repeat leaving a 3Kb backbone, yet no restriction patterns 
showing 3Kb and 1Kb or 3KB and 2.6Kb were observed. Most samples (Figure 13B 
samples C and D, and Fifure 14A top) contained multiple fragments of varying intensities 
often seen with undigested plasmid samples. For clarification, the samples were Southern 
blotted and hybridised with a DM56 repeat probe to check the position of the repeat 
fragments on the gel (Figure 14A bottom). This probe was in general use in the laboratory 
for the detection of repeat alleles by Southern blot and consists of a CTG repeat PCR 
product amplified with oligonucleotide primers DM-C and DM-ER from the DM1 3’UTR 
(Figure 20). The repeat positive clones were digested with a fresh aliquot of EcoRI 
enzyme, and electrophoresed alongside undigested and XhoI restricted samples. XhoI 
digestion was included for the samples for clarification of plasmid size since only one XhoI 
site should be present in the clone, from the 3’ end of the insert. If multiple inserts had 
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present, so this was not the case. Insert fragments released by EcoRI were smeary, 
indicating a range of repeat lengths. These were judged to be smaller than 250 repeats in 
all but two samples (Figure 14B arrows). From the Southern and the second digest, 
samples 5 and 8 (originally from the 800 repeat pool) contained the largest inserts at 
around the correct size for a 250 repeat (Figure 14A top and B arrows). These were 
streaked out to single colonies from the same culture used to isolate plasmid DNA for the 
restriction analysis. Plasmid DNA was isolated and digested with EcoRI and the products 
electrophoresed beside undigested sample or XhoI digested sample (Figure 14C). There 
was a large amount of insert variation present, but the average size of the bands was 
equivalent to the most predominant bands in the parent clones, 5 and 8. The asterisked, 
clone 8 derivative was selected for cloning into the final targeting construct. Verification of 
the insert by sequencing was attempted, but it proved impossible to sequence across the 
full stretch of repeats so the expansion may be imperfect, however the first 50 repeats at 
the 5’ end (where sequence information was good) are pure.  
3.4.5.1  Further attempts to clone 800 repeats  
To try a different approach to clone an 800 repeat array, small-pool PCR was used to 
amplify single molecules from the patient DNA. One of the amplified aliquots contained a 
750 repeat and also a 5 repeat allele (Figure 15A). The 750 repeat allele fell into the range 
for congenital DM1 classification, and so attempts were made to clone it in place of 800 
repeats. A second round of PCR was performed using the aliquot with semi-nested primers 
as previously described (Figure 12; 25 cycles). The product was gel isolated using low 
melting temperature agarose, ligated directly and transformed into Top10f’ with blue-white 
selection. Transformants were restricted with EcoRI and found to have massively variable 
insert sizes (Figure 15B). Clone 10 was selected for further purification, as the top insert 
band was the correct size for 800 repeats, and present at a high level compared to the 
smaller insert fragments. It was hoped this plasmid could be made homogeneous for a 
large insert. The clone was streaked out to single colonies as previously described. EcoRI 
restriction analysis revealed that the insert ranges had again reduced in size (Figure 15C). 
This clone was abandoned and clones 3, 12 and 24 were analysed by restriction digest to 
check the restriction sites (Figure 15D). EcoRI should release the insert because of 
flanking sites within the MCS. PvuI should not cut within the insert so a duplex digest with 
EcoRI and PvuI should leave a fragment of the same size as that when EcoRI is used alone, 
yet both larger fragments have reduced in size and only smaller band sizes remain 
constant. XhoI does not cut within the vector, and so should result in a single band of 
5665bp for an insert of 800 repeats and the vector backbone. Yet digestion with XhoI gave Christine Haworth    Chapter 3, 87 
 
a doublet band. If two inserts had been cloned then one would see a doublet band with 
XhoI, and also if two plasmids were present with different array lengths -which could 
happen if repeats result in deletions during replication or mismatch repair.  
 
Figure 14 Unexpected restriction pattern of repeat clones A Top EcoRI restriction did not 
release inserts. No bands corresponding to repeat arrays were observed. A Bottom Southern blot 
of the same gel confirms presence of repeats. Arrows indicate inserts of the correct size for 200-
250 repeats. B Clones found to be positive for the repeats by Southern blot in A were re-digested 
with fresh EcoRI and electrophoresed beside undigested samples to confirm enzyme activity; XhoI 
linearisation was included to confirm plasmid size and rule out rearrangements. Arrows indicate 
inserts of the correct size for 250 repeats. Note that insert bands appeared smeary possibly 
indicating insert heterogeneity within the clones. C Clones 5 and 8 (identified as 250 repeat clones 
in B) were streaked out to single colonies, DNA was isolated and re-analysed for insert size. Note 
the variation in insert size between the clones. The range of variation is similar to the predominant 
fragment size in the parental clone. The asterix denotes the clone selected for construct 
generation. The arrow indicates insert size corresponding to 250 repeats. D Clones selected for the 
final construct. EcoRI-digested. 8* corresponds to the 250-repeat clone in C. The 5 repeat clone 
was selected previously (Figure 13B left hand clone of A).  Christine Haworth    Chapter 3, 88 
 
 
Figure 15 Cloning 750 repeats. A A 750 repeat band was identified from SP-PCR of patient 
DNA and used as a template for the second round PCR (Figure 12) unfortunately this sample also 
contained the normal 5 repeat allele which preferentially amplified. B Massive variability between 
repeat-containing inserts in the cloned product. Some clones contain large repeat inserts (arrows). 
Most have a mixture of large and small fragments. Clone 10 was selected for further analysis 
because the large band was proportionally high in the mix compared to other clones. C The 
overnight culture of clone 10 used for DNA analysis in B, was streaked out to single colonies. DNA 
was isolated and re-analysed with EcoRI. The large band disappeared, with no insert bands above 
250 repeats observed. D Restriction analysis of selected clones with larger inserts. The sizes for a 
750 repeat band are: EcoRI: 2653 bp + 3000 bp; XhoI: 5665 bp; EcoRI/PvuI: 2653 bp + 1710 bp 
+1096 bp + 191 bp + 16 bp. The XhoI doublet probably originates from different sized inserts.  
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Attempts so far involved the analysis of many clones since it looked as if the repeats were 
reducing and expanding during the cloning and bacterial transformation. Streaking out 
existing transformants and probing with repeats should reveal those clones with the largest 
inserts since more probe would bind. Clones 29; 32 and 36 (Figure 15B) were chosen 
based on insert size, streaked out to single colonies, picked and transferred to nylon 
membrane and hybridised to a DM56 repeat probe. There was an obvious variation in the 
strength of the hybridisation signal between clones (Figure 16A), those corresponding to 
the strongest were propagated and analysed by EcoRI restriction. Again there is a massive 
variation in the length of the repeat fragments, with large deletions apparent between 
sibling isolates (Figure 16B), and compared to the parental clones (from Figure 15B). We 
concluded that the 800 repeat was too unstable to clone. 
 
 
Figure 16 Identification and DNA analysis of repeat clones. A Single colonies from clones 29; 
32 and 36 (Figure 15B) probed with DM 56 repeat probe. + (positive control) = pLoxEGFP250 in 
JM109; - (negative control) = pLoxEGFP in JM109. B EcoRI restriction analysis of DNA from the 
high signal colonies reveals high variability of insert sizes both within and between clones. Christine Haworth    Chapter 3, 90 
 
By this time Mankodi et al. had published evidence that 250 repeats expressed within the 
3’ UTR of an mRNA unrelated to DM1 was sufficient to induce DM-like symptoms in 
mice. Because of this information and time constraints the mouse model was limited to 5 
and 250 repeats. 
3.4.5.2  Propagation of repeat constructs  
The hallmark of myotonic dystrophy pathogenesis is the formation of ribonuclear foci; 
aggregates of the mutant RNA trapped within the nucleus. Until the floxed 250 repeat 
construct was tested for foci formation in mammalian cells (which is addressed in chapter 
four), we did not realise that there was any significant instability with expansions of 250 
repeats whilst amplifying the DNA in bacteria. During testing, not all EGFP positive cells 
harboured CUG ribonuclear foci, which made us wonder if there were smaller length 
repeat inserts within the DNA preparation used. To test this, DNA was linearised and 
serially diluted to single molecules, then subjected to PCR across the repeat tract. 
Surprisingly, the preferentially amplified size within this particular preparation 
corresponded to 27 repeats, not 250 (Figure 17A left). Restriction analysis of the insert 
fragment revealed a ladder of repeat lengths ranging from 250 to 5 repeats (Figure 17 A 
right). The original overnight culture was then streaked out to single colonies and analysed 
for insert size. The clone with the most homogeneous population of repeat tract was 
selected (Figure 17 B), streaked out and reanalysed. Clone 250a* was selected as the 
master stock for future floxed plasmid preparations (Figure 17 C). 
Throughout the time of this thesis three large-scale preparations each of the original and 
the floxed 250 repeat targeting constructs have been made. Each time it was necessary to 
reselect the correct repeat length. For each batch, the construct was re-transformed into 
JM109 without blue-white selection and a single colony used for inoculation of each of ten 
100ml overnight cultures. A 1.5ml sample was taken from the culture and analysed for 
insert size whilst the remaining culture was pelleted by centrifugation and stored at -20
oC. 
Clones were selected based on the size and homogeneity of repeat length (Figure 18), and 
the corresponding pellets prepped. Different host cells have been used to culture the 
plasmid, DH5α, Top10F’ and JM109. The latter two contain lacI
q, which affords 
constitutive expression of the repressor giving tighter control of gene expression. Whilst 
Top10F’ and JM109 give much higher yields compared to DH5α, there seems to be no 
significant difference in homogeneity of repeat length (data not shown). 
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Figure 17 Repeat array contraction during plasmid propagation. A Dilution PCR and restriction 
analysis showing variation in repeat length after propagating pLoxEGFP250 from a glycerol stock. 
B EcoRI restriction analysis of subcultures of the original pLoxEGFP250 glycerol stock in A. The 
number of bands in each derivative has reduced, and the overall range of the band-sizes is similar 
to the original. C A second set of subcultures from a and b in B. The number of bands in each 
derivative has reduced again, the overall range of the band-sizes similar to the original. Christine Haworth    Chapter 3, 92 
 
 
Figure 18 Heterogeneity of repeat length in floxed 250 preparations. A Original denotes 
master stock plasmid pLoxEGFP250a*(Figure 17C) used for transformation. 1-10 denotes 
subcultured single colony transformants, analysed by EcoRI digestion to release the cloned repeat 
array. Sample 1 was selected and is shown in SP-PCR analysis in B. B SP-PCR analysis of 
pLoxEGFP250 constructs used throughout this research. 500 molecule dilutions; 7 replicates. 
Samples: Original floxed 250; batch #2 and transformant 1 from A. Note the presence of deletion 
products ranging from 250 to approximately 5 repeats.  
 
3.5 The mouse model 
3.5.1 Targeted integration 
Precise alteration of endogenous genes is a method usually used for null or knockout 
models. Here we attempted to use ES cells for random integration of the master construct 
followed by targeted integration to that construct, to produce a gain-of-function model 
where control and mutant mice differ only in the number of repeats, free of positional 
effects.  
ES cells derived from preimplantation embryos retain totipotency which reduces as the 
number of passages increase (Nagy et al., 1993). This would allow genetic manipulation 
by targeting in the early passages. We proposed that if the passage number was kept low, 
two rounds of manipulation are possible. The first, a random integration of the master 
construct followed by clone selection. The second, targeted integration of the 5 and 250 
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blastocysts, which would then be implanted into the uterus of the pseudopregnant foster 
mother to produce chimeras, hopefully with colonisation of the germ-line. 
The ES cell-line CGR8.8 was a kind gift from Professor R.W. Davies (I.B.L.S., University 
of Glasgow), originally derived from mouse strain 129j/Olac (Nichols et al., 1990). These 
cells had already been shown to give germ-line transmission in the Davies laboratory. 
Before proceeding with the integration, a kill-curve was done to select the optimum dose 
of G418 to use for selection of transgene-positive cells. It was important to use the lowest 
effective dose to ensure single copy integrants would be isolated, and that selection was 
not biased towards those cells expressing large amounts of neomycin due to the presence of 
multiple copies of the transgene. One hundred CGR8.8 embryonic stem cells were seeded 
into each well of a gelatinised 12 well plate. After 48 hours, 0; 100; 200; 300 and 
400µg/ml G418 was added to the medium in duplicate wells. The G418 supplemented 
medium was replaced each day and the state of the cells noted.  Cell death began in the 
higher concentrations after 48hrs, and cells were completely dead by day 6. Few cells 
remained at 200µg/ml G418. At day ten, no colonies could be seen at 200µg/ml G418, and 
so this concentration was chosen for the selection of transfectants. 
To test promoter function in ES cells, pLoxEGFP was linearised and transfected into 
CGR8.8 embryonic stem cells using electroporation, and the media supplemented with the 
cytokine leukaemia inhibitory factor (Lif) to maintain the undifferentiated state of the cells 
(Nichols et al., 1990). Unfortunately it was not possible to include a cell-type positive 
control such as 3T3 cells for electroporation due to contamination prevention guidelines of 
the ES cell facility. G418 was added after 24 hours to select for stable transfectants. 
Colonies appeared after 7 days and were viewed using fluorescent microscopy. Few cells 
exhibited EGFP fluorescence. This could have been due to a low rate of transfection, often 
experienced in primary cell-lines such as ES cells. ES cells require close cell-cell contact 
in order to maintain the undifferentiated state. The cells that did fluoresce were situated on 
the perimeter of the ES cell colony where the cells are most likely to be differentiating 
(Figure 19). Since each colony is derived from a single cell, EGFP fluorescence should be 
apparent throughout the colony. This was not the case so it is reasonable to conclude that 
the promoter is not functioning in the undifferentiated state, as has been reported (Chung et 
al., 2002).  Christine Haworth    Chapter 3, 94 
 
 
Figure 19 EGFP fluorescence in CGR8.8 129/Ola ES cells. Fluorescent micrograph after 
transfection showing EGFP fluorescence at the perimeter of a colony.  
Although it was disappointing to conclude that the CMV promoter was not available for 
clone selection in the undifferentiated cells, it was not relevant for the mouse model, and 
may be beneficial. As explained in 3.4.1, the CMV promoter satisfies the criteria required 
in that it is at least as powerful and as active temporally as the DMPK promoter, which 
drives expression of the DM1 mutation. It did mean that in order to select clones based on 
EGFP expression levels, the clones would need to be differentiated after transfection with 
Cre. 
The master transgene TgStopEGFP•TK was excised from the pStopEGFP•TK construct on 
a KpnI-XbaI fragment (Figure 20) removing the unnecessary bacterial growth genes, and 
introduced into ES cells by electroporation. Cells were plated onto a MEF feeder layer and 
after 24hrs, transformants were selected for using G418 supplemented medium. Massive 
cell death occurred on day six revealing 20 bright circular colonies. Once they had reached 
1-2mm in diameter, 18 undifferentiated colonies were picked. The cells were disassociated 
and the clones expanded by growth first in 96 well plates, then 24 well plates, again on a 
MEF feeder layer. The differentiation state of each clone was determined by visual 
microscopic inspection and 70% of the sample frozen down. The remaining 30% was 
expanded by 3 days further culture. DNA was extracted and subjected to three different 
PCR analyses: ‘EGFP’ to confirm the presence of the construct by amplification of a 
portion of the EGFP ORF ‘Concatemer’ to ascertain the presence of arrays. In this assay 
primers are positioned to face away from the body of the construct such that a product is 
only made when the construct has integrated as a tandem array; and ‘mUSF’ to verify the 
presence of PCR grade DNA in the sample. Primers mUSF-A and mUSF-BR were used to 
amplify a 1019 bp fragment within the mouse upstream stimulatory factor (mUSF) 
housekeeping gene. The generation of a PCR product in this reaction confirmed the 
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The EGFP PCR was also subjected to Southern hybridisation to an EGFP probe for 
sequence confirmation. Twelve of the clones were positive for EGFP and so contained the 
transgene (Figure 21A). Of these clones, two were determined by concatemer PCR to 
contain more than one insert (Figure 21B). DNA usually integrates into the genome at a 
single point either as a single molecule, or a head to tail array (Brinster et al., 1981). The 
expected band size if an array was present was 437 bp if the array is in the usual head to 
tail arrangement, which is what we see in clone 12. Clone 15 shows a smaller band of ~220 
bp. If the clones were head to head, or tail to tail, the band would be 410 bp or 450 bp 
respectively. This sample was not positive for EGFP (Figure 21), so possibly this clone 
resulted from a DNA rearrangement.  
 
 
Figure 20 The position of PCR amplimers relative to the transgene. Schematic diagram of 
linear pStopEGFP5/250 (not to scale) illustrating the position of amplimers used in PCR analyses. 
Product sizes are given for pStopEGFP5; pStopEGFP250 and DmtD162 (genotyping control) 
templates. NP = template sequence not present. Restriction sites used for transgene isolation are 
also shown. 
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Figure 21 PCR analyses of pStopEGFP•TK ES cell clones A Southern blot of EGFP PCR 
hybridises to an EGFP probe. Twelve clones were positive for the transgene. B Concatomer PCR: 
Clones 12 and 15 were positive for arrays. C Most preparations were positive for PCR grade DNA. 
 
The cells were at passage 11 as they were plated into 96 well plates and a high proportion 
of colonies looked undifferentiated. That is to say that the cells upon visual microscopic 
inspection were growing as densely-packed bright circular colonies with few patches of 
flattened differentiating cells (Nichols et al., 1990). As the clones were expanded, the 
number of undifferentiated colonies was much reduced and only in clones 5 and 14 did the 
colonies look dense, bright and round. Unfortunately both were negative for EGFP (Figure 
21A). 
The design of our model was such that the only difference between lines was the length of 
the repeat tract. To do this we were attempting to randomly integrate the master construct 
and then using negative selection to target differing repeat lengths to this construct by 
homologous recombination. To free the model of positional effects was advantageous 
because it would remove the further consideration of the integration site in an already 
complicated disease. Transgenic models such as ours are usually generated by random 
integration however, with several lines selected from each transgene to control for position 
effects. For example during the generation of HSA
SR/LR myotonic mice, in some lines the 
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(Mankodi et al., 2000). At this point in our experiments, doubts had been raised by another 
researcher over the integrity of the CGR8.8 cells we had both been using, since they had 
failed repeatedly to obtain homologous recombinants (C. Winchester, personal 
communication). This coupled with the differentiated look of our ‘construct positive’ 
clones led us to suspend work on the ES cell strategy, and attempt random integration of 
the second round constructs (pStopEGFP5 and pStopEGFP250) directly to generate the 
model by the usual random integration route. This would also establish the function of the 
Cre-lox strategy in vivo before returning to, or perhaps repeating the lengthier ES cell 
targeting strategy at a later date. 
3.5.2 Random integration 
Pronuclear injections into B6D2 hybrid zygotes were carried out by the Central Research 
Facility at the University of Glasgow by the procedure documented in “Manipulating the 
Mouse Embryo” (Hogan, 1994). The transgene was excised on an AclI fragment (Figure 
20) which contained 1146bp 5’ and 583bp 3’ flanking DNA to insulate the ends of the 
transgene from exonuclease digestion. The DNA was purified using DEAE sephacel, and 
for the TgStopEGFP5 and the first round of TgStopEGFP250 injections was diluted to 
1.8ng/µl in injection buffer, corresponding to approximately 100 molecules per injection. 
The initial injection concentration was low in order to bias the procedure towards single 
copy integrants. Since Cre recombinase excises DNA between two loxP sites, arrays 
present within the genome would complicate the excision process, and therefore 
unpredictably affect activation of EGFP expression.  
The number of live births totalled 16 after pronuclear injection with TgStopEGFP5 and166 
after pronuclear injection with TgStopEGFP250. The number of live births was smaller for 
TgStopEGFP5 simply because fewer eggs were injected after the detection of a successful 
integrant.  For the TgStopEGFP250 injections, three batches of DNA were used, each 
prepared from separate cultures and verified by restriction digestion. The first batch was at 
a concentration of 1.8ng/µl, as for TgStopEGFP5. The second was diluted to three different 
concentrations to increase the chances of integration: 1ng/µl; 5ng/µl and 10ng/µl, all 
single-use aliquots to avoid freeze-thaw nicks in the DNA. The third batch was supplied at 
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3.5.3 Genotyping 
Once implant mice were weaned, usually between four and six weeks of age, 1cm tail-tips 
were removed under anaesthetic and the DNA extracted. The presence of the transgene 
was assayed using MTT multiplex PCR, routinely used in our laboratory for the 
genotyping of DmtD162 mice. This PCR amplifies three separate bands in the control 
DmtD162 mice (mUSF; DM-C/DM-ER and DM-R/DM-QR) and two in TgStopEGFP5 
and TgStopEGFP250 mice (mUSF and DM-C/DM-ER). The mUSF set of primers are an 
internal control for the presence of PCR grade DNA, so any samples which did not show 
up positive for this 1 Kb product were re-analysed with increased amounts of DNA 
sample, or repurified DNA. If the result was still negative, a second tail tip was used. The 
extra 180bp PCR product in the DmtD162 control originates from the presence of further 
DMPK 3’UTR sequence 3’ to the repeat region, not present in the TgStopEGFP5 and 
TgStopEGFP250, amplified by DM-R and DM-QR. The third set of primers, DM-C and 
DM-ER amplify the repeat region in both DmtD162 and the EGFP constructs (Figure 20).  
 
Figure 22 Implant genotyping by PCR Top: MTT multiplex PCR DNA analysis on tail-tip lysates. 
Bottom Southern blot of the above agarose gel and hybridisation to the DM56 repeat probe. Arrows 
indicate putative positive mice, black TgStopEGFP5; white TgStopEGFP250.  
 
Two mice positive for the repeat region of the transgene were identified, number 6869 
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then subjected to three further PCR assays for verification: ‘EGFP’ and ‘Intron’ PCR to 
confirm the presence of the construct and DM-H/DM-BR PCR to confirm the presence and 
length of the repeat region. At this stage mouse number 6869 TgStopEGFP5 was 
confirmed as positive for the transgene, but 6877 TgStopEGFP250 was negative (Figure 
23). The analyses were repeated using second tail tips from the same batch of mice and the 
results were still found to be positive for mouse number 6869 TgStopEGFP5 and negative 
for 6877 TgStopEGFP250 (data not shown). Tail-tip lysates from mouse 6869 
TgStopEGFP5 were used as a positive control for all further PCR genotyping of implants. 
 
 
 
Figure 23 Further analysis of putativeTgStopEGFP5/250 mice. Three DNA analyses: Mouse 
number 6869 TgStopEGFP5 is positive, 6877 TgStopEGFP250 is negative. Intron PCR produces a 
product of 341bp if the construct is present regardless of repeat length. DM-H/DM-BR PCR spans 
the repeats producing band sizes of 252bp for 5 repeats and 927bp for 250. EGFP PCR produces 
a 369bp product within the ORF.  
 
The donor egg genotype used for pronuclear injection was derived from a female C57Bl6 - 
male DBA/2 cross, so to obtain a pure background positive mouse 6869 TgStopEGFP5 
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multiplex PCR and Southern blot hybridisation to the DM56 repeat probe; DM-H/DM-BR 
PCR was used to verify the repeat length and EGFP PCR to show the transgene was 
transmitted through the germline and to identify mice for breeding (Figure 24). Note that 
segregation of the transgene was not 50:50. The founder mouse 6869 Tg(StopEGFP5) 
fathered 74 offspring in total, 11 of which were positive for the transgene, and so could 
have been mosaic, the transgene having integrated after the single cell stage. This apparent 
effect on segregation could also be the result of embryonic lethality, caused by the 
unfortunate integration of the construct into an essential gene. Since the founder mouse 
was male, any male offspring produced will be DBA/2 for the Y chromosome, so for the 
F2 generation, female transgenics were selected to establish the line.  
 
 
Figure 24 Genotyping of the Tg(StopEGFP5) F1 generation. A sample of 6869 Tg(StopEGFP5) 
offspring PCR genotyping detecting transmission of the transgene. F1 mice 10279; 10284 and 
10294 are positive. MUSF was also amplified to confirm the presence of PCR grade DNA (data not 
shown). 
 
Figure 25 A representative proportion of implant genotype analyses. The presence of 
amplifiable DNA is determined using MTT PCR. Repeat (DM-H/DM-BR) and Intron PCR verify the 
presence of the construct and repeat (DM-H/DM-BR) PCR also verifies the CTG array length. Christine Haworth    Chapter 3, 101 
 
In total 182 live births were analysed after pronuclear injection, 16 with TgStopEGFP5 and 
166 with TgStopEGFP250. Finally, to ensure no positives were missed, before sacrifice all 
implant mice were assayed using EGFP PCR; H-BR PCR; and either mUSF or MTT PCR 
(Figure 25), followed by Southern blot analysis using the EGFP or DM56 repeat probe as 
appropriate (data not shown). No positive mice were obtained for TgStopEGFP250. 
 
3.6 The Cre-lox mechanism ex vivo 
To test the function of the Cre-Lox mechanism in vivo, cell lines were established from the 
tails of the F3 and F4 C57Bl6 backcross of mouse Tg(StopEGFP5) (Figure 26).  
 
Figure 26 Pedigree of tail cell-lines Derivation of tail cell-lines from founder mouse 6869 
Tg(StopEGFP5) during C57Bl6 backcross. Line D did not become immortal within the time scale. 
 
These lines strictly-speaking were ex vivo and as such should be a good reflection of the 
situation in the living animal. Tail tips were removed and wiped with 70% ethanol before 
removing the bones using a scalpel. The tail tissue was flattened out and parallel 1-2mm 
cuts made almost all the way along the length but leaving a small piece of tissue uncut to 
keep the strands together. The tissue was then placed onto a 60mm culture dish skin side 
up and the strands splayed out. The tissue was pressed very firmly in order to adhere to the 
dish surface, and prewarmed culture medium added gently dropwise. The dishes were 
incubated at 37ºC until cells could be seen growing out from the tissue, which was then 
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were then incubated without passage until they began to grow once again. At this stage the 
cells had overcome senescence, whereby the cells lost the ability to divide, and were 
considered immortal. Once the lines were continuously dividing, cells were transfected 
with the Cre-expressing plasmid pCre. The experiment was controlled for using mouse 
fibroblast 3T3 cells: The constitutively expressed pLoxEGFP served as a positive 
transfection control, whilst co-transfection with pStopEGFP5 and pCRE acted as a positive 
Cre-lox mechanism control. The pStopEGFP5 and pCRE plasmids were also transfected 
alone to show no fluorescence prior to Cre activation. The Tg(StopEGFP5) cell-lines were 
also transfected with pLoxEGFP to show that the cells were able to be transfected. All cells 
on the coverslip were analysed 24 hours later using fluorescent microscopy. None of the 
Tg(StopEGFP5) cell-lines tested showed Cre activated EGFP fluorescence after 
transfection with pCre (Figure 27). This experiment was carried out three times in total. 
The same result was obtained; no EGFP fluorescence could be detected after pCre 
transfection of the Tg(StopEGFP5) tail cell-lines. 
Why transfection with pCre did not activate EGFP fluorescence was not clear in this 
experiment. Possibly the construct had suffered rearrangement within the mouse genome 
causing the mechanism to malfunction. To test whether activation was working at the DNA 
level, cells were transfected again as described in the previous experiment. DNA was 
extracted and subjected to PCR with primers that lay outside the region of Cre excision 
(Figure 20). This detects a shift between product sizes from 2925 bp before excision to 328 
bp after excision. The mechanism was found to be functioning correctly in all three lines 
since both bands could be detected after pCre transfection (Figure 28). 
It is possible that the amount of EGFP produced was too low to be visualised directly by 
fluorescence microscopy. To enhance the EGFP signal α-GFP primary antibody was used 
with an AMCA-conjugated secondary, which according to the manufacturer can give an 
eightfold increase in signal. The cell-lines and control 3T3 cells were grown on coverslips 
and transfected with pCre, or pLoxEGFP as a positive control for both transfection and the 
antibody hybridisation. Control 3T3 cells were also transfected with pCre or pLoxEGFP, 
also pStopEGFP5 or pStopEGFP5 + pCre as a positive control for pCre function, and no 
DNA. After antibody hybridisation, using fluorescence microscopy, all samples transfected 
with pLoxEGFP showed blue and green fluorescence (Figure 29) data not shown for 
3T3/pLoxEGFP). All the cells on each coverslip were analysed. In 3T3 cells, no 
fluorescence was detected with pCre (Figure 29) or pStopEGFP5 alone (data not shown), 
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transfected with pStopEGFP5+pCre were EGFP positive (Figure 29). It was noted that the 
signal was at a similar level for cells exhibiting very strong EGFP fluorescence but was 
generally enhanced for those cells with lower levels of EGFP fluorescence (Figure 29 
arrows). However, there was still no signal for the lines tested for Cre activation (Figure 29 
 
Figure 27 Cre activation of Tg(StopEGFP5) tail lines. Brightfield and fluorescent micrographs. 
PCre transfection of the Tg(StopEGFP5) tail cell-lines should have activated EGFP fluorescence by 
removal of the loxP-flanked polyA signal but no signal was detectable using fluorescent 
microscopy. The controls show that technically the experiment is valid, since transfection of 
pStopEGFP5 or pCre alone does not result in EGFP fluorescence, whereas co-transfection of 
pStopEGFP5 and pCre activates fluorescence showing that the excision mechanism is working. 
PLoxEGFP transfections were used to confirm the ability of the cells to take up and express 
plasmid DNA. 
            
Figure 28 Cre-lox excision at the DNA level. Cre assay PCR showing a reduction in product size 
from Tg(StopEGFP5) cell-line DNA after Cre excision. Constitutively expressing pLoxEGFP 
functions as a positive control for transfection, and a size marker for Cre excision.  Christine Haworth    Chapter 3, 104 
 
 
Figure 29 Enhancement of EGFP detection using αGFP. Fluorescent micrograph. 
Tg(StopEGFP5) cell lines were transfected with pCre, which should activate EGFP expression. 
Anti-GFP primary antibody and AMCA (blue) conjugated secondary antibodies were used against Christine Haworth    Chapter 3, 105 
 
EGFP to try to amplify the fluorescent signal. There is a slight increase in the detection of EGFP 
expressing cells using these antibodies (white arrows) when compared to EGFP alone. However, 
even after enhancing detection with αGFP/AMCA, EGFP still could not be detected in pCre-
transfected Tg(StopEGFP5) cell lines.  
 
 
 
Figure 30 EGFP RNA analysis pre and post Cre-lox excision. Top EGFP RT-PCR. The 
increase in transcript after pCre activation of expression is small. 20 cycles were used with the 
conditions described below. Bottom Optimisation to ensure amplification is within the linear range. 
Cells were transfected with pLoxEGFP as previously described, and harvested after 24 hrs. This 
preparation was ‘100%’ since it was comparable to the test sample transfection rate. The sample 
was then diluted using untransfected 3T3 cells. Total RNA was prepared from the mixes, and 
500ng of RNA was reverse-transcribed in a 10µl volume, 1µl of which was used in each PCR 
reaction. Reverse transcriptase was omitted from the ‘no RT‘ controls. Amplification was limited to 
10; 15; 20 and 25 cycles. 15 or 20 cycles were deemed to be in the linear range depending on the 
amount of starting sample. NB There is contamination in the ‘no RT’ controls probably due to 
plasmid DNA binding to the RNA purification column. 
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To check whether the EGFP transcript was being expressed pStopEGFP5 cells were 
transfected with pCre; reagent alone (no DNA) or pLoxEGFP as a positive control, and 
RNA isolated after 24hours. Samples were subjected to optimised EGFP RT-PCR (Figure 
30 Bottom) to ensure that product levels seen after amplification were a reflection of the 
amount of starting template. Unfortunately the experiment shows contamination in one of 
the ‘no RT’ controls and so should ideally have been repeated (Figure 30 Top). If the 
increase in EGFP transcript after Cre activation is real, and not due to contamination, then 
the increase is not large. If time allowed, this experiment would have been repeated, using 
Cre assay primers which span the intron to distinguish between pre and post Cre-excised 
transcripts. For the mouse model, it is important to ascertain whether there is read-through 
transcription of the SV40 PolyA signal in the absence of Cre. In this case RNA transcribed 
would not result in EGFP fluorescence, but would still contain the repeat region -which is 
the basis of DM pathogenesis, although low levels of expanded triplet repeats have been 
shown to be without pathogenic effect in mice (Mahadevan et al., 2006). 
 
3.7 Discussion 
Our aim was to create a conditional mouse model of DM1, based on the limited expression 
of expanded CUG repeats linked to an EGFP reporter, using the Cre-lox system. 
Expression of the repeat tract would be defined by the pattern of Cre recombinase 
expression, obtained by crossing our Lox-repeat transgenic line with available Cre 
expressing lines. We planned to generate the transgenic lines using two rounds of 
integration in ES cells; the first, a random integration of the construct backbone, to obtain 
an integration site target to which the second round constructs containing differing lengths 
of repeat tract could be targeted by homologous recombination. Five constructs were 
created as described in Figure 5: One founder construct pStopEGFP•TK and a 5 and 250 
repeat version each of the pStopEGFP targeting construct and the constitutively expressed 
pLoxEGFP construct. The 800 repeat form proved too elusive for the time available to 
carry out this work. Three further pLoxEGFP constructs arising from spontaneous 
deletions during in vitro Cre excision were isolated and the 3’UTR length verified by 
restriction digest. The component parts of all these constructs were tested in at least one 
stage of their construction and shown to be functional.  
One transgenic mouse was generated using the normal repeat allele TgStopEGFP5 by 
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F3 and F4 and used to test the Cre-lox mechanism in vitro. EGFP fluorescence could not 
be detected after pCre transfection by fluorescent microscopy directly, or by using α-GFP 
to increase the signal. PCR analysis of the transfectants revealed the excision mechanism 
to be functional at the DNA level. 
3.7.1 Repeats 
We successfully generated the pStopEGFP•TK construct required for first round random 
integration and pStopEGFP5 and pStopEGFP250 for second round targeting of repeats to 
integration by homologous recombination. It was our intention to use 5; 250 and 800 
expanded repeat tracts for our mouse model to reflect the normal; adult-onset and 
congenital forms of the disease. Whilst the cloning of 5 repeats was straightforward, 250 
repeats was difficult and 800 repeats unsuccessful due to deletions generated during 
bacterial propagation of the DNA. It was not clear at the outset that the repeat tract itself 
was changing. We were attempting to clone from a size distribution generated from patient 
DNA, and often a large band when gel purified will contain a small amount of 
contaminating short sequences. During cloning of the 250 repeat it was assumed that these 
fragments were also cloned, and selected for because they might be expected to grow more 
rapidly since the insert would be smaller. For this reason small colonies were also picked, 
which would be expected to contain larger or ‘difficult to propagate’ inserts, but these did 
not show any increase in size or insert homogeneity. It became clear as larger repeat 
lengths were attempted it was probable that clones containing long repeats were 
undergoing a rearrangement either during transformation into the host, or during 
replication within the bacterium, creating a population of plasmids whereby repeats had 
been lost, and also perhaps part of the 3’UTR, losing the EcoRI or XhoI site, or duplicating 
it leading to the appearance of partially digested samples and large doublets respectively. 
Intraplasmid rearrangements have been shown to be mediated by CTG repeats in E. coli 
(Hashem et al., 2002; Wojciechowska et al., 2005). Another factor influencing 
rearrangements may have been introduced as the repeats were cloned. Here, blue-white 
screening was used whereby the insert is cloned into the lacZ gene. This disrupts 
translation of β-galactosidase and the subsequent hydrolysis of x-gal substrate to an 
insoluble blue dye, resulting in white colonies for cloned inserts. Using this mechanism 
means that the cloned insert was also expressed. It has been shown that in E.coli, induction 
of transcription of repeats results in an increase of deletions within the array (Bowater et 
al., 1997). Expression must not have been the only factor since heterogeneity within the 
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repeat constructs without blue-white screening, where the lacZ gene was repressed by LacI 
(lacI
q) (as in Figure 18A). It would be interesting to see how recently developed bacterial 
hosts such as SURE or stbl2 cells would fare. SURE cells have tight lacZ control and are 
recombination (recABJ), UV and SOS repair deficient, designed to grow up plasmids 
harbouring repeated sequences and those with abnormal secondary structure such as Z-
form DNA.  
An alternative method designed to create large repeat tracts is to clone arrays of interrupted 
repeats as done by de Haro et al. to create a Drosophila model of DM1 (de Haro et al., 
2006). Here 24 blocks of (CUG)20CUCGA were used to create an interrupted repeat of 
480, (iCUG)480. In this instance expression of (iCUG)480 led to DM-like symptoms of 
muscle wasting and degeneration. Furthermore, (iCUG)480-induced symptoms could be 
modified by altering levels of MBNL1 and CUG-BP1, RNA binding proteins implicated as 
pivotal in DM pathogenesis. So clearly a pure repeat tract is not necessary to induce DM-
like symptoms. Whether interruption of the repeats modifies the effect of the mutated array 
in any other way has not yet been established, but recent research indicates that 
interruptions reduce the rate of repeat expansion (Braida, unpublished) and may modify 
disease progression as proposed by Matsuura et al. in SCA10 (Matsuura et al., 2006). 
3.7.2 Random integration 
We set out to use ES cells to generate our transgenic model, but because of perceived 
doubts about the integrity of the cell line, we switched to random integration, the usual 
method for generation of transgenic models such as ours. We used the new transgenic 
services of Glasgow University’s Central Research Facility to carry out the injections. 
They successfully generated a Tg(StopEGFP5) transgenic mouse using pronuclear 
injection. However, multiple attempts to generate the mutant Tg(StopEGFP250) mouse 
failed. According to the literature (Hogan, 1994; Pinkert, 1994) and our in-house training 
course (“Transgenic mice: Applications and Methodology” run by Dr. J.B.Wilson) one 
would expect to obtain four positive transgenic animals from each 100 eggs injected. In 
generating transgenic mice by pronuclear microinjection, typically 50-80% of eggs survive 
the injection, and 10-30% of implanted microinjected eggs can be expected to reach term. 
Of those mice born usually 20-40% are transgenic (Hogan, 1994). We obtained 1 
transgenic mouse from 182 live births. We have been unable to obtain complete records as 
to the number of eggs injected to create all 182 live mice, since it transpires that records 
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eggs that were injected with TgStopEGFP250, 716 survived injection (34%), 710 were 
implanted and of these 82 (12%) were born live, and 1 pup was found dead. None of these 
animals were positive for the transgene (dead pup not tested). The survival rate in these 
experiments was half the expected rate for injections. This could have been due to the 
injection process, handling, culture conditions or the DNA preparation. Efficiency in terms 
of DNA integration and development of eggs to term depends on the concentration of the 
DNA, with increasing concentration resulting in higher frequencies of integration, but a 
reduction in survival (Hogan, 1994). Brinster et al. found 1-2µg/ml to be optimal (Brinster 
et al., 1985). Here 4 batches of DNA were prepared by 3 different recommended methods 
of purification: CsCl/agarose gel/NA45 paper; endofree maxiprep/agarose gel/dialysis, and 
endofree maxiprep/agarose gel/DEAE sephacell. Although a low concentration of DNA 
was used to bias towards incorporation of single molecules, it was within the optimal 
range. 
The number of mice born was low, 12% of implants, but just within the expected range for 
live births after implantation (10-30%). Reasons causing this could be technical such as 
overculture of embryos followed by oviduct rather than uterine transfer, or construct 
related such as embryonic lethality caused by ‘leaky’ transcription of repeats through the 
SV40 terminator. During genotyping of the TgStopEGFP5 F1 progeny it was noted that the 
transgene segregation was not 50:50 as would be expected from integration during the 
single cell stage. Analysis of the F1 progeny using a chi
 square test showed that transgene 
integration most likely happened during the 4 cell stage. Results calculated for transgene 
integration at each of the early stages of embryonic cell division were: 1 cell, 36.54; 2 cell, 
4.05; 4 cell, 0.38 and 8 cell, 9.37. The control TgStopEGFP5 was the only positive 
transgenic mouse to come from the facility, the number of total injections unknown, but at 
least 2 other research groups were using the service. Although aliquots had been given it 
transpired that the DNA had been stored at 4ºC and repeatedly used. This would result in 
reduced concentration due to molecular adhesion to the tube wall over time, and perhaps 
degradation. Subsequent batches were given as single use tubes to overcome this, storage 
specified as -20ºC. The 5 and10ng/µl concentrations in this second batch would also have 
compensated for reduced concentration, although (assuming injection of equivalent 
numbers) the numbers of mice being born seemed to reduce with increasing concentration; 
20; 14 and 11 from 1; 5 and10ng/µl respectively, indicating that this perhaps was not an 
issue. Technically, it could be that integration is more difficult for larger repeats, but DM 
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generated (300 repeats: Seznec et al., 2000 ; 250 repeats: Mankodi et al., 2000; 162 
repeats: Monckton et al., 1997 ), so this strategy should also have been possible.  
It has been recently published that over expression of 5 CTG repeats in a mouse model 
results in a major phenotype a few days after induction or after nine months without 
induction due to a leaky promoter (Mahadevan et al., 2006). Our TgStopEGFP5 mouse 
was produced in 2003 and since it was deemed a normal control line and appeared healthy, 
no phenotypic analyses were carried out. It was later sacrificed due to unspecified ill-health 
aged 22 months. 
3.7.3 Cre-lox mechanism and activated fluorescence 
The mechanism of Cre-Lox activation of EGFP expression is functional in vitro at the 
DNA level and in cell culture, by pre-treatment of pStopEGFP5 or pStopEGFP 250 with 
recombinant Cre prior to transfection, and in vivo by co-transfection of pStopEGFP5 or 
pStopEGFP 250 and pCre into DmtD162 kidney; Cos7; Hela and 3T3 cells. It is not clear 
why no fluorescence was seen after pCre transfection of TgStopEGFP5 tail lines even after 
α-GFP enhancement. Is it that the EGFP expression levels are too low? Ideally the EGFP 
RT-PCR analysis on pCre transfected TgStopEGFP5 tail lines should be repeated, since 
contamination was evident within the controls, albeit low level (Figure 30). So, whilst it is 
not possible to determine whether low levels of RNA are expressed before Cre activation 
from this analysis, it is apparent that the levels of RNA present after Cre activation are not 
high. It is assumed during the transfection process that equal amounts of DNA enter the 
cell when comparing tail cells transfected with pCre to the pLoxEGFP control, but the 
actual EGFP transcriptional target gene may vary hugely in copy number between the two, 
since the target for pCre is endogenous. Cre recombinase also catalyses the integration of 
the circularised excision product, so at any one time it can be assumed that only half of the 
target gene will be activated for fluorescence. It could still be that the EGFP levels are too 
low to be detected, which could have been investigated by comparing expression levels in 
another GFP fluorescent mouse. Another explanation in this ex-vivo experiment, is that Cre 
recombinase itself is interfering with transcription. If high levels of EGFP are produced in 
the control EGFP transfection, then it can be assumed that high levels of Cre are produced 
in the pCre transfection since the promoters are of a similar strength. Large amounts of Cre 
may lead to continuously occupied lox binding sites, which would be expected to interfere 
with transcription. Allowing plasmid loss post-transfection by extended incubation of the 
cells could test this theory. As transfected cells divide, the plasmid is lost naturally in the 
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disappears, the amount of Cre within the cell would diminish, freeing lox binding sites and 
allowing production of EGFP. These cell-lines are representative of a single integration 
event not fully characterised. Positional effects can contribute to the level of expression 
within a gene. There may be more rearrangements, tandem integration or arrays, each of 
which could adversely affect Cre excision, so there are a multitude of reasons as to why 
Cre does not activate EGFP fluorescence in these single-founder cell-lines. Whilst the ex 
vivo approach should give a good reflection of what’s happening in the mouse model, the 
amounts of pCre DNA entering the cell in a transient transfection are extremely variable 
and unpredictable. In the true in vivo situation where Cre and lox mouse lines are crossed 
in order to induce expression, only one transgene would be present in each cell so this 
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4  Design and characterisation of a cell culture 
model of DM1 pathogenesis 
4.1 Synopsis 
In both myotonic dystrophies type 1 and type 2, the mutant transcript becomes trapped 
within the nucleus forming foci, which co-localise to three members of the muscleblind 
family of double-stranded RNA binding proteins MBNL1; MBNL2 and MBNL3. MBNL 
proteins act in opposition to CUG-BP1, a single-stranded binding protein, to regulate the 
alternative splicing of target genes during development. Recruitment of MBNL1 to nuclear 
foci of expanded repeat arrays transcribed from the mutant gene, is thought to alter the 
dynamic balance between these regulators, resulting in the missplicing of genes, some of 
which can be directly related to a specific symptom of the disease. 
In chapter three we generated founder and targeting constructs to create a conditional 
mouse model of DM1, based on the limited expression of CTG repeats positioned within 
the 3’UTR of the EGFP gene using the Cre-lox system. Here we have used the targeting 
constructs pStopEGFP5 and pStopEGFP250, which allow transcription of EGFP and the 
repeat tract only after Cre excision of the upstream SV40 polyA signal, and their 
constitutively-expressing floxed derivatives pLoxEGFP5 and pLoxEGFP250, to create an 
inducible cell-culture model of DM1 to study early pathogenic changes. Our model 
replicated the key markers of pathogenesis observed in DM patient cells. In HeLa cells, we 
have shown that expression of the expanded repeat transcripts from constitutively 
expressed construct pLoxEGFP250 (chapter 3) formed foci within the nucleus, which co-
localised with MBNL1 protein. Foci were also formed in Cos7 and 3T3 cells. Since 
MBNL1 and CUG-BP1 proteins are central to the aberrant splicing seen in DM we also 
confirmed their presence within the cell. During co-localisation experiments using an 
MBNL1/GFP fusion protein it was noted that expression of MBNL1/GFP, therefore 
increasing the amount of available MBNL1 within the cell, increased the size of foci 
formed, supporting the MBNL sequestration hypothesis, but also suggesting a protective 
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4.2 Introduction 
Recent evidence suggests that the genes affected in myotonic dystrophy employ alternative 
splicing to produce different isoforms, regulated during development through a dynamic 
balance between two splicing regulators MBNL1 and CUG-BP1 (Ho et al., 2004). These 
proteins are antagonistic, favouring either the inclusion or exclusion of exons by adjacent 
site-specific binding during splicing of the messenger RNA, producing the embryonic or 
adult form of the gene when appropriate. Sequestration of MBNL1 protein within nuclear 
foci, and/or the increase in nuclear CUG-BP1 activity seen in DM1 patient cells, is thought 
to alter the balance between the two regulators and causes regulation of splicing to shift in 
favour of the production of embryonic or dysfunctional forms (by using cryptic splice 
sites) of the proteins concerned (Ladd et al., 2005; Lin et al., 2006). Although it is clear 
that missplicing is caused by this shift in the balance of regulation, little is known about the 
mechanism of regulation itself, and what regulates the regulators. CUG-BP1 is a single 
stranded binding protein whereas MBNL1 binds double-stranded RNA, so it may not be as 
straightforward as binding stoichiometry during splicing. In fact recent research indicates 
the mechanism may involve complex formation between either CUG-BP1 or MBNL1 and 
another splicing factor, heterogeneous nuclear ribonucleoprotein H (hnRNP H) (Paul et al., 
2006). In DM1 patient cells, and in cells expressing expanded CTG arrays, the activity and 
concentration of CUG-BP1 increases in the nucleus (Timchenko et al., 2001), but the 
overall total of nuclear and cytoplasmic CUG-BP1 is constant. What causes this and the 
reasons for it are unknown, so significant gaps remain in our understanding of DM 
pathogenesis. 
Myotonic dystrophy is a multisystemic disease, which varies in severity between 
individuals and progresses throughout the lifetime of the individual. The mutation expands 
somatically at varying rates between tissues and continues as the patient ages, the 
symptoms increasing in severity caused by the increase in array length. Sample donations 
from patients are invasive involving tissue biopsies and so are infrequent, nowadays rarely 
done since the advent of molecular CTG repeat analysis used for diagnosis, rather than 
skeletal muscle histology (Harper, 2001). The poor availability of patient samples and the 
variation between them confounds analyses done using them. Mouse models, and cell-lines 
generated from patient tissue have been used and are useful for pathogenic study, but the 
disease process is fixed and already underway. When we look at samples from patients it is 
not clear whether primary or secondary changes are being studied. For instance, 
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Koga et al., 1994). Salvatori et al. reported that decreased expression of DMPK correlated 
with the proportion of type 1 fibres compared to type 2, and that the decrease therefore was 
probably due to secondary effects resulting from type 2 fibre atrophy rather than a direct 
effect of the repeat on DMPK levels (Salvatori et al., 2005). It is therefore difficult to use 
patient samples to study the primary events arising from the earliest transcription of the 
mutant gene, as may be the case with the congenital form of DM1. An inducible tissue 
culture model would help to fill these gaps. Cell-culture based systems are easy to use, 
readily available and consistent. Depending on the cell-type used, the model would help to 
unite data already obtained from both human cells and samples and mouse models to study 
the effects of expanded CTG arrays on the processing of downstream targets. Since DM is 
a multisystemic disorder not purely affecting muscle, we chose to use non-muscle derived 
cell-lines to encompass rather than exclude any possible global effects. 
4.3 Validation of an inducible model  
Here we utilise transient transfection as a means to activate expanded array expression 
from the targeting constructs generated in chapter 3, allowing the study of pathogenesis 
from the first hours of expanded repeat transcription.  
4.3.1 Cre, Lox and foci 
The model is based on the expression of normal length or expanded CUG repeats placed 
within the 3’UTR of an EGFP reporter transcript. The induction of EGFP fluorescence and 
therefore expanded array expression by the Cre-lox excision mechanism has already been 
shown in 3T3 cells (Chapter 3.44, Figure 10). Here, pStopEGFP5 and pCre were 
transfected into 3T3 cells, EGFP fluorescence could only be detected when the two 
plasmids were transfected together. In the same experiment, in vitro Cre-excised derivative 
pLoxEGFP was also transfected into 3T3 cells and produced EGFP fluorescence. 
Activation of EGFP by Cre excision has also been successfully achieved in Cos7; HeLa 
and DmtD162 kidney cell-lines using co-transfections of pStopEGFP5 or pStopEGFP250 
and pCre plasmids (data not shown).  
In both myotonic dystrophy type 1 and type 2, the mutant transcripts become trapped 
within the nucleus and are retained in the form of foci (Davis et al., 1997; Liquori et al., 
2001). To determine whether our expressed transcripts form foci within the nucleus, Cos7 
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in situ hybridisation with Cy3 (red) conjugated (CAG)10 or (CTG)10 oligonucleotides 
performed. The CAG repeat oligonucleotide is expected to bind to the CUG expanded 
array, whilst the CTG repeat oligonucleotide should not, acting as a negative control. 
Nuclei were counter-stained with DAPI, a fluorescent blue dye.  
 
Figure 31 Nuclear foci in Cos7 cells expressing 250 repeats. A Fluorescent micrographs Low 
power magnification of Cos7 cells co-transfected with pStopEGFP250 or pStopEGFP5 and pCre. 
Foci can bee seen in the pStopEGFP250 repeat/pCre co-transfectants but not in the pStopEGFP5 
repeat/pCre co-transfectants. B High power magnification (X63) detailing foci within the nucleus in 
Cos7 cells co-transfected with pStopEGFP250 and pCre plasmids. Christine Haworth    Chapter 4, 116 
 
Foci were detected in the nuclei of cells when co-transfected with pCre and 
pStopEGFP250, but not with pCre and pStopEGFP5 (Figure 31). No foci were detected 
using the Cy3-(CTG)10 (data not shown). The Cy3-(CAG)10 fluorescent in situ 
hybridisations were repeated using HeLa and 3T3 cell-lines. Foci were detected in nuclei 
when co-transfected with pCre and pStopEGFP250 but not with pCre and pStopEGFP5 
(Figure 32). Therefore, in our model, the transcribed RNA containing expanded CUG 
repeats forms foci within the nucleus, and in cell-types other than muscle; monkey kidney 
(Cos7), human epithelial (HeLa) and mouse fibroblasts (3T3). It was observed that in 
general the foci were larger in Cos7 cells, and smaller and more well-defined in HeLa and 
3T3 cells (Figure 31 and 32), which, if MBNL1 is limiting in foci formation, could be due 
to differences in endogenous MBNL1 levels between the cell-lines. 
 
Figure 32 Fluorescent micrographs showing nuclear foci of expanded repeat transcripts in 
HeLa and 3T3 cells Fluorescent micrographs. No foci are detected by Cy3-(CAG)10 in situ 
hybridisation using constructs expressing only 5 repeats. Hela cells were transfected with 
pStopEGFP5 and pCre. 3T3 cells were transfected with constitutively-expressing pLoxEGFP5. NB 
All cells on the coverslips were assessed for foci formation, representative samples have been 
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Here we used co-transfection to test the Cre-lox mechanism and foci formation, which 
results in a low number of cells expressing both plasmids and consequently a low number 
of cells expressing the expanded array. Single versus double transfection has been shown 
in chapter 3 to give significantly increased EGFP fluorescence when using equivalent 
amounts of DNA (Chapter 3.44 Figure 10, pStopEGFP5 + pCre vs. pLoxEGFP5). Single 
transfections could be used to activate expression in our model using the cell-lines made in 
Chapter 3 (3.4.2) for testing neomycin function: HeLa and Cos7 cells stably transfected 
with pStopEGFP5 or pStopEGFP250. Expression of the reporter and expanded array could 
be activated by the simple transfection of pCre.  
4.3.2 Stable cell-lines 
To confirm Cre-lox function in these lines, Cos7 and HeLa pStopEGFP5 and 
pStopEGFP250 stable cell-lines (KpnI-XbaI fragment, chapter 3, Figure 20) were 
transfected with pCre. Cos7 and HeLa cells were transfected with pLoxEGFP as a positive 
control for transfection and fluorescence, or pCre alone as a negative control. EGFP 
fluorescence was detected microscopically in the pLoxEGFP control transfection, but not 
in the clones, HeLa or Cos7 cells using pCre (data not shown). The experiment was 
repeated, and produced the same negative result (data not shown). PCR analyses had been 
performed previously to confirm the presence of the transgene: EGFP PCR on the Cos7 
clones and for the Hela clones, EGFP (chapter 3, Figure 9) and DMH-BR PCR over the 
CTG repeat region (Chapter 3, Figure 20 for primer positions). To confirm the presence of 
the promoter, CMV PCR was carried out on a subset of the Cos7 clones, selected to reflect 
high, medium and low levels of EGFP product, since this could relate to the transgene 
expression level which may have been useful in future analyses. The construct was present 
in most clones as determined by EGFP and H-BR PCR analysis, but in the PCR obtained 
for the CMV promoter, product was absent in most isolates (Figure 33). Ideally the 
reaction should have been repeated since there is contamination present in the Cos7 
untransfected control, however this has no bearing on the interpretation of the negative 
result. Perhaps the close proximity of the 5’ end to the promoter region had resulted in 
promoter sequence loss due to endonuclease activity during integration. To check this, the 
KpnI -XbaI transgene fragment (Chapter 3, Figure 20) was tested by direct transfection into 
Cos7 cells to make sure it was functional. No fluorescence was evident (data not shown). 
A larger AclI fragment, incorporating a further ~300 bp of flanking region (Chapter 3, 
Figure 20) was isolated and co-transfected into Cos7 cells with pCre, and successfully 
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cells and ten clones from each of pStopEGFP5 and pStopEGFP250 isolated. 
Unfortunately, once again, transfection with pCre did not activate EGFP fluorescence (data 
not shown). 
 
Figure 33 The transgene is present within the stable clones. PCR analyses carried out to verify 
the transgene integrity. A Cos7 clones. CMV PCR was carried out on a subset of samples 
asterisked in the EGFP analysis. B HeLa clones. Most clones positive for DNA amplified both 
EGFP and H-BR PCR products. Note the different repeat lengths in “250” clones. 
It is not clear why this approach was unsuccessful. Possibly, the transfection of pCre used 
to activate the stable lines, resulted in many copies of the recombinase in comparison to the 
low copy number of the integrated transgene. This could have generated high levels of 
recombinase relative to the target transgene, interfering with transcription of the reporter 
gene by physically blocking RNA polymerase with incessant loxP binding. 
4.3.3 The constitutively expressed transgene 
The advantage of using stably pStopEGFP5/250-transfected cells was to increase the 
number of cells actively expressing EGFP after transfection. Since cells already harbour 
pStopEGFP5/250 integrated within the genome, cells need only a single plasmid 
transfection of pCre for EGFP gene expression, rather than the pCre + pStopEGFP5/250 
co-transfections previously used for transgene expression. So, rather than induce 
expression of EGFP via transient Cre activation of stable pStopEGFP5/250 cell-lines, this 
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34). In fact, transient transfection of the constitutively expressing floxed transgene confers 
an advantage over stably integrated transgenes due to the lack of position effects, often 
noted after genome integration. 
 
Figure 34 Two different approaches for single plasmid activation. Schematic diagram 
depicting the differences between two approaches to activation of transcription using a single 
plasmid transfection. Top pStopEGFP5/250 is first integrated into the genome of the chosen cell-
line and clones selected by neomycin resistance. EGFP transcription is then activated by excision 
after transfection with pCre. Bottom Constitutively expressing pLoxEGFP5/250 is transfected 
directly into the chosen cell-line. 
Floxed constructs were generated in chapter 3 (chapter 3, Figure 11B) by in vitro excision 
of pStopEGFP5 and pStopEGFP250 using recombinant Cre recombinase. During isolation, 
some constructs were identified with variations in the length of cloned repeats. PCR 
analysis revealed the arrays to be reduced to approximately 150, 100 and 110 triplet 
repeats. To confirm that the floxed pLoxEGFP250 products formed nuclear foci, HeLa 
cells were transfected with floxed products pLoxEGFP5 and pLoxEGFP250. The 100 and 
150-repeat floxed constructs were also included in the experiment to discover to what 
extent shortened arrays would form foci. Transfected cells were subjected to in situ 
hybridisation using Cy3-labelled (CAG)10 oligonucleotides. PLoxEGFP5 was included as a 
negative control for foci formation and no foci were detected. In pLoxEGFP constructs 
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Figure 35 Foci formation with 100, 150 and 250 repeats in HeLa cells The top row of pictures 
show the three channels DAPI; EGFP and Cy3 separately and merged for the pLoxEGFP5 
transfectants. No foci are detected with Cy3-(CAG)10. The bottom row shows the three channels 
DAPI, EGFP and Cy3-(CAG)10 merged for pLoxEGFP constructs with 100, 150 and 250 repeats. 
Foci are apparent within the nucleus. 
 
4.3.4 EGFP and RNA foci 
From the experiments conducted so far, it is clear that although the EGFP transcript is 
retained in the nucleus in the form of foci, enough transcript escapes into the cytoplasm to 
produce detectable levels of EGFP. However, it is not always the case that EGFP and foci 
are detected within the same cell. Looking at transfections so far in Cos7; HeLa and 3T3 
cells, on occasion EGFP positive cells were devoid of foci, and in contrast some foci 
positive cells showed no green fluorescence (Figure 36). The occurrence of EGFP-positive 
foci-negative cells can be explained by the heterogeneous nature of repeat length in any 
one plasmid preparation (discussed in chapter 3, figure 15); cells transfected with small 
numbers of repeats would not be expected to form foci. Those cells with foci but no EGFP 
fluorescence are harder to explain, but foci formation must be a dynamic process: Repeats 
must be present before MBNL can bind. During a transient transfection, we are using a 
population of cells in different stages of the cell cycle with transfection complexes present 
over a period of 24 hours; not every complex will enter the cell and the contents 
transcribed at exactly the same moment. If a cell is transfected later rather than sooner 
within this timeframe, and if MBNL binds as the transcript is generated, in these particular 
cells the RNA binding protein would not be limiting, so all transcripts could be retained 
within the nucleus resulting in no EGFP translation. A time-course correlation between 
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is found to be most consistent at 48hrs, whereas these samples are processed at 24 hours 
post transfection, which could further affect the correlation. 
 
 
Figure 36 EGFP positive cells do not always exhibit foci Fluorescent micrograph illustrating the 
lack of correlation between EGFP fluorescence and the presence of foci in HeLa cells transfected 
with pLoxEGFP250  
 
In our model, expansions of 100 repeats and above form nuclear foci. It is possible that in 
cells harbouring the 5 repeat construct, the RNA becomes aggregated within the nucleus 
but is not detected using the Cy3-(CAG)10 oligonucleotide because there are 50 fold fewer 
target repeats: 5 vs. 250. To address this, a Cy3-GFP oligonucleotide was synthesised. The 
body of the two constructs is identical and so an oligonucleotide directed to the EGFP 
portion should have equivalent amounts of target RNA. Any differences in the pattern of 
staining should be due to the location and density of the target rather than absolute number 
of repeats. HeLa cells were transiently transfected with pLoxEGFP5 or pLoxEGFP250 
construct and after 24 hours in situ hybridisation was performed with Cy3-GFP, or Cy3-
(CAG)10  oligonucleotides as a positive control for the presence of foci. Unfortunately the 
Confocal 488nm laser was out of alignment and awaiting maintenance, rendering the 
EGFP signal more faint and grainy than usual, but still useful to identify EGFP positive 
cells, the Cy3 and DAPI channels were unaffected. The Cy3-(CAG)10 control samples 
showed the expected pattern of staining with nuclear foci apparent in the pLoxEGFP250 
transfectants, and no staining in the pLoxEGFP5 transfectants (Figure 37). Of the Cy3-Christine Haworth    Chapter 4, 122 
 
GFP samples, no foci or general staining could be detected in the pLoxEGFP 5 
transfectants. In the EGFP positive portion of the pLoxEGFP 250 transfectants some cells, 
but not all exhibited foci-like staining in the nucleus, and many cells showed bright 
staining in the cytoplasm (Figure 37). Throughout this project in situ hybridisation to 
pLoxEGFP 250 transfectants with Cy3-(CAG)10 does highlight repeat RNA within the 
cytoplasm which peaks at 16 hours post transfection in 3T3 cells (see Chapter 5.3.1.1 ‘the 
dynamics of foci formation’) but not as seen here with Cy3-GFP. In this experiment few 
cells showed foci, most staining was found in the cytoplasm, and a significant number of 
cells exhibited EGFP fluorescence with no staining, something not seen as often with Cy3-
(CAG)10 probes. If the cytoplasmic staining is seen in EGFP positive cells in the 
pLoxEGFP250 transfectants, it is strange then that no cytoplasmic staining is seen in cells 
transfected with pLoxEGFP5. To conclude from this experiment, either the hybridisation 
itself failed, which is unlikely since the control Cy3(CAG)10 samples showed the expected 
results, or the Cy3-GFP is in fact not sensitive enough to detect a single copy target 
without amplification as afforded by a 50 fold increase in repeat number (250 vs. 5 
repeats). If foci were formed with arrays of 5 repeats, they would not be detected by Cy3-
(CAG)10 fluorescent in situ hybridisation. Taneja et al. looked extensively at the 
distribution of the DMPK transcript using a mixture of thirteen different 40-45bp probes 
placed throughout the transcript, in normal and DM1 patient cells. They observed focus 
formation only in DM1 patient cells and not in normal cells (Taneja et al., 1995). This 
conclusion has since been confirmed using riboprobes (Houseley et al., 2005), which 
confer more sensitive detection of target nucleic acid, since they are single-stranded and 
have a higher specific activity. Foci detected with (CAG)10  oligonucleotides therefore are a 
feature of expanded repeat expression and are specific to these cells.  
 
4.3.5 RNA binding proteins 
The most recently published literature suggests that the missplicing seen in myotonic 
dystrophy is caused by a shift in equilibrium between two opposing splicing regulators 
with trans dominant effects on specific pre-mRNA targets; primarily CUG-BP1 and 
MBNL1 RNA-binding proteins (de Haro et al., 2006; Kanadia et al., 2006; Lin et al., 
2006; Paul et al., 2006). 
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Figure 37 Foci detection using Cy3-GFP in situ hybridisation. Merged 3 channel fluorescent 
micrographs (EGFP; DAPI and Cy3) showing the failure of Cy3-GFP oligonucleotides to detect foci 
in control pLoxEGFP250 transfected HeLa cells, as well as the test pLoxEGFP5 transfected cells. 
Foci can clearly be seen in the control pLoxEGFP250 transfected HeLa cells using Cy3(CAG)10. 
Note that the green colouration originates from construct EGFP and not the fluorescent probe GFP, 
which is red (Cy3).  
 
4.3.5.1  CUG-BP1  
CUG-BP1 is a member of the CELF (CUG-BP and ETR-3 like factor) family of binding 
proteins. These proteins regulate the splicing of target mRNAs during development. In 
myotonic dystrophy patient cells, it had been noted that the concentration and activity of 
CUG-BP1 increased within the nucleus (Roberts et al., 1997; Timchenko et al., 2001). 
This led Philips et al. to look for CUG binding sites. They noticed CUG binding sites 
within muscle specific enhancers of the chicken (cardiac troponin T) cTnT gene, and went 
on to confirm it to be alternatively regulated during development by CUG-BP1, and more 
importantly to be mis-spliced in adult DM1 patients (Philips et al., 1998). Since this first 
data was published a plethora of CUG-BP1 target genes, some which can be directly 
related to symptoms have been discovered to be mis-spliced in DM1, such as chloride 
channel 1 causing the hallmark myotonia (Cooper et al., 2001; Mankodi et al., 2002) and 
the insulin receptor, insulin resistance (Savkur et al., 2001).  
Therefore in order to model this dynamic antagonism in the chosen cell-lines, it is 
important that CUG-BP1 is present. HeLa and 3T3 cells were transfected with 
pLoxEGFP5; pLoxEGFP250; pLoxEGFP (3T3 cells only) or transfection reagent alone 
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proteins were extracted. Total protein was extracted from the 3T3 transfectants. Each 
protein sample (50µg) was separated by SDS-PAGE (4-12%) before transfer and 
immobilisation onto a membrane. Protein bands were detected using α-CUG-BP1 
hybridisation followed by HRP-conjugate-chemiluminescent detection. CUG binding 
protein was detected in 3T3 extracts and the nuclei of HeLa cells (Figure 38). The levels of 
CUG-BP1 between the three HeLa nuclear samples appeared equivalent, although because 
no protein loading control was used it is impossible to confirm this.  
 
Figure 38 CUG-BP1 is expressed in HeLa and 3T3 cells 50µg nuclear extracts (HeLa) whole cell 
(3T3). The doublet seen in 3T3 cells is likely to consist of hyper and hypo-phosphorylated forms of 
CUG-BP1 (Roberts et al., 1997). 
Anti-CUG-BP1 analysis was repeated in HeLa cells to study the levels of the binding 
protein in separated cytoplasmic and nuclear fractions. Although in the transient 
transfection not every cell expresses the repeat (routinely in our hands, ~65% express the 
EGFP reporter as visualised by fluorescent microscopy), it may still be possible to detect 
an increase in the levels of nuclear CUG-BP1 caused by the expression of 250 CUG 
repeats. 
HeLa cells were transfected with pLoxEGFP5; pLoxEGFP250 or transfection reagent 
alone and harvested after 24 hours. Nuclear and cytoplasmic fractions were prepared, and 
50µg of each protein sample separated by SDS-PAGE (4-12%), before transfer and 
immobilisation onto a membrane. Protein bands were detected using α-CUG-BP1 
hybridisation followed by HRP-conjugate-chemiluminescent detection (Figure 39). CUG-
BP1 was detected in the nucleus of HeLa cells at much higher levels than in the cytoplasm. 
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Figure 39 CUG-BP1 in HeLa nuclear and cytoplasmic fractions. CUG-BP1 is present at much 
higher levels in the nucleus compared to the cytoplasm of HeLa cells. 
 
4.3.5.2  MBNL  
MBNL is recruited to foci of mutant RNA within the nucleus (Miller et al., 2000; Fardaei 
et al., 2001; Fardaei et al., 2002), and works in opposition to the splicing regulator CUG-
BP1. Using mouse models that over-express CUG-BP1 (Ho et al., 2005), or are 
nullizygous for MBNL1 protein (Kanadia et al., 2003), it has been shown that alteration of 
the balance between these two proteins leads to missplicing equivalent to that seen in 
myotonic dystrophy. In addition, chloride channel defects resulting from the over-
expression of CUG-BP1 in the mouse, have been reversed by increasing expression of 
MBNL1 (Kanadia et al., 2006). The current model of pathogenesis suggests that in 
myotonic dystrophy, MBNL depletion by foci formation may lead to the shift in MBNL1-
CUG-BP1 equilibrium, resulting in the splicing of developmentally inappropriate isoforms.  
The presence of MBNL in cultured cells was investigated by immunocytochemistry using 
αMBNL1 polyclonal antibody (αEXP42, a gift from Maurice Swanson, Miller et al., 
2000). Cells were fixed during exponential growth and the antibody hybridised overnight. 
Control cells were incubated without αMBNL1. Antibody binding was detected using an 
anti-rabbit AMCA conjugated secondary antibody followed by fluorescence microscopy. 
Control cells with no αMBNL1 showed slight background secondary antibody staining 
throughout the cytoplasm and the nucleus, but staining in the αMBNL1 sample was 
stronger, and primarily in the nucleus (Figure 40).  Christine Haworth    Chapter 4, 126 
 
 
Figure 40 Nuclear MBNL staining in HeLa cells. Fluorescent micrographs showing MBNL 
staining primarily in the nucleus of HeLa cells. Anti-vimentin was used as a positive control for the 
immunocytochemistry procedure. 
 
Overall the amount of fluorescence is lower than expected. Since MBNL is most abundant 
in the nucleus this could be due to difficulty of antibody entry through the nuclear 
membrane, or an effect of the fixation method used. To take a different approach western 
transfer and hybridisation was used. HeLa cells were transfected with pLoxEGFP5; 
pLoxEGFP250 or transfection reagent alone and harvested after 24 hours. Nuclear and 
cytoplasmic fractions were collected. At the same time, total protein was extracted from 
3T3 cells to establish the presence of MBNL in this cell-line. Protein samples were 
separated by SDS-PAGE (4-12%) before membrane transfer. Protein bands were detected 
using α-MBNL monoclonal (MCA-MBNL, Encor Biotechnology Inc), followed by HRP-
conjugate-chemiluminescent detection. Preliminary results indicated that MBNL was 
present (Figure 41). Ideally the hybridisation should have been optimised to increase the 
level of signal, which was faint. No signal was obtained using 3T3 cell extracts (data not 
shown). This was not an unexpected result since the HeLa cell chemiluminescent signal 
was faint; even though the extracts were nuclear indicating that the hybridisation was 
possibly at fault.  
 
Figure 41 Western showing MBNL in HeLa nuclear and cytoplasmic fractions. MBNL was 
detected in the nuclear fraction. Christine Haworth    Chapter 4, 127 
 
4.3.5.3  Co-localisation between MBNL and foci 
MBNL1, MBNL2 and MBNL3 have been shown to co-localise with nuclear foci of 
expanded repeats in DM1 and DM2 patient cells (Fardaei et al., 2002). To determine 
whether MBNL was recruited to RNA foci in this system, double labelling was performed. 
In order to minimise antibody usage the cell-culture surface area was scaled down 
compared to the previous ICC, by growing HeLa cells in 8-well 81mm
2 chamber slides. 
The cells were transfected 24 hours after plating, with pLoxEGFP250 or pLoxEGFP5. The 
following day, subsets of each transfection were either processed singly for Cy3-(CAG)10 
in situ hybridisation or αMBNL1 (αEXP42) immunocytochemistry as positive controls for 
each procedure, or by double labelling with αMBNL1 immunocytochemistry followed by 
Cy3-(CAG)10 in situ hybridisation. In the pLoxEGFP250 positive controls, foci were 
detected in samples with Cy3-(CAG)10 in situ hybridisation, but no fluorescence was seen 
using αMBNL1 immunocytochemistry (data not shown). In the double-labelled 
pLoxEGFP250 sample, fluorescent microscopy revealed nuclear foci staining by Cy3-
(CAG)10  in the pLoxEGFP250 sample, but no MBNL staining by αMBNL1/AMCA 
immunocytochemistry (Figure 42). No foci were seen in any of the pLoxEGFP5 samples 
(data not shown).  
 
 
Figure 42 Failed attempt to visualise MBNL in foci Fluorescent micrographs. HeLa cells 
transfected with pLoxEGFP250 followed by αMBNL/AMCA ICC and Cy3-(CAG)10  double labelling. 
Foci can be identified in the nucleus of EGFP positive cells, but no staining is seen using αMBNL, 
and therefore no co-localisation. 
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The experiment was repeated several times unsuccessfully: Cy3 positive foci did not show 
co-localised (or otherwise) staining with αMBNL1/AMCA. Another researcher had also 
encountered difficulties with the procedure (Houseley, personal communication). Antibody 
hybridisation appears to have failed since there is no general nuclear staining as seen in the 
HeLa cells during the ICC test (Figure 40). There could be a number of technical reasons 
for this. The antibody may have bound, but become disassociated during the in situ portion 
of the experiment -caused by formamide in the hybridisation buffer. Also, the foci do not 
appear as sharp when compared to in situ hybridisation done in a single labelling 
experiment (Figure 32). This could be due to partial degradation of RNA within foci 
during the antibody staining, from RNAses within the polyclonal antibody serum. 
Degradation of RNA in this way could also lead to the release of bound MBNL proteins. 
Some antibodies are not suited to ICC, and require high concentrations compared to 
western blots, but the antibody aliquot was insufficient for use at higher concentrations. 
There were obstacles that hindered analysis making it unclear as to whether endogenous 
MBNL does not co-localise with foci or if the double labelling procedure itself is at fault. 
The experimental design was flawed due to the absence of a positive control for the 
antibody staining of foci within the nucleus. It was also observed that the rate of 
transfection was reduced when using chamber slides, perhaps due to the formation of a 
deep meniscus. This caused cells to settle around the edge, and may also have interfered 
with complex dispersion lowering the number of target cells for study. The choice of 
secondary fluorophore, AMCA, is not ideal since the fluorescent signal from the lower, 
blue end of the spectrum is not as strong as the middle range, but since EGFP utilises the 
middle range and Cy3 from the far end, there was no other choice using the microscope 
equipment we had available. Far-red fluorophores such as Cy5 are too faint under 
fluorescent microscopy. Dyes with similar emission frequencies would now be a viable 
option since the confocal we have can visualise infrared, and can also distinguish between 
different emission spectra e.g. EGFP vs. FITC. 
To address some of the issues with the experimental design, a plasmid expressing 
MBNL1/GFP fusion protein under the control of the CMV promoter (a kind gift from 
Marion Hamshere (Fardaei et al., 2001)) was used to help visualise endogenous MBNL in 
cells expressing expanded CUG arrays. Although the use of the same reporter protein in 
two different constructs in the same transfection was likely to confuse analysis, it could 
resolve some doubts about the procedure. From the experiments performed so far, it was 
not clear whether endogenous MBNL does not co-localise with foci or if the double Christine Haworth    Chapter 4, 129 
 
labelling procedure itself was at fault. In our experiments pLoxEGFP250 constructs did not 
produce EGFP (i.e. green) foci. If MBNL1/GFP fusion protein does produce EGFP foci in 
the presence of pLoxEGFP250, these could be used as a positive marker for α-MBNL1 
immunocytochemistry to establish whether the double labelling procedure is working. It 
would also confirm the integrity of the α-MBNL1 used in the previous experiments. 
HeLa cells were seeded into chamber slides and transfected singly with MBNL1/GFP 
plasmid, or co-transfected with MBNL1/GFP plasmid + pLoxEGFP250 or MBNL1/GFP 
plasmid + pLoxEGFP5. After 24 hours, immunocytochemistry was performed with 
αMBNL1/AMCA followed by in situ hybridisation with Cy3-(CAG)10. No foci were 
detected in the MBNL1/GFP sample (Figure 43A) or the co-transfected MBNL1/GFP 
plasmid + pLoxEGFP5 (data not shown). Cy3 positive foci were detected in the co-
transfected MBNL1/GFP plasmid + pLoxEGFP250 sample which co-localised both to 
EGFP foci and αMBNL1/AMCA (Figure 43A). This suggests that MBNL1/GFP fusion 
protein is recruited to the RNA foci. It also confirms the integrity of the MBNL1 antibody. 
It is strange that the anti-MBNL staining in the co-transfected 250 repeat cells is 
perinuclear in this particular cell (Figure 43A), and that no Cy3 foci-positive cells were 
seen showing co-localised anti-MBNL staining within the nucleus. In the MBNL1/GFP 
control there is less general fluorescence within the nucleus using the antibody/AMCA 
combination compared to EGFP fluorescence (Figure 43A), which suggests that entry of 
the antibody was hindered, only detecting a small proportion of the MBNL present. 
However, this result cannot be representative, in this transfection only a few EGFP positive 
cells per well were observed, perhaps because the transfection was inefficient due to the 
use of chamber slides. Also, each EGFP positive cell is not guaranteed to include both 
plasmids resulting in very few cells of interest. So because the small scale was causing a 
problem, and it looked as if EGFP from MBNL1/GFP may be co-localising with foci, the 
transfections were repeated on a larger scale using coverslips, but without ICC.  
HeLa cells were transfected singly with MBNL1/GFP plasmid, pLoxEGFP250 or 
pLoxEGFP5. Co transfections were performed with MBNL1/GFP plasmid and 
pLoxEGFP250 or MBNL1/GFP plasmid and pLoxEGFP5. The transfectants were then 
subjected to in situ hybridisation with Cy3-(CAG)10.  All cells on the coverslip were 
assessed. Neither Cy3 foci nor EGFP foci were detected in MBNL1/GFP; pLoxEGFP5 or 
MBNL1/GFP plasmid and pLoxEGFP5 transfections (data not shown). Cy3 foci were 
detected in pLoxEGFP250, and MBNL1/GFP plasmid and pLoxEGFP250 co-
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seen in the MBNL1/GFP plasmid + pLoxEGFP250 co-transfections indicating that the 
presence of both plasmids is required in order to form EGFP foci. Where EGFP foci are 
present, the positions co-localise with the Cy3-labelled RNA foci in the nucleus (Figure 
43B Merged), indicating that both MBNL and CUG repeats are present within the same 
structure. It is difficult to form a conclusion with absolute certainty however because of the 
use of the same reporter protein to locate both MBNL and CUG-repeat expression. Ideally 
the experiment should be repeated, substituting an alternative fluorescent protein fusion 
such as EBFP (blue), or ECFP (cyan) for EGFP in the MBNL construct. 
It was mentioned earlier, that although the EGFP transcript is retained in the nucleus in the 
form of foci, clearly enough transcript escapes into the cytoplasm to produce detectable 
levels of EGFP. The reason for this is not known. It could be that the DNA sequence 
surrounding the repeat region within the construct may be important. The woodchuck post-
transcriptional element for instance has been shown to induce nuclear export of mutant 
DM1 transcripts when placed 3’ to the repeats (Mastroyiannopoulos et al., 2005). This 
escape could also be explained if MBNL is required to form foci, and is the limiting factor 
in their formation. Excess EGFP transcripts produced from a strong promoter may deplete 
MBNL stores leaving sufficient free of bound MBNL, to be exported to the cytoplasm to 
generate high enough levels of EGFP for visualisation. There are two pieces of evidence to 
support this: Firstly it is borne out by the difference in fluorescence levels between 
constructs containing 5 and 250 repeats: The 250 repeat transfectants exhibit lower 
fluorescence when transfected with the equivalent amount of DNA (chapter 5, Figure 45), 
probably because some of the expanded transcripts are retained within the nucleus, bound 
to MBNL. Secondly, during co-transfection with pLoxEGFP250 and MBNL1/GFP, 
preliminary results suggest that the foci are larger than those formed from pLoxEGFP250 
and endogenous MBNL (Figure 43B white vs. pink arrows). Since both constructs utilise 
EGFP as a reporter, in a co-transfection it is only possible to hint at which cells contain 
which plasmids. The expression pattern of EGFP from MBNL1/GFP is mostly 
concentrated within the nucleus (Figure 43A), whereas that from pLoxEGFP250 is evenly 
spread throughout the cell (Figure 43C). Using this information it is possible to map the 
cells (Figure 43D). Foci from this experiment were studied in greater detail using animated 
z-stacks taken using confocal microscopy. Here MBNL1/GFP foci are large suggesting 
that most MBNL is sequestered into foci, since increasing the amount of MBNL increases 
the size of the foci (Figure 44). It was interesting to note that the foci were not present 
within nucleoli, which appear as voids in DAPI-stained nuclei.  Christine Haworth    Chapter 4, 131 
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Figure 43 Fluorescent micrograph showing co-localisation of MBNL1/GFP with foci. A 
MBNL1/GFP and MBNL1/GFP + pLoxEGFP250 transfected HeLa cells with Cy3-(CAG)10 in situ 
hybridisation and αMBNL1/AMCA immunocytochemistry. EGFP foci (green arrows) are formed in 
the presence of both MBNL and repeat plasmids, which co-localise to Cy3-(CAG)10 foci within the 
nucleus. Note that in the left hand panel, EGFP fluorescence is much higher than the blue AMCA 
fluorescence within the nucleus indicating antibody entry is hindered. B MBNL1/GFP + 
pLoxEGFP250 or pLoxEGFP250 (panel C) transfected HeLa cells with Cy3-(CAG)10 in situ 
hybridisation. EGFP foci (green arrows) co-localise to Cy3 foci (white arrows) indicating co-
localisation of MBNL1/GFP and expanded array foci. Note that the RNA foci are larger in MBNL-
GFP + pLoxEGFP250 (white arrows) compared to pLoxEGFP250 alone (pink arrows) see map D 
indicating that the size of foci may be dependent on the amount of MBNL present. D Schematic 
map of the probable plasmid content within cells, based on the distribution pattern of EGFP 
expression comparing MBNL1/GFP alone (e.g. in A), with pLoxEGFP250 alone (e.g. in C). 
 
 
 
 
 
 
  
 
 
 
Figure 44 (movie) The effect of MBNL1/GFP on foci size. 3D animated confocal Z-stack. Hela 
cells transfected with pLoxEGFP250 alone (left) or with pLoxEGFP250 and MBNL1/GFP (right) 
after in situ hybridisation with Cy3-(CAG)10. Foci are increased in size and reduced in number in 
cells expressing pLoxEGFP250 and MBNL1/GFP. DAPI (nucleus) and Cy3 (foci) merged. See 
attached CD. 
 
 
4.4 Discussion 
We set out to determine whether the constructs generated to create an in vivo mouse model 
of myotonic dystrophy type 1, could be utilised to produce an in vitro model of DM1 
pathogenesis to study the earliest affected genes. Two approaches were investigated: pCre 
activation of pStopEGFP5 or pStopEGFP250 stable cell lines in HeLa and Cos7 cells; and 
direct transfection of HeLa; Cos7 and 3T3 cell-lines with the constitutively expressing 
pLoxEGFP5 or pLoxEGFP250. It is not clear why the former approach failed as many 
clones were generated (10 each of pStopEGFP5 and pStopEGFP5), and in different cell-Christine Haworth    Chapter 4, 133 
 
types (HeLa; Cos7 and DmtD162 kidney). PCR analysis throughout the construct 
confirmed its presence within the cell clones. It is possible that transfection of pCre used to 
activate the stable lines, resulted in over expression of the recombinase in comparison to 
the low copy number of the integrated transgene. This might have interfered with 
transcription of the reporter gene, by physically blocking RNA polymerase by continual 
loxP binding. The latter constitutive approach however was successful for reporter 
expression, and chosen for validation. Nuclear foci are formed in both DM1 and DM2 
patient cells and co-localise with MBNL protein (Fardaei et al., 2002), this pathogenic 
marker is used as a diagnostic feature of myotonic dystrophy (Bonifazi et al., 2006). In our 
cell-culture system, foci were identified in the nucleus 24 hours post transfection using 
pLoxEGFP250, but not detected using pLoxEGFP5. Foci co-localised with MBNL1/GFP 
fusion protein, and endogenous MBNL in perinuclear foci using αMBNL/AMCA and Cy3-
(CAG)10 double labelling. Interestingly, foci tended to be larger in Cos7 cells, and smaller 
and more well defined in HeLa and 3T3 cells, and those foci formed in the presence of 
excess MBNL (in the form of MBNL1/GFP) were larger than foci formed without 
additional MBNL. These observations were incidental and not substantiated, but could 
indicate that MBNL protein is limiting in foci formation, possibly preventing transcript 
exit into the cytoplasm up until that limit is reached.  
4.4.1 Cell-lines 
Our model is generic in terms of the cell-types affected in myotonic dystrophy. It is not 
biased by the specific function of a particular tissue and as such may be used to study the 
genesis of global effects, likely to be a good target for therapeutic intervention, and which 
may be important in the study of the congenital form of the disease.  
The original intention was to use ES cells as the basis of the cell-culture model. 
Pleuripotent embryonic stem cells can be differentiated into almost any cell lineage 
(O'Shea, 1999; Nagy et al., 2006), including those tissues characteristically affected in 
myotonic dystrophy such as skeletal (Dekel et al., 1992) and cardiac muscle (Sachinidis et 
al., 2003). An inducible model able to differentiate into the tissue of choice would be an 
invaluable and versatile tool to study and delineate the multisystemic facets of myotonic 
dystrophy throughout development. Unfortunately, due to questions raised over the 
pleuripotency of the clones generated in chapter 3, it was not deemed feasible to generate 
an ES cell-based model at this moment in time, but would be worth doing in the future. Christine Haworth    Chapter 4, 134 
 
Our model has been tested using a variety of cell-types from different organisms each 
positive for foci formation. As the project evolved, published research started to indicate 
that missplicing was fundamental to the disease process. As a result of this Cos7 (green 
African monkey kidney) cells were rejected for the model due to the poorly characterised 
genome sequence important for primer design in alternative splicing analysis. Both HeLa 
(human epithelial) and 3T3 (murine fibroblast) cells however are well-established general 
laboratory cell-lines, and produce a high rate of transfection with DNA. The genome 
project recently completed for both human and mouse can be utilised in conjunction with 
these cell lines to unite previously published data: Murine culture system with mouse 
model data and the human with patient data. The immediacy using transient constitutive 
transfection, allows study of the early pathogenesis and also overcomes confounding issues 
such as somatic expansion, and positional effects seen in other stable in vivo systems. 
4.4.2 MBNL 
At the time these experiments were designed and carried out, the focus of pathogenesis 
was on CUG-BP1. It wasn’t known that the balance of two splicing regulators was pivotal 
to the pathogenesis of DM. In hindsight, although it has not been established that 
missplicing in DM is limited to MBNL1 and CUG-BP1 disequilibrium, ideally we need to 
determine that the levels of MBNL1 and CUG-BP1 in cells chosen for the model are 
equivalent to those cell-types affected in the disease to enable the same changes in 
splicing. 
It was interesting to note that foci formed with MBNL1/GFP were large. Increasing the 
amount of MBNL1 available increases their size, suggesting that most MBNL1 is 
sequestered into foci. Is MBNL1 required for foci formation? Research by Housley et al. 
indicates that, in Drosophila, although muscleblind (the MBNL1 orthologue) does co-
localise with foci, muscleblind is not required for foci formation. In some cells, induced 
expression of (CUG)162 resulted in the formation of CUG positive foci where muscleblind 
could not be detected using standard immunohistochemical methods (Houseley et al., 
2005). This could be confirmed using existing mouse models to generate MBNL knockout-
repeat expressing mice. Lack of foci would indicate a prerequisite of MBNL for foci 
formation. If this was so, as has been reported by MBNL1 siRNA knockdown experiments 
in DM1 myoblasts (Dansithong et al., 2005), then MBNL could play a protective role in 
DM1. It has recently been shown that foci formation is separable from missplicing. Both 
expanded CAG and CUG repeats formed MBNL-associated nuclear foci, but mis-regulated 
splicing was only seen with CUG repeat expression (Ho et al., 2005). This questions the Christine Haworth    Chapter 4, 135 
 
hypothesis that sequestration of MBNL into foci causes the shift of CUG-BP1/MBNL1-
regulated splicing toward embryonic variants. More recently, involvement of the RNAi 
mechanism has been implicated. Long CNG repeat hairpins are a target for dicer, from 
which it generates gene-silencing siRNAs to that target. In the case of DM1, dicer cleaves 
the mutant repeat transcript into many short 21nt CUG repeats (Krol et al., 2007). Recently 
Mahadevan et al. created an inducible mouse model where low level expanded repeat 
expression leads to foci formation, but a lack of phenotypic effects. The control cohort 
over-expressing 5 CUG repeats does not form nuclear foci but surprisingly exhibited 
myotonia, heart conduction defects and RNA missplicing (Mahadevan et al., 2006). 
Perhaps short cytoplasmic CUG repeats are toxic, leading to repeat-associated CUG-BP1 
within the cytoplasm, which in turn would raise levels of CUG-BP1 (Timchenko et al., 
2001) causing missplicing. It would be interesting therefore to investigate the role of short 
CUG repeats in the cytoplasm. It may be that MBNL1 is protective up to a limit, until 
sequestration leads to an irrevocable imbalance between splicing regulators, allowing 
unimpeded activity of CUG-BP1. It would explain why long repeats are more pathogenic 
since larger repeats would deplete MBNL1 more rapidly resulting in earlier onset and 
increased severity. Additionally, foci have been shown to be formed by as little as 57 
repeats, lengths that are not pathogenic in people (Amack et al., 1999). 
From published research, it is clear that both reduced levels of MBNL, and increased levels 
of CUG-BP1 lead to aberrant splicing of target genes, but it is also clear that there is much 
to discover, that the mechanism of pathogenesis is not so straightforward.  Christine Haworth    Chapter 5, 136 
 
5   The effects of expanded CUG-repeat expression 
on mRNA steady state levels and splicing 
patterns  
5.1 Synopsis 
Myotonic dystrophy type 1 is a multisystemic disease in which the missplicing of genes 
can be directly related to important clinical features, such as the chloride channel to 
myotonia, or the insulin receptor to diabetes. Many symptoms nevertheless have yet 
resisted clear explanation: cataracts, testicular atrophy, heart block, anaesthetic sensitivity 
and mental retardation for example. Here we have used an in vitro cell culture model to 
discover further genes possibly aberrantly spliced in myotonic dystrophy, to attempt to 
clarify some of the unexplained symptoms. Affymetrix whole and exon transcript arrays 
were used to determine differential transcript levels and alternative exon usage between 
murine fibroblast 3T3 cells transfected with either 5 (pLoxEGFP5) or 250 (pLoxEGFP250) 
CUG repeats. For the exon arrays 0 (pLoxEGFP) repeats were also compared. Using whole 
genome arrays, 6 genes were down-regulated and 128 up-regulated. With exon arrays, 58 
genes showed alternative exon usage. Six genes were selected for further bioinformatics 
analysis: MtmR4, which has possible neuromuscular involvement; Kcnk4, Narg1, Ttyh1 
and Bptf, potentially related to brain development; and Cacna1c, a promising candidate for 
heart conductance defects and sudden death.  
5.2 Background 
In myotonic dystrophy, the expanded repeat transcript becomes trapped within nuclear 
foci. Recruitment and sequestration of the splicing regulator MBNL1 to these foci, is 
thought to alter the dynamic equilibrium between itself and another splicing regulator 
CUG-BP1, resulting in the production of developmentally inappropriate splice isoforms. 
The first gene discovered to be mis-spliced was cardiac troponin T (cTNT) (Philips et al., 
1998), originally identified as a target of CUG-BP1, whose activity and concentration 
within the cell is altered in DM1 (Timchenko et al., 2001). Cardiac troponin T is the 
tropomyosin-binding subunit of the troponin complex, regulating muscle contraction in 
response to alterations in intracellular calcium ion concentration. It is normally expressed 
in adult heart, and embryonically within skeletal muscle, but in DM1 is also expressed in Christine Haworth    Chapter 5, 137 
 
adult skeletal muscle (Philips et al., 1998; Ladd et al., 2005). Mutations in the gene are 
associated with cardiomyopathy (Thierfelder et al., 1994), which features in DM1 but is 
not always present (Harper, 2001). A clear link as to how missplicing in this gene could 
result in cardiac conduction system defects however, has not yet been established. It wasn’t 
until splicing of the chloride channel 1 gene (CLCN1) was found to be abnormal, resulting 
in the loss of chloride channel 1 (CLCN1) function and producing the definitive myotonia, 
that it was generally believed that aberrant splicing could also be responsible for the other 
symptoms of DM1 (Charlet et al., 2002; Mankodi et al., 2002). Missplicing of the CLCN1 
gene in DM1 skeletal muscle tissue compared to unaffected adult expression patterns 
results in the inclusion of exons normally reserved for the embryo, as well as the use of 
cryptic acceptor sites causing premature chain termination during translation (Charlet et 
al., 2002). Since then, other missplicing events have been identified, accounting for further 
phenotypic effects. Exclusion of an adult-specific exon in the insulin receptor transcript 
has been associated with the specific type of insulin resistant diabetes seen in DM1 
(Savkur et al., 2001). The microtubule-associated protein tau (MAPT) transcript undergoes 
complex, regulated alternative splicing, giving rise to several mRNA species differentially 
expressed in the nervous system. In DM1, the proportion of splice variants is disrupted 
(Sergeant et al., 2001; Leroy et al., 2006). Deletions in this gene have been associated with 
developmental delay and learning disability (Shaw-Smith et al., 2006), which is seen in 
congenital DM1. Myotubularin related protein 1 (MTMR1), also aberrantly spliced (Buj-
Bello et al., 2002), contains the consensus sequence for the tyrosine phosphatase activity of 
myotubularin (MTM). Mutations in MTM have been identified as being responsible for X-
linked myotubular myopathy (Buj-Bello et al., 1999), and mice deficient for the gene 
develop a generalized and progressive myopathy starting at around 4 weeks of age, with 
amyotrophy and accumulation of central nuclei in skeletal muscle fibers leading to death at 
6-14 weeks (Buj-Bello et al., 2002). There may be a link therefore between the progressive 
muscle wasting and myopathy, and MTMR1 mis-processing in DM1. Aberrant splicing is 
also witnessed in transcripts of two major proteins of the sarcoplasmic reticulum, the 
ryanodine receptor 1 (RyR1) and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 
(SERCA) 1 or 2. The foetal variant, ASI(-) of RyR1 which lacks residue 3481-3485, and 
SERCA1b which differs at the C-terminus, were significantly increased in skeletal muscles 
from DM1 patients and the HSA
LR DM1 transgenic mouse model (Kimura et al., 2005). In 
addition, a novel variant of SERCA2 was significantly decreased in DM1 patients (Kimura 
et al., 2005). Chemically increased Ca
2+ in mouse skeletal muscle induced some DM-like 
symptoms –myotonia, balding and cataracts (Takahashi et al., 1999), so inappropriately 
spliced RyR1 and SERCA1 mRNAs might contribute to impaired Ca2+ homeostasis in Christine Haworth    Chapter 5, 138 
 
DM1 muscle, and increased calcium levels seen in cultured DM1 cells (Benders et al., 
1996).  
Many missplicing events linked to symptoms have now been identified in myotonic 
dystrophy, but the list is not exhaustive. There are many symptoms not explained, some of 
which are more distressing for patients and their families to live with such as somnolence 
and dementia. Here we utilise the cell-culture model –consisting of murine 3T3 cells 
expressing either 0, 5 or 250 repeats within the 3’UTR of the EGFP gene (chapter four), to 
attempt to identify genes mis-spliced early in the pathogenesis of the disease, which are 
most likely to make good therapeutic targets. The objective is to identify further genes mis-
spliced as a direct result of expanded CUG repeat expression, using whole transcript and 
exon microarray analysis. Exon arrays became available during the course of the 
experiments, and are the most suitable chips to use to identify changes in exon inclusion 
and exclusion since probesets span all exons within the transcript. In whole transcript 
arrays most probsets are situated only at the 3’ end of the gene. Using these arrays it was 
thought possible to identify splice variants due to altered mRNA levels resulting from 
nonsense mediated decay, a mechanism activated when missplicing results in a premature 
termination codon situated in an exon other than the 3’ terminal exon –as observed in DM1 
with the chloride channel 1 transcript (Nagamitsu et al., 2000; Charlet et al., 2002)– as 
well as those differing in the 3’ termini, although none have yet been reported in DM. 
5.3 Microarray analysis 
Our model is based on a transient rather than a stable transfection system, in order to 
identify the earliest pathogenic events. Even though experimental parameters can be 
adjusted to optimise the rate of transfection, only a proportion of cells will contain the 
construct. We decided therefore to increase the proportion of construct-positive cells by 
separating the EGFP positive and non-fluorescent fractions from each transfection using 
fluorescent activated cell sorting (FACS). For each transfection, this would result in two 
pools of cells differing only in the expression of EGFP and also provide a tight internal 
negative control to limit technical variation between treated ‘EGFP on’ and untreated 
‘EGFP off’ fractions. RNA isolated from the ‘on’ and ‘off’ pools of each of the 
pLoxEGFP5 and pLoxEGFP250 transfected 3T3 cells gave four samples which could then 
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Table 10 EGFP ‘on’ and ‘off’ fractions used for differential gene expression analysis 
Differences between 1 and 3 result from expanded array expression. Although samples 2 and 4 
appear to be duplication, they are required to control for the fidelity of cell sorting. 
  Sample  Interpretation 
1  pLoxEGFP250 ‘on’  Test sample 
2  pLoxEGFP250 ‘off’  Internal negative control 
3  pLoxEGFP5 ‘on’  Negative test sample 
4  pLoxEGFP5 ‘off’  Internal negative control 
 
 
5.3.1 Parameter selection 
5.3.1.1  Dynamics of foci formation 
It was first necessary to establish the optimal time-point for RNA isolation after 
transfection –a point that would reflect the patient situation where aggregates of the mutant 
transcript are formed and retained within the nucleus in discrete foci, and at the same time 
express the EGFP reporter at a sufficient level for cell separation to increase the proportion 
of cells harbouring the construct. A time course experiment was set up to correlate foci 
formation and EGFP detection. Murine 3T3 cells were plated into 52 Petri dishes 
containing coverslips. The next day 13 dishes were each transfected with pLoxEGFP (0 
repeats); pLoxEGFP5 (5 repeats) or pLoxEGFP250 (250 repeats) constructs, or reagent 
alone. At time zero, and then every four hours for a total of 48 hours, a dish for each 
transfection was removed and the live cells photographed using fluorescence microscopy. 
The coverslips were then removed, fixed and stored in PBS until all time-points had been 
gathered. The remaining cells in the dishes after coverslip removal were trypsinised and 
stored in RNAlater solution, to be used at a later date out with this thesis to study the effect 
of expanded repeat tracts on the dynamics of gene missplicing. The coverslip samples were 
then processed in one batch for Cy3-(CAG)10 in situ hybridisation. Faint EGFP 
fluorescence was observed at 8 hrs post transfection and peaked in intensity between 20 
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Figure 45 Fluorescent micrographs charting EGFP fluorescence over 48 hrs. Live cell 
micrographs taken using brightfield and fluorescence microscopy. 3T3 cells were transfected with 
pLoxEGFP5 or pLoxEGFP250 constructs and samples photographed at 4-hour intervals over 48 
hours. EGFP fluorescence can be detected at 8 hours post transfection and peaked between 20 
and 32 hours. The intensity of EGFP fluorescence in the pLoxEGFP250 transfected sample did not 
reach as high a level as the pLoxEGFP negative and pLoxEGFP5 normal control samples, 
probably because of transcript retention within the nucleus. Christine Haworth    Chapter 5, 141 
 
No foci or Cy3 staining were detected in pLoxEGFP (0 repeats, negative control), and 
pLoxEGFP5 (normal control) transfections (data not shown). With construct 
pLoxEGFP250, Cy3-(CAG)10 in situ hybridisation illustrates the dynamics of foci 
formation within the cell over time. RNA was first detected faintly at 8hrs (data not 
shown). Of notable interest was the high amount of general fluorescence within the 
cytoplasm as the RNA levels increased and peaked between 16 and 20 hours. Over time 
the RNA became more discreet within foci, both within the nucleus and the cytoplasm, 
finally primarily in the nucleus from 28hrs (Figure 46A). It was not clear whether 
cytoplasmic RNA returned to the nucleus and became concentrated into foci, or if the foci 
were initially present but masked by the abundance of RNA, later revealed after RNA 
degradation perhaps, but in a previous parallel experiment using HeLa cells, general 
staining and some indistinct foci were apparent within the nucleus at 8hrs (Figure 47). It 
would be interesting to repeat this experiment using 1hr intervals between 6 and 12 hours 
post transfection, to clarify the presence of foci and pattern of general staining in the cell; 
whether cytoplasmic as well as nuclear, and whether foci are formed as a primary or 
secondary event. Cytoplasmic foci have not been reported in the literature, but have been 
observed by other researchers (L.Timchenco, personal communication) and were apparent 
in DM1 fibroblast patient cell-lines (a kind gift from J. D. Brook) (Figure 46D). However, 
it has been proposed that the presence of cytoplasmic foci is a phenotype of some, but not 
all, patient cell-lines (S. Reddy, personal communication). 
The CMV promoter ensured high-level expression of the transcripts, which was confirmed 
by bright EGFP fluorescence. However, Houseley et al. observed bright general staining in 
cells without foci, expressing GFP-tagged CUG expansions using a single-copy GFP 
Riboprobe (Houseley et al., 2005), so it was surprising that we did not see general staining 
in pLoxEGFP5 cells above background, especially within the cytoplasm (Figure 46B). 
This however, may have been an artefact due to the stringency of hybridisation since the 
Cy3-(CAG)10 probe (30 nucleotides) would only bind to 15 nucleotides of the (CAG)5 
repeat, and could have failed to hybridise, or have been washed away during processing. Christine Haworth    Chapter 5, 142 
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Figure 46 The dynamics of foci formation. Fluorescent micrographs. Cy3-(CAG)10 in situ 
hybridisation on 3T3 cells transfected with pLoxEGFP250; pLoxEGFP5 or pLoxEGFP, sampled at 
4 hourly intervals. A. The presence of EGFP fluorescence and foci formation over time. In 
3T3/pLoxEGFP250 cells, EGFP fluorescence can be visualised faintly from 8 hours and peaks 
between 24 and 32 hours. Cy3-(CAG)10 staining is predominantly cytoplasmic as well as nuclear at 
16 and 20 hours post transfection, but becomes more discreet over time with foci mainly nuclear Christine Haworth    Chapter 5, 144 
 
from 28 hours post transfection. B. Low (X16) and high (X63) power images of 3T3 cells 
transfected with pLoxEGFP5 20 hours post transfection, showing that no Cy3-(CAG)10 staining is 
present in the normal control. C. High power (X63) images of 3T3/pLoxEGFP250 transfections at 
16 hours showing intense Cy3-(CAG)10 staining in the cytoplasm. By 48 hours the staining is 
limited to discrete foci predominantly within the nucleus. D. Cy3-(CAG)10 staining in patient DM1 
fibroblast cell-lines (left and middle) reveals cytoplasmic foci. These have also been observed 
using pLoxEGFP250 in 3T3 cells (right). 
 
Figure 47 Foci are apparent in HeLa cells at 8hrs post transfection. Fluorescent micrograph. 
HeLa cells transfected with pLoxEGFP250 show Cy3-(CAG)10 staining within the nucleus and 
diffuse foci at 8 hrs post transfection. 
 
Not all EGFP positive cells transfected with pLoxEGFP250 exhibited foci (Figure 46A). 
This could have been due to plasmid heterogeneity as previously described (chapter 3), or 
the confocal plane may not have passed through the focus. Foci are spread throughout the 
nucleoplasm avoiding the nucleoli (chapter 4 Figure 44 3D movies). Therefore, when 
taking a representative image, the focal plane will not pass through all foci, and could miss 
all of them. To assess the presence of nuclear and cytoplasmic foci within EGFP positive 
cells, foci were identified in individual cells by focusing through the whole thickness of the 
cell dorsally to ventrally and the presence noted (Figure 48B). All EGFP positive cells on 
each slide were counted. This resulted in a variable number (14-54) of cells assessed at 
each time point, but was enough to give an indication of foci and EGFP correlation.  
The 48hr time-point was selected to prepare RNA for microarray analysis since the Cy3-
(CAG)10 staining pattern most closely reflected the situation in patient cells, where RNA is 
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Figure 48 Cytoplasmic CUG repeats and the presence of nuclear foci within EGFP positive 
cells charted over time post transfection. A Bright general cytoplasmic staining and cells with 
defined cytoplasmic foci were counted as positive, in cells positive for nuclear foci. B Greater than 
97 percent of EGFP positive cells contained nuclear foci at each time interval. Error bars show the 
95% confidence interval. Time points 0, 4, 8, 40 and 44 hrs were not determined. 
Unfortunately the intensity of EGFP fluorescence at this time-point was reduced, probably 
because of the sequestration of the RNA within the nucleus, also the proportion of EGFP 
positive cells was low probably due to faster growth of untransfected cells, making the 
acquisition of fluorescent cells by FACS more prolonged. Pilot tests were carried out to 
ensure that the cells could survive the separation procedure and that the RNA made from 
them was of good quality (addressed in 5.3.1.2.3).  
5.3.1.2  Fluorescent activated cell sorting (FACS)  
The use of the FACS separation system FACSCalibur (BD Biosciences), was kindly 
provided by Prof. J.Mottram (Wellcome Centre for Molecular Parasitology, Anderson 
College, Glasgow). 
Firstly, parameters for cell-separation were established. 
5.3.1.2.1 Cell density 
The pattern of gene expression varies during different phases of cell growth, so in order to 
maintain consistency it was important that the cells would be actively growing at harvest. 
The exponential phase is considered to be up to 95% confluence. Pervious experiments 
indicated that the transfection of cells with densities below 50% resulted in cell death (data 
not shown), so cells were plated at different densities in large tissue culture flasks and 
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transfection. This would allow the maximum exponential growth post transfection. Cells 
were then photographed after 24 and 48 hrs. 
5.3.1.2.2 Gates and purity 
Cells were sorted during FACS using gates set with control samples. This was first tested 
using fluorescent beads. Voltage gates were optimised for each bead colour separately and 
used to sort and collect green beads from an approximately equal mixture of non-
fluorescent, fluorescent green and fluorescent red beads in PBS. For sorting, three modes 
are available: Single cell, where only single positive beads are collected; Recovery, where 
all events containing a positive bead are collected; and exclusion, where all negative beads 
are rejected. Single cell sorting was not used since it was expected that the yield would be 
low. Using the recovery mode, the proportion of green beads was enriched from 56% to 
69%. In exclusion mode, where only pure positive fractions are collected, 98% of the 
beads recovered were green (Figure 49). Therefore exclusion mode was chosen for future 
cell sorting. 
Following these successful attempts at sorting, the gates were then established for 
separating EGFP positive cells from non-expressing cells. For the control samples 3T3 
cells were transfected with either regent alone or pLoxEGFP5, and harvested after 24 
hours. After separation optimisation, the reagent alone sample produced a single ‘negative’ 
grouping. The pLoxEGFP5-transfected sample produced two groupings: negative and 
EGFP positive, since not all cells in the sample would be expressing EGFP, thus allowing 
identification of the EGFP positive fraction (Figure 50). Gates were drawn around the two 
fractions and the fluorescence intensity within each gate (region 1 and 2) plotted for each 
sample. The shape of the curves within region 1 is similar for each sample, indicating that 
there are few contaminating EGFP positive cells within the untransfected cell gate. 
Correspondingly, when events collected using region 2 are plotted, few cells were counted 
from the negative sample indicating little untransfected-cell contamination within the 
EGFP positive gate (Figure 50). The separation procedure was lengthy. In the previous 
experiment, setting the gates, collection and concentration of 1 X 10
5 EGFP positive and 1 
X 10
5 negative events took on average 5 hours.  
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Figure 49 Calibration beads shown before and after sorting. A. Facscalibur acquisition dot-plot 
showing the differences in the bead mixture based on emission spectra during passage through the 
488 nm laser. Each crossing of the laser beam is termed an event, which can include more than 
one bead. Separation parameters were optimised for a mixture of non-fluorescent, red fluorescent 
and green fluorescent beads. Each grouping corresponds to clear (grey arrow); FITC (green arrow) 
and PE (red arrow) beads. Sort gates were then drawn around the regions to be collected (not 
shown). B. The bead mixture before and after sorting and recovery using two different sort modes. 
In recovery mode, every positive event is collected, even if a contaminating bead is present. This 
results in high recovery of positive events, but lower purity. In exclusion mode only events 
containing positive beads are collected, mixtures are rejected. This results in a pure but lower yield 
of positive events. 
 
The 3T3 transfections were repeated, again using reagent-alone or pLoxEGFP5. Both 
samples were used to refine the gate settings. The EGFP positive fraction was sorted and 
collected from the pLoxEGFP5 sample. After sorting, the proportion of EGFP-positive 
cells detectable by fluorescence microscopy was much higher (63%; 28 of 44 cells) than in 
the unsorted sample (26.5%; 21 of 79 cells), and EGFP fluorescence could be detected in 
most but not all cells (Figure 51). The reason why some cells appeared non-fluorescent 
during microscopy was unclear, but could have been because fluorescence detection during 
FACS is more sensitive than the eye or camera, or due to the position of the gates, or 
plasmid loss from the cell. As a precaution the gate drawn for collection of the negative 
sample was tightened. 
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Figure 50 Establishment of sort gates. Reagent-only and pLoxEGFP5-transfected 3T3 cells 
were used to establish separation settings. Acquisition dot plots (left) show a single cell-group in 
the reagent-only sample corresponding to untransfected cells. In the pLoxEGFP5-transfected 
sample two groups are apparent, corresponding to untransfected and EGFP-positive fractions. 
Gates were drawn around the two groups –region 1 and 2 – and the number and fluorescence 
intensity of events plotted in each (histograms middle and right). Region 1 histograms (middle) 
show similar area curves indicating few contaminating EGFP positive cells within the negative gate. 
Region 2 histograms (right) show few negative cells (top) contaminating the EGFP positive gate. 
 
 
5.3.1.2.3 Cell viability and RNA integrity 
It was of concern that the cells used during the sorting –and those recovered would have 
been stored in PBS for a considerable amount of time. To ensure that cells collected using 
the cell-sorter could survive the procedure, pLoxEGFP5-transfected cells were saved at 
each stage of the sorting in the previous experiment, plated into tissue culture dishes and 
incubated overnight. The cells were photographed using brightfield and fluorescent 
microscopy from all stages of the experiment; starting sample; post trypsin harvest; 
recovered sorted cells and unsorted post sort (starting sample after the experiment) and 
appeared healthy, with no bacterial or fungal contamination observed (Figure 51). Leftover 
starting sample was also tested for viability using trypan blue reagent, a diazo dye used to 
stain cells with disrupted outer membranes. Cells with an intact membrane exclude the 
dye, and dead cells are coloured blue. Cells were found to be a healthy with few taking up 
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sample in PBS on ice for the extended period of 5 hours was not found to be detrimental to 
cell viability. 
 
Figure 51 Cell viability after the sorting procedure Brightfield and fluorescent micrographs. 
pLoxEGFP5 transfected 3T3 cells were used to test the sorting procedure and subsequent cell 
viability. The starting sample was photographed. Samples were taken at the stages indicated, 
plated onto tissue culture dishes and incubated overnight. The sorting procedure was not found to 
be detrimental to cell viability. The proportion of EGFP positive cells was increased in the sorted 
compared to the unsorted and post-trypsin samples. 
 
Figure 52 Cell viability after storage on ice. Left, brightfield and right, fluorescent micrographs. 
3T3 Cells from the post-trypsin harvest were stored on ice for 5 hours and tested for viability using 
trypan blue reagent. A few cells took up the dye but most cells did not, indicating the majority had 
an intact membrane and were still alive.  
The separation procedure was prolonged, allowing the collection of one positive and one 
negative fraction from one transfection per day. Since three replicates of each sample were 
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necessary to store sorted cells to allow all replicates collected to be processed at the same 
time, limiting technical variations, whilst maintaining quality. To confirm the integrity of 
RNA during storage of the samples, RNA was extracted from unsorted and sorted cells 
stored in RNA-later solution. RNA-later is a proprietary solution formulated for the storage 
of cell and tissue samples without compromising the integrity of the RNA prior to 
extraction. Mouse 3T3 cells were transfected with reagent alone; pLoxEGFP5; or 
pLoxEGFP250. After 24 hours, cells were harvested and stored in RNAlater for 11 weeks 
at -20ºC. The pLoxEGFP5 and pLoxEGFP250 transfections were repeated, EGFP positive 
and negative fractions sorted and 5 X 10
5 events collected from each fraction as described 
previously. The samples were stored for one week in RNAlater at -20ºC. The cells from all 
samples were collected as previously described, and RNA extracted using RNeasy mini kit 
(Qiagen), the method recommended by the Molecular Biology Support Unit for microarray 
analysis. RNA was visualised using guanidinium hydrochloride agarose gel 
electrophoresis, and assayed using the Bioanalyser (Agilent Technologies). The RNA 
stored before sorting was of the same quality as RNA prepared from live 3T3 cells, but the 
RNA extracted form sorted cells showed signs of degradation (Figure 53A+B). This could 
have been due to temperature rises in the sample during sorting, so to counteract this, the 
sorting protocol was modified such that the source sample was aliquotted and stored on 
ice, each aliquot discarded after 30 minutes sampling. The buffers were also kept on ice 
and topped up more frequently. When recovering the sample it proved difficult to form a 
pellet and a significant amount of cellular material remained bound to the wall of the tube. 
The number of cells (events) recovered from each FACS is small, so no losses could be 
tolerated. For this reason, we decided to store collected cells in RNA lysis buffer, the first 
solution used in the RNA extraction, at -80ºC since this would reduce the sample loss to 
zero. After these measures were adopted, RNA integrity was no longer compromised 
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Figure 53 RNA integrity following storage in RNAlater solution. A. Guanidinium thiocyanite 
agarose gel electrophoresis. The samples on the left hand gel had been stored in RNAlater for 11 
weeks without affecting the quality of the RNA extracted. RNA was compared to that extracted from 
live cells as a control. The samples on the right hand gel were first sorted using FACS, then stored 
in RNAlater solution for 3 weeks. The sample quality of the positive fractions is reduced since the 
intensity of the ribosomal RNA band at 28s is not higher than that of the 18s band. B. Bioanalyser 
results. A proportionately large 5s peak compared to the 18s and 28s peaks, and the deviation Christine Haworth    Chapter 5, 152 
 
from the baseline between the 18s and 28s peaks indicated sample degradation within the positive 
cell-fractions. C. After minor modification of sample handling during sorting, the RNA isolated was 
of better quality using the same criteria of ribosomal RNA comparison. Note the proportionately 
small 5s peak and the low baseline between 18 and 28s peaks, indicating a lack of degradation. 
 
5.3.2 Transcript expression array 
The Affymetrix “GeneChip Mouse Genome 430 2.0 Array” allows for the analysis of 
39,000 transcripts in a single array. Each transcript is represented by multiple probe sets 
(four adjacent oligonucleotides) allowing several measurements to be made to accurately 
evaluate individual transcript levels. Whilst coverage of the mouse genome may not be 
absolutely complete, it is comprehensively represented on the array since the probe sets 
were derived from sequences selected from GenBank
®, dbEST, and RefSeq, which are 
further refined by comparison with the draft assembly of the mouse genome (Whitehead 
Institute for Genome Research MGSC, April 2002). In this particular GeneChip, the bias 
for the probeset position is towards the 3’ end of the transcript, which is not ideal for the 
analysis of alternatively spliced isoforms. It should however reveal any missplicing that 
results in a premature termination codon, since this would lead to nonsense mediated decay 
and reduced levels of transcript (Nagamitsu et al., 2000), as is the case with the chloride 
channel in DM1 (Charlet et al., 2002). 
5.3.2.1  Sample preparation for whole transcript arrays 
The samples were prepared in triplicate, in parallel, such that three chips were hybridised 
for each sample group pLoxEGFP5 ‘on’; pLoxEGFP5 ‘off’; pLoxEGFP250 ‘on’ and 
pLoxEGFP250 ‘off’ –twelve chips in total. The mouse 3T3 cells used for transfections 
were plated at diluting densities some weeks before starting the experiment such that cells 
plated for each transfection had the same passage number, even though the transfections 
were staggered over two consecutive days for 3 weeks. Mouse 3T3 cells were plated to 
give 50% confluence after 24 hours growth, then transfected with pLoxEGFP5 or 
pLoxEGFP250. After 48 hours, the cells were harvested using trypsin and washed in ice 
cold PBS, and kept cool throughout processing. EGFP positive and EGFP negative 
fractions were sorted and collected from transfected samples using a FACSCalibur cell-
sorter, with the parameters established in section 5.3.1.2. On any particular day, only one 
negative and one positive fraction was collected from a single transfection, so after sorting, 
cells were concentrated by centrifugation, resuspended in RNA lysis buffer and stored at -
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until three replicates each of pLoxEGFP5 and pLoxEGFP250 EGFP positive and EGFP 
negative fractions had been gathered. Total RNA was prepared, and transferred to MBSU 
for quality assessment and to carry out the microarray hybridisation procedure. 
RNA samples were labelled using the Affymetrix one-cycle gene chip target labelling 
protocol, which does not involve amplification of the sample. After hybridisation, signals 
were first normalised using robust microchip average (RMA (Irizarry et al., 2003)), then 
scored for differential expression between pLoxEGFP5 vs. pLoxEGFP250 transfected 
samples using Rank Products (Breitling et al., 2004). Expression differences were also 
ordered according to Iterative Group Analysis (iGA), which statistically identifies 
functional classes of genes with significant changes (Breitling et al., 2004). These genes 
may be members of a pathway for instance. Not all members of the group need to be 
changed and not by a large amount. 
5.3.2.2  Results of analysis 
The comparison of pLoxEGFP5- vs. pLoxEGFP250- should give an indication of the 
fidelity of separation since each sample should contain only the untransfected fraction of 
non-fluorescent cells, and so there should be no difference in gene expression levels. 
According to the rank product analysis however, with a false discovery rate of less than 
5%, in the pLoxEGFP250- sample, 106 genes are up-regulated and 10 are down-regulated, 
relative to pLoxEGFP5-. It is possible therefore that the separation was not absolute, or 
that some pLoxEGFP250 transfected cells did not fluoresce perhaps because of transcript 
retention, thus contaminating the negative sample with cells expressing expanded arrays. 
Likewise, there should be no difference in transcript expression between pLoxEGFP250+ 
vs. pLoxEGFP5- and pLoxEGFP250+ vs. pLoxEGFP250-, since again, both pLoxEGFP5- 
and pLoxEGFP250- samples should contain only untransfected cells. In fact the 
differences between these two are large (312 up and 79 down-regulated compared to 49 up 
and 5 down-regulated respectively, (Table 11: Tests 2 and 5)), compared to the differential 
expression within pLoxEGFP250+ vs. pLoxEGFP250- (Table 11, Test 3), indicating that 
the nature of pLoxEGFP250+ and pLoxEGFP250- is similar. Down-regulated genes 
identified within pLoxEGFP250- vs. pLoxEGFP5- were compared to those listed in 
pLoxEGFP250+ vs. pLoxEGFP5- (Table 11, Tests 5 and 2). If there was contamination of 
pLoxEGFP250+ within the pLoxEGFP250- sample then one would expect the same genes 
to be listed. Seven of the 10 genes were found within the 5% cut off, so indicating probable 
contamination of the pLoxEGFP250- sample with pLoxEGFP250+. The down-regulated 
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pLoxEGFP5+ vs. pLoxEGFP250- analyses (Table 11, Tests 1 and 6). Again if there was 
contamination of pLoxEGFP250- with pLoxEGFP250+, the same genes would be 
expected in the lists. At the same 5% limit, 5 of 6 genes were also listed within the 42 up-
regulated genes (N.B. up-regulated genes were compared because the base-line was 
reversed in the pLoxEGFP5+ vs. pLoxEGFP250- (test 6, Table 11) comparison).  
Table 11 Up and down regulation of transcripts 
Test vs. baseline  Up  Down  Test 
1.  250+ vs. 5+  128  6  Extended CUG repeats 
2.  250+ vs. 5-  312  79  Extended CUG repeats and construct related 
3.  250+ vs. 250-  49  5  Extended CUG repeats and construct related 
4.  5+ vs. 5-  130  90  Normal length repeats and construct related 
5.  250- vs. 5-  106  10  Separation control 
6.  5+ vs. 250-  42  66  Normal length repeats, construct related and separation 
control 
Note–False discovery rate limit ≤ P=0.05. 
 
To detect structure in the relationship between our samples, a principle components 
analysis (PCA) was carried out (at the MBSU). Briefly, PCA is a type of factor analysis, 
which uses a mathematically defined transformation of a given multivariable data set. This 
simplifies the data so that the greatest variance lies on the first coordinate – termed the 
principle component. It reduces the dimensionality of the data in effect, by combining 
variables until only the defining components remain, and is commonly used with 
microarray data sets to look at the relationship between samples. The results of the analysis 
show the relationships between the pairs of separated ‘EGFP on’ and ‘EGFP off’ samples, 
for each replicate of pLoxEGFP5 and pLoxEGFP250. In general the relationship between 
EGFP off samples (-5(1); -5(2); -5(3); -250(2) and -250(3)) and EGFP on samples (+5(1); 
+5(2); +5(3); +250(2) and +250(3)), irrespective of whether they were derived from 5 or 
250 CUG repeat expression, shifts upwards and to the right for negative samples. The 
exception to this is the -250(1) and +250(1) pair, where the shift is downwards (Figure 
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microarray analysis was subjected to semi-quantitative EGFP RT-PCR. Unfortunately, the 
-250(1) sample was used up during array hybridisation, but comparison of +250(1) EGFP 
PCR product levels with other EGFP+ RNA fractions should indicate whether the +250(1) 
sample belonged with the positive or negative group. RT-PCR was carried out using the 
remaining RNA samples. To ensure that the levels of product seen after amplification were 
a quantification of template in the starting sample, the number of cycles required to 
generate linearity of the PCR product was established using control RNA. Total RNA from 
untransfected, and pLoxEGFP-transfected 3T3 cells was mixed in varying proportions: 0; 
1; 5; 10; 20; 50 and 100% pLoxEGFP-transfected, and used to determine the optimal 
number of cycles for amplification (Figure 30 Bottom).  
 
 
Figure 54 Samples +250(1) and -250(1) were not accidentally switched A. Principle component 
analysis. Mathematical algorithm plotting the relationship between the FACS-separated sample 
pairs suggested +250(1) and -250(1) may have been switched. B. Semi-quantitive EGFP RT-PCR 
indicates that the levels of PCR product amplified from +250(1) were equivalent to the other 
EGFP+ fractions, therefore a switch was unlikely. 
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For both control and test samples 500 ng of RNA was reverse-transcribed, and 2/5 of the 
reaction product used for the EGFP PCR analysis. Fifteen cycles were used for the 
amplification (Figure 54B). Note that it was not possible to include a “no RT” control due 
to the very limited amounts of sample. In fact, the samples would be expected to be 
positive for DNA since they were not DNase treated (small amounts of plasmid DNA such 
as pLoxEGFP5/250 used for the transfections tend to co-isolate with RNA during 
preparation). This was of little consequence here since we were looking at the level of 
separation. If the product arose from plasmid DNA rather than transcript, the separation 
level was still a valid measure. The amount of EGFP product amplified from the +250(1) 
sample was found to be equivalent to the other EGFP positive samples, which suggested 
the samples had not been accidentally switched.  
Whilst this data set was incomplete since some samples were used up during array 
hybridisation, there were enough to indicate the level of separation, and at the molecular 
level it was clear that separation was not totally successful. As predicted from the 
microarray results, EGFP negative samples are contaminated with EGFP transcripts across 
all samples, whether pLoxEGFP5 or pLoxEGFP250 derived. In conclusion, since the 
separation had failed, reliable data was restricted to the pLoxEGFP250+ vs. pLoxEGFP5+ 
comparison (Test 1 Table 11) since both these fractions must contain the construct. 
In this comparison 128 genes were up-regulated (Table 12) and 6 down-regulated (Table 
13). Genes subjected to non-sense mediated decay would appear to be down-regulated in 
this analysis, as would those with exon exclusion in alternatively spliced 3’ ends. Of the 6 
down-regulated genes 3 were unannotated RIKEN DNA bank cDNAs, the remainder 
comprised Hes1 (hairy and enhancer of split 1); D3Ertd300e (DNA segment, Chr 3, 
ERATO Doi 300, expressed) and Tfrc (transferrin receptor). Hes1 is involved in neuronal 
differentiation (Bae et al., 2000) and also tenuously thought to be a negative regulator of 
myogenesis due to its ‘helix-loop-helix’ domain, and its role in maintenance of the 
undifferentiated state (Kageyama et al., 2000). At the time of this analysis, nothing was 
known about the function of the D3Ertd300e gene product (also known as p38 interacting 
protein), since then researchers have found it is critically required for the regulation of 
gastrulation in the mouse. Zohn et al. created a mouse model with a splicing defect in this 
gene, which exhibits exencephaly and spina bifida. These mutations are not completely 
penetrant, probably because low levels of transcripts are processed normally. The same 
researchers showed that mutant embryos homozygous for a more severe p38IP allele are 
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to form somites or form only a few anterior somites (Zohn et al., 2006). Some aspects of 
this phenotype are reminiscent of the congenital form of DM1 such as misshapen head and 
impaired muscle development, so in hindsight this gene should have been selected for 
further characterisation.  
Iterative Group Analysis (iGA) predicted the involvement of iron homeostasis (transferrin 
receptor), and nucleolus organisation and biogenesis pathways. Nucleoli, the sites of 
ribosome biosynthesis, enlarge in response to large protein production requirements. Due 
to the nuclear retention of EGFP transcripts in the pLoxEGFP250 sample, a high protein 
production requirement would not be expected compared to pLoxEGFP5 transfected cells 
where the transcript is not thought to be retained in the nucleus. Supporting this, during 
transfection experiments, EGFP fluorescence from pLoxEGFP250 transfected cells was 
generally found to be of a lower intensity than in pLoxEGFP5 transfected cells (Figure 45), 
therefore differences relating to this pathway may be due to artefact. Up-regulated genes 
(Table 12) were also assessed to determine whether mutations in these genes could lead to 
DM-like symptoms, but no connections could be made. IGA analysis was used to facilitate 
interpretation by prediction of the putatively affected pathways, most of which were found 
to be cell-growth and metabolism related, such as gelatinase A activity; glucuronate and 
glycospingolipid metabolism; lysosome organisation and biogenesis, and response to sterol 
depletion; all of which could relate to the effects of excessive EGFP protein production in 
pLoxEGFP5 transfected cells. It was stated earlier that an increase in the number of genes 
down-regulated upon CUG repeat expression could be due to nonsense mediated decay. 
This could also result from decreased mRNA stability. Houseley et al. found that over-
expression of an MBNL1/GFP fusion protein in Drosophila already expressing CUG 
repeats, resulted in increased stability of the CUG repeat transcript (Houseley et al. 2005). 
CUGBP1 has deadenylase activity, if MBNL1 aided mRNA stability in other transcripts, it 
follows then that depletion by CUG repeat expression may appear as an increase in down-
regulated genes. Conversely, for those genes up-regulated, the stability of the mRNA could 
be increased.  
After extensive analysis of the genes listed using published literature, connections between 
the genes listed and DM symptoms seemed tentative. By this time Affymetrix had 
developed mouse exon arrays, which were ideally suited for the discovery of alternative 
splice forms, so no genes were selected for further characterisation from this analysis. 
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Table 12 Genes up-regulated; pLoxEGFP250+ vs. pLoxEGFP5+. 
FDR 
 
Fold 
Change 
Gene Symbol 
 
Gene Title 
 
0  2.22  Dbp  D site albumin promoter binding protein 
0  2.46  Pla2g1b  Soluble PLA2-Ib precursor (Pla2g1b) 
0  2.37  Ogn  osteoglycin 
0  2.23  Ogn  osteoglycin 
0  2.15  Tmsb4x  thymosin, beta 4, X chromosome 
0  2.11  C3  complement component 3 
0  2.07  C1s  complement component 1, s subcomponent 
0  2.57  Cyr61  cysteine rich protein 61 
0  2.07  Lcn2  lipocalin 2 
0.1  2.17  D530037H12Rik  RIKEN cDNA D530037H12 gene 
0.09 
 
1.98 
 
Efemp1 
 
epidermal growth factor-containing fibulin-like extracellular 
matrix protein 1 
0.08  2.31  Cyr61  cysteine rich protein 61 
0.15  1.92  Cbr2  carbonyl reductase 2 
0.21  1.95  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 
0.2  1.9  Trp53inp1  transformation related protein 53 inducible nuclear protein 1 
0.19  1.87  Nt5e  5' nucleotidase, ecto 
0.18  1.83  Matn2  matrilin 2 
0.17 
 
2.08 
 
--- 
 
Avian musculoaponeurotic fibrosarcoma (v-maf) AS42 
oncogene homolog (Maf), mRNA 
0.21  2.12  Sepp1  selenoprotein P, plasma, 1 
0.2  1.87  Svs5  seminal vesicle secretion 5 
0.19  1.86  Dcn  decorin 
0.18 
 
1.91 
 
Maf 
 
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 
oncogene homolog 
0.17  1.35  Car9  carbonic anhydrase 9 
0.17  1.8  Tgfbi  transforming growth factor, beta induced 
0.2  1.56  Fos  FBJ osteosarcoma oncogene 
0.19 
 
1.84 
 
Rbmy1a1 
 
RNA binding motif protein, Y chromosome, family 1, 
member A1 
0.19  1.78  Tgfbi  transforming growth factor, beta induced 
0.36  1.82  Sqrdl  sulfide quinone reductase-like (yeast) 
0.48  1.88  Fzd10  frizzled homolog 10 (Drosophila) 
0.47  2.06  Abca1  ATP-binding cassette, sub-family A (ABC1), member 1 
0.65  1.74  Zc3h6  zinc finger CCCH type containing 6 
0.62 
 
1.74 
 
Nfkbiz 
 
nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, zeta 
0.61  1.83  1110032E23Rik  RIKEN cDNA 1110032E23 gene 
0.79  1.69  Matn2  matrilin 2 
0.8  1.68  Tgfbi  transforming growth factor, beta induced 
0.81  1.72  Capn6  calpain 6 
0.81 
 
 
 
 
 
 
 
1.69 
 
 
 
 
 
 
 
Ugt1a2 ///  
Ugt1a6a /// 
Ugt1a10 /// 
Ugt1a7c /// 
 Ugt1a5 /// Ugt1a9 
/// Ugt1a6b /// 
Ugt1a1 
 
UDP glucuronosyltransferase 1 family, polypeptide A2 /// 
UDP glucuronosyltransferase 1 family, polypeptide A6A /// 
UDP glycosyltransferase 1 family, polypeptide A10 /// UDP 
glucuronosyltransferase 1 family, polypeptide A7C /// UDP 
glucuronosyltransferase 1 family, polypeptide A5 /// UDP 
glucuronosyltransferase 1 family, polypeptide A9 /// UDP 
glucuronosyltransferase 1 family, polypeptide A6B /// UDP 
glucuronosyltransferase 1 family, polypeptide A1 
0.82  1.26  Adm  adrenomedullin 
0.85  1.74  Enpp2  ectonucleotide pyrophosphatase/phosphodiesterase 2 
0.88  1.68  ---  --- 
1.02 
 
1.73 
 
Steap2 
 
PREDICTED: six transmembrane epithelial antigen of 
prostate 2 [Mus musculus], mRNA sequence 
1  1.39  Ccng2  cyclin G2 
1.02  1.66  2310047A01Rik  RIKEN cDNA 2310047A01 gene 
1.16  1.86  Aldh3a1  aldehyde dehydrogenase family 3, subfamily A1 
1.13  1.68  Aldh6a1  aldehyde dehydrogenase family 6, subfamily A1 
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1.13  1.65  Ppil6  peptidylprolyl isomerase (cyclophilin)-like 6 
1.15  1.64  Alcam  activated leukocyte cell adhesion molecule 
1.29  1.66  Rab6b  RAB6B, member RAS oncogene family 
1.3  1.47  Eno2  enolase 2, gamma neuronal 
1.29  1.67  Mtss1  metastasis suppressor 1 
1.27 
 
 
1.64 
 
 
--- 
 
 
0 day neonate eyeball cDNA, RIKEN full-length enriched 
library, clone:E130004J04 product:unclassifiable, full insert 
sequence 
1.34  1.62  Islr  immunoglobulin superfamily containing leucine-rich repeat 
1.35  1.64  Luc7l2  LUC7-like 2 (S. cerevisiae) 
1.45  1.65  1810011O10Rik  RIKEN cDNA 1810011O10 gene 
1.46  1.74  Car6  carbonic anhydrase 6 
1.44  1.69  Ly6c  lymphocyte antigen 6 complex, locus C 
1.41  1.68  Cdsn  corneodesmosin 
1.41  1.62  H1f0  H1 histone family, member 0 
1.4  1.61  Ii  Ia-associated invariant chain 
1.48  1.62  Pink1  PTEN induced putative kinase 1 
1.48 
 
1.61 
 
Tomm7 
 
translocase of outer mitochondrial membrane 7 homolog 
(yeast) 
1.46  1.61  Mapk12  mitogen-activated protein kinase 12 
1.48 
 
1.65 
 
Pdlim5 
 
PDZ and LIM domain 5, mRNA (cDNA clone MGC:46824 
IMAGE:4457868) 
1.49  1.57  Tmem53  transmembrane protein 53 
1.47  1.63  Ly6a  lymphocyte antigen 6 complex, locus A 
1.52  1.49  Lss  lanosterol synthase 
1.56  1.68  Mgp  matrix Gla protein 
1.72  1.62  Gchfr  GTP cyclohydrolase I feedback regulator 
1.7  1.59  Pla2g1b  phospholipase A2, group IB, pancreas 
1.96  1.59  BC010787  cDNA sequence BC010787 
1.97  1.59  Cyba  cytochrome b-245, alpha polypeptide 
1.99  1.59  Pltp  phospholipid transfer protein 
2.03  1.62  Sdpr  serum deprivation response 
2.03  1.59  Hexb  hexosaminidase B 
2.07  1.58  Hdac11  histone deacetylase 11 
2.04  1.6  Sulf2  sulfatase 2 
2.03  1.6  Haghl  hydroxyacylglutathione hydrolase-like 
2.01  1.58  Dcxr  dicarbonyl L-xylulose reductase 
2.09  1.33  Ccng2  cyclin G2 
2.1  1.57  Wdr34  WD repeat domain 34 
2.07  1.57  LOC545323  similar to neurobeachin-like 1 
2.22  1.56  Erbb2ip  Erbb2 interacting protein 
2.3  1.56  Dzip1  DAZ interacting protein 1 
2.33  1.57  Cldn10  Claudin 10 (Cldn10), transcript variant 1, mRNA 
2.34  1.57  Tgfbi  transforming growth factor, beta induced 
2.36  1.58  Igfbp3  insulin-like growth factor binding protein 3 
2.34 
 
 
1.59 
 
 
 
 
 
Transcribed locus, moderately similar to XP_484812.1 
PREDICTED: hypothetical protein XP_484812 [Mus 
musculus] 
2.36  1.56  Irf2bp2  interferon regulatory factor 2 binding protein 2 
2.6 
 
1.58 
 
Eif2s3y 
 
eukaryotic translation initiation factor 2, subunit 3, structural 
gene Y-linked 
2.58  1.36  AI451617  expressed sequence AI451617 
2.58  1.61  BC049816  cDNA sequence BC049816 
2.56  1.54  Hrasls3  HRAS like suppressor 3 
2.7  1.55  Alcam  activated leukocyte cell adhesion molecule 
2.72  1.6  Sdpr  serum deprivation response 
2.77  1.67  Mmp2  matrix metallopeptidase 2 
2.75  1.69  0910001A06Rik  RIKEN cDNA 0910001A06 gene (0910001A06Rik), mRNA 
2.79  1.54  Neu1  neuraminidase 1 
2.76  1.14  Acss2  acyl-CoA synthetase short-chain family member 2 
2.74  1.61  2210419I08Rik  RIKEN cDNA 2210419I08 gene 
2.9  1.68  Aspn  asporin 
3.01  1.52  Ranbp2  RAN binding protein 2 
2.99  1.54  Maf  avian musculoaponeurotic fibrosarcoma (v-maf) AS42 Christine Haworth    Chapter 5, 160 
 
      oncogene homolog 
3.24  1.56  1500004A08Rik  RIKEN cDNA 1500004A08 gene 
3.21  1.52  ---  --- 
3.56  1.79  ---  --- 
3.54  1.55  Xdh  xanthine dehydrogenase 
3.52  1.42  6330406I15Rik  RIKEN cDNA 6330406I15 gene 
3.76  1.52  Foxc1  forkhead box C1 
3.75  1.51  Tgm2  transglutaminase 2, C polypeptide 
3.76 
 
1.52 
 
Galntl2 
 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2 
3.84 
 
1.53 
 
AI325464 
 
Expressed sequence AI325464, mRNA (cDNA clone 
MGC:30834 IMAGE:4006813) 
3.92  1.13  Adm  adrenomedullin 
4.08  1.52  Gstm1  glutathione S-transferase, mu 1 
4.09  1.51  Psap  prosaposin 
4.22  1.53  Calu  calumenin 
4.21  1.64  Mmp2  matrix metallopeptidase 2 
4.19 
 
1.52 
 
Hsd3b7 
 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 7 
4.42 
 
1.51 
 
Rnase4 
 
ribonuclease, RNase A family 4 
 
FDR, False discovery rate; ---, unannotated cDNA or EST sequences. 
 
Table 13 Genes downregulated; pLoxEGFP250+ vs. pLoxEGFP5+. 
FDR 
Fold 
Change  Gene Symbol  Gene Title 
0  -2.69  ---  --- 
3.5  -1.88  Hes1  hairy and enhancer of split 1 (Drosophila) 
3  -1.57  D3Ertd300e  DNA segment, Chr 3, ERATO Doi 300, expressed 
3.25  -1.57  Tfrc  transferrin receptor 
3  -1.75  AI662270  expressed sequence AI662270 
3.83 
 
-1.57 
 
1810054D07Rik 
 
RIKEN cDNA 1810054D07 gene 
 
FDR, False discovery rate; ---, unannotated cDNA or EST sequences. 
 
Table 14 Genes upregulated; pLoxEGFP250+ vs. pLoxEGFP5-. 
FDR 
Fold 
Change  Gene Symbol  Gene Title 
0  6.29  1110032E23Rik  RIKEN cDNA 1110032E23 gene 
0  4.99  Tmsb4x  thymosin, beta 4, X chromosome 
0  4.17  Car6  carbonic anhydrase 6 
0  4.15  Sdpr  serum deprivation response 
0  3.8  Sdpr  serum deprivation response 
0  3.74  Sdpr  serum deprivation response 
0  3.74  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 
0  3.51  Sqrdl  sulfide quinone reductase-like (yeast) 
0  3.15  Alcam  activated leukocyte cell adhesion molecule 
0  3.01  Dcn  decorin 
0 
 
3.02 
 
Gsta1 /// Gsta2 
 
glutathione S-transferase, alpha 1 (Ya) /// glutathione S-
transferase, alpha 2 (Yc2) 
0 
 
3.12 
 
Efemp1 
 
epidermal growth factor-containing fibulin-like extracellular 
matrix protein 1 
0 
 
2.94 
 
Rbmy1a1 
 
RNA binding motif protein, Y chromosome, family 1, member 
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0  2.9  2210419I08Rik  RIKEN cDNA 2210419I08 gene 
0  2.89  Alcam  activated leukocyte cell adhesion molecule 
0 
 
2.88 
 
Maf 
 
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 
oncogene homolog 
0  2.66  9430093N24Rik  MKIAA1983 protein 
0  2.59  Alcam  activated leukocyte cell adhesion molecule 
0  2.55  Mapk12  mitogen-activated protein kinase 12 
0  2.58  Cyba  cytochrome b-245, alpha polypeptide 
0  2.49  Ccl2  chemokine (C-C motif) ligand 2 
0  2.55  Alcam  activated leukocyte cell adhesion molecule 
0  2.44  ---  --- 
0 
 
2.45 
 
Gatm 
 
glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
0  2.4  Grem1  gremlin 1 
0  2.41  Mtss1  metastasis suppressor 1 
0  2.42  Gpnmb  glycoprotein (transmembrane) nmb 
0  2.36  Ccl7  chemokine (C-C motif) ligand 7 
0 
 
2.32 
 
Eif2s3y 
 
eukaryotic translation initiation factor 2, subunit 3, structural 
gene Y-linked 
0  2.52  Fyb  FYN binding protein 
0 
 
2.3 
 
H60 
 
PREDICTED: histocompatibility 60 [Mus musculus], mRNA 
sequence 
0  2.3  Rorb  RAR-related orphan receptor beta 
0  2.26  Igf2r  insulin-like growth factor 2 receptor 
0.03  2.25  Cdsn  corneodesmosin 
0.03  2.2  Ampd3  AMP deaminase 3 
0.03  2.15  Ppil6  peptidylprolyl isomerase (cyclophilin)-like 6 
0.03  2.21  BC034507  cDNA sequence BC034507 
0.03  2.46  Pla2g1b  Soluble PLA2-Ib precursor (Pla2g1b) 
0.03  2.15  Ociad2  OCIA domain containing 2 
0.03  2.24  Kctd4  potassium channel tetramerisation domain containing 4 
0.02  2.1  Ass1  argininosuccinate synthetase 1 
0.02  2.15  Mtss1  metastasis suppressor 1 
0.02  2.22  3110004L20Rik  RIKEN cDNA 3110004L20 gene 
0.02  2.09  Gchfr  GTP cyclohydrolase I feedback regulator 
0.02  2.15  Enpp2  ectonucleotide pyrophosphatase/phosphodiesterase 2 
0.02  2.03  Ctsb  cathepsin B 
0.04  2.03  Gadd45a  growth arrest and DNA-damage-inducible 45 alpha 
0.04  2.01  Svs5  seminal vesicle secretion 5 
0.04 
 
2 
 
Dusp3 
 
dual specificity phosphatase 3 (vaccinia virus phosphatase 
VH1-related) 
0.04  2.08  BC034507  cDNA sequence BC034507 
0.04  1.98  Tnfaip2  tumor necrosis factor, alpha-induced protein 2 
0.04  1.97  Nqo1  NAD(P)H dehydrogenase, quinone 1 
0.04  1.97  Tgfbi  transforming growth factor, beta induced 
0.06  1.98  H1f0  H1 histone family, member 0 
0.07 
 
2.05 
 
Plf /// Plf2 /// 
Mrpplf3 
proliferin /// proliferin 2 /// mitogen regulated protein, proliferin 3 
 
0.07  1.94  U90926  cDNA sequence U90926 
0.07  2.04  BC049816  cDNA sequence BC049816 
0.09 
 
1.98 
 
Erbb3 
 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 
(avian) 
0.12  2.02  Cth  cystathionase (cystathionine gamma-lyase) 
0.12  2.32  Cyr61  cysteine rich protein 61 
0.11  1.96  Igf2r  insulin-like growth factor 2 receptor 
0.11  1.93  Dpysl3  dihydropyrimidinase-like 3 
0.11  2.19  Hcn1  hyperpolarization-activated, cyclic nucleotide-gated K+ 1 
0.11  1.95  9430041P20Rik  RIKEN cDNA 9430041P20 gene 
0.11 
 
 
 
 
 
1.91 
 
 
 
 
 
Ugt1a2 
Ugt1a6a 
Ugt1a10 
Ugt1a7c 
Ugt1a5 
Ugt1a9 
UDP glucuronosyltransferase 1 family, polypeptide A2 /// UDP 
glucuronosyltransferase 1 family, polypeptide A6A /// UDP 
glycosyltransferase 1 family, polypeptide A10 /// UDP 
glucuronosyltransferase 1 family, polypeptide A7C /// UDP 
glucuronosyltransferase 1 family, polypeptide A5 /// UDP 
glucuronosyltransferase 1 family, polypeptide A9 /// UDP Christine Haworth    Chapter 5, 162 
 
 
 
 
 
Ugt1a6b 
Ugt1a1 
glucuronosyltransferase 1 family, polypeptide A6B /// UDP 
glucuronosyltransferase 1 family, polypeptide A1 
0.12 
 
2.21 
 
--- 
 
Avian musculoaponeurotic fibrosarcoma (v-maf) AS42 
oncogene homolog (Maf), mRNA 
0.13 
 
1.95 
 
Malat1 
 
metastasis associated lung adenocarcinoma transcript 1 (non-
coding RNA) 
0.16  2.36  Cyr61  cysteine rich protein 61 
0.17  1.92  Tgfbi  transforming growth factor, beta induced 
0.19  1.88  Tgm2  transglutaminase 2, C polypeptide 
0.2  1.86  Hdac11  histone deacetylase 11 
0.19  1.93  Pik3r5  phosphoinositide-3-kinase, regulatory subunit 5, p101 
0.21 
 
1.82 
 
Hsd3b7 
 
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 7 
0.2  1.85  Ntn1  netrin 1 
0.23  1.85  Ctsb  cathepsin B 
0.22  1.83  Tgfbi  transforming growth factor, beta induced 
0.22  1.88  Emb  embigin 
0.22  1.8  Gnpda2  glucosamine-6-phosphate deaminase 2 
0.23  1.87  ---  --- 
0.22  1.82  Masp1  mannan-binding lectin serine peptidase 1 
0.23  1.82  Aldh2  aldehyde dehydrogenase 2, mitochondrial 
0.23  1.8  Hexb  hexosaminidase B 
0.23  1.84  Trp53inp1  transformation related protein 53 inducible nuclear protein 1 
0.23  1.83  Wdr34  WD repeat domain 34 
0.24  1.92  C3  complement component 3 
0.24 
 
 
 
 
 
 
1.78 
 
 
 
 
 
 
 
Ugt1a2 /// 
Ugt1a6a /// 
Ugt1a10 /// 
Ugt1a7c /// 
Ugt1a5 /// 
Ugt1a9 /// 
Ugt1a6b /// 
Ugt1a1 
UDP glucuronosyltransferase 1 family, polypeptide A2 /// UDP 
glucuronosyltransferase 1 family, polypeptide A6A /// UDP 
glycosyltransferase 1 family, polypeptide A10 /// UDP 
glucuronosyltransferase 1 family, polypeptide A7C /// UDP 
glucuronosyltransferase 1 family, polypeptide A5 /// UDP 
glucuronosyltransferase 1 family, polypeptide A9 /// UDP 
glucuronosyltransferase 1 family, polypeptide A6B /// UDP 
glucuronosyltransferase 1 family, polypeptide A1 
0.24  1.79  2810013C04Rik  RIKEN cDNA 2810013C04 gene 
0.24  1.8  2610003J06Rik  RIKEN cDNA 2610003J06 gene 
0.25  1.85  Sulf2  sulfatase 2 
0.24  1.99  H3f3b  H3 histone, family 3B 
0.27  1.89  1110013L07Rik  RIKEN cDNA 1110013L07 gene 
0.29  1.77  Gpc1  glypican 1 
0.32  1.86  Parp12  poly (ADP-ribose) polymerase family, member 12 
0.32  1.87  C1s  complement component 1, s subcomponent 
0.34  1.78  Vegfc  vascular endothelial growth factor C 
0.41  1.78  Evi2a  ecotropic viral integration site 2a 
0.42  1.75  Neu1  neuraminidase 1 
0.42  1.76  Vegfc  vascular endothelial growth factor C 
0.43  1.73  Nt5e  5' nucleotidase, ecto 
0.47  1.77  Hs6st2  heparan sulfate 6-O-sulfotransferase 2 
0.48  1.73  Gsto2  glutathione S-transferase omega 2 
0.47 
 
1.74 
 
Grina 
 
glutamate receptor, ionotropic, N-methyl D-asparate-
associated protein 1 (glutamate binding) 
0.47  1.72  Cxcl5  chemokine (C-X-C motif) ligand 5 
0.48  1.72  Htra1  HtrA serine peptidase 1 
0.49  1.74  Vat1  vesicle amine transport protein 1 homolog (T californica) 
0.5  1.73  Gstm1  glutathione S-transferase, mu 1 
0.51  1.71  H1f0  H1 histone family, member 0 
0.51  1.71  Cryzl1  crystallin, zeta (quinone reductase)-like 1 
0.5  1.7  Rassf5  Ras association (RalGDS/AF-6) domain family 5 
0.5  1.73  Jarid1d  jumonji, AT rich interactive domain 1D (Rbp2 like) 
0.53  1.7  Mgst2  microsomal glutathione S-transferase 2 
0.54  1.71  Ddit3  DNA-damage inducible transcript 3 
0.56  1.7  Psap  prosaposin 
0.57  1.87  AI256396  EST AI256396 
0.57  1.77  Xdh  xanthine dehydrogenase 
0.59  1.76  Cbr2  carbonyl reductase 2 Christine Haworth    Chapter 5, 163 
 
0.59  1.79  1500005K14Rik  RIKEN cDNA 1500005K14 gene 
0.58  2.04  Sepp1  selenoprotein P, plasma, 1 
0.59  1.69  Them2  thioesterase superfamily member 2 
0.59  1.7  Psap  prosaposin 
0.6  1.72  Tgm2  transglutaminase 2, C polypeptide 
0.59  1.7  Ctsl  cathepsin L 
0.6  1.82  B230342M21Rik  RIKEN cDNA B230342M21 gene 
0.61 
 
1.83 
 
Gdpd1 
 
glycerophosphodiester phosphodiesterase domain containing 
1 
0.61  1.76  Igfbp3  insulin-like growth factor binding protein 3 
0.63  1.68  Ii  Ia-associated invariant chain 
0.63  1.68  Htra1  HtrA serine peptidase 1 
0.68 
 
1.67 
 
Gas2 
 
Growth arrest specific 2, mRNA (cDNA clone MGC:18565 
IMAGE:4237356) 
0.72  1.74  B430320C24Rik  RIKEN cDNA B430320C24 gene 
0.72  1.7  D430039N05Rik  RIKEN cDNA D430039N05 gene 
0.71  1.7  Ctso  cathepsin O 
0.72  1.72  Rapgef3  Rap guanine nucleotide exchange factor (GEF) 3 
0.71  2.04  Abca1  ATP-binding cassette, sub-family A (ABC1), member 1 
0.75  1.66  Pdlim1  PDZ and LIM domain 1 (elfin) 
0.79  1.66  Rnf157  ring finger protein 157 
0.79  1.69  Gstm1  glutathione S-transferase, mu 1 
0.85  1.73  Igfbp3  insulin-like growth factor binding protein 3 
0.85  1.96  ---  --- 
0.84 
 
1.7 
 
Pscdbp 
 
pleckstrin homology, Sec7 and coiled-coil domains, binding 
protein 
0.84  1.69  Ctsb  cathepsin B 
0.84  1.64  ---  --- 
0.85  1.73  Ly6a  lymphocyte antigen 6 complex, locus A 
0.84  1.68  Tgfbi  transforming growth factor, beta induced 
0.86  1.7  Ctsb  cathepsin B 
0.88  1.67  Vegfc  vascular endothelial growth factor C 
0.96  1.66  Cnp1  cyclic nucleotide phosphodiesterase 1 
0.98  1.64  Gnpda2  glucosamine-6-phosphate deaminase 2 
1.01 
 
1.63 
 
Napb 
 
N-ethylmaleimide sensitive fusion protein attachment protein 
beta 
1.05  1.62  Atp6ap2  ATPase, H+ transporting, lysosomal accessory protein 2 
1.05  1.63  Laptm4b  lysosomal-associated protein transmembrane 4B 
1.06  1.68  Itgb7  integrin beta 7 
1.05 
 
1.61 
 
Bphl 
 
biphenyl hydrolase-like (serine hydrolase, breast epithelial 
mucin-associated antigen) 
1.06  1.81  Fzd10  frizzled homolog 10 (Drosophila) 
1.05 
 
 
1.69 
 
 
Phex 
 
 
phosphate regulating gene with homologies to endopeptidases 
on the X chromosome (hypophosphatemia, vitamin D resistant 
rickets) 
1.05  1.63  A930001N09Rik  RIKEN cDNA A930001N09 gene (A930001N09Rik), mRNA 
1.05  1.64  Ptgs1  prostaglandin-endoperoxide synthase 1 
1.06  1.65  Klhl24  kelch-like 24 (Drosophila) 
1.06  1.65  Sh2d5  SH2 domain containing 5 
1.06  1.66  Tgm2  transglutaminase 2, C polypeptide 
1.06 
 
1.62 
 
P2rx4 
  purinergic receptor P2X, ligand-gated ion channel 4 
1.06  1.63  Plxnd1  plexin D1 
1.07 
 
1.62 
 
Malat1 
 
metastasis associated lung adenocarcinoma transcript 1 (non-
coding RNA) 
1.09  1.61  Hrsp12  heat-responsive protein 12 
1.1  1.62  Dcxr  dicarbonyl L-xylulose reductase 
1.1  1.64  Trim44  tripartite motif-containing 44 
1.11  1.65  Rassf5  Ras association (RalGDS/AF-6) domain family 5 
1.16  1.59  Klhl24  kelch-like 24 (Drosophila) 
1.15  1.68  Dhrs6  dehydrogenase/reductase (SDR family) member 6 
1.15  1.26  Adm  adrenomedullin 
1.17  1.6  Kif21a  kinesin family member 21A 
1.19  1.62  Cst6  cystatin E/M Christine Haworth    Chapter 5, 164 
 
1.2  1.19  Adm  adrenomedullin 
1.22  1.6  Bbs7  Bardet-Biedl syndrome 7 
1.26  1.59  Scara5  scavenger receptor class A, member 5 (putative) 
1.27  1.59  A630026N12Rik  RIKEN cDNA A630026N12 gene 
1.39 
 
 
 
 
 
 
 
1.58 
 
 
 
 
 
 
 
Ugt1a2 /// 
Ugt1a6a /// 
Ugt1a10 /// 
Ugt1a7c /// 
Ugt1a5 /// 
Ugt1a9 /// 
Ugt1a6b /// 
Ugt1a1 
UDP glucuronosyltransferase 1 family, polypeptide A2 /// UDP 
glucuronosyltransferase 1 family, polypeptide A6A /// UDP 
glycosyltransferase 1 family, polypeptide A10 /// UDP 
glucuronosyltransferase 1 family, polypeptide A7C /// UDP 
glucuronosyltransferase 1 family, polypeptide A5 /// UDP 
glucuronosyltransferase 1 family, polypeptide A9 /// UDP 
glucuronosyltransferase 1 family, polypeptide A6B /// UDP 
glucuronosyltransferase 1 family, polypeptide A1 
1.38  1.59  Hspa4l  heat shock 70kDa protein 4 like 
1.4  1.65  Trappc6a  trafficking protein particle complex 6A 
1.4  1.65  Emb  embigin 
1.39  1.61  Itgb2  integrin beta 2 
1.39  1.64  Tcn2  transcobalamin 2 
1.41  1.59  Enah  Enabled homolog (Drosophila) (Enah), mRNA 
1.4 
 
1.63 
 
Phyhd1 /// Lrrc8 
 
phytanoyl-CoA dioxygenase domain containing 1 /// leucine 
rich repeat containing 8 
1.45  1.62  Klhl24  kelch-like 24 (Drosophila) 
1.45  1.66  Capn6  calpain 6 
1.45  1.65  1810011O10Rik  RIKEN cDNA 1810011O10 gene 
1.5  1.62  5730457F11Rik  RIKEN cDNA 5730457F11 gene 
1.49  1.59  Msln  mesothelin 
1.51  1.64  Uhrf2  ubiquitin-like, containing PHD and RING finger domains 2 
1.54  1.59  0610031J06Rik  RIKEN cDNA 0610031J06 gene 
1.55 
 
1.62 
 
Sirt5 
 
sirtuin 5 (silent mating type information regulation 2 homolog) 5 
(S. cerevisiae) 
1.58  1.57  6230421P05Rik  RIKEN cDNA 6230421P05 gene 
1.59  1.57  Bhlhb5  basic helix-loop-helix domain containing, class B5 
1.65  1.56  Ghitm  growth hormone inducible transmembrane protein 
1.67  1.63  2810003C17Rik  RIKEN cDNA 2810003C17 gene 
1.7  1.62  Gsta4  glutathione S-transferase, alpha 4 
1.73  1.56  Ndrg4  N-myc downstream regulated gene 4 
1.72  1.57  Dbp  D site albumin promoter binding protein 
1.72  1.58  Creg1  cellular repressor of E1A-stimulated genes 1 
1.73  1.56  Atp6ap2  ATPase, H+ transporting, lysosomal accessory protein 2 
1.78  1.61  1110046J04Rik  RIKEN cDNA 1110046J04 gene 
1.78  1.57  MGI:2446326  suprabasin 
1.88  1.57  5730469M10Rik  RIKEN cDNA 5730469M10 gene 
1.87  1.59  Jarid1b  jumonji, AT rich interactive domain 1B (Rbp2 like) 
1.93  1.72  LOC231914  similar to mKIAA0060 protein 
1.95  1.6  ---  Expressed sequence R75581 (R75581), mRNA 
1.94  1.58  9130227C08Rik  RIKEN cDNA 9130227C08 gene 
1.93  1.64  Hist1h2bc  histone 1, H2bc 
1.96  1.3  Ccng2  cyclin G2 
1.96  1.59  Hba-a1  hemoglobin alpha, adult chain 1 
2.04  1.59  Matn2  matrilin 2 
2.08  1.57  D330001F17Rik  RIKEN cDNA D330001F17 gene 
2.14 
 
1.53 
 
Stch 
 
stress 70 protein chaperone, microsome-associated, human 
homolog 
2.19 
 
1.55 
 
Sema3c 
 
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3C 
2.22  1.57  Atp6v0b  ATPase, H+ transporting, V0 subunit B 
2.25 
 
1.58 
 
Sema3a 
 
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3A 
2.24  1.61  Phyh  phytanoyl-CoA hydroxylase 
2.33 
 
1.6 
 
Grina 
 
glutamate receptor, ionotropic, N-methyl D-asparate-
associated protein 1 (glutamate binding) 
2.37  1.62  Foxf1a  forkhead box F1a 
2.42 
 
1.54 
 
Malat1 
 
metastasis associated lung adenocarcinoma transcript 1 (non-
coding RNA) 
2.53  1.67  Enpp2  ectonucleotide pyrophosphatase/phosphodiesterase 2 Christine Haworth    Chapter 5, 165 
 
2.58  1.54  Aldh6a1  aldehyde dehydrogenase family 6, subfamily A1 
2.59  1.53  Hexb  hexosaminidase B 
2.6  1.55  Dpp7  dipeptidylpeptidase 7 
2.61 
 
 
1.53 
 
 
--- 
 
 
Adult male medulla oblongata cDNA, RIKEN full-length 
enriched library, clone:6330544N02 product:unclassifiable, full 
insert sequence 
2.61  1.57  ---  Transcribed locus 
2.61  1.52  Tspyl4  TSPY-like 4 
2.67  1.63  Ahr  aryl-hydrocarbon receptor 
2.71  1.55  2510042P03Rik  RIKEN cDNA 2510042P03 gene 
2.7  1.54  9130022K13Rik  RIKEN cDNA 9130022K13 gene 
2.69  1.54  Laptm4b  lysosomal-associated protein transmembrane 4B 
2.71  1.51  Igfbp6  insulin-like growth factor binding protein 6 
2.8  1.51  Abhd4  abhydrolase domain containing 4 
2.8  1.5  4921509J17Rik  RIKEN cDNA 4921509J17 gene 
2.82  1.79  Aldh3a1  aldehyde dehydrogenase family 3, subfamily A1 
2.83  1.51  1110003E01Rik  RIKEN cDNA 1110003E01 gene 
2.94  1.53  Atp6ap2  ATPase, H+ transporting, lysosomal accessory protein 2 
3.02  1.29  Ccng2  cyclin G2 
3.09  1.53  D5Ertd593e  DNA segment, Chr 5, ERATO Doi 593, expressed 
3.1  1.61  Dpysl3  dihydropyrimidinase-like 3 
3.11 
 
1.51 
 
Serpinb6a 
 
Serine (or cysteine) peptidase inhibitor, clade B, member 6a, 
mRNA (cDNA clone MGC:6042 IMAGE:3481963) 
3.18  1.53  Parvb  Parvin, beta (Parvb), mRNA 
3.2  1.54  Zhx1  zinc fingers and homeoboxes protein 1 
3.24  1.54  Creg1  cellular repressor of E1A-stimulated genes 1 
3.25  1.6  Vat1  vesicle amine transport protein 1 homolog (T californica) 
3.25  1.53  MGI:2446326  suprabasin 
3.26  1.53  ---  --- 
3.43  1.51  5133401H06Rik  RIKEN cDNA 5133401H06 gene 
3.46  1.49  Gba  glucosidase, beta, acid 
3.56 
 
 
 
1.56 
 
 
 
1200016E24Rik 
A130040M12Rik 
E430024C06Rik 
/// LOC433071 
RIKEN cDNA 1200016E24 gene /// RIKEN cDNA 
A130040M12 gene /// RIKEN cDNA E430024C06 gene /// 
hypothetical gene supported by AK004796; BC040222 
 
3.61 
 
1.49 
 
U2af1-rs1 
 
U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 1, 
related sequence 1 
3.59  1.53  Zc3h6  zinc finger CCCH type containing 6 
3.58  1.51  5031439G07Rik  RIKEN cDNA 5031439G07 gene 
3.6  1.5  Igfbp4  insulin-like growth factor binding protein 4 
3.59  1.51  Igfbp4  insulin-like growth factor binding protein 4 
3.59  1.5  Igfbp4  insulin-like growth factor binding protein 4 
3.58  1.51  Ghitm  growth hormone inducible transmembrane protein 
3.66  1.5  Acpl2  acid phosphatase-like 2 
3.79 
 
 
1.56 
 
 
2010309G21Rik 
/// LOC207685 
/// LOC547243 
RIKEN cDNA 2010309G21 gene /// hypothetical protein 
LOC207685 /// similar to Ig lambda-2 chain 
 
3.78  1.53  1810011O10Rik  RIKEN cDNA 1810011O10 gene 
3.79  1.49  ---  --- 
3.81  1.49  Tpp1  tripeptidyl peptidase I 
3.99  1.55  Rapgef3  Rap guanine nucleotide exchange factor (GEF) 3 
4.01  1.48  Echdc3  enoyl Coenzyme A hydratase domain containing 3 
4.06  1.49  Il1rl1  interleukin 1 receptor-like 1 
4.05  1.52  Irg1  immunoresponsive gene 1 
4.03  1.47  Irf2bp2  interferon regulatory factor 2 binding protein 2 
4.06  1.49  Tob1  transducer of ErbB-2.1 
4.06  1.52  6030443O07Rik  RIKEN cDNA 6030443O07 gene 
4.06  1.47  Gla  galactosidase, alpha 
4.12  1.49  Dpp7  dipeptidylpeptidase 7 
4.12  1.48  1110003E01Rik  RIKEN cDNA 1110003E01 gene 
4.12  1.5  Ndrg4  N-myc downstream regulated gene 4 
4.28  1.48  Rnase4  ribonuclease, RNase A family 4 
4.29  1.49  ---  --- 
4.28  1.48     Christine Haworth    Chapter 5, 166 
 
4.27  1.34  Hist1h1c  histone 1, H1c 
4.48 
 
1.51 
 
Steap2 
 
PREDICTED: six transmembrane epithelial antigen of prostate 
2 [Mus musculus], mRNA sequence 
4.49  1.47  Bcl2l11  BCL2-like 11 (apoptosis facilitator) 
4.48  1.47  Decr1  2,4-dienoyl CoA reductase 1, mitochondrial 
4.5  1.48  ---  Transcribed locus 
4.5  1.53  Arrdc3  arrestin domain containing 3 
4.5 
 
 
 
 
 
 
1.51 
 
 
 
 
 
 
Gstm1 /// 
LOC433943 /// 
LOC436518 /// 
LOC547390 
 
 
 
glutathione S-transferase, mu 1 /// similar to Glutathione S-
transferase Mu 1 (GST class-mu 1) (Glutathione S-transferase 
GT8.7) (pmGT10) (GST 1-1) /// similar to Glutathione S-
transferase Mu 1 (GST class-mu 1) (Glutathione S-transferase 
GT8.7) (pmGT10) (GST 1-1) /// similar to Glutathione S-
transferase Mu 1 (GST class-mu 1) (Glutathione S-transferase 
GT8.7) (pmGT10) (GST 1-1) 
4.49 
 
 
 
1.57 
 
 
 
Uty /// 
LOC546404 /// 
LOC546411 
 
ubiquitously transcribed tetratricopeptide repeat gene, Y 
chromosome /// similar to male-specific histocompatibility 
antigen H-YDb /// similar to male-specific histocompatibility 
antigen H-YDb 
4.59  1.47  Capg  capping protein (actin filament), gelsolin-like 
4.58  1.47  LOC546143  hypothetical protein LOC546143 
4.59  1.5  B930075F07  hypothetical protein B930075F07 
4.6  1.49  Atp6v0b  ATPase, H+ transporting, V0 subunit B 
4.62  1.49  2310047A01Rik  RIKEN cDNA 2310047A01 gene 
4.65  1.47  Hspa4l  heat shock 70kDa protein 4 like 
4.63  1.49  2410006H16Rik  RIKEN cDNA 2410006H16 gene 
4.62  1.47  1700022C21Rik  RIKEN cDNA 1700022C21 gene 
4.69 
 
1.5 
 
Gdpd1 
 
glycerophosphodiester phosphodiesterase domain containing 
1 
4.89  1.56  Saa3  serum amyloid A 3 
4.87  1.54  Zfand2a  zinc finger, AN1-type domain 2A 
4.86  1.36  Eno2  enolase 2, gamma neuronal 
4.85  1.46  Gba  glucosidase, beta, acid 
4.84  1.49  Foxg1  forkhead box G1 
4.82  1.47  Ccnt2  cyclin T2 
4.82  1.31  Ddit4  DNA-damage-inducible transcript 4 
4.84  1.49  ---  --- 
4.85  1.5  Gsto1  glutathione S-transferase omega 1 
4.85  1.46  Atg10  autophagy-related 10 (yeast) 
4.86  1.47  P2rx4  purinergic receptor P2X, ligand-gated ion channel 4 
4.85  1.49  Mitf  microphthalmia-associated transcription factor 
4.87  1.48  Ldh2  lactate dehydrogenase 2, B chain 
4.85  1.61  2310043N10Rik  RIKEN cDNA 2310043N10 gene 
4.89  1.45  Dstn  Destrin (Dstn), mRNA 
4.89  1.45  B230315F11Rik  RIKEN cDNA B230315F11 gene 
4.88  1.5  1810015C04Rik  RIKEN cDNA 1810015C04 gene 
4.87  1.45  Scpep1  serine carboxypeptidase 1 
4.96 
 
1.48 
 
Dusp1 
 
dual specificity phosphatase 1 
 
 
Table 15 Genes downregulated; pLoxEGFP250+ vs. pLoxEGFP5-. 
FDR 
Fold 
Change  Gene Symbol  Gene Title 
0  -2.28  Has2  hyaluronan synthase 2 
0  -2.06  6530401D17Rik  RIKEN cDNA 6530401D17 gene 
0  -2.02  5930437A14Rik  RIKEN cDNA 5930437A14 gene 
0  -1.93  Has2  hyaluronan synthase 2 
0  -1.89  X83313  EST X83313 
0  -1.93  Dlk1  delta-like 1 homolog (Drosophila) 
0  -1.87  Hivep3 
human immunodeficiency virus type I enhancer binding 
protein 3 
0  -1.96  2010012C16Rik  RIKEN cDNA 2010012C16 gene Christine Haworth    Chapter 5, 167 
 
0  -2.09  AI662270  expressed sequence AI662270 
0.1 
 
-1.75 
 
Grem2 
 
gremlin 2 homolog, cysteine knot superfamily (Xenopus 
laevis) 
0.09  -1.76  B230120H23Rik  RIKEN cDNA B230120H23 gene 
0.08  -1.94  AI662270  expressed sequence AI662270 
0.08  -1.78  Dcp2  DCP2 decapping enzyme homolog (S. cerevisiae) 
0.07  -1.84  Sp100  nuclear antigen Sp100 
0.33  -1.82  Oas1a  2'-5' oligoadenylate synthetase 1A 
0.31  -1.75  Asb4  ankyrin repeat and SOCS box-containing protein 4 
0.35  -1.89  Egr3  early growth response 3 
0.61  -1.72  Tyki  thymidylate kinase family LPS-inducible member 
0.58  -1.66  Kbtbd8  kelch repeat and BTB (POZ) domain containing 8 
0.9  -1.72  Igf2bp3  insulin-like growth factor 2, binding protein 3 
1.14  -1.71  Mlf1  myeloid leukemia factor 1 
1.09  -1.65  ---  --- 
1.04  -1.7  ---  --- 
1.08  -1.69  Sp100  nuclear antigen Sp100 
1.04  -1.51  Dusp9  dual specificity phosphatase 9 
1.08  -1.6  Isg20l1  interferon stimulated exonuclease gene 20-like 1 
1.22  -1.64  5730596K20Rik  RIKEN cDNA 5730596K20 gene 
1.18  -1.7  Lphn2  latrophilin 2 
1.17  -1.69  Adamtsl1  ADAMTS-like 1 
1.2  -1.67  Odz3  odd Oz/ten-m homolog 3 (Drosophila) 
1.16  -1.62  Adam12  a disintegrin and metallopeptidase domain 12 (meltrin alpha) 
1.19  -1.61  Thbs1  thrombospondin 1 
1.18  -1.64  Tmem47  transmembrane protein 47 
1.26  -1.58  ---  RNA transcript from U17 small nucleolar RNA host gene 
1.26  -1.86  Iigp1  interferon inducible GTPase 1 
1.28  -1.72  Iigp1  interferon inducible GTPase 1 
1.24  -1.57  Mcm5 
minichromosome maintenance deficient 5, cell division cycle 
46 (S. cerevisiae) 
1.21  -1.6  Samd9l  sterile alpha motif domain containing 9-like 
1.26  -1.64  Cacna1c 
Calcium channel, voltage-dependent, L type, alpha 1C subunit 
(Cacna1c), mRNA 
1.27  -1.57  Egfl9  EGF-like-domain, multiple 9 
1.29  -1.91  Serpine1  serine (or cysteine) peptidase inhibitor, clade E, member 1 
1.4  -1.57  Thbs1  thrombospondin 1 
1.53  -1.63  8030463A06Rik  RIKEN cDNA 8030463A06 gene (8030463A06Rik), mRNA 
1.52 
 
-1.55 
 
 
 
PREDICTED: similar to protease [Mus musculus], mRNA 
sequence 
1.51  -1.62  Iigp2  interferon inducible GTPase 2 
1.54  -1.62  Tnc  tenascin C 
1.51  -1.56  Cdh11  cadherin 11 
1.67  -1.61  Id2  inhibitor of DNA binding 2 
1.86  -1.55  ---  --- 
1.92  -1.53  Hnrpdl  heterogeneous nuclear ribonucleoprotein D-like 
2.29  -1.52  Ddx49  DEAD (Asp-Glu-Ala-Asp) box polypeptide 49 
2.48  -1.52  2310001H13Rik  RIKEN cDNA 2310001H13 gene 
2.53  -1.59  2900073C17Rik  RIKEN cDNA 2900073C17 gene 
2.52  -1.57  ---  Transcribed locus 
2.49  -1.59  Tgtp  T-cell specific GTPase 
2.8  -1.52  ---  --- 
2.88  -1.5  Tbrg4  transforming growth factor beta regulated gene 4 
2.91  -1.51  Flnc  filamin C, gamma (actin binding protein 280) 
2.95  -1.64  ---  Transcribed locus 
3.1  -1.58  Ror1  receptor tyrosine kinase-like orphan receptor 1 
3.05  -1.53  Oasl2  2'-5' oligoadenylate synthetase-like 2 
3.47  -1.47  D19Bwg1357e 
DNA segment, Chr 19, Brigham & Women's Genetics 1357 
expressed 
3.63  -1.49  5033421C21Rik  RIKEN cDNA 5033421C21 gene 
3.73  -1.54  Slfn8  schlafen 8 
3.83  -1.51  Thbs1  thrombospondin 1 
3.83  -1.49  Mybl2  myeloblastosis oncogene-like 2 
3.99  -1.43  Pa2g4  proliferation-associated 2G4 Christine Haworth    Chapter 5, 168 
 
4.24  -1.49  Angpt1  angiopoietin 1 
4.3  -1.48  MGI:1933403 
type 1 tumor necrosis factor receptor shedding 
aminopeptidase regulator 
4.31  -1.48  Cdc6  cell division cycle 6 homolog (S. cerevisiae) 
4.25  -1.61  Igtp  interferon gamma induced GTPase 
4.38  -1.57  Sp100-rs  similar to component of Sp100-rs 
4.36  -1.56  Psip1  PC4 and SFRS1 interacting protein 1 
4.85  -1.55  Ifi44  interferon-induced protein 44 
4.85  -1.26  AA408556  expressed sequence AA408556 
4.96  -1.49  C1ql3  C1q-like 3 
4.99  -1.6  Hmgcs1 
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1, mRNA 
(cDNA clone MGC:36620 IMAGE:5347038) 
4.94  -1.41  Usp18  ubiquitin specific peptidase 18 
4.94 
 
-1.63 
 
Hey1 
 
hairy/enhancer-of-split related with YRPW motif 1 
 
FDR, False discovery rate; ---, unannotated cDNA or EST sequences. 
 
Table 16 Genes up-regulated; pLoxEGFP5+ vs. pLoxEGFP5-. 
FDR 
Fold 
Change  Gene Symbol  Gene Title 
0  3.59  ---  --- 
0  3.44  1110032E23Rik  RIKEN cDNA 1110032E23 gene 
0 
 
3.13 
 
Gsta1 /// Gsta2 
 
glutathione S-transferase, alpha 1 (Ya) /// glutathione S-
transferase, alpha 2 (Yc2) 
0  2.56  Sdpr  serum deprivation response 
0  2.52  Sdpr  serum deprivation response 
0  2.38  Sdpr  serum deprivation response 
0  2.4  Car6  carbonic anhydrase 6 
0  2.32  Tmsb4x  thymosin, beta 4, X chromosome 
0  2.21  Alcam  activated leukocyte cell adhesion molecule 
0  1.94  Gadd45a  growth arrest and DNA-damage-inducible 45 alpha 
0  1.97  9430093N24Rik  MKIAA1983 protein 
0  1.88  Dpysl3  dihydropyrimidinase-like 3 
0  1.86  Nqo1  NAD(P)H dehydrogenase, quinone 1 
0  1.91  Ddx3y  DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 
0  1.93  Sqrdl  sulfide quinone reductase-like (yeast) 
0  1.8  Ccl2  chemokine (C-C motif) ligand 2 
0  1.85  LOC433022  hypothetical LOC433022 
0  1.96  D3Ertd300e  DNA segment, Chr 3, ERATO Doi 300, expressed 
0  1.79  Grem1  gremlin 1 
0  1.75 
Plf /// Plf2 /// 
Mrpplf3 
proliferin /// proliferin 2 /// mitogen regulated protein, proliferin 
3 
0  1.74  Fyb  FYN binding protein 
0  1.8  2210419I08Rik  RIKEN cDNA 2210419I08 gene 
0  1.77  Alcam  activated leukocyte cell adhesion molecule 
0  1.73  Ptprc  Alternatively spliced Ly-5 glycoprotein mRNA, 5' end 
0 
 
1.73 
 
Gatm 
 
glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
0  1.75  Dub1  deubiquitinating enzyme 1 
0  1.7  Lynx1  Ly6/neurotoxin 1 
0  1.68  Ass1  argininosuccinate synthetase 1 
0  1.71  U90926  cDNA sequence U90926 
0.03  1.76  Alcam  activated leukocyte cell adhesion molecule 
0.03 
 
 
1.62 
 
 
2010309G21Rik /// 
LOC207685 /// 
LOC547243 
RIKEN cDNA 2010309G21 gene /// hypothetical protein 
LOC207685 /// similar to Ig lambda-2 chain 
 
0.03 
 
1.66 
 
H60 
 
PREDICTED: histocompatibility 60 [Mus musculus], mRNA 
sequence 
0.03  1.72  Tiparp  TCDD-inducible poly(ADP-ribose) polymerase 
0.06  1.64  LOC433022  hypothetical LOC433022 Christine Haworth    Chapter 5, 169 
 
0.06  1.62  Cyba  cytochrome b-245, alpha polypeptide 
0.06  1.64  A130040M12Rik  RIKEN cDNA A130040M12 gene 
0.05  1.69  Hist1h2bc  histone 1, H2bc 
0.11 
 
1.72 
 
Malat1 
 
metastasis associated lung adenocarcinoma transcript 1 (non-
coding RNA) 
0.13  1.7  Parp12  poly (ADP-ribose) polymerase family, member 12 
0.12  1.64  0610040B09Rik  RIKEN cDNA 0610040B09 gene 
0.12  1.68  Evi2a  ecotropic viral integration site 2a 
0.12  1.6  Gpnmb  glycoprotein (transmembrane) nmb 
0.12  1.62  2810013C04Rik  RIKEN cDNA 2810013C04 gene 
0.11  1.59  Gsta4  glutathione S-transferase, alpha 4 
0.11  1.7  Kctd4  potassium channel tetramerisation domain containing 4 
0.11  1.62  Dcn  decorin 
0.11  1.59  Igf2r  insulin-like growth factor 2 receptor 
0.1  1.63  ---  --- 
0.1  1.6  Dusp4  dual specificity phosphatase 4 
0.1  1.78  Rorb  RAR-related orphan receptor beta 
0.1  1.67  Sfrs2ip  splicing factor, arginine/serine-rich 2, interacting protein 
0.12  1.58  Mtss1  metastasis suppressor 1 
0.15 
 
1.59 
 
Rbmy1a1 
 
RNA binding motif protein, Y chromosome, family 1, member 
A1 
0.15  1.66  Mep1a  meprin 1 alpha 
0.18  1.63  3110004L20Rik  RIKEN cDNA 3110004L20 gene 
0.2  1.57  Ccl7  chemokine (C-C motif) ligand 7 
0.23  1.59  Mapk12  mitogen-activated protein kinase 12 
0.22  1.56     
0.34  1.58  ---  Transcribed locus 
0.33  1.58  Calr3  calreticulin 3 
0.34  1.55  Seh1l  SEH1-like (S. cerevisiae 
0.4  1.52  D11Ertd730e  DNA segment, Chr 11, ERATO Doi 730, expressed 
0.41  1.56  Traf1  Tnf receptor-associated factor 1 
0.44  1.51  ---  Transcribed locus 
0.46  1.51  9130227C08Rik  RIKEN cDNA 9130227C08 gene 
0.47  1.52  E430024C06Rik  RIKEN cDNA E430024C06 gene 
0.46  1.52  B430320C24Rik  RIKEN cDNA B430320C24 gene 
0.46  1.5  Myd116  myeloid differentiation primary response gene 116 
0.54  1.53  Edn1  endothelin 1 
0.56  1.52  Atf3  activating transcription factor 3 
0.62  1.51  Gpc1  glypican 1 
0.61  1.51  BC034507  cDNA sequence BC034507 
0.7  1.49  Ociad2  OCIA domain containing 2 
0.72  1.52 
LOC432995 /// 
LOC436333 
hypothetical gene supported by BC047216 /// hypothetical 
gene supported by BC047216 
0.71  1.49  Vegfc  vascular endothelial growth factor C 
0.76  1.48  2810003C17Rik  RIKEN cDNA 2810003C17 gene 
0.82 
 
1.48 
 
Erbb3 
 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 
(avian) 
0.81  1.5  Gadd45b  growth arrest and DNA-damage-inducible 45 beta 
0.81  1.48  Ampd3  AMP deaminase 3 
0.85  1.51  Zfp622  zinc finger protein 622 
0.91  1.54  BC034507  cDNA sequence BC034507 
0.95  1.51  Hcn1  hyperpolarization-activated, cyclic nucleotide-gated K+ 1 
0.95  1.48  Sqstm1  sequestosome 1 
0.94  1.47  Atp6v0b  ATPase, H+ transporting, V0 subunit B 
0.94  1.5  Foxf1a  forkhead box F1a 
0.98 
 
1.51 
 
Maf 
 
avian musculoaponeurotic fibrosarcoma (v-maf) AS42 
oncogene homolog 
0.99  1.48  Dazl  deleted in azoospermia-like 
0.98  1.53  Trim44  tripartite motif-containing 44 
1.04  1.47  3110023G01Rik  RIKEN cDNA 3110023G01 gene 
1.07  1.48  Hmox1  heme oxygenase (decycling) 1 
1.05  1.64  Alcam  activated leukocyte cell adhesion molecule 
1.16 
 
1.5 
 
Napb 
 
N-ethylmaleimide sensitive fusion protein attachment protein 
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1.18 
 
1.47 
 
Eif2s3y 
 
eukaryotic translation initiation factor 2, subunit 3, structural 
gene Y-linked 
1.24 
 
 
 
1.45 
 
 
 
1200016E24Rik /// 
A130040M12Rik /// 
E430024C06Rik /// 
LOC433071 
RIKEN cDNA 1200016E24 gene /// RIKEN cDNA 
A130040M12 gene /// RIKEN cDNA E430024C06 gene /// 
hypothetical gene supported by AK004796; BC040222 
 
1.25  1.47  Ppifs  peptidylprolyl isomerase F, opposite strand transcription unit 
1.24  1.46  Ahr  aryl-hydrocarbon receptor 
1.39  1.47  Zfand2a  zinc finger, AN1-type domain 2A 
1.39  1.57  Efemp1 
epidermal growth factor-containing fibulin-like extracellular 
matrix protein 1 
1.41  1.44  Vegfc  vascular endothelial growth factor C 
1.44  1.45  ---  --- 
1.47  1.45  9430041P20Rik  RIKEN cDNA 9430041P20 gene 
1.63  1.43  Pik3r5  phosphoinositide-3-kinase, regulatory subunit 5, p101 
1.68  1.45  Mtss1  metastasis suppressor 1 
1.84  1.44  Hs6st2  heparan sulfate 6-O-sulfotransferase 2 
1.9  1.47  LOC231914  similar to mKIAA0060 protein 
1.93  1.47  2900093K20Rik  RIKEN cDNA 2900093K20 gene 
2.36  1.42  1110013L07Rik  RIKEN cDNA 1110013L07 gene 
2.41  1.42  Csf1r  colony stimulating factor 1 receptor 
2.5  1.43  1110051M20Rik  RIKEN cDNA 1110051M20 gene 
2.61  1.44  ---  Transcribed locus 
2.69 
 
1.43 
 
Dusp3 
 
dual specificity phosphatase 3 (vaccinia virus phosphatase 
VH1-related) 
2.72  1.41  Rbm3  RNA binding motif protein 3 
2.84  1.41  Bhlhb5  basic helix-loop-helix domain containing, class B5 
2.87  1.41  4930535I16Rik  RIKEN cDNA 4930535I16 gene 
3.29 
 
1.41 
 
Malat1 
 
metastasis associated lung adenocarcinoma transcript 1 (non-
coding RNA) 
3.28  1.4  Stx3  syntaxin 3 
3.96  1.4  ---  --- 
4.17  1.39  Lmo1  LIM domain only 1 
4.39 
 
1.4 
 
9130008F23Rik 
 
RIKEN cDNA 9130008F23 gene 
 
FDR, False discovery rate; ---, unannotated cDNA or EST sequences. 
 
Table 17 Genes down-regulated; pLoxEGFP5+ vs. pLoxEGFP5-. 
FDR 
Fold 
Change  Gene Symbol  Gene Title 
0  -1.81  Dlk1  delta-like 1 homolog (Drosophila) 
0 
 
-1.75 
 
Cacna1c 
 
Calcium channel, voltage-dependent, L type, alpha 1C subunit 
(Cacna1c), mRNA 
0  -1.78  6530401D17Rik  RIKEN cDNA 6530401D17 gene 
0 
 
-1.71 
 
Tomm7 
 
translocase of outer mitochondrial membrane 7 homolog 
(yeast) 
0 
 
-1.7 
 
Sc4mol 
 
Sterol-C4-methyl oxidase-like, mRNA (cDNA clone 
MGC:11745 IMAGE:3152545) 
0  -1.68  Lcn2  lipocalin 2 
0  -1.78  Car9  carbonic anhydrase 9 
0 
 
-1.74 
 
Hivep3 
 
human immunodeficiency virus type I enhancer binding 
protein 3 
0  -1.65  Odz3  odd Oz/ten-m homolog 3 (Drosophila) 
0  -1.68  Asb4  ankyrin repeat and SOCS box-containing protein 4 
0  -1.69  Ogn  osteoglycin 
0  -1.66  Haghl  hydroxyacylglutathione hydrolase-like 
0.31  -1.58  Gpc6  glypican 6 
0.29  -1.62  Fos  FBJ osteosarcoma oncogene 
0.27  -1.61  Lancl2  LanC (bacterial lantibiotic synthetase component C)-like 2 Christine Haworth    Chapter 5, 171 
 
0.25  -1.64  5930437A14Rik  RIKEN cDNA 5930437A14 gene 
0.29  -1.6  ---  --- 
0.28  -1.66  Col3a1  procollagen, type III, alpha 1 
0.89 
 
-1.57 
 
AI325464 
 
Expressed sequence AI325464, mRNA (cDNA clone 
MGC:30834 IMAGE:4006813) 
0.95  -1.48  Igf2bp3  insulin-like growth factor 2, binding protein 3 
1  -1.6  X83313  EST X83313 
1.05  -1.57  Nfix  nuclear factor I/X 
1  -1.55  ---  Transcribed locus 
1.08  -1.55  Hnrpab  heterogeneous nuclear ribonucleoprotein A/B 
1.16  -1.53  Ror1  receptor tyrosine kinase-like orphan receptor 1 
1.12  -1.55  Psip1  PC4 and SFRS1 interacting protein 1 
1.11 
 
-1.55 
 
Apbb2 
 
Amyloid beta (A4) precursor protein-binding, family B, member 
2, mRNA (cDNA clone MGC:100042 IMAGE:30550087) 
1.11  -1.54  Has2  hyaluronan synthase 2 
1.07  -1.54  ---  Transcribed locus 
1.13  -1.59  Rtn4  RTN4 (Rtn4) mRNA, complete cds, alternatively spliced 
1.1  -1.56  Arf6  ADP-ribosylation factor 6 
1.06  -1.6  Ogn  osteoglycin 
1.09  -1.53  Acss2  acyl-CoA synthetase short-chain family member 2 
1.09  -1.58  Il13ra1  interleukin 13 receptor, alpha 1 
1.17  -1.61  Nrn1  neuritin 1 
1.28  -1.56  6330406I15Rik  RIKEN cDNA 6330406I15 gene 
1.32  -1.53  Tgfb1i4  TSC22-related inducible leucine zipper 1b (Tilz1b) 
1.37  -1.52  D630048P19Rik 
Optic atrophy 3 (human), mRNA (cDNA clone MGC:106414 
IMAGE:6404450) 
1.44  -1.56  Pcbp3  Poly(rC) binding protein 3 (Pcbp3), mRNA 
1.77  -1.5  D530037H12Rik  RIKEN cDNA D530037H12 gene 
1.78  -1.51  8430408J07Rik  RIKEN cDNA 8430408J07 gene 
1.93  -1.5  Il13ra1  interleukin 13 receptor, alpha 1 
2.21  -1.5  Cp  ceruloplasmin 
2.18  -1.47  Iigp1  interferon inducible GTPase 1 
2.38  -1.49  5730555F13Rik  RIKEN cDNA 5730555F13 gene 
2.39  -1.5  Cog1  component of oligomeric golgi complex 1 
2.68  -1.46  Mlf1  myeloid leukemia factor 1 
2.67 
 
-1.47 
 
Ctsb 
 
Cathepsin B, mRNA (cDNA clone MGC:6211 
IMAGE:3500700) 
2.61 
 
-1.48 
 
Zfp289 /// 
LOC434076 
zinc finger protein 289 /// similar to zinc finger protein 289 
 
2.76  -1.46  Tmem45a  transmembrane protein 45a 
2.78  -1.49  H2-T23  histocompatibility 2, T region locus 23 
2.9  -1.48  Tead1  TEA domain family member 1 (Tead1), mRNA 
2.91  -1.48  Rpap1  RNA polymerase II associated protein 1 
3.04  -1.47  Cald1  Caldesmon 1 (Cald1), mRNA 
3.16  -1.47  Arntl2  aryl hydrocarbon receptor nuclear translocator-like 2 
3.16  -1.46  Dclre1b  DNA cross-link repair 1B, PSO2 homolog (S. cerevisiae) 
3.25  -1.48  Asb4  ankyrin repeat and SOCS box-containing protein 4 
3.24  -1.47  A730054J21Rik  RIKEN cDNA A730054J21 gene 
3.27  -1.41  2610005L07Rik  RIKEN cDNA 2610005L07 gene 
3.25  -1.47  6330406I15Rik  RIKEN cDNA 6330406I15 gene 
3.2  -1.46  Dscr1l1  Down syndrome critical region gene 1-like 1 
3.18  -1.45  5730596K20Rik  RIKEN cDNA 5730596K20 gene 
3.19  -1.48  Cp  ceruloplasmin 
3.25  -1.45  Rgs20  regulator of G-protein signaling 20 
3.2  -1.45  C1ql3  C1q-like 3 
3.24  -1.46  Cdh11  cadherin 11 
3.33  -1.45  Col1a1  procollagen, type I, alpha 1 
3.34  -1.47  ---  Transcribed locus 
3.29  -1.47  Cp  ceruloplasmin 
3.24  -1.47  Cp  ceruloplasmin 
3.32  -1.44  2010012C16Rik  RIKEN cDNA 2010012C16 gene 
3.47  -1.45  5033421C21Rik  RIKEN cDNA 5033421C21 gene 
3.42  -1.46  Chrdl1  Chordin-like 1 (Chrdl1), mRNA 
3.39  -1.46  ---  Adult male medulla oblongata cDNA, RIKEN full-length Christine Haworth    Chapter 5, 172 
 
enriched library, clone:6330531L09 product:unclassifiable, full 
insert sequence 
3.41  -1.43  LOC56628  MHC (A.CA/J(H-2K-f) class I antigen 
3.38  -1.41  Phf20  PHD finger protein 20 
3.36  -1.44  Ccnc  cyclin C 
3.37  -1.43  C030045D06Rik  RIKEN cDNA C030045D06 gene 
3.52 
 
-1.46 
 
Pdlim5 
 
PDZ and LIM domain 5, mRNA (cDNA clone MGC:46824 
IMAGE:4457868) 
3.55  -1.44  Phf3  PHD finger protein 3 
3.79 
 
-1.44 
 
Psmb9 
 
proteosome (prosome, macropain) subunit, beta type 9 (large 
multifunctional peptidase 2) 
3.96  -1.43  Adam12  a disintegrin and metallopeptidase domain 12 (meltrin alpha) 
4.52  -1.44  Islr  immunoglobulin superfamily containing leucine-rich repeat 
4.5  -1.43  Pcdhb21  protocadherin beta 21 
4.47  -1.45  Fmod  fibromodulin 
4.52  -1.43  Thy1  thymus cell antigen 1, theta 
4.72  -1.43  Osmr  oncostatin M receptor 
4.76  -1.49  AI451617  expressed sequence AI451617 
4.83  -1.42  Scd2  stearoyl-Coenzyme A desaturase 2 
4.98 
 
-1.42 
 
Adamtsl1 
 
ADAMTS-like 1 
   
FDR, False discovery rate; ---, unannotated cDNA or EST sequences. 
 
5.3.3 Exon expression array 
In the Affymetrix GeneChip
® Mouse Exon 1.0 ST Array, probesets are interspersed evenly 
throughout the length of the transcript, with at least four probes per exon. At least one 
probeset is present per exon, and forty probes per transcript on average. The array is very 
comprehensive, designed to identify exon skipping; intron retention (by placement of 
probes within introns adjacent to exon-intron boundaries in genes known to undergo events 
of this type); mutually exclusive exon usage; alternative promoter usage; alternative 
polyadenylation and alternative splicing donor/acceptor sites with changes over 25 bp (the 
size of a probe). Exon sequences were compiled from existing cDNA-based information 
taken from REFSeq and GenBank® mRNAs, and ESTs from dbEST. Predicted exon 
sequences were included derived from information taken from GENSCAN 
(genes.mit.edu/GENSCAN.html); Ensembl: (www.ensembl.org/); Vega: 
(vega.sanger.ac.uk/); geneid and sgp: (www1.imim.es/software/geneid/index.html); 
TWINSCAN: (genes.cs.wustl.edu/); Exoniphy: (genome.ucsc.edu/cgi-
bin/hgTrackUi?g=exoniphy&db=hg16); MicroRNA Registry: 
(www.sanger.ac.uk/Software/Rfam/mirna/); MITOMAP: (www.mitomap.org/) and 
Structural RNA Predictions: (genome.ucsc.edu/cgi-bin/hgTrackUi?g=rnaGene&db=hg16). 
It is unlikely that an alternative exon would not be included within these measures, but if it 
were not, the exon would not be identified. Cryptic exons such as those of the chloride 
channel in DM however, are likely to be under represented. Christine Haworth    Chapter 5, 173 
 
 
5.3.3.1  Sample preparation for exon arrays 
Samples were prepared in triplicate, in parallel, such that three chips were hybridised for 
each sample group pLoxEGFP; pLoxEGFP5 and pLoxEGFP250 –nine chips in total. It has 
been noted that on occasion cells have been observed that contain foci but do not show 
EGFP fluorescence when viewed microscopically. Although this was well controlled for 
by sample choice in the whole transcript array, it was clear from the EGFP RT-PCR 
(Figure 54B) the quality of separation at the molecular level was poor. Also, recently 
published data by Mahadevan et al. 2006, hinted that over-expression of 5 CUG repeats 
may be pathogenic (Mahadevan et al., 2006). For these reasons the basic design of the 
experiment was simplified to pLoxEGFP vs. pLoxEGFP5 vs. pLoxEGFP250, without cell 
sorting. This means that if pLoxEGFP5 over-expression is pathogenic, differences should 
be apparent in comparison to the zero repeat sample pLoxEGFP. 
 
Figure 55 Construct expression in exon array samples. A Fluorescent micrographs. Exon array 
starting samples. Live 3T3 cells transfected with pLoxEGFP; pLoxEGFP5 or pLoxEGFP250 prior to 
harvest. Cells were 60% confluent. EGFP fluorescence was apparent in all samples. B EGFP RT-
PCR. Each sample with and without reverse transcriptase. The EGFP product was present in all 
samples, faintly in pLoxEGFP250. C DM-H/DM-BR RT-PCR over the repeat region. No repeats are 
apparent in pLoxEGFP replicates; 5 repeats are present in the pLoxEGFP5 samples and a faint 
presence of 250 repeats can be seen in the pLoxEGFP250 samples. Note that in both EGFP and 
DM-H/DM-BR RT-PCRs the amount of pLoxEGFP250 products are much lower than pLoxEGFP5, 
even though EGFP fluorescence in the starting sample is almost as high as pLoxEGFP and 
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Cells were transfected as described in 5.3.2.1 ‘Sample preparation for whole transcript 
arrays’ using pLoxEGFP; pLoxEGFP or pLoxEGFP250. To ensure the cells were always 
in the exponential phase, after 24 hours, they were harvested using trypsin, diluted 1:3 and 
incubated for a further 24 hours. Total RNA was prepared and a portion subjected to EGFP 
RT-PCR to confirm expression of the construct, and DM-H/DM-BR PCR to confirm the 
repeat length. The results show that the expected repeat length is present in each sample, 
and that EGFP is also transcribed in each (Figure 55).  
The amount of construct expression in both RT-PCRs using the pLoxEGFP250 sample is 
low compared to pLoxEGFP5. The reasons for this are not clear since EGFP fluorescence 
is clearly present in the starting sample confocal images, although they are of a lower 
intensity (Figure 55A). It may be that the RNA within foci is not as easily isolated or 
reverse-transcribed. Hamshere et al. reported that expanded DMPK polyA+ alleles were 
underrepresented in nuclear polyA+ fractions, suggesting this may be the case (Hamshere 
et al., 1997), although their method of isolation was based on phenol-chloroform extraction 
compared to the guanidinium based extraction used here. In the recent reversible mouse 
model generated by Mahadevan et al., lines with expanded repeats also showed low 
expression of repeat arrays using quantitative real-time PCR. However, it is not clear 
which chemistry was used for RNA isolation (Langlois et al., 2003; Mahadevan et al., 
2006). 
5.3.3.2  Results of analysis 
Genes known to be mis-spliced in DM do not always show a large difference or fold 
change between any two particular RNA isoforms (Kanadia et al., 2006; Lin et al., 2006). 
In some transcripts a new isoform has appeared, such as the 6b/7a/8 or 6/7a/7/8a/8 exon 
inclusion of CLCN1, expressed at a low level compared to the ‘normal’ 6/7/8 transcript 
(Figure 65, right). In DM, the proportions of a collection of alternative transcripts are often 
changed, with some forms only present in DM samples. Therefore the differential splicing 
analysis was ranked according to p-value of alternative splicing (the interaction between 
the two ANOVA factors -probeset level within the gene and transcript level between the 
samples with 0, 5 and 250 repeats), rather than a high fold change between transcript 
isoforms.  
GeneChip differences were analysed by 2-way ANOVA analysis using Partek® Genomics 
Suite software, on three metaprobeset levels, core; extended and full. The core set 
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sequence tags (EST), and the full set comprises confirmed cDNAs; ESTs and predicted 
splice products. All three lists were studied during gene selection. Significance was limited 
to a p-value of ≤0.001 for alternative exon usage ANOVAs. Between the test samples: 
pLoxEGFP0; pLoxEGFP5 and pLoxEGFP250 repeats, 29; 54 and 58 genes showed 
alternative exon usage the core (Table 18), extended (Table 19) and full (Table 20) 
probesets respectively.  
Table 18 Genes with differential exon usage using the core metaprobeset 
gene_assignment 
 
 
p-value  
Alternative 
splicing 
NM_198017 // C430003P19Rik // RIKEN cDNA C430003P19 gene // 7 F3 // 109359 /// A  3.75E-11 
NM_015744 // Enpp2 // ectonucleotide pyrophosphatase/phosphodiesterase 2 // 15 D  9.33E-08 
NM_027135 // Sec24d // SEC24 related gene family, member D (S. cerevisiae) // 3   2.15E-06 
BC029239 // Timm8b // translocase of inner mitochondrial membrane 8 homolog b (y  2.52E-06 
NM_008444 // Kif3b // kinesin family member 3B // 2 86.0 cM // 16569 /// AK08154  2.81E-06 
XM_975671 // LOC674573 // similar to Mitogen-activated protein kinase kinase kin  3.16E-06 
XM_001000465 // 9930012K11Rik // RIKEN cDNA 9930012K11 gene // 14 D2 // 268759   4.55E-06 
NM_010764 // Man2b1 // mannosidase 2, alpha B1 // 8 C2|8 37.0 cM // 17159 /// AK  4.58E-06 
NM_028066 // F11 // coagulation factor XI // 8 B1.1|8 25.0 cM // 109821  7.81E-06 
NM_178224 // Cbs // cystathionine beta-synthase // 17 A-C|17 17.4 cM // 12411 //  8.68E-06 
NM_054048 // Rcor2 // REST corepressor 2 // 19 A // 104383 /// AK205817 // Rcor2  9.16E-06 
NM_021536 // Rhot1 // ras homolog gene family, member T1 // 11 B5|11 47.26 cM //  9.90E-06 
NM_027347 // Crsp3 // cofactor required for Sp1 transcriptional activation, subu  1.27E-05 
NM_025982 // Tspan31 // tetraspanin 31 // 10 D3 // 67125 /// AK160269 // Tspan31  1.35E-05 
NM_016774 // Atp5b // ATP synthase, H+ transporting mitochondrial F1 complex, be  1.48E-05 
NM_146226 // Apeh // acylpeptide hydrolase // 9 F2 // 235606 /// BC034199 // Ape  2.17E-05 
XM_897143 // LOC622510 // hypothetical LOC622510 // 2 C3 // 622510 /// XM_922075  2.51E-05 
NM_021398 // Slc43a3 // solute carrier family 43, member 3 //  // 58207 /// NM_0  2.97E-05 
XM_994018 // 2600009E05Rik // RIKEN cDNA 2600009E05 gene // 2 F3 // 77006 /// XM  4.36E-05 
NM_001001454 // Ttyh1 // tweety homolog 1 (Drosophila) // 7 A1 // 57776 /// NM_0  4.57E-05 
XM_992228 // Epn2 // epsin 2 // 11 B2 // 13855 /// NM_010148 // Epn2 // epsin 2   4.73E-05 
NM_023220 // 2010106G01Rik // RIKEN cDNA 2010106G01 gene // 2 F3 // 66552 /// BC  4.94E-05 
NM_026127 // 4833420G17Rik // RIKEN cDNA 4833420G17 gene // 13 D2.3 // 67392 ///  5.73E-05 
XM_988508 // Bptf/Falz // fetal Alzheimer antigen // 11 E1 // 207165 /// XM_903112 //  6.02E-05 
NM_013680 // Syn1 // synapsin I // X A1-A4|X 6.2 cM // 20964  7.13E-05 
NM_008782 // Pax5 // paired box gene 5 // 4 B1|4 20.7 cM // 18507  7.66E-05 
NM_183315 // Ctxn1 // cortexin 1 // 8 A1.1|8 13.0 cM // 330695  7.87E-05 
XM_990359 // Cbx1 // chromobox homolog 1 (Drosophila HP1 beta) // 11 D|11 58.0 c  9.36E-05 
BC067070 // 4932415G12Rik // RIKEN cDNA 4932415G12 gene // 10 C2 // 67723  9.39E-05     
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Table 19 Genes with differential exon usage using the extended metaprobeset 
gene_assignment 
 
 
p-value 
Alternative  
splicing 
NM_133916 // Eif3s9 // eukaryotic translation initiation factor 3, subunit 9 (et  1.41E-08 
NM_133215 // Mtmr4 // myotubularin related protein 4 // 11 C // 170749  2.90E-08 
NM_198017 // C430003P19Rik // RIKEN cDNA C430003P19 gene // 7 F3 // 109359 /// A  8.71E-08 
NM_015744 // Enpp2 // ectonucleotide pyrophosphatase/phosphodiesterase 2 // 15 D  1.50E-07 
XR_004056 // LOC382931 // similar to 3-phosphoglycerate dehydrogenase // 14 E2.1  1.80E-07 
XM_983388 // Ppp2r5a // protein phosphatase 2, regulatory subunit B (B56), alpha  4.83E-07 
NM_013854 // Abcf1 // ATP-binding cassette, sub-family F (GCN20), member 1 // 17  8.97E-07 
NM_177615 // C78409 // expressed sequence C78409 // 10 D3 // 216441  9.90E-07 
NM_007992 // Fbln2 // fibulin 2 // 6 D-E|6 37.2 cM // 14115 /// AK017870 // 5730  2.27E-06 
NM_001039080 // Rbms2 // RNA binding motif, single stranded interacting protein   3.44E-06 
XM_001000465 // 9930012K11Rik // RIKEN cDNA 9930012K11 gene // 14 D2 // 268759   5.23E-06 
NM_008431 // Kcnk4 // potassium channel, subfamily K, member 4 // 19 A|19 4.5 cM  5.35E-06 
NM_019426 // Atf7ip // activating transcription factor 7 interacting protein //   1.14E-05 
NM_008782 // Pax5 // paired box gene 5 // 4 B1|4 20.7 cM // 18507  1.38E-05 
XM_983442 // Kcnmb4 // potassium large conductance calcium-activated channel, su  1.43E-05 
NM_007801 // Ctsh // cathepsin H // 9 E3.1|9 50.0 cM // 13036 /// BC080767 // Ct  1.55E-05 
NM_025813 // Mfsd1 // major facilitator superfamily domain containing 1 // 3 E2   1.58E-05 
NM_053089 // Narg1 // NMDA receptor-regulated gene 1 // 3 D // 74838 /// AK07804  1.63E-05 
AK020953 // B230104C08Rik // RIKEN cDNA B230104C08 gene // 6 G3 // 77841  1.68E-05 
NM_008149 // Gpam // glycerol-3-phosphate acyltransferase, mitochondrial // 19 D  1.86E-05 
NM_021398 // Slc43a3 // solute carrier family 43, member 3 //  // 58207 /// NM_0  2.67E-05 
XM_001052047 // Lhx3 // LIM homeobox protein 3 // 2 A2-C1|2 16.0 cM // 16871 ///  2.68E-05 
NM_178892 // Tiparp // TCDD-inducible poly(ADP-ribose) polymerase // 3 E1 // 999  3.14E-05 
XM_001005692 // LOC673486 // similar to eukaryotic translation initiation factor  3.32E-05 
NM_009392 // Tlx2 // T-cell leukemia, homeobox 2 // 6 C3-D1|6 35.5 cM // 21909  3.56E-05 
BC029239 // Timm8b // translocase of inner mitochondrial membrane 8 homolog b (y  3.82E-05 
NM_172339 // Snapc4 // small nuclear RNA activating complex, polypeptide 4 // 2   4.77E-05 
XM_979043 // Gm1027 // gene model 1027, (NCBI) // 4 C7 // 381538 /// NM_028209 /  4.80E-05 
XM_994018 // 2600009E05Rik // RIKEN cDNA 2600009E05 gene // 2 F3 // 77006 /// XM  5.13E-05 
NM_030109 // Sf3b2 // splicing factor 3b, subunit 2 // 19 A // 319322 /// AK1890  5.14E-05 
NM_011883 // Rnf13 // ring finger protein 13 // 3 D // 24017 /// AF037206 // Rnf  5.51E-05 
XM_984379 // Prpf19 // PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cere  6.50E-05 
NM_001001144 // Scap // SREBP cleavage activating protein // 9 F2 // 235623 ///   6.68E-05 
NM_026476 // 2610101N10Rik // RIKEN cDNA 2610101N10 gene // 9 E4 // 67958 /// AK  6.76E-05 
NM_145959 // D15Ertd621e // DNA segment, Chr 15, ERATO Doi 621, expressed // 15   6.79E-05 
NM_013746 // Plekhb1 // pleckstrin homology domain containing, family B (evectin  7.23E-05 
XM_986293 // Rhox12 // reproductive homeobox 12 // X A3.3 // 382282  7.68E-05 
XM_992477 // Ak3l1 // adenylate kinase 3 alpha-like 1 // 4 C6|4 47.6 cM // 11639  8.22E-05 
NM_028411 // Tmem138 // transmembrane protein 138 // 19 B // 72982 /// AK007197   8.40E-05 
NM_023671 // Clns1a // chloride channel, nucleotide-sensitive, 1A // 7 E3|7 50.0  8.68E-05 
XM_923609 // Ptpn23 // protein tyrosine phosphatase, non-receptor type 23 // 9 F  8.94E-05 
NM_133781 // Cab39 // calcium binding protein 39 // 1 C5 // 12283 /// XM_976988   9.03E-05 
NM_175004 // Ptrh2 // peptidyl-tRNA hydrolase 2 // 11 C // 217057 /// AK031620 /  9.27E-05 
NM_001013026 // Ttf2 // transcription termination factor, RNA polymerase II // 3  9.80E-05 
NM_028247 // Slc16a10 // solute carrier family 16 (monocarboxylic acid transport  1.25E-05 
NM_054048 // Rcor2 // REST corepressor 2 // 19 A // 104383 /// AK205817 // Rcor2  1.25E-05 
---  2.79E-05 
NM_028066 // F11 // coagulation factor XI // 8 B1.1|8 25.0 cM // 109821  3.45E-05 
NM_001038663 // Mapk1 // mitogen activated protein kinase 1 // 16 A3|16 9.82 cM   4.47E-05 
NM_026127 // 4833420G17Rik // RIKEN cDNA 4833420G17 gene // 13 D2.3 // 67392 ///  7.35E-05 
NM_211355 // 1110034C04Rik // RIKEN cDNA 1110034C04 gene // 12 E // 68734 /// AK  9.97E-05 
XR_003366 // LOC384857 // similar to Keratin, type II cytoskeletal 8 (Cytokerati  1.26E-05 
AK029589 // 4930405O22Rik // RIKEN cDNA 4930405O22 gene //  // 414079 /// AK1604  1.29E-05 
NM_019468 // G6pd2 // glucose-6-phosphate dehydrogenase 2 // 5 C3.1|5 39.0 cM //  2.87E-05     
Genes selected for further bioinformatics analysis are highlighted in red 
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Table 20 Genes with differential exon usage using the full metaprobeset 
Gene_assignment 
 
 
p-value 
Alternative  
splicing 
NM_177615 // C78409 // expressed sequence C78409 // 10 D3 // 216441  7.95E-07 
NM_133215 // Mtmr4 // myotubularin related protein 4 // 11 C // 170749  6.48E-08 
NM_198017 // C430003P19Rik // RIKEN cDNA C430003P19 gene // 7 F3 // 109359 /// A  8.96E-08 
NM_133916 // Eif3s9 // eukaryotic translation initiation factor 3, subunit 9 (et  1.15E-07 
NM_008008 // Fgf7 // fibroblast growth factor 7 // 2 F-G // 14178 /// AK037172 /  4.59E-07 
---  1.30E-06 
NM_008149 // Gpam // glycerol-3-phosphate acyltransferase, mitochondrial // 19 D  1.86E-06 
---  2.88E-06 
NM_013854 // Abcf1 // ATP-binding cassette, sub-family F (GCN20), member 1 // 17  3.84E-06 
NM_173182 // Fndc3b // fibronectin type III domain containing 3B // 3 A3 // 7200  5.08E-06 
NM_001039080 // Rbms2 // RNA binding motif, single stranded interacting protein   5.42E-06 
NM_019426 // Atf7ip // activating transcription factor 7 interacting protein //   5.87E-06 
NM_008431 // Kcnk4 // potassium channel, subfamily K, member 4 // 19 A|19 4.5 cM  6.38E-06 
XM_994149 // Gcn1l1 // GCN1 general control of amino-acid synthesis 1-like 1 (ye  6.56E-06 
NM_053089 // Narg1 // NMDA receptor-regulated gene 1 // 3 D // 74838 /// AK07804  9.64E-06 
---  9.97E-06 
---  1.06E-05 
XM_983388 // Ppp2r5a // protein phosphatase 2, regulatory subunit B (B56), alpha  1.23E-05 
AK029589 // 4930405O22Rik // RIKEN cDNA 4930405O22 gene //  // 414079 /// AK1604  1.30E-05 
NM_009781 // Cacna1c // calcium channel, voltage-dependent, L type, alpha 1C sub  1.48E-05 
NM_007801 // Ctsh // cathepsin H // 9 E3.1|9 50.0 cM // 13036 /// BC080767 // Ct  1.63E-05 
---  1.78E-05 
AK020953 // B230104C08Rik // RIKEN cDNA B230104C08 gene // 6 G3 // 77841  2.13E-05 
XM_001000465 // 9930012K11Rik // RIKEN cDNA 9930012K11 gene // 14 D2 // 268759 /  3.20E-05 
NM_008591 // Met // met proto-oncogene // 6 4.0 cM // 17295 /// AK021346 // D730  3.39E-05 
NM_001001144 // Scap // SREBP cleavage activating protein // 9 F2 // 235623 ///   3.46E-05 
---  3.53E-05 
NM_026127 // 4833420G17Rik // RIKEN cDNA 4833420G17 gene // 13 D2.3 // 67392 ///  3.62E-05 
NM_178654 // Pkn2 // protein kinase N2 // 3 H1 // 109333 /// AK083670 // D030063  3.70E-05 
NM_009392 // Tlx2 // T-cell leukemia, homeobox 2 // 6 C3-D1|6 35.5 cM // 21909  3.79E-05 
XM_001052047 // Lhx3 // LIM homeobox protein 3 // 2 A2-C1|2 16.0 cM // 16871 ///  4.01E-05 
NM_011883 // Rnf13 // ring finger protein 13 // 3 D // 24017 /// AF037206 // Rnf  4.02E-05 
NM_007458 // Ap2a1 // adaptor protein complex AP-2, alpha 1 subunit // 7 B2 // 1  4.20E-05 
XM_001005692 // LOC673486 // similar to eukaryotic translation initiation factor  4.38E-05 
XM_994018 // 2600009E05Rik // RIKEN cDNA 2600009E05 gene // 2 F3 // 77006 /// XM  4.38E-05 
NM_001033259 // D130073L02Rik // RIKEN cDNA D130073L02 gene // 10 B4 // 215999 /  4.82E-05 
BC029239 // Timm8b // translocase of inner mitochondrial membrane 8 homolog b (y  4.92E-05 
NM_011161 // Mapk11 // mitogen-activated protein kinase 11 //  // 19094 /// NM_0  5.09E-05 
NM_054048 // Rcor2 // REST corepressor 2 // 19 A // 104383 /// AK205817 // Rcor2  5.23E-05 
XM_001001499 // Akap11 // A kinase (PRKA) anchor protein 11 // 14 D3 // 219181 /  5.65E-05 
NM_026476 // 2610101N10Rik // RIKEN cDNA 2610101N10 gene // 9 E4 // 67958 /// AK  5.84E-05 
XM_979043 // Gm1027 // gene model 1027, (NCBI) // 4 C7 // 381538 /// NM_028209 /  5.85E-05 
NM_001005331 // Eif4g1 // eukaryotic translation initiation factor 4, gamma 1 //  5.85E-05 
XM_984379 // Prpf19 // PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cere  6.23E-05 
NM_030109 // Sf3b2 // splicing factor 3b, subunit 2 // 19 A // 319322 /// AK1890  6.36E-05 
NM_021605 // Nek7 // NIMA (never in mitosis gene a)-related expressed kinase 7 /  6.46E-05 
---  6.62E-05 
---  6.64E-05 
NM_028411 // Tmem138 // transmembrane protein 138 // 19 B // 72982 /// AK007197   6.67E-05 
---  6.70E-05 
NM_033075 // D17H6S56E-5 // DNA segment, Chr 17, human D6S56E 5 // 17 B1|17 19.0  6.75E-05 
NM_019468 // G6pd2 // glucose-6-phosphate dehydrogenase 2 // 5 C3.1|5 39.0 cM //  7.60E-05 
NM_175093 // Trib3 // tribbles homolog 3 (Drosophila) // 2 G3 // 228775 /// NM_1  7.90E-05 
XM_986293 // Rhox12 // reproductive homeobox 12 // X A3.3 // 382282  8.27E-05 
---  8.45E-05 
NM_019710 // Smc1l1 // SMC (structural maintenance of chromosomes 1)-like 1 (S.   9.51E-05 
NR_002854 // Dlx1as // distal-less homeobox 1, antisense // 2 C2|2 44.0 cM // 11  9.88E-05 
XM_975459 // Trim55 // tripartite motif-containing 55 // 3 A2 // 381485/// XM9  9.93E-05   
Genes selected for further bioinformatics analysis are highlighted in red 
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Genes were selected for further analysis by using web-based bioinformatics such as USCS 
(http://genome.ucsc.edu/cgi-bin/hgGateway) and MGI 
(http://gbrowse.informatics.jax.org/cgi-bin/gbrowse/mouse_current/) genome browser 
gateways. The browsers show alignments of a comprehensive set of sequences from public 
domain databases that include known and predicted DNA and mRNA sequences, both full 
length and expressed sequence tags. Often exon inclusion or exclusion was apparent within 
the alignments, and published alternative splice isoforms could be identified. Genes with 
known alternatively spliced exons were considered good candidates. In addition, NCBI 
OMIM database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM) and MGI 
(http://www.informatics.jax.org/) gene detail searches were used to identify candidate 
genes whose disruption resulted in symptoms related to those observed in DM. Six genes 
were selected (Table 21) and the function, known alternative splicing and possible 
relations to DM1 symptoms were summarised: 
Table 21 Alternative splice ANOVA p-values using core, extended and full probeset data.  
  Core   Extended  Full 
MtmR4  4.99E-01  2.90E-08  6.48E-08 
Kcnk4  2.38E-03  5.35E-06  6.38E-06 
Narg1  9.19E01  1.63E-05  9.64E-06 
Ttyh1  4.57E-05  6.96E-01  1.54-04 
Bptf  6.02E-05  1.41E-01  2.32-01 
Cacna1c  2.87E-02  1.54E-02  1.48E-05 
Note–Significant values are shown in red 
 
5.3.3.2.1 MtmR4 
The myotubularin gene MTM1, is the archetypal member of a family of highly conserved 
protein-tyrosine phosphatase-like enzymes, of which there are at least ten members (MTM1 
and MTMR1-9). MTM1 is mutated in X-linked myotubular myopathy, causing a severe 
congenital myopathy characterised by the presence of disorganized skeletal muscle with 
fibres that contain centrally located nuclei (Laporte et al., 1996; Buj-Bello et al., 1999). Christine Haworth    Chapter 5, 179 
 
Mutations in MTMR2 result in the neurodegenerative disorder type 4B Charcot-Marie-
Tooth disease (CMT4B), a demyelinating motor and sensory neuropathy that starts in 
infancy, characterized by the presence of foci of abnormally folded myelin sheaths and 
Schwann cell proliferation in peripheral nerves (Berger et al., 2002). CMT4B causes 
progressive symmetric distal and proximal weakness starting in the lower extremities. 
Also, cranial-nerve deficits are observed in most patients. Recently, MTMR1 was shown to 
be mis-spliced in DM. Researchers identified 6 alternatively spliced mRNA isoforms of 
MTMR1, one which is muscle specific, induced during myogenesis, and represents the 
major isoform in adult skeletal muscle. The authors found reduced levels of the muscle-
specific isoform and the appearance of an abnormal MTMR1 transcript in cultured 
differentiated muscle cells and in skeletal muscle from congenital myotonic dystrophy 
patients, leading them to postulate that MTMR1 may play a role in muscle formation (Buj-
Bello et al., 2002). They also showed that mice deficient for the gene develop a 
generalized and progressive myopathy (Buj-Bello et al., 2002). Little is known about the 
function of the remaining myotubularin family members including MtmR4, identified in 
this microarray analysis, but given the effects of MTMR1 and MTMR2 mutations, MTMR4 
warrants further investigation. Zhao et al. found expression of MTMR4 in all human tissues 
examined except lung, small intestine, stomach, salivary gland, adrenal gland, and uterus 
(Zhao et al., 2001).  
MtmR4 was found to have three significant exon differences. Interestingly expression of 
either 5 or 250 CUG repeats lead to alternative exon splicing in different exons (Figure 
56). It is impossible to compare alternative splicing at the core probeset level with the DM 
missplicing of MTMR1 since alternative exons 2.1; 2.2 and 2.3 are not represented, this 
would need to be investigated molecularly. Buj-Bello et al. (2002) also reports, but does 
not specify, newly identified mis-spliced exons (Buj-Bello et al., 2002), which could relate 
to the differences documented here.  Christine Haworth    Chapter 5, 180 
 
 
Figure 56 Alternative exon usage in MtmR4. Graph plotting probeset value. Data for 5 and 250 
repeats were subtracted from 0 repeats (pLoxEGFP). Each exon is represented by one or more 
probesets that have been spaced proportionately to the genomic sequence for clarity. Probesets 
corresponding to probable alternative exon usage are circled. Refseq sequences are aligned to 
show the position of the exon within the gene. Refseq: NM133215 length 24,080 bp . Arrows (and 
red lines) indicate single nucleotide differences, which terminate the open reading frame. This may 
affect probe hybridisation at this position, but does not account for the differences between the 
samples, and therefore probably has no relevance. 
 
5.3.3.2.2 Kcnk4 
A little mentioned indication in myotonic dystrophy, but problematic when performing 
surgical procedures, is that of anaesthetic sensitivity. In DM1, patients have a higher 
sensitivity to sedatives, anaesthetic, and neuromuscular blocking agents which can result in 
cardiovascular and respiratory complications, thought to originate from muscular fatigue 
and myotonia (Aldridge, 1985; Klompe et al., 2007). KCNK4 is a stretch and 
polyunsaturated fatty acids activated tandem pore-domain potassium (K2P) channel. A 
voltage insensitive background potassium channel, which restores the membrane resting 
potential close to equilibrium (Lesage et al., 2000). The channel is highly expressed in 
brain (Fink et al., 1998; Lesage et al., 2000) and the role of K2P channels in general 
anesthesia and neuroprotection have been proposed recently. Harinath et al. 2004, 
identified TREK-1 and TRAAK channels (also known as Kcnk2 and Kcnk4) as molecular Christine Haworth    Chapter 5, 181 
 
targets for trichloroethanol (an active metabolite of the general anaesthetic chloral hydrate) 
and suggested that activation of these channels might contribute to the CNS depressant 
effects of chloral hydrate (Harinath et al., 2004). The channel is also activated by the 
glutamate release inhibitor Riluzole, a potent neuroprotective agent with anticonvulsant, 
anaesthetic (Mantz et al., 1992) and anti-ischaemic properties in brain (Heurteaux et al., 
2006), retina (Ettaiche et al., 1999; Izumi et al., 2003) and spinal cord (Lang-Lazdunski et 
al., 1999). This drug also has shown protective effects in animal models of Parkinson’s 
disease (Boireau et al., 1994; Benazzouz et al., 1995); in other models of acute 
neurodegenerative diseases (Kennel et al., 2000; Fumagalli et al., 2006) and in human 
neurodegenerative diseases (Howard et al., 2002; Jankovic et al., 2002; Killestein et al., 
2005; Wu et al., 2006; Mitsumoto et al., 2007). If activation of this channel by Riluzole 
confers such beneficial neuroprotective effects, it is feasible then that dysfunction of 
KCNK4 –possibly brought about by alternative splicing– could have the opposite 
degenerative effects, such as retinal degeneration and cortical atrophy. 
Two KCNK4 alternative splice variants have been characterised in human with a third 
detected on northern analysis. Gene expression in mouse is limited to the neuronal system, 
but in human is expressed more widely, mainly in the heart and brain but also in the liver, 
skeletal muscle, kidney and pancreas (Fink et al., 1998; Ozaita et al., 2002). Any 
differences between their function, or developmental expression of the alternative 
transcripts, has not yet been established.  
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Figure 57 Alternative exon usage in Kcnk4. Graph plotting probeset value. Data for 5 and 
250 repeats were subtracted from 0 repeats (pLoxEGFP). Each exon is represented by one 
or more probesets which are spaced proportionately to the genomic sequence. Probesets 
corresponding to probable alternative exon usage are circled. Refseq sequences are 
aligned to show the position of the exon within the gene. Refseq: NM008431 length 8,826 bp. 
 
Kcnk4 was found to have three possible exon differences, which differ from those of the 
human orthologue published by Ozaita et al. No information was found in the literature 
concerning embryonic transcript expression. Again, expression of either 5 or 250 CUG 
repeats lead to alternative exon splicing (Figure 57). 
 
5.3.3.2.3 Narg1  
Localized at excitatory synapses, NMDA receptors are one of the major classes of 
ionotropic neurotransmitter receptors of mammalian brain (Stephenson, 2006). Sugiura et 
al. showed that highly specific NMDA receptor-dependent regulation of NARG1, NARG2 
and NARG3 gene expression plays an important role in the transition from proliferation of 
neuronal precursors to differentiation of neurons. Narg1 (also known as murine N-terminal 
acetyltransferase 1, mNAT1) is an embryonic gene highly expressed in the developing 
brain in regions of neuronal proliferation and migration and subsequently down-regulated 
during early postnatal development, in part, by the onset of N-methyl-d-aspartate (NMDA) 
receptor function (Sugiura et al., 2001). Narg1 and its co-subunit, Ard1, assemble to form 
a functional acetyltransferase. Throughout brain development, Narg1 and Ard1 are highly 
expressed in areas of cell division and migration, and are down-regulated as neurons 
differentiate (Sugiura et al., 2003). Suguira et al., also found that Narg1 and Ard1 are 
expressed in proliferating mouse P19 embryonic carcinoma cells; treatment of these cells 
with retinoic acid initiated exit from the cell cycle, neuronal differentiation, and down-
regulation of Narg1 and Ard1 as the NMDA receptor 1 gene was induced. The results 
provided direct evidence that Narg1 and Ard1 form an N-terminal acetyltransferase in mice 
and suggested that expression and down-regulation of this enzyme complex played an 
important role in the generation and differentiation of neurons. (Sugiura et al., 2003), so it 
follows that inappropriate regulation could affect neuronal generation in the newborn. 
NARG1 could have a role in other symptoms of DM, such as retinal degeneration, 
cataracts and testicular atrophy: In the eye, NARG1 is also required to control retinal 
neovascularisation in adult ocular endothelial cells (Paradis et al., 2002), and involved in Christine Haworth    Chapter 5, 183 
 
corneal morphogenesis. Narg1 (also known as Tubedown1) is highly expressed in mouse 
embryonic cornea (E18.5) and also in adult corneal endothelium (Saika et al., 2001). 
 There are two known isoforms of the protein produced by alternative splicing in the 
mouse (swissprot Q9BXJ9-1 and Q9BXJ9-4). Interestingly, NARG1 may also be 
important in spermatogenesis since expression levels varied throughout spermatogenesis in 
the rat (He et al., 2002).  
In our analysis, Narg1 was found to have three possible exon differences. Again, 
expression of either 5 or 250 CUG repeats lead to alternative exon splicing (Figure 58). 
 
 
 
Figure 58 Alternative exon usage in Narg1. Graph plotting probeset value. Data for 5 and 250 
repeats were subtracted from 0 repeats (pLoxEGFP). Each exon is represented by one or more 
probesets which are spaced proportionately to the genomic sequence. Probesets corresponding to 
probable alternative exon usage are circled. Refseq sequences are aligned to show the position of 
the exon within the gene. Refseq: NM053089 length 57,883 bp. 
 
5.3.3.2.4 Ttyh1 
Myotonic dystrophy is a multisystemic disease, which affects the brain to varying degrees. 
Cerebral atrophy and white matter lesions are often observed in DM1 (Damian et al., 1993; 
Antonini et al., 2004). Neurofibriliary tangles (NFTs) –which are present in Alzheimer’s 
and most other dementias (Robert et al., 2007)– are also seen in DM1 brains (Kiuchi et al., 
1991). These are formed from insoluble aggregates of abnormally phosphorylated neuronal Christine Haworth    Chapter 5, 184 
 
microtubule associated protein tau. It would seem that the tau mis-splicing of exon 2 is 
responsible for neuronal loss since changes in tau isoform ratios leads to NFT formation, 
but it is not known if tangles are pathogenic; a benign marker of pathogenesis, or 
protective. There is a link between Tau mutations and learning disabilities, but the 
association is not absolutely clear since in mouse models, the formation of NFTs can be 
disassociated from tau induced neuronal loss (Andorfer et al., 2005; Santacruz et al., 
2005). Alzheimer’s disease is classed as a tauopathy, but lacks any genetic tau mutation yet 
NFT are formed, and there is neuronal loss, so the mechanism of pathogenesis is in part 
unclear. The brain lesions observed in DM1 can be explained by tau induced neuronal loss, 
nevertheless this need not exclude involvement of other genes. 
 
Figure 59 Alternative exon usage in Ttyh1. Graph plotting probeset values. Data for 5 and 250 
repeats were subtracted from 0 repeats (pLoxEGFP). Each exon is represented by one or more 
probesets which are spaced proportionately to the genomic sequence. Probesets corresponding to 
probable alternative exon usage are circled. Genbank mRNA sequences are aligned. Red 
markings indicate base differences. The arrow marks known alternative exon usage. Refseq Christine Haworth    Chapter 5, 185 
 
sequences are aligned to show the position of the exon within the gene. Refseq: NM021324 length 
16,709 bp. 
Human TTYH1 is related to the drosophila gene family tweety  (flightless behavioural, 
Campbell et al., 2000), expression is restricted to neuronal tissue and testis (Matthews et 
al., 2007). There are two known splice variants, the least common one of which is a swell-
activated maxi chloride channel, probably controlling cell volume (Suzuki, 2006). 
Mathews et al., expressed mouse Ttyh1 in non-neuronal human kidney (HEK) cells which 
caused axon-like protrusions to occur. They observed the highest concentration of TTYH1 
at the tips of the protrusions, where adhesion and guidance molecules are also expressed. 
The protein was also found to be associated with integrin alpha 5. Integrins play a key role 
in cell migration relative to extracellular matrix, in cell adhesion to basement membranes 
and resulting cell polarization. Their data suggested a role for TTYH1 in process 
formation, cell adhesion and possibly as a transmembrane receptor (Matthews et al., 2007), 
functions important during brain development. 
Ttyh1 was found to have four possible exon differences, and yet again, expression of either 
5 or 250 CUG repeats lead to alternative exon splicing. The latter two differences were 
positioned within the 3’ UTR, where alternative splice variants have been sequenced 
previously and deposited in genbank (Figure 59).  
 
 
5.3.3.2.5 Bptf 
BPTF is involved in brain development and chromatin remodelling. Also Known as Fac1, 
Nurf301 and falz, Bptf was identified by the reactivity of its encoded protein to a 
monoclonal antibody prepared against brain homogenates from patients with Alzheimer's 
disease. The gene’s discoverers determined that it is developmentally regulated, since they 
found abundant expression in fetal brain, where it is present throughout the gray and white 
matter of the developing spinal cord at 18-22 gestational weeks. In the adult, expression 
was found to be at low levels in brain and spinal cord, except in neurodegenerative 
diseases where the protein is up-regulated (Bowser et al., 1995). Functionally, the subunit 
composition suggests that it represents the human ortholog of the nurf301 component of 
the Drosophila nucleosome remodelling factor (NURF) complex. Wysoka et al., 
discovered that the gene product preferentially bound to trimethylated histone H3 lysine 4 
tails (H3K4me3), which mark the transcription start sites of virtually all transcriptionally 
active genes (Yan et al., 2006), allowing activation by chromatin remodelling by the Christine Haworth    Chapter 5, 186 
 
NURF complex (Wysocka et al., 2006). Human NURF is enriched in brain, Barak et al. 
demonstrated that it regulates human ENGRAILED, a homeodomain protein that regulates 
neuronal development in the mid-hindbrain. They also showed that hNURF potentiates 
neurite outgrowth in cell culture, and suggest a role for the transcription factor complex in 
neuronal growth (Barak et al., 2003). 
Human BPTF is alternatively spliced, two different isoforms have been described 
completely (Entrez nucleotide sequence database ID: NM182641 -isoform 1 and 
NM004459 -isoform 2) and four named isoforms formed by alternative splicing are listed 
in the Swissprot database (Swissprot ID Q12830-1, Q12830-2, Q12830-3, Q12830-4). 
From the analysis, expression of either 5 or 250 CUG repeats lead to six possible exon 
differences between the two samples compared to EGFP. The exon difference noted in 
pLoxEGFP5 corresponds to a known alternatively spliced exon in the human gene (Figure 
60), which is excluded in isoform 2 (NM004459) and included in isoform 1 (NM182641). 
As mentioned earlier, BPTF is thought to be developmentally regulated, but it is not clear 
whether this is done by isoform switching, or if the isoforms co-exist. 
 
Figure 60 Alternative exon usage in Bptf. Graph plotting probeset values. Data for 5 and 250 
repeats were subtracted from 0 repeats (pLoxEGFP). Each exon is represented by one or more 
probesets which are spaced proportionately to the genomic sequence. Probesets corresponding to 
probable alternative exon usage are circled. Refseq sequences are aligned to show the position of Christine Haworth    Chapter 5, 187 
 
the exon within the gene. The arrow identifies the exon excluded after expression of the 
pLoxEGFP5 transgene also excluded in human isoform 2. Refseq: mouse, NM176850 length 
98,842 bp; human, NM004459.6 and NM182641.3. 
 
5.3.3.2.6 Cacna1c 
CACNA1C is the pore-forming subunit of the L-type, voltage dependent calcium channel 
responsible for excitation-contraction coupling in the heart (see Striessnig, 1999 for 
review); heart development (Rottbauer et al., 2001), and is expressed in developing 
skeletal muscle (Chaudhari et al., 1993). Cardiac conduction defects have been well 
documented in myotonic dystrophy, both in patients and mouse models (Berul et al., 2000; 
Harper, 2001; Pall et al., 2003; Mahadevan et al., 2006).  
Excitation-contraction coupling in the heart is a carefully ordered process. In order for 
blood to be pumped directionally through the heart, atrial blood must first be squeezed into 
the ventricles and then out into the aorta. The atrial contraction triggered by the sino-atrial 
node, and the delay whilst atrial action potentials are restored and the ventricles fill with 
blood, is referred to as the PR interval. The QRS complex (the peak on an ECG, Figure 61) 
relates to the spread of electrical activity triggered by the atrio-ventricular node. This 
spreads down the centre of the heart and upwards through the ventricles resulting in 
ventricular contraction, which after returning to resting potential is termed the QT interval. 
 
Figure 61 The electrocardiogram (ECG). Schematic diagram depicting the nomenculature of 
electrical peaks and troughs during a heartbeat. P, P wave; PR, PR interval; QRS, QRS complex; 
QT, QT interval; T, T wave. Adapted from Merck Manuals online medical library 
(http://www.merck.com/mmpe/index.html). 
Molecularly excitation-contraction coupling is controlled by ion transport. Myocardiocytes 
possess a negative membrane potential when at rest. Electrical signals cause voltage gated 
calcium channels to depolarise, releasing calcium ions into the cell. The influx of calcium 
results in further release of free calcium into the cell from the sarcoplasmic reticulum, Christine Haworth    Chapter 5, 188 
 
causing the cell to contract. After a delay potassium channels open, allowing potassium to 
flow out of the cell for repolarisation. Cav1.2 is the L-type or long lasting, voltage 
dependent calcium channel responsible for excitation-contraction coupling in the heart. It 
mediates calcium influx in response to membrane depolarisation, and controls sustained 
contraction of the myocardium via calcium-induced Ca
2+ release from the sarcoplasmic 
reticulum. The Cacna1c gene product is the chief pore-forming subunit of Cav1.2, 
responsible for the calcium current, and is associated with auxiliary subunits α
2δ, β and γ, 
which modulate membrane expression and current properties (Tuluc et al., 2007). 
Although the Cav1.2 controls the main calcium current in the heart, it also has other 
cellular functions; excitation-coupling in smooth muscle, hormone release (in mice, 
selective ablation in beta cells resulted in impaired insulin secretion and systemic glucose 
intolerance (Schulla et al., 2003)), regulation of transcription, and synaptic integration 
(Catterall et al., 2005 for review).  
Mutations in CACNA1C lead to conductance defects in the heart –a major complication in 
myotonic dystrophy. Particular amino acid substitutions in the cardiac Cav1.2 channel have 
been shown to cause elevated ST levels and short QT intervals (Figure 61) on 
electrocardiograms and result in sudden cardiac death (Antzelevitch et al., 2007). In DM1 
however ECGs generally reveal different variations –a long PR interval and wide QRS 
complex (Figure 61) (Bu'Lock et al., 1999), which could result from different voltage 
sensitivities in the same gene caused by aberrant splicing (Soldatov et al., 1995; Tang et 
al., 2004). Indeed, mutations in exon8/8a of this gene lead to Timothy syndrome, an 
autosomal dominant disorder characterised by long QT intervals (Figure 61) and 
ventricular cardiac arrhythmias (Splawski et al., 2004; Splawski et al., 2005; Faber et al., 
2007).  
Aberrant splicing of Cav1.2 could also play a role in anaesthetic sensitivity. Volatile 
anaesthetics depress cardiac contractility by inhibition of cardiac L-type calcium channels 
(Gingrich et al., 2005), so further depression of an already sub-functional channel could 
worsen complications and result in heart and respiratory failure. It seems likely then that 
dysregulation of CACNA1C alternative splicing could play a major role in the defective 
heart conductance observed in DM, and also contribute to anaesthetic sensitivity. 
CACNA1C is subject to extensive alternative splicing with 19 of 55 exons alternatively 
spliced (Tang et al., 2004; Murakami et al., 2006). The N-terminus is associated with 
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(Kobrinsky et al., 2005). Both embryonic and adult specific isoforms are produced from 
combinatorial splicing of exons 31-33 resulting in shifts in the voltage dependence of 
activation (Diebold et al., 1992; Tang et al., 2004). 
 
 
Figure 62 Alternative exon usage in Cacna1c. Graph plotting probeset values. Data for 5 and 
250 repeats were subtracted from 0 repeats (pLoxEGFP). Each exon is represented by one or 
more probesets which have been spaced equally rather than proportionately to the genomic 
sequence for clarity. Probesets corresponding to probable alternative exon usage are circled. 
Refseq sequences are aligned. Refseq: NM009781 length 602,340 bp. F denotes area of 
embryonic alternative splicing. Christine Haworth    Chapter 5, 190 
 
Cacna1c was found to have at least two possible exon differences. Expression of either 5 
or 250 CUG repeats lead to alternative exon splicing (Figure 62).  
Preliminary analysis of probeset data at the full metaprobeset level (data not shown), which 
has a much lower p-value (1.48E-05 vs. 2.87E-02 at the core level) indicates differential 
exon usage around the foetal region. This is consistent with the inappropriate foetal 
isoform switching seen in DM patients and warrants further investigation. 
 
5.4 Expression of known genes 
In anticipation of the microarray results we wanted to look at the expression of genes 
already known to be mis-spliced in myotonic dystrophy. We chose the chloride channel 1 
(Clcn1) and cardiac troponin T (Tnnt2) genes for study since the splicing patterns had 
already been well characterised in mouse models. For Tnnt2, exon 5 inclusion is promoted 
by the expression of expanded CUG repeats and in Clcn1, exon 7a inclusion which leads to 
the formation of a premature termination codon and probably nonsense mediated decay 
(Mankodi et al., 2002; Kanadia et al., 2003; Kanadia et al., 2006). Mouse 3T3 cells were 
transfected with reagent alone; pLoxEGFP; pLoxEGFP5 or pLoxEGFP250 and harvested 
after 24 hours incubation. Total RNA was extracted, and used as a template for first strand 
cDNA synthesis primed with random hexamers. Primers were designed as described in 
Κanadia et al. 2003 to amplify Tnnt2 cDNA between exons 2 and 6 and Clcn1 between 
exons 5 and 8. The PCR annealing temperature and magnesium chloride concentrations 
were optimised in order to detect reaction products using ethidium bromide staining and 
agarose gel electrophoresis (Figure 63).  
 
Figure 63 Detection of Tnnt2 transcripts in 3T3 cells. Agarose gel separated RT-PCR. 3T3 cells 
were transfected with constitutively expressing pLoxEGFP constructs containing 0; 5 or 250 CUG Christine Haworth    Chapter 5, 191 
 
repeats and analysed by RT-PCR . Primers were positioned between exons 2 and 6. Isoform sizes 
were estimated from Kanadia et al. 2003, the positions and exon content indicated on the RHS. 
The expression of expanded CUG repeats has been reported to increase the inclusion of exon 5, 
but in this experiment levels were too low to detect. No difference in the expression pattern was 
seen between treatments. *See Figure 64 legend. 
 
The Tnnt2 banding pattern obtained for the adult FVBN heart cDNA corresponded in size 
to that previously published (Figure 63) (Kanadia et al., 2003) where exon 5 exclusion is 
the predominant isoform. Inclusion of exon 5, as seen in DM1 patients, should result in a 
product of approximately 170 bp, but a fragment of this size was not detected in any of the 
transfected 3T3 cells or in the control heart cDNA. A small product of approximately 
75bp, not referred to in the literature, was generated using these primers. It was evident in 
all 3T3 cDNA samples and also in FVBN heart control cDNA (Figure 63, top, question 
mark). The size of the band could have corresponded to a product of exon 2 spliced 
directly to exon 6 (calculated using genescan intron-exon prediction on mouse 
chromosome 1 genomic sequence AC108813.8) yet a product of identical size was also 
obtained using tail genomic DNA (data not shown), indicating the sequence template 
lacked introns. In the published literature, figures were tightly cropped (Kanadia et al., 
2003; Ho et al., 2005), so it was impossible to ascertain whether this fragment was an 
artefact in our hands alone. During optimisation of the PCR, where a range of MgCl2 
concentrations were tested, the presence and intensity of the small reaction product did not 
change in proportion to the two larger bands, and always appeared to be the most 
significant product (Figure 64), indicating good sequence identity with the primers. 
Increasing the annealing temperature to the calculated melting temperature of the probe 
(72ºC) had no effect (data not shown), also indicating good sequence identity. Ideally, the 
fragment could have been excised, cloned and sequenced. Since small PCR products 
preferentially amplify in a reaction, to try to increase the detection sensitivity of the upper 
bands, the original gel was Southern blotted and hybridised to a probe generated from the 
doublet PCR product from FVBN heart (Figure 63*). No Tnnt2 exon 5 inclusion–
corresponding to a 170bp fragment –was detected in any of the samples (Figure 64).  There 
is a smudge around this area in the pLoxEGFP250-transfected samples, but the result is not 
clear and it is difficult to conclude anything from the poor separation of bands, but there 
clearly are slight differences. Ideally, the PCR products should be separated using 
polyacrylamide gel electrophoresis, to improve resolution.  
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Figure 64 cTnnt2 RT-PCR A A decrease in the magnesium chloride concentration does not 
reduce the predominance of the 70 bp band, which originates from RNA since no product is 
present in the no RT control, but contains only genomic sequence and so is not an alternatively 
spliced product of cTnnt2. B Southern blot of the Tnnt2 gel (Figure 63) hybridised to FVBN doublet 
band (Figure 63*) The 180bp band corresponding to exon 5 inclusion is not present in control 
samples but may be present in pLoxEGFP250 transfected 3T3 cells as a smudge. 
 
The prepared cDNA samples were also used to ascertain the presence of the Clcn1 
transcript in 3T3 cells, and the effect of CTG repeat expression on Clcn1 splicing patterns. 
Briefly, random-primed cDNA prepared from 3T3 cells transfected with pLoxEGFP; 
pLoxEGFP5, pLoxEGFP250 or reagent alone and FVBN skeletal muscle, was used as a 
template for the exon 5-8 Clcn1 primer set published by Kanadia et al. 2003. The PCR 
products were separated by agarose gel electrophoresis. From the 3T3 samples, four bands 
were obtained (Figure 65). The predicted sizes for isoforms including and excluding exon 
7a were calculated using cDNA accession numbers AY046403, AY046404, and the sizes 
correspond to the smallest PCR products. The larger two products could be further 
products of alternative exon missplicing implicated in DM1, extended 6-7a and 8a 
(Mankodi et al., 2002), but identification of the exon content would require sequencing, 
since information relating to the sequence and the PCR product sizes has not been 
published. The proportion of alternatively-spliced transcripts in 3T3 cells is different to the 
skeletal muscle control, which has a much higher incidence of the smallest product 
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between the test samples, therefore expression of expanded CUG repeats has surprisingly 
no effect on the pattern of Clcn1 alternative splicing in 3T3 cells. 
 
Figure 65 Detection of Clcn1 transcripts in 3T3 cells. Agarose gel separated RT-PCR. 3T3 cells 
were transfected with constitutively expressing pLoxEGFP constructs containing 0; 5 or 250 CUG 
repeats and analysed by RT-PCR. Primers were positioned within exons 5 and 8. The predicted 
sizes for isoforms indicated on the RHS are: 6-7-8, 340 bp; 6-7a-7-8, 419 bp (cDNA accession 
numbers AY046403, AY046404). The proportion of alternatively-spliced transcripts in 3T3 cells is 
different to the skeletal muscle control, which has a much higher incidence of the smallest product 
corresponding to the adult form of Clcn1 with no inclusion of exons 7a and 8a. No variation is seen 
between the test samples. Therefore expression of expanded CUG repeats has no effect on the 
pattern of Clcn1 alternative splicing in 3T3 cells. 
 
5.5 Discussion 
Microarray analyses were carried out in order to identify further novel genes aberrantly 
spliced after the expression of expanded CUG repeats in a cell culture system. Mouse 
fibroblast 3T3 cells transfected with 5 or 250 repeats from the pLoxEGFP construct were 
separated based on EGFP fluorescence. RNA was isolated and used for whole transcript 
microarray analysis. In the most reliable comparison between EGFP positive fractions 
pLoxEGFP250+ vs. pLoxEGFP5+, 138 genes were up-regulated and 6 down-regulated. No 
genes were selected for further analysis at this point due to the launch of the more ideally 
suited exon microarray chips. For this, RNA was isolated from mouse fibroblast 3T3 cells 
expressing 0, 5 or 250 repeats from the pLoxEGFP construct without FACS separation. 
Between the test samples: pLoxEGFP0; pLoxEGFP5 and pLoxEGFP250 repeats, 29; 54 
and 58 genes showed alternative exon usage within the core (Table 18), extended (Table 
19) and full (Table 20) probesets respectively.  Six genes were selected from those 
identified, based on previously known alternative exon usage, and the possible correlation 
of gene function and symptoms in myotonic dystrophy explored in the literature and 
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Since transient transfection does not result in all cells expressing the EGFP construct, in 
the whole transcript analysis, cells were separated using FACS to enrich the number of 
cells expressing the reporter with or without repeats. Even with total separation, this would 
include some cells expressing EGFP with no apparent foci, which has been explained by 
the heterologous population of repeat lengths in the starting plasmid, where a small 
percentage of deletions have been identified (Chapter 3: Growing repeats and Chapter 4 
EGFP and RNA foci). Since repeat lengths as small as 100 formed foci the small amount 
of EGFP positive; non-foci containing cells collected during FACS was not expected to 
skew the results. However, after the analysis, EGFP RT-PCR on the leftover samples 
revealed EGFP template within the “negative EGFP” cell fractions, indicating that either a 
significant proportion of “EGFP negative foci positive” cells were present, or that the 
separation was not pure. Ideally, Cy3-(CAG)10 in situ hybridisation analysis should have 
been attempted on “EGFP negative” separated samples before RNA isolation, but it seems 
that separation is most likely the fault since high numbers of “EGFP negative foci positive” 
cells were not observed during pLoxEGFP250 transfections in general. If sample 
separation was very poor then the numbers of differentially expressed genes would be 
expected to be near zero. In test 4 (Table 2: pLoxEGFP5+ vs. pLoxEGFP5-) the 
differences in the numbers of genes unregulated (130; listed in Table 16) and down-
regulated (90; listed in Table 17) were notable however, this was also the case with test 2 
(Table 2: pLoxEGFP250+ vs. pLoxEGFP5-) the differences in the numbers of genes 
unregulated (312; listed in Table 14) and down-regulated (79; listed in Table 15), 
suggesting that some form of enrichment between positive and negative EGFP fractions 
had occurred. Indeed, the Cacna1c gene was identified in both pLoxEGFP5+ vs. 
pLoxEGFP5- (Table 17) and pLoxEGFP250+ vs. pLoxEGFP5- (Table 15) down-regulated 
gene comparisons. It would be prudent then to reanalyse these lists to possibly identify 
further mis-spliced genes. 
The experiment at the time it was designed was well controlled for the possibility of poor 
separation. PLoxEGFP5 samples were considered to be equivalent to the normal or control 
situation, and results could then be reanalysed by using the difference between 
pLoxEGFP5 positive and pLoxEGFP250 positive chips only. Doubt was cast on the 
negativity of the pLoxEGFP5 samples when Mahadevan et al. (2006) reported that over-
expression of 5 CUG repeats in the mouse resulted in myotonia, cardiac conduction 
abnormalities, histopathology and also RNA splicing defects, in the absence of detectable 
nuclear inclusions. Since our model also utilised the pCMV promoter, it was reasonable to 
expect that the pLoxEGFP5 could also be pathogenic. For the exon array analysis then, Christine Haworth    Chapter 5, 195 
 
FACS separation was not carried out, and pLoxEGFP (0 repeats) was added as the 
negative control.  
Myotonic dystrophy affects so many systems, that it is difficult to select a gene whose 
deficiency does not replicate at least some of the symptoms of DM. Consequently little 
bias has been used in the selection of genes for further analysis. It is interesting to note that 
the Cacna1c gene, the candidate gene for conduction defects in DM, was also identified in 
the whole transcript analysis in the down-regulated pLoxEGFP5+ vs. pLoxEGFP 5- 
comparison, and in the down-regulated pLoxEGFP250+ vs. pLoxEGFP5- comparison. 
Here the levels of the Cacna1c transcript were reduced 1.75 fold in the 5+ fraction and 
1.64 fold in the 250+ fraction compared to out best negative pLoxEGFP5- (Table 17 and 
Table 15). This was the only gene of those selected from the exon array analysis that was 
also identified in the whole transcript arrays. This is not surprising since differences in 
transcript levels using these arrays rely on 3’ end alternative splice events or nonsense 
mediated decay due to the use of cryptic splice sites outside the terminal exon, which is not 
expected to be a frequent event. In DM1 missplicing identified to date, this happens only in 
the chloride channel 1 gene. 
It is not clear from the literature whether the splicing differences identified here match 
existing developmental patterns. As was already mentioned, the patterns in Mtmr4 are 
impossible to match at the core probeset level since these intron-derived exons are not 
represented; this is also true of Cacna1c. For the other selected genes, no developmental 
patterns have been published.  
It was noted that in the genes selected that often, alternative exon usage was apparent in 
both samples compared to the EGFP baseline, but not necessarily in the same exon. Is this 
an artefact of the selection procedure, or is it statistically significant? It could be an artefact 
of the analysis. Using Partek Genomic suite, a higher alternative exon usage score may be 
given to those genes differing between both samples. Of the 25 highest ranking genes from 
the full data set 21 genes showed alternative exon usage in both samples compared to 
EGFP, and in different exons, so an artefact does seem likely. In light of this, it would be 
prudent to repeat the analyses, and separately compare EGFP vs. pLoxEGFP5 and EGFP 
vs. pLoxEGFP250, to determine whether the same genes are selected. If the differences are 
real it may be that we are looking at the result of two different effects: That of increased 
levels of CUG-BP1 (pLoxEGFP 5), as seen in the recent mouse model, and increased 
CUG-BP1 combined with depletion of MBNL (pLoxEGFP250).  Christine Haworth    Chapter 5, 196 
 
The results of the exon array analyses were searched for known genes Clcn1; Insr; Ryr1; 
Tnnt2; Serca (also known as atp2a1) and Amphiphysin (Amph -also known as Bin1). The 
p-values were high (Table 22), indicating that the genes were unlikely to be mis-spliced. 
Why these genes were not mis-spliced in 3T3 cells is uncertain. It may be that since the 
origin of the cells was embryonic, the levels of MBNL1 and CUG-BP1 are already 
‘altered’ and that further depletion of MBNL by expanded repeats would make no change 
to the pattern of splicing. Of those genes known to be misspliced in DM1, there is no 
information in the literature concerning alternative splicing in 3T3 cells. 
Table 22 Alternative splicing p-values of genes known to be mis-spliced in DM1 
  Core  Extended  Full 
Clcn1  0.586979  0.609543  0.535062 
Insr  0.395370  0.106255  0.059114 
Ryr1  0.396188  0.319517  0.130963 
Tnnt2  0.965664  1  0.775952 
Serca  0.172591  0.176744 
 
0.675686 
 
Amph  0.492576 
 
0.0217275 
 
0.357725 
 
 
In the analysis presented in this chapter, core probeset data has been used. Hence before 
primer design, the alternative exon usage should also be assessed at the extended and the 
full metaprobeset levels, since changes in these further probesets would affect primer 
position. Indeed in most of the genes selected, p-values are highest in these sets (Table 21). 
Ideally, the selected genes would next be characterised by RT-PCR using primers 
surrounding the exons in question, firstly using samples generated with the culture system 
described, then patient cells and also mouse DM models in order to assess possible isoform 
changes during development. Candidate cDNAs would then be cloned and sequenced to 
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6  Discussion 
6.1 DM1 as an RNA processing disorder  
Up until fairly recently our understanding of the pathogenesis of myotonic dystrophy was 
making slow progress. The DM1 locus is a gene dense region, and the effects of the 
expanded CTG repeat are complex. Expansion of the CTG repeat results in the spread of 
heterochromatin centered on the CTG repeat region (Otten et al., 1995), resulting in 
reduced expression of surrounding genes such as SIX5 (Klesert et al., 1997; Thornton et 
al., 1997). Since only repeat-containing transcripts are retained in the nucleus, the 
proportional expression pattern of functionally distinct isoforms of the DMPK gene itself is 
also altered (Groenen et al., 2000; Tiscornia et al., 2000; Wansink et al., 2003; van Herpen 
et al., 2005), leading to reduced levels of functionally distinct isoforms (Groenen et al., 
2000). Despite extensive research into these effects, haploinsufficiency at the DM1 locus 
alone does not appear to account for the extensive multisystemic effects seen in patients. 
The main pathogenic effects arise from a toxic gain-of-function of the expanded repeat 
RNA (Philips et al., 1998; Kuyumcu-Martinez et al., 2006). Expression of the mutant RNA 
results in nuclear retention of the transcript and sequestration of the splicing regulator 
MBNL1 to that transcript within foci (Miller et al., 2000; Fardaei et al., 2002). At the same 
time mutant RNA expression increases the MBNL1 antagonist CUG-BP1, by some 
unknown mechanism that may involve phosphorylation whilst bound to short single 
stranded CUG repeats within the cytoplasm (possibly generated by dicer), followed by 
nuclear relocalisation (Timchenko, personal communication). The alteration in the 
antagonistic balance between CUG-BP1 and MBNL1 splicing regulators results in a failure 
of embryonic to adult alternative splicing events in a number of genes, of which there are 
now many identified in DM1 (Ho et al., 2004; Lin et al., 2006). Some are clearly directly 
responsible for specific aspects of the pathology, for instance the chloride channel to 
myotonia and the insulin receptor to insulin resistance, for others the relationship is less 
clear (Savkur et al., 2001; Mankodi et al., 2002).  
In order to identify further genes misspliced in DM1, we generated a murine cell culture 
model of myotonic dystrophy type 1 which mimicked the nuclear expanded RNA foci 
formation and MBNL1 co-localisation seen in patient cells. The formation of foci was 
observed with as few as 100 CUG repeats in HeLa cells. MBNL1 co-localisation to the 
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pLoxEGFP250. Notably, the foci formed in these cells appeared to be larger, and fewer in 
number, than cells transfected with pLoxEGFP250 alone, suggesting the extent of foci 
formation was limited by the availability of MBNL1. Using this system and Affymetrix 
exon array analysis to compare effects of 0; 5 and 250 CUG repeat expression on the 
transcriptome, we identified 29; 54 and 58 genes that showed alternative exon usage within 
the core, extended and full probesets respectively. From this list, bioinformatics analysis 
revealed several nominee genes possibly mis-spliced in DM1 –MtmR4, which has possible 
neuromuscular involvement; Kcnk4, Narg1, Ttyh1 and Bptf, potentially related to brain 
development; and Cacna1c, a promising candidate for heart conductance defects and 
sudden death. The discovery of mis-splicing in the pore-forming unit of Cacna1c, if 
confirmed, could be of major consequence to patients undergoing surgery. Identification of 
the gene as a target in DM allows the anaesthetist to avoid the use of sedatives with effects 
on this channel and select alternative agents, possibly avoiding the complications of 
surgery in DM patients altogether.  
However DM1 is not just a spliceopathy, DMPK insufficiency and DM1 locus chromatin 
disruption also play a probable role, but there are further questions. CUG-BP1 is a 
developmental splicing regulator instrumental in the embryonic-adult alternative splicing 
switch, but CUG-BP1 has another function in addition to this. The protein has deadenylase 
activity, controlling polyA tail length and mRNA stability (Paillard et al., 2003; Moraes et 
al., 2006). What are the effects of elevated levels in relation to this role, and are there other 
functions? Are there as yet unidentified additional functions of MBNL1, MBNL2 or 
MBNL3, and what would be the consequence of depleted reserves on them? What about 
RNAi? Small 21nt RNAs have been reported by both Cho et al. and Krol et al.. Cho et al. 
showed that the DM1 3’UTR is transcribed bi-directionally generating 21nt RNAs in both 
the normal and expanded allele, and suggested a role for the RNAi pathway in DMPK 
regulation (Cho et al., 2005; Krol et al., 2007).  
Here, other RNA processing disorders are contrasted and compared, including DM2, 
looking for similarities and dissimilarities to try to gain insight into as yet unanswered 
questions, and also to solicit new ones. 
6.2 Other RNA processing disorders 
The pathogenesis of myotonic dystrophy can probably be mostly explained by the 
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development, and haploinsufficiency of DMPK and neighbouring genes. Yet one big 
question remains: How does the congenital form arise? Missplicing in myotonic dystrophy 
is in some instances borne from a failure of isoform switching between the embryonic and 
adult forms of target genes, therefore it is unlikely to be caused by MBNL1 depleted mis-
regulated splicing since embryonic forms are entirely appropriate in the neonate. More 
importantly, there have been no reports of a congenital form in DM2, and therefore in the 
newborn, DM1 pathogenesis must most likely arise from the differences between myotonic 
dystrophy type 1 and type 2.  
Historically, patients with presentations clinically similar to DM1, but without the DMPK 
expansion were diagnosed with proximal myotonic myopathy (PROMM) (Ricker, 1999). 
These patients had symptoms similar to DM1, but muscle weakness was mainly proximal, 
and wasting slight. Over time, with the accumulation of clinical data, the differences 
between PROMM and DM1 became less significant, and the disease was re-classed as a 
second type of myotonic dystrophy, DM2 (Ranum et al., 1998; Ricker et al., 1999; Liquori 
et al., 2001). Type 2 in general is a milder form of the disorder, closely resembling that of 
adult onset DM1. Whereas DM1 patients initially present because of daytime sleepiness 
and apathy, or distal weakness and stiffness, or in juvenile cases –developmental delay, 
DM2 patients first complain of muscle pain, stiffness or fatigue, or lower extremity 
weakness (Harper, 2001). Distal weakness such as facial muscle involvement is less 
pronounced as is bulbar involvement, so speech and swallowing are less often affected. 
Muscle atrophy is less pronounced. Although the muscle defects between the two types 
differ slightly, other symptoms, such as cataracts; hypogonadism and insulin sensitivity are 
equivalent (see Finsterer, 2002 and Day et al., 2003 for review). 
Both mutations consist of an untranslated expanded repeat, which becomes trapped in the 
nucleus: A CTG expansion in the 3’ UTR of the DMPK gene in DM1 and in DM2, a 
CCTG expansion within intron 1 of the CNBP gene. MBNL proteins 1, 2 and 3 are 
recruited to foci within their respective aggregate mutant transcripts and sequestered 
(Fardaei et al., 2002). This is believed to result in deregulation of alternative splicing 
events dynamically controlled by MBNL1 and CUG-BP1 during development. Indeed, in a 
mouse MBNL1
ΔE3 model missplicing of Clcn1, Tnnt2 and Tnnt3 was observed in the 
homozygote, also cataracts; centralised nuclei and split fibres within skeletal muscle, but 
no atrophy was apparent at 11 weeks. There was also no evidence of neonatal muscle 
weakness associated with the congenital form (Kanadia et al., 2003). MBNL1 
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relevant to both types 1 and 2, but appears an unlikely explanation for the increase in 
severity of muscle wasting or CNS involvement in DM1. 
It is the differences then that become interesting. In DM1, 50 to ~3000 repeat tracts result 
in the disease (Harper, 2001). In DM2, between 75 and 11,000 CCTG repeats are required 
(Liquori et al., 2001). Why are more repeats necessary in DM2 to elicit a pathological 
response? What of the genes themselves; the flanking regions, expression patterns and 
expression levels?  
The genes at the two DM loci have no apparent similarities. Research indicates that 
flanking genes around a locus can be responsible for disease pathogenesis, such as in 
fascioscapularhumeral muscular dystrophy, where deletion of a repressor binding site 
results in increased transcription of the neighbouring FRG1 gene (Gabellini et al., 2002). 
At the DM1 locus however, none of the surrounding genes RSHL1, DMWD or SIX5 have 
been satisfactorily implicated in the disease. Six5 insufficiency in mice leads to cataracts as 
in DM1, but not of the same type. It would be reasonable to use existing mouse models to 
attempt to create the complete pathogenic spectrum, by perhaps combining existing models 
MBNL1
ΔE3 and
 the Six5 or DMPK knockout mice. 
Phosphorylation of CUG-BP1 by DMPK results in a decrease of nuclear CUG-BP1 in vitro 
(Roberts et al., 1997), so would haploinsufficiency of the kinase result in a reduced 
requirement for MBNL1 sequestration in order to elicit a response from a smaller number 
of repeats? In DM2, longer repeats would then be required to deplete MBNL1 to shift the 
dynamic CUG-BP1/MBNL1 balance as far.  
In DM2, only the repeat array is retained within the nucleus, not the CNBP transcript –
levels of CNBP protein are not affected (Margolis et al., 2006). In DM1 however, the 
mutant transcript is retained resulting in an alteration of the proportion of functionally 
distinct DMPK isoforms (Groenen et al., 2000). Most isoforms in normal individuals are 
expressed in many tissues including heart, skeletal muscle, liver and brain, except for 
isoform 2 which is only found in the heart and skeletal muscle (Fu et al., 1993; swissprot 
Q09013), and isoform 14 which is only found in the brain, with high levels in the striatum 
(cognitive function), cerebellar cortex (motor function) and pons (respiration regulation), 
all functions which are affected in DM1 (Gennarelli et al., 1995). Alteration of the isoform 
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FXTAS shares interesting links with DM pathology. Although from the symptoms there is 
no obvious similarity (gait ataxia and intention tremor), except that the disease is late-onset 
(in Wells et al., 2006, chapter 10). In FXTAS, miRNA-mediated post-transcriptional 
control is probably disrupted by over-expression of the miRNA guide protein FMR1 
(Plante et al., 2006; Plante et al., 2006). Of DM1, the CTG array is known to form a single 
hairpin of a type capable of invoking RNAi (Langlois et al., 2005). Could this result in 
short CUG repeats entering the cytoplasm and lead to an increase of CUG-BP1 protein? 
Small 21nt CUG RNAs have been detected in DM1 patient cells, and a recent mouse 
model has shown that over-expression of short 5-repeat CTG arrays is sufficient to mimic 
DM pathogenesis in mice (Mahadevan et al., 2006). Presumably the 5-repeat transcripts 
generated in this model play a role in the alteration of cellular CUG-BP1 levels perhaps by 
phosphorylation of bound protein increasing localisation to the nucleus. These mice suffer 
from myotonia and splicing defects, but there is no mention of a congenital defect such as 
brain involvement. This may be due to the design of the transgene whereby repeat 
transcription is induced at any one point in time, rather than being expressed during 
development, which incidentally, would be difficult to orchestrate in this model since 
animals die 3-4 weeks after induction. However, it may also be because production of 5 
CUG repeats may not mimic the microRNA function of dicer-generated short 21nt RNAs, 
possibly generated from CUG hairpins. In addition to increasing nuclear CUG-BP1 levels 
by binding and phosphorylation, this could lead to protein insufficiency through RNA 
mediated gene silencing. If DMPK is regulated by dicer as indicated by the presence of 
21nt CUG RNAs, then expanded repeats may be detrimental to the cellular RNAi process 
affecting unrelated post transcriptionally-regulated genes in DMPK positive tissues.  
It has not yet been established whether the DM2 mutant array is capable of forming similar 
hairpins, if so would short 21nt CCTG repeats be less toxic than CTG repeats? RNAi 
generation of short cytoplasmic CTG repeats leading to increased CUG-BP1 levels is 
consistent with the observation that MBNL1 sequestration is separable from misregulated 
splicing (Ho et al., 2005), since CAG repeats may not lead to increased levels of CUG-
BP1. Further research is required to establish whether RNAi gene silencing plays a role in 
the pathogenesis in either or both DM1 and DM2 and whether this could be implicated in 
the congenital form, perhaps by the silencing of specific DMPK isoforms in the brain and 
other tissues.  
It was mentioned earlier that CUG-BP1 levels increase in concentration and activity within 
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mouse model (Ho et al., 2005). Here the splicing disruption and abnormal muscle 
histology was reproduced, but effects in other DM systems such as the brain are not 
apparent since expression was limited to heart and skeletal muscle. What are the effects of 
increased CUG-BP1 activity in other tissues during development and on other roles of 
CUG-BP1? Deadenylation by CUG-BP1 was reported in 2003 by Paillard et al. Possible 
over activity by CUG-BP1 could lead to shortened target polyA tails of other genes within 
the cell, affecting their stability. This is probably the cause of occulopharangeal muscular 
dystrophy. The PABP2B protein –defective in OPMD, binds with high affinity to the 
polyA tail of messenger RNA, controlling adenylate addition to approximately 250 
nucleotides. In OPMD patients, the protein becomes aggregated with bound RNA and 
other proteins. It is not clear whether the disease arises from disrupted adenylation, or 
sequestration of the ‘other’ unidentified proteins, but symptoms are late onset, and include 
ptosis, dysphagia and generalised muscle wasting –as in DM. Analysis of DM2 skeletal 
muscle showed no increase in CUG-BP1 (Lin et al., 2006). If levels are not elevated in 
DM2, it may be that DM2 symptoms arise from MBNL1 depletion rather than over-
expression of CUG-BP1. This would still alter the antagonistic balance between the 
splicing regulators, but given the additional role of CUG-BP1 in deadenylation, could 
result in a milder phenotype. It would be interesting to delineate the effects of CUG-BP1 
over-expression with respect to deadenylation from splicing regulation. This could be 
possible by over-expression of MBNL1 in the existing CUG-BP1 over-expressor mouse 
model. 
A protein known to associate with PABPB2 is FRG1 implicated in fascioscapulohumeral 
muscular dystrophy (FSHD), which is caused by a deletion, rather than an expansion, of 
D4Z4 repeats believed to function as a binding site for a transcriptional repressor complex 
(van Deutekom et al., 1993; Gabellini et al., 2002). The repressor limits transcription of 
flanking genes FRG1; FRG2 and ANT1, but in mouse models, only over-expression of 
FRG1 develops a muscular dystrophy with features characteristic of human FSHD 
(Gabellini et al., 2006). In this model, missplicing was identified in muscle-related genes 
Mtmr1 and Tnnt3 transcripts in the mice and in FSHD patient muscle cell cultures, genes 
also mis-spliced in DM (Buj-Bello et al., 2002; Kanadia et al., 2003). In contrast, Osborne 
et al. found that FRG1 levels in FSHD patient skeletal muscle biopsies were not raised, 
and splicing patterns in MTMR1 and TNNT3 were normal (Osborne et al., 2007). Both sets 
of data appear robust so it is not clear where the discrepancies arise. The presence of FRG1 
pseudogenes should be noted however, which would require careful consideration for the 
choice of PCR amplimer design to accurately measure transcript levels.  Christine Haworth    Chapter 6, 203 
 
Huntington disease-like 2 (HDL2) also shares missplicing with DM1. Abnormal splicing is 
observed in amyloid precursor protein (APP) and microtubule associated protein tau 
(MAPT) (Rudnicki et al., 2007), as in DM1 (Jiang et al., 2004; Leroy et al., 2006). HDL2 
is almost indistinguishable from the polyglutamine associated classical Huntington disease, 
yet the CTG expansion at the 3’ end of the junctophilin-3 (JPH3) gene leads variably to 
polyleucine; polyalanine; or is untranslated depending on the splice variant (Margolis et 
al., 2001). How the expansion in HDL2 leads to an almost identical phenotype to HD is 
unclear, but an RNA gain-of function mechanism seems likely. The HDL2 repeat is 
transcribed in the CTG orientation, which produces RNA inclusions that co-localise with 
MBNL1. Lengthwise, the expansion in HDL2 is shorter ~60 repeats, which in DM1 terms 
is only mildly pathogenic. This makes MBNL1 sequestration less likely, yet if the 
expression levels of the affected gene were higher than DMPK, it would corroborate over-
expression of 5 repeats being toxic (Mahadevan et al., 2006). Expression patterns differ 
between the two genes JPH3 and DMPK, which could account for differences in pathology 
to DM. DMPK has low levels of expression in brain, and is high in heart, skeletal muscle 
and testis (Sarkar et al., 2004). Whereas JPH3 is present at high levels in brain, modest in 
testis and minimal elsewhere (Takeshima et al., 2000). 
Expression of the ATXN8OS gene with 116 CTG repeats in mice successfully demonstrates 
the pathogenicity of the non-coding expansion in SCA8 (Moseley et al., 2006). This length 
of repeat is in the pathogenic range for DM1, but symptoms are not related. In SCA8 
movement is affected, –gait, speech hand and eye coordination (in Wells et al., 2006, 
chapter 28), caused by degeneration of the cerebellum, in DM1 pathogenesis is primarily 
muscle-related. The differences again –as in HDL2, probably derive from the expression 
patterns of the two genes. In the mouse model, repeat positive ATXN8OS transcripts were 
only found in the cerebellum; basal ganglia; frontal lobe and parietal lobe (Moseley et al., 
2006). 
Of the RNA processing disorders discussed here, it seems likely that SCA 8 and HDL2 
share a similar RNA gain of function mechanism with DM1 -notably MBNL1 associated 
RNA foci are apparent in HDL2. The differences in the pathology probably arise from the 
pattern of mutant RNA expression. Less is known about these pathogenic mechanisms than 
DM1, so perhaps DM1 pathogenesis may shed light on the disease process in these 
instances. Two interesting areas have been highlighted since they take further research of 
DM1 pathogenesis in two directions little studied so far–the involvement of RNAi, and the 
effects of over-deadenylation by CUG-BP1.  The consequences of shortened polyA tails in Christine Haworth    Chapter 6, 204 
 
OPMD share remarkable similarity to characteristic symptoms of DM1 –ptosis and 
dysphagia, perhaps hinting at the possibility of over-active deadenylation by CUG-BP1 in 
DM1. In FXTAS, miRNA-mediated post-transcriptional control is probably disrupted. If 
DMPK is regulated by dicer as indicated by the presence of 21nt CUG RNAs in DM1 
patient cells, then expanded repeats may be detrimental to this universal process but 
limited to DMPK positive tissues, which would explain the phenotypic differences between 
the two diseases. These two pathways are applicable to both myotonic dystrophy type 1 
and type 2, but with perhaps variable effect since the expression patterns of DMPK and 
CNBP are not the same, which may therefore account for some of the differences between 
the two types. Our model could be used to address some of these questions. Since the 
model is based on the expression of expanded CUG repeats within the immediate DMPK 
3’ UTR effects would be limited to this and would not include the consequences of 
haploinsufficiency of DMPK or the surrounding genes. Chromatin disruption would not be 
an issue since here the expansion is extra-genomic. The model would be ideal for 
investigation into the role of the RNAi silencing mechanism, both on the transgene itself 
and RNA levels generally within the transcriptome. Also, with a simple modification, 
DM2 CCTG repeats could be expressed allowing the assessment of the relative increases 
of CUG-BP1 after CTG or CCTG expression to help determine whether DM2 is primarily 
MBNL1-depletion mediated, lacking additional CUG-BP1 effects. This would indicate that 
the differences between the two types arise from the other role(s) of CUG-BP1, such as 
increased deadenylation, which could also be investigated using this system. The length of 
PolyA tails could be determined and the affected genes identified. In this model the cell-
type is not restricted. Results could be compared between cell-lines derived from different 
tissues, and at different developmental stages, perhaps gaining further insight into the 
elusive pathogenesis of the congenital form.  
The progression of our understanding of DM1 pathogenesis as an RNA processing disorder 
has enabled access to a plethora of information from other research areas within this 
expanding group of diseases. Insights gained from the similarities and differences has 
opened up further avenues of research into myotonic dystrophy pathogenesis, and what is 
already known about DM will facilitate understanding of other diseases within the field. 
Understanding has not only progressed in areas of disease, but also in the mechanisms of 
normal human biology such as the role of CUG-BP1 as a splicing regulator. New 
directions of research into the pathogenesis of myotonic dystrophy should in turn reveal 
new therapeutic targets, and subsequently, yield new therapies. 205 
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